menu
    • menu
    [{"orgOrder":0,"company":"Ateria Health","sponsor":"Immuron","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Dietary Supplement","year":"2022","type":"Financing","leadProduct":"Bovine Colostrum","moa":"\nLPS","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Ateria Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ateria Health \/ Immuron","highestDevelopmentStatusID":"15","companyTruncated":"Ateria Health \/ Immuron"},{"orgOrder":0,"company":"Ateria Health","sponsor":"Immuron","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Dietary Supplement","year":"2022","type":"Financing","leadProduct":"Bovine Colostrum","moa":"\nLPS","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Ateria Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ateria Health \/ Immuron","highestDevelopmentStatusID":"15","companyTruncated":"Ateria Health \/ Immuron"},{"orgOrder":0,"company":"H2O Health and Agriculture LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Dietary Supplement","year":"2014","type":"Inapplicable","leadProduct":"Bovine Colostrum","moa":"\nLPS","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"H2O Health and Agriculture LLC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"H2O Health and Agriculture LLC \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"H2O Health and Agriculture LLC \/ Undisclosed"},{"orgOrder":0,"company":"Milky Way Life Sciences LLC","sponsor":"Beth Israel Deaconess Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Bovine Colostrum","moa":"\nLPS","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Milky Way Life Sciences LLC","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Milky Way Life Sciences LLC \/ Beth Israel Deaconess Medical Center","highestDevelopmentStatusID":"6","companyTruncated":"Milky Way Life Sciences LLC \/ Beth Israel Deaconess Medical Center"},{"orgOrder":0,"company":"Immuron","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"AUSTRALIA","productType":"Dietary Supplement","year":"2024","type":"Funding","leadProduct":"Bovine Colostrum","moa":"\nLPS","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuron \/ US Department of Defense","highestDevelopmentStatusID":"15","companyTruncated":"Immuron \/ US Department of Defense"},{"orgOrder":0,"company":"Immuron","sponsor":"Medical Technology Enterprise Consortium","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"AUSTRALIA","productType":"Dietary Supplement","year":"2022","type":"Funding","leadProduct":"Bovine Colostrum","moa":"\nLPS","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuron \/ Medical Technology Enterprise Consortium","highestDevelopmentStatusID":"15","companyTruncated":"Immuron \/ Medical Technology Enterprise Consortium"},{"orgOrder":0,"company":"Immuron","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"AUSTRALIA","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Bovine Colostrum","moa":"\nLPS","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuron \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Immuron \/ Undisclosed"},{"orgOrder":0,"company":"Immuron","sponsor":"US Department of Defense | Naval Medical Research Center","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"AUSTRALIA","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Travelan","moa":"\nLPS","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuron \/ US Department of Defense | Naval Medical Research Center","highestDevelopmentStatusID":"8","companyTruncated":"Immuron \/ US Department of Defense | Naval Medical Research Center"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"RTX-1688","moa":"15-hydroxyprostaglandin dehydrogenase","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"TRYP-0082","moa":"5-HT2A receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tryp Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Radiolabeled Compound","year":"2016","type":"Inapplicable","leadProduct":"14-C APD421","moa":"5-HT3 receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Acacia Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acacia Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Acacia Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Xiling Lab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"SMP-100","moa":"5-HT3 receptor","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Xiling Lab","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Xiling Lab \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Xiling Lab \/ Undisclosed"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"CJ-12406","moa":"5-HT4 receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HK inno.N \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HK inno.N \/ Undisclosed"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"DA-6886","moa":"5-HT4 receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dong-A ST Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Dong-A ST Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"LX1033","moa":"5-HT4 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lexicon pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"LX1033","moa":"5-HT4 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lexicon pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ildong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Mosapride Citrate","moa":"Serotonin 4 (5-HT4) receptor | Serotonin 3 (5-HT3) receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ildong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ildong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ildong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Mosapride Citrate","moa":"Serotonin 4 (5-HT4) receptor | Serotonin 3 (5-HT3) receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Hanmi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hanmi Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hanmi Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Lunan Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Mosapride Citrate","moa":"5-HT4 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Lunan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lunan Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lunan Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Mosapride Citrate","moa":"5-HT4 receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Eunpyeong St. Mary's Hospital","sponsor":"Dong-A ST Co., Ltd. | Daewoong Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Mosapride Citrate","moa":"5-HT4 receptor","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Eunpyeong St. Mary's Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eunpyeong St. Mary's Hospital \/ Dong-A ST Co., Ltd. | Daewoong Pharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"Eunpyeong St. Mary's Hospital \/ Dong-A ST Co., Ltd. | Daewoong Pharmaceutical"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"PCS12852","moa":"5-HT4 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Processa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Processa Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Processa Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Intact Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Licensing Agreement","leadProduct":"PCS12852","moa":"5-HT4 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Processa Pharmaceuticals","amount2":0.46000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.46000000000000002,"dosageForm":"Tablet","sponsorNew":"Processa Pharmaceuticals \/ Intact Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Processa Pharmaceuticals \/ Intact Therapeutics"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Rose Pharma | National Center for Research Resources","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"ROSE-010","moa":"5-HT4 receptor","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mayo Clinic \/ Rose Pharma | National Center for Research Resources","highestDevelopmentStatusID":"7","companyTruncated":"Mayo Clinic \/ Rose Pharma | National Center for Research Resources"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"TAK-906 Maleate","moa":"5-HT4 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Yuhan Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"YH 12852","moa":"5-HT4 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Yuhan Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yuhan Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Yuhan Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Yuhan Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"YH 12852","moa":"5-HT4 receptor","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Yuhan Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yuhan Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Yuhan Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Peptide, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Motilitone","moa":"5-HT4 receptor\/D2 receptor","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dong-A ST Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Dong-A ST Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Motilitone","moa":"5-HT4 receptor\/D2 receptor","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dong-A ST Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Dong-A ST Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Zeria Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Acotiamide","moa":"Acetylcholinesterase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Zeria Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zeria Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zeria Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Zeria Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Acotiamide HCl Hydrate","moa":"Acetylcholinesterase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Zeria Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Zeria Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zeria Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"University of California, Irvine","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Neostigmine","moa":"Acetylcholinesterase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"University of California, Irvine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"University of California, Irvine \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"University of California, Irvine \/ Merck & Co"},{"orgOrder":0,"company":"Virtua Health","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Neostigmine","moa":"Acetylcholinesterase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Virtua Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Virtua Health \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Virtua Health \/ Merck & Co"},{"orgOrder":0,"company":"Centre Hospitalier de l'Universite de Montreal","sponsor":"Allergan","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Centre Hospitalier de l'Universite de Montreal","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre Hospitalier de l'Universite de Montreal \/ Allergan","highestDevelopmentStatusID":"8","companyTruncated":"Centre Hospitalier de l'Universite de Montreal \/ Allergan"},{"orgOrder":0,"company":"Albany Medical College","sponsor":"Allergan","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Albany Medical College","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Albany Medical College \/ Allergan","highestDevelopmentStatusID":"11","companyTruncated":"Albany Medical College \/ Allergan"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Gastroenterology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Noveome Biotherapeutics \/ Parexel","highestDevelopmentStatusID":"7","companyTruncated":"Noveome Biotherapeutics \/ Parexel"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Noveome Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Noveome Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Yuhan Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Revaprazan","moa":"acid pump inhibitors","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Yuhan Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yuhan Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Yuhan Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"University of California","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"Adenosine Analog","moa":"Adenosine A2A receptor","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adial Pharmaceuticals \/ University of California","highestDevelopmentStatusID":"1","companyTruncated":"Adial Pharmaceuticals \/ University of California"},{"orgOrder":0,"company":"RDD Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic receptor alpha","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"RDD Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Gel","sponsorNew":"RDD Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"RDD Pharma \/ Undisclosed"},{"orgOrder":0,"company":"RDD Pharma","sponsor":"US Department of Defense | Spaulding Clinical, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic receptor alpha","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"RDD Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Gel","sponsorNew":"RDD Pharma \/ US Department of Defense | Spaulding Clinical, LLC","highestDevelopmentStatusID":"7","companyTruncated":"RDD Pharma \/ US Department of Defense | Spaulding Clinical, LLC"},{"orgOrder":0,"company":"Norgine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Methoxamine","moa":"Adrenergic receptor alpha-1","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Norgine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Norgine \/ Undisclosed"},{"orgOrder":0,"company":"Valerio Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Clonidine","moa":"Adrenergic receptor alpha-2","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Valerio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Valerio Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Valerio Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Clonidine","moa":"Adrenergic receptor alpha-2","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Monopar Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Monopar Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Clonidine","moa":"Adrenergic receptor alpha-2","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Monopar Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Monopar Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Clonidine","moa":"Adrenergic receptor alpha-2","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Monopar Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Monopar Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Clonidine","moa":"Adrenergic receptor alpha-2","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Monopar Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Monopar Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Clonidine","moa":"Adrenergic receptor alpha-2","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Monopar Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Monopar Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Clonidine","moa":"Adrenergic receptor alpha-2","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Monopar Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Monopar Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Clonidine","moa":"Adrenergic receptor alpha-2","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Monopar Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Monopar Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Clonidine","moa":"Adrenergic receptor alpha-2","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BetterLife Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"BetterLife Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Norgine","sponsor":"Goldman Sachs Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Financing","leadProduct":"Sodium Chloride","moa":"||Adrenergic receptor Alpha-2 (ADRA2)","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Powder for Solution","sponsorNew":"Norgine \/ Goldman Sachs Asset Management","highestDevelopmentStatusID":"15","companyTruncated":"Norgine \/ Goldman Sachs Asset Management"},{"orgOrder":0,"company":"University of Texas Health Science Center at San Antonio","sponsor":"South Texas Veterans Health Care System","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2010","type":"Inapplicable","leadProduct":"Sodium Chloride","moa":"Adrenergic receptor Alpha-2 (ADRA2)","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"University of Texas Health Science Center at San Antonio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"University of Texas Health Science Center at San Antonio \/ South Texas Veterans Health Care System","highestDevelopmentStatusID":"1","companyTruncated":"University of Texas Health Science Center at San Antonio \/ South Texas Veterans Health Care System"},{"orgOrder":0,"company":"Entrinsic bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Sodium Chloride","moa":"||Adrenergic receptor Alpha-2 (ADRA2)","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Entrinsic bioscience","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Entrinsic bioscience \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Entrinsic bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases | Recordati Rare Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2010","type":"Inapplicable","leadProduct":"Hemin","moa":"ALAS","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mayo Clinic \/ National Institute of Diabetes and Digestive and Kidney Diseases | Recordati Rare Diseases","highestDevelopmentStatusID":"8","companyTruncated":"Mayo Clinic \/ National Institute of Diabetes and Digestive and Kidney Diseases | Recordati Rare Diseases"},{"orgOrder":0,"company":"Wageningen University and Research","sponsor":"Ministry of Economic Affairs | Givaudan France Naturals | Nexira | Wecare | Roquette Freres | Ingredion Pharma Solutions | Ingredia S.A. | Darling | Winclove Probiotics B.V. | Bioiberica","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Curcumin","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Wageningen University and Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wageningen University and Research \/ Ministry of Economic Affairs | Givaudan France Naturals | Nexira | Wecare | Roquette Freres | Ingredion Pharma Solutions | Ingredia S.A. | Darling | Winclove Probiotics B.V. | Bioiberica","highestDevelopmentStatusID":"1","companyTruncated":"Wageningen University and Research \/ Ministry of Economic Affairs | Givaudan France Naturals | Nexira | Wecare | Roquette Freres | Ingredion Pharma Solutions | Ingredia S.A. | Darling | Winclove Probiotics B.V. | Bioiberica"},{"orgOrder":0,"company":"Eisai","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Teprenone","moa":"aldosterone antagonists (spironolactone type)||Undisclosed","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eisai \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Eisai \/ Undisclosed"},{"orgOrder":0,"company":"Changhai Hospital","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Teprenone","moa":"aldosterone antagonists (spironolactone type)","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Changhai Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Changhai Hospital \/ Eisai","highestDevelopmentStatusID":"11","companyTruncated":"Changhai Hospital \/ Eisai"},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"BELGIUM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"AGMB-129","moa":"ALK-5 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"AgomAb Therapeutics N.V","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AgomAb Therapeutics N.V \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AgomAb Therapeutics N.V \/ Undisclosed"},{"orgOrder":0,"company":"Norgine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"NRL001","moa":"Alpha-1 adrenoceptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Norgine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Norgine \/ Undisclosed"},{"orgOrder":0,"company":"Norgine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"NRL001","moa":"Alpha-1 adrenoceptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Norgine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Norgine \/ Undisclosed"},{"orgOrder":0,"company":"Norgine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"NRL001","moa":"Alpha-1 adrenoceptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Norgine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Norgine \/ Undisclosed"},{"orgOrder":0,"company":"Norgine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"NRL001","moa":"Alpha-1 adrenoceptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"Norgine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Norgine \/ Undisclosed"},{"orgOrder":0,"company":"Norgine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"NRL001","moa":"Alpha-1 adrenoceptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"Norgine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Norgine \/ Undisclosed"},{"orgOrder":0,"company":"Norgine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"NRL001","moa":"Alpha-1 adrenoceptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"Norgine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Norgine \/ Undisclosed"},{"orgOrder":0,"company":"Children's Hospital Medical Center, Cincinnati","sponsor":"CSL Behring | National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Alpha-1 Proteinase Inhibitor","moa":"Alpha-1 antitrypsin","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Children's Hospital Medical Center, Cincinnati","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Hospital Medical Center, Cincinnati \/ CSL Behring | National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Children's Hospital Medical Center, Cincinnati \/ CSL Behring | National Institutes of Health"},{"orgOrder":0,"company":"Spyre Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"SPY001","moa":"Alpha-4-beta-7 integrin","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Spyre Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spyre Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Spyre Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Spyre Therapeutics","sponsor":"Aeglea BioTherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"SPY001","moa":"Alpha-4-beta-7 integrin","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Spyre Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spyre Therapeutics \/ Aeglea BioTherapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Spyre Therapeutics \/ Aeglea BioTherapeutics"},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"Fairmount Funds Management LLC","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Private Placement","leadProduct":"SPY001","moa":"Alpha-4-beta-7 integrin","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Aeglea BioTherapeutics","amount2":0.20999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0.20999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Aeglea BioTherapeutics \/ Fairmount Funds Management LLC","highestDevelopmentStatusID":"4","companyTruncated":"Aeglea BioTherapeutics \/ Fairmount Funds Management LLC"},{"orgOrder":0,"company":"Enterin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"ENT-01","moa":"Alpha-synuclein","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Enterin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Enterin \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Enterin \/ Undisclosed"},{"orgOrder":0,"company":"Valenta Pharm JSC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"RUSSIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Magaldrate","moa":"antiacid aluminum salts","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Valenta Pharm JSC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Valenta Pharm JSC \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Valenta Pharm JSC \/ Undisclosed"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Morinidazole","moa":"antiprotozoal substances (metronidazole type)","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Neutec Ar-Ge San ve Tic A.?","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"TURKEY","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Rabeprazole Sodium","moa":"antiulcer agents (benzimidazole derivatives)","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Neutec Ar-Ge San ve Tic A.?","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neutec Ar-Ge San ve Tic A.? \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Neutec Ar-Ge San ve Tic A.? \/ Undisclosed"},{"orgOrder":0,"company":"Avrio Health","sponsor":"Arcadia Consumer Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"Sennosides","moa":"AQP-3","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Avrio Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Avrio Health \/ Arcadia Consumer Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Avrio Health \/ Arcadia Consumer Healthcare"},{"orgOrder":0,"company":"Avrio Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sennosides","moa":"AQP-3","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Avrio Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Avrio Health \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Avrio Health \/ Undisclosed"},{"orgOrder":0,"company":"University of Nottingham","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Bisacodyl","moa":"Aquaporin-3; Sodium\/Potassium Transporting ATPase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"University of Nottingham","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Nottingham \/ Sanofi","highestDevelopmentStatusID":"11","companyTruncated":"University of Nottingham \/ Sanofi"},{"orgOrder":0,"company":"University of Nottingham","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Bisacodyl","moa":"Aquaporin-3; Sodium\/Potassium Transporting ATPase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"University of Nottingham","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Nottingham \/ Sanofi","highestDevelopmentStatusID":"11","companyTruncated":"University of Nottingham \/ Sanofi"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Bisacodyl","moa":"Aquaporin-3; Sodium\/Potassium Transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Giellepi S.p.A","sponsor":"Tigermed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Diosmin","moa":"Aryl hydrocarbon receptor","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Giellepi S.p.A","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Giellepi S.p.A \/ Tigermed","highestDevelopmentStatusID":"1","companyTruncated":"Giellepi S.p.A \/ Tigermed"},{"orgOrder":0,"company":"Anterogen Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Asc","moa":"ASC","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Anterogen Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Anterogen Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Anterogen Co \/ Undisclosed"},{"orgOrder":0,"company":"Frantz Viral Therapeutics","sponsor":"Laser Surgery Care | Anal Dysplasia Clinic MidWest","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Artesunate","moa":"antimalarials (artemisin dervatives)","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Frantz Viral Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Frantz Viral Therapeutics \/ Laser Surgery Care | Anal Dysplasia Clinic MidWest","highestDevelopmentStatusID":"8","companyTruncated":"Frantz Viral Therapeutics \/ Laser Surgery Care | Anal Dysplasia Clinic MidWest"},{"orgOrder":0,"company":"Frantz Viral Therapeutics","sponsor":"Amarex Clinical Research | University of California, San Francisco | Anal Dysplasia Clinic MidWest | Laser Surgery Care","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Artesunate","moa":"antimalarials (artemisin dervatives)","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Frantz Viral Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"Frantz Viral Therapeutics \/ Amarex Clinical Research | University of California, San Francisco | Anal Dysplasia Clinic MidWest | Laser Surgery Care","highestDevelopmentStatusID":"8","companyTruncated":"Frantz Viral Therapeutics \/ Amarex Clinical Research | University of California, San Francisco | Anal Dysplasia Clinic MidWest | Laser Surgery Care"},{"orgOrder":0,"company":"Jiangsu Famous Medical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Bacillus Licheniformis","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Jiangsu Famous Medical Technology","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Famous Medical Technology \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Jiangsu Famous Medical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Anabio R&D","sponsor":"Vietstar Biomedical Research | Thai Binh University of Medicine and Pharmacy","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"VIETNAM","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"Bacillus Subtilis","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Anabio R&D","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anabio R&D \/ Vietstar Biomedical Research | Thai Binh University of Medicine and Pharmacy","highestDevelopmentStatusID":"1","companyTruncated":"Anabio R&D \/ Vietstar Biomedical Research | Thai Binh University of Medicine and Pharmacy"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2019","type":"Inapplicable","leadProduct":"IBP-9414","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Infant Bacterial Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bacterial Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2015","type":"Inapplicable","leadProduct":"IBP-9414","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Infant Bacterial Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bacterial Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Centre Hospitalier Intercommunal Creteil","sponsor":"BioGaia Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Probiotic","year":"2017","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Centre Hospitalier Intercommunal Creteil","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Drops","sponsorNew":"Centre Hospitalier Intercommunal Creteil \/ BioGaia Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Centre Hospitalier Intercommunal Creteil \/ BioGaia Pharma"},{"orgOrder":0,"company":"NovoNatum Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"NovoNatum Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NovoNatum Ltd \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"NovoNatum Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Infant Bacterial Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bacterial Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Infant Bacterial Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bacterial Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Infant Bacterial Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bacterial Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Infant Bacterial Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bacterial Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Infant Bacterial Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bacterial Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Infant Bacterial Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bacterial Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Infant Bacterial Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bacterial Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Infant Bacterial Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bacterial Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Infant Bacterial Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bacterial Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Infant Bacterial Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bacterial Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioGaia Pharma","sponsor":"Atlantia Food Clinical Trials | CTC Clinical Trial Consultants","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"BioGaia Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioGaia Pharma \/ Atlantia Food Clinical Trials | CTC Clinical Trial Consultants","highestDevelopmentStatusID":"1","companyTruncated":"BioGaia Pharma \/ Atlantia Food Clinical Trials | CTC Clinical Trial Consultants"},{"orgOrder":0,"company":"BioGaia Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"BioGaia Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioGaia Pharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"BioGaia Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Infant Bacterial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Infant Bacterial Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Infant Bacterial Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Children's Investigational Research Program, LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2010","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Children's Investigational Research Program, LLC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Drops","sponsorNew":"Children's Investigational Research Program, LLC \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Children's Investigational Research Program, LLC \/ Undisclosed"},{"orgOrder":0,"company":"Case Western Reserve University","sponsor":"BioGaia Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2014","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Case Western Reserve University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"Case Western Reserve University \/ BioGaia Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Case Western Reserve University \/ BioGaia Pharma"},{"orgOrder":0,"company":"Scioto Biosciences","sponsor":"Genome & Company","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2020","type":"Series B Financing","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Scioto Biosciences","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Scioto Biosciences \/ Genome & Company","highestDevelopmentStatusID":"7","companyTruncated":"Scioto Biosciences \/ Genome & Company"},{"orgOrder":0,"company":"University of Florida","sponsor":"Metabolic Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Gastroenterology","graph2":"Phase II","graph3":"University of Florida","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"University of Florida \/ Metabolic Solutions","highestDevelopmentStatusID":"8","companyTruncated":"University of Florida \/ Metabolic Solutions"},{"orgOrder":0,"company":"World Health Organization","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh | Center for Public Health Kinetics | Kenya Medical Research Institute | University of Washington | Malawi-Liverpool-Wellcome Trust Clinical Research Programme | University of Liverpool | Ce","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Antibiotic","year":"2017","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Gastroenterology","graph2":"Phase III","graph3":"World Health Organization","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"World Health Organization \/ International Centre for Diarrhoeal Disease Research, Bangladesh | Center for Public Health Kinetics | Kenya Medical Research Institute | University of Washington | Malawi-Liverpool-Wellcome Trust Clinical Research Programme | University of Liverpool | Ce","highestDevelopmentStatusID":"10","companyTruncated":"World Health Organization \/ International Centre for Diarrhoeal Disease Research, Bangladesh | Center for Public Health Kinetics | Kenya Medical Research Institute | University of Washington | Malawi-Liverpool-Wellcome Trust Clinical Research Programme | University of Liverpool | Ce"},{"orgOrder":0,"company":"Spaarne Gasthuis","sponsor":"ZonMw","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"Bacterial 70S ribosome","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Spaarne Gasthuis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spaarne Gasthuis \/ ZonMw","highestDevelopmentStatusID":"10","companyTruncated":"Spaarne Gasthuis \/ ZonMw"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Bismuth Potassium Citrate","moa":"Bacterial cell wall synthesis","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"OPS-2071","moa":"Bacterial DNA replication","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Holdings","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"OPS-2071","moa":"Bacterial DNA replication","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Otsuka Holdings","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Holdings \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Otsuka Holdings \/ Undisclosed"},{"orgOrder":0,"company":"Yokohama City University","sponsor":"Aska Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Rifaximin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Yokohama City University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Yokohama City University \/ Aska Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Yokohama City University \/ Aska Pharmaceutical"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Rifaximin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Zydus Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"Actavis Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Rifaximin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Actavis Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Actavis Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Actavis Inc \/ Undisclosed"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Antibiotic","year":"2016","type":"Inapplicable","leadProduct":"Rifaximin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sandoz B2B \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sandoz B2B \/ Undisclosed"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Rifaximin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Alfasigma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Alfasigma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Alfasigma \/ Undisclosed"},{"orgOrder":0,"company":"University of Michigan","sponsor":"Commonwealth Diagnostics International, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Rifaximin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"University of Michigan","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Michigan \/ Commonwealth Diagnostics International, Inc.","highestDevelopmentStatusID":"11","companyTruncated":"University of Michigan \/ Commonwealth Diagnostics International, Inc."},{"orgOrder":0,"company":"Alvogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Rifaximin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Alvogen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alvogen \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Alvogen \/ Undisclosed"},{"orgOrder":0,"company":"Alvogen","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Rifaximin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Alvogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alvogen \/ Bausch Health","highestDevelopmentStatusID":"15","companyTruncated":"Alvogen \/ Bausch Health"},{"orgOrder":0,"company":"Columbia University","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Rifaximin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Columbia University \/ Bausch Health","highestDevelopmentStatusID":"1","companyTruncated":"Columbia University \/ Bausch Health"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Antibiotic","year":"2012","type":"Inapplicable","leadProduct":"Rifaximin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Cedars-Sinai","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Rifaximin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Cedars-Sinai","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cedars-Sinai \/ Bausch Health","highestDevelopmentStatusID":"7","companyTruncated":"Cedars-Sinai \/ Bausch Health"},{"orgOrder":0,"company":"Salix Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Rifaximin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Salix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Salix Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Salix Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Colgate Palmolive","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Triclosan","moa":"Bacterial enoyl-[acyl-carrier-protein] reductase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Colgate Palmolive","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Colgate Palmolive \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Colgate Palmolive \/ Undisclosed"},{"orgOrder":0,"company":"First Affiliated Hospital of Zhejiang University","sponsor":"Peking Union Medical College Hospital | Nanfang Hospital, Southern Medical University | Third Affiliated Hospital of Third Military Medical University | The First Affiliated Hospital with Nanjing Medical University | Centers for Disease Control and Preven","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Antibiotic","year":"2016","type":"Inapplicable","leadProduct":"Amoxicillin Trihydrate","moa":"Bacterial penicillin-binding protein","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"First Affiliated Hospital of Zhejiang University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"First Affiliated Hospital of Zhejiang University \/ Peking Union Medical College Hospital | Nanfang Hospital, Southern Medical University | Third Affiliated Hospital of Third Military Medical University | The First Affiliated Hospital with Nanjing Medical University | Centers for Disease Control and Preven","highestDevelopmentStatusID":"1","companyTruncated":"First Affiliated Hospital of Zhejiang University \/ Peking Union Medical College Hospital | Nanfang Hospital, Southern Medical University | Third Affiliated Hospital of Third Military Medical University | The First Affiliated Hospital with Nanjing Medical University | Centers for Disease Control and Preven"},{"orgOrder":0,"company":"Central Hospital, Nancy, France","sponsor":"Soci\u00e9t\u00e9 Francophone Nutrition Clinique et M\u00e9tabolisme | Fimatho | Fresenius Kabi AB Brunna","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Amoxicillin Trihydrate","moa":"Bacterial penicillin-binding protein","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Central Hospital, Nancy, France","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Central Hospital, Nancy, France \/ Soci\u00e9t\u00e9 Francophone Nutrition Clinique et M\u00e9tabolisme | Fimatho | Fresenius Kabi AB Brunna","highestDevelopmentStatusID":"6","companyTruncated":"Central Hospital, Nancy, France \/ Soci\u00e9t\u00e9 Francophone Nutrition Clinique et M\u00e9tabolisme | Fimatho | Fresenius Kabi AB Brunna"},{"orgOrder":0,"company":"Academisch Medisch Centrum - Universiteit van Amsterdam","sponsor":"ZonMw | Dutch Digestive Diseases Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Amoxicillin Trihydrate","moa":"Bacterial penicillin-binding protein","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Academisch Medisch Centrum - Universiteit van Amsterdam","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ ZonMw | Dutch Digestive Diseases Foundation","highestDevelopmentStatusID":"11","companyTruncated":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ ZonMw | Dutch Digestive Diseases Foundation"},{"orgOrder":0,"company":"Chulalongkorn University","sponsor":"Kidney Foundation of Thailand | Siam Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"THAILAND","productType":"Antibiotic","year":"2016","type":"Inapplicable","leadProduct":"Cefepime","moa":"Bacterial penicillin-binding protein","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Chulalongkorn University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chulalongkorn University \/ Kidney Foundation of Thailand | Siam Bioscience","highestDevelopmentStatusID":"11","companyTruncated":"Chulalongkorn University \/ Kidney Foundation of Thailand | Siam Bioscience"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Doripenem","moa":"Bacterial penicillin-binding protein","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibiotic","year":"2016","type":"Inapplicable","leadProduct":"Piperacillin Sodium","moa":"Bacterial penicillin-binding protein","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Unity Health Toronto","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Propranolol Hydrochloride","moa":"Beta-2 adrenergic receptor","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Unity Health Toronto","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Unity Health Toronto \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Unity Health Toronto \/ Undisclosed"},{"orgOrder":0,"company":"Neothetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Salmeterol Xinafoate","moa":"Beta-2 adrenergic receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Neothetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neothetics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Neothetics \/ Undisclosed"},{"orgOrder":0,"company":"Neothetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Salmeterol Xinafoate","moa":"Beta-2 adrenergic receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Neothetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neothetics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Neothetics \/ Undisclosed"},{"orgOrder":0,"company":"Neothetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Salmeterol Xinafoate","moa":"Beta-2 adrenergic receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Neothetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neothetics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Neothetics \/ Undisclosed"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Neothetics","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Salmeterol Xinafoate","moa":"Beta-2 adrenergic receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evofem Biosciences \/ Neothetics","highestDevelopmentStatusID":"10","companyTruncated":"Evofem Biosciences \/ Neothetics"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Neothetics","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Salmeterol Xinafoate","moa":"Beta-2 adrenergic receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evofem Biosciences \/ Neothetics","highestDevelopmentStatusID":"10","companyTruncated":"Evofem Biosciences \/ Neothetics"},{"orgOrder":0,"company":"Thomas Jefferson University","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Mirabegron","moa":"Beta-3 adrenergic receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Thomas Jefferson University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Thomas Jefferson University \/ Astellas Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Thomas Jefferson University \/ Astellas Pharma"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Vibegron","moa":"Beta-3 adrenergic receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Urovant Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Urovant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Vibegron","moa":"Beta-3 adrenergic receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Urovant Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Urovant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"VenterPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SPAIN","productType":"Carbohydrate","year":"2015","type":"Inapplicable","leadProduct":"Gaxilose","moa":"Beta-galactosidase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"VenterPharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VenterPharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"VenterPharma \/ Undisclosed"},{"orgOrder":0,"company":"\u00d6rebro University","sponsor":"Kerry Group","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Beta Glucan","moa":"Beta-glucan receptor","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"\u00d6rebro University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"\u00d6rebro University \/ Kerry Group","highestDevelopmentStatusID":"1","companyTruncated":"\u00d6rebro University \/ Kerry Group"},{"orgOrder":0,"company":"CinPhloro Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"CIN-103","moa":"Beta-secretase-1","graph1":"Gastroenterology","graph2":"Phase II","graph3":"CinPhloro Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CinPhloro Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CinPhloro Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Myungmoon Pharm. Co., LTD.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Chenodeoxycholic Acid","moa":"Bile acid receptor FXR","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Myungmoon Pharm. Co., LTD.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Myungmoon Pharm. Co., LTD. \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Myungmoon Pharm. Co., LTD. \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Tropifexor","moa":"Bile acid receptor FXR","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Albireo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"A3384","moa":"Bile acids","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Albireo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Albireo \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Albireo \/ Undisclosed"},{"orgOrder":0,"company":"Pharmascience Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Cholestyramine","moa":"Bile acids","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Pharmascience Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Pharmascience Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pharmascience Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Colesevelam Hydrochloride","moa":"Bile acids","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ironwood Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ironwood Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Colesevelam Hydrochloride","moa":"Bile acids","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ironwood Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ironwood Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Colesevelam Hydrochloride","moa":"Bile acids","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ironwood Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ironwood Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"IW-3718","moa":"Bile acids","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ironwood Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ironwood Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"IW-3718","moa":"Bile acids","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ironwood Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ironwood Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"IW-3718","moa":"Bile acids","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ironwood Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ironwood Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"IW-3718","moa":"Bile acids","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ironwood Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ironwood Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"University of Copenhagen","sponsor":"Carlsberg Group","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Glucose","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"University of Copenhagen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Copenhagen \/ Carlsberg Group","highestDevelopmentStatusID":"1","companyTruncated":"University of Copenhagen \/ Carlsberg Group"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide type 1 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mayo Clinic \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Mayo Clinic \/ Pfizer Inc"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"EPS Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Radiolabeled Compound","year":"2014","type":"Inapplicable","leadProduct":"13-C Calcium Carbonate","moa":"Calcium","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Otsuka Pharmaceutical \/ EPS Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Otsuka Pharmaceutical \/ EPS Corporation"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Radiolabeled Compound","year":"2017","type":"Inapplicable","leadProduct":"13-C Calcium Carbonate","moa":"Calcium","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Calcium Carbonate","moa":"Calcium","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Tilray","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Tilray","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tilray \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Tilray \/ Undisclosed"},{"orgOrder":0,"company":"Unity Health Toronto","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Controlled Substance","year":"2014","type":"Inapplicable","leadProduct":"Nabilone","moa":"Cannabinoid CB1 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Unity Health Toronto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Unity Health Toronto \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Unity Health Toronto \/ Undisclosed"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Nimacimab","moa":"Cannabinoid CB1 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Skye Bioscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Skye Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Controlled Substance","year":"2015","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"Cannabinoid CB1 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"Cannabinoid CB1 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tetra BioPharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Tetra BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"DanCann Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"Tetrahydrocannabinol","moa":"Cannabinoid CB1 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tetra BioPharma \/ DanCann Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Tetra BioPharma \/ DanCann Pharma"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"Cannabinoid CB1 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tetra BioPharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Tetra BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Avicanna","sponsor":"Tetra BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Partnership","leadProduct":"Tetrahydrocannabinol","moa":"Cannabinoid CB1 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Avicanna \/ Tetra BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"Avicanna \/ Tetra BioPharma"},{"orgOrder":0,"company":"Benuvia","sponsor":"Medra Brasil Medicamentos","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Licensing Agreement","leadProduct":"Tetrahydrocannabinol","moa":"Cannabinoid CB1 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Benuvia","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Benuvia \/ Medra Brasil Medicamentos","highestDevelopmentStatusID":"15","companyTruncated":"Benuvia \/ Medra Brasil Medicamentos"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Tetra BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Licensing Agreement","leadProduct":"Tetrahydrocannabinol","moa":"Cannabinoid CB1 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IntelGenx \/ Tetra BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Tetra BioPharma"},{"orgOrder":0,"company":"LaSanta S A S","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"COLOMBIA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"Cannabinoid CB1 receptor","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"LaSanta S A S","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LaSanta S A S \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"LaSanta S A S \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Olorinab","moa":"Cannabinoid CB2 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Olorinab","moa":"Cannabinoid CB2 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Obefazimod","moa":"||Cap binding complex","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Sodium Sulfate","moa":"Carbonic anhydrase 2; Carbonic anhydrase 1","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Prisma Health-Upstate","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Methocarbamol","moa":"Carbonic anhydrase I","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Prisma Health-Upstate","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prisma Health-Upstate \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Prisma Health-Upstate \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"RO5459072","moa":"Cathepsin S","graph1":"Gastroenterology","graph2":"Phase I","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"OnQuality Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"OQL051","moa":"CDK4","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"OnQuality Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OnQuality Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"OnQuality Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OnQuality Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"OQL051","moa":"CDK4","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"OnQuality Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OnQuality Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"OnQuality Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibiotic","year":"2016","type":"Inapplicable","leadProduct":"Surotomycin","moa":"Cell membrane","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibiotic","year":"2016","type":"Inapplicable","leadProduct":"Surotomycin","moa":"Cell membrane","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Miglustat","moa":"Ceramide glucosyltransferase","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"University of North Carolina","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lubiprostone","moa":"Chloride channel protein 2","graph1":"Gastroenterology","graph2":"Phase I","graph3":"University of North Carolina","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of North Carolina \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"University of North Carolina \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Cobiprostone","moa":"Chloride channel protein 2","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Lubiprostone","moa":"Chloride channel protein 2","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Parexel","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Parexel"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Lubiprostone","moa":"Chloride channel protein 2","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Lubiprostone","moa":"Chloride channel protein 2","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Lubiprostone","moa":"Chloride channel protein 2","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Lubiprostone","moa":"Chloride channel protein 2","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zydus Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Lubiprostone","moa":"Chloride channel protein 2","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Mallinckrodt Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Mallinckrodt Pharmaceuticals"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Lubiprostone","moa":"Chloride channel protein 2","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Lubiprostone","moa":"Chloride channel protein 2","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Mallinckrodt Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Mallinckrodt Pharmaceuticals"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Mallinckrodt Pharmaceuticals | Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Lubiprostone","moa":"Chloride channel protein 2","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Mallinckrodt Pharmaceuticals | Takeda Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Mallinckrodt Pharmaceuticals | Takeda Pharmaceutical"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Sucampo Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Lubiprostone","moa":"Chloride channel protein 2","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Sucampo Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Sucampo Pharmaceuticals"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Mallinckrodt Pharmaceuticals | Sucampo Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Lubiprostone","moa":"Chloride channel protein 2","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Mallinckrodt Pharmaceuticals | Sucampo Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Mallinckrodt Pharmaceuticals | Sucampo Pharmaceuticals"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Takeda Pharmaceutical | Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Lubiprostone","moa":"Chloride channel protein 2","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Takeda Pharmaceutical | Mallinckrodt Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Takeda Pharmaceutical | Mallinckrodt Pharmaceuticals"},{"orgOrder":0,"company":"University of South Alabama","sponsor":"Takeda Pharmaceutical | Sucampo Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lubiprostone","moa":"Chloride channel protein 2","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"University of South Alabama","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of South Alabama \/ Takeda Pharmaceutical | Sucampo Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"University of South Alabama \/ Takeda Pharmaceutical | Sucampo Pharmaceuticals"},{"orgOrder":0,"company":"Augusta University","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lubiprostone","moa":"Chloride channel protein 2","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Augusta University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Augusta University \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Augusta University \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"University of Michigan","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lubiprostone","moa":"Chloride channel protein 2","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"University of Michigan","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Michigan \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"University of Michigan \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Dartmouth-Hitchcock Medical Center","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Lubiprostone","moa":"Chloride channel protein 2","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Dartmouth-Hitchcock Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dartmouth-Hitchcock Medical Center \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Dartmouth-Hitchcock Medical Center \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Texas Tech University Health Sciences Center, El Paso","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Lubiprostone","moa":"Chloride channel protein 2","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Texas Tech University Health Sciences Center, El Paso","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Texas Tech University Health Sciences Center, El Paso \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"9","companyTruncated":"Texas Tech University Health Sciences Center, El Paso \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Par Pharmaceutical","sponsor":"Novum Pharmaceutical Research Services","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Lubiprostone","moa":"Chloride channel protein 2","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Par Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Par Pharmaceutical \/ Novum Pharmaceutical Research Services","highestDevelopmentStatusID":"10","companyTruncated":"Par Pharmaceutical \/ Novum Pharmaceutical Research Services"},{"orgOrder":0,"company":"Cedars-Sinai","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lubiprostone","moa":"Chloride channel protein 2","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Cedars-Sinai","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cedars-Sinai \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"Cedars-Sinai \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Trio Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Netazepide","moa":"Cholecystokinin B receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Trio Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trio Medicines \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Trio Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Trio Medicines","sponsor":"Ferring Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"YF476","moa":"Cholecystokinin B receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Trio Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Trio Medicines \/ Ferring Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Trio Medicines \/ Ferring Pharmaceuticals"},{"orgOrder":0,"company":"Trio Medicines","sponsor":"Ferring Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"YF476","moa":"Cholecystokinin B receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Trio Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Trio Medicines \/ Ferring Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Trio Medicines \/ Ferring Pharmaceuticals"},{"orgOrder":0,"company":"Trio Medicines","sponsor":"Ferring Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"YF476","moa":"Cholecystokinin B receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Trio Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Trio Medicines \/ Ferring Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Trio Medicines \/ Ferring Pharmaceuticals"},{"orgOrder":0,"company":"Trio Medicines","sponsor":"Ferring Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"YF476","moa":"Cholecystokinin B receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Trio Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Trio Medicines \/ Ferring Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Trio Medicines \/ Ferring Pharmaceuticals"},{"orgOrder":0,"company":"Trio Medicines","sponsor":"Royal Liverpool University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"YF476","moa":"Cholecystokinin B receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Trio Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trio Medicines \/ Royal Liverpool University Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Trio Medicines \/ Royal Liverpool University Hospital"},{"orgOrder":0,"company":"Trio Medicines","sponsor":"Norwegian University of Science and Technology","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"YF476","moa":"Cholecystokinin B receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Trio Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trio Medicines \/ Norwegian University of Science and Technology","highestDevelopmentStatusID":"8","companyTruncated":"Trio Medicines \/ Norwegian University of Science and Technology"},{"orgOrder":0,"company":"Trio Medicines","sponsor":"Columbia University | University of Cambridge","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"YF476","moa":"Cholecystokinin B receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Trio Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trio Medicines \/ Columbia University | University of Cambridge","highestDevelopmentStatusID":"8","companyTruncated":"Trio Medicines \/ Columbia University | University of Cambridge"},{"orgOrder":0,"company":"Columbia University","sponsor":"Trio Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"YF476","moa":"Cholecystokinin B receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Columbia University \/ Trio Medicines","highestDevelopmentStatusID":"8","companyTruncated":"Columbia University \/ Trio Medicines"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ursodeoxycholic Acid","moa":"Bile acid receptor FXR||Cholesterol","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Integra LifeSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2015","type":"Inapplicable","leadProduct":"Collagenase Inhibitor","moa":"Collagen","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Integra LifeSciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Integra LifeSciences \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Integra LifeSciences \/ Undisclosed"},{"orgOrder":0,"company":"ProofPilot","sponsor":"Qina","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Collagen","moa":"Collagen hydrolysis","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"ProofPilot","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ProofPilot \/ Qina","highestDevelopmentStatusID":"1","companyTruncated":"ProofPilot \/ Qina"},{"orgOrder":0,"company":"Palette Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"||Collagen synthesis","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Palette Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Palette Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Palette Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Nekkar Lab","sponsor":"Tigermed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Nekkar Lab","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nekkar Lab \/ Tigermed","highestDevelopmentStatusID":"1","companyTruncated":"Nekkar Lab \/ Tigermed"},{"orgOrder":0,"company":"Pharmbio Korea","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Oral Sulfate","moa":"Colon","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Pharmbio Korea","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmbio Korea \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pharmbio Korea \/ Undisclosed"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antibe Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Antibe Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Contract Sales Organization","sponsor":"Tetra BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Miscellaneous","year":"2020","type":"Partnership","leadProduct":"Triethanolamine Salicylate","moa":"COX-2","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Contract Sales Organization","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Contract Sales Organization \/ Tetra BioPharma","highestDevelopmentStatusID":"15","companyTruncated":"Contract Sales Organization \/ Tetra BioPharma"},{"orgOrder":0,"company":"Uniquity Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Solrikitug","moa":"CRLF2","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Uniquity Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Uniquity Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Uniquity Bio \/ Undisclosed"},{"orgOrder":0,"company":"University Hospital, Rouen","sponsor":"Laboratoire Dielen","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Amino Acid","year":"2025","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase 1; Amidophosphoribosyltransferase; Glutamine synthetase","graph1":"Gastroenterology","graph2":"Phase II","graph3":"University Hospital, Rouen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital, Rouen \/ Laboratoire Dielen","highestDevelopmentStatusID":"8","companyTruncated":"University Hospital, Rouen \/ Laboratoire Dielen"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Amino Acid","year":"2021","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase-1","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Emmaus Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Emmaus Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Amino Acid","year":"2020","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase-1","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Emmaus Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Emmaus Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Amino Acid","year":"2020","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase-1","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Emmaus Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Emmaus Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Partner International","sponsor":"Emmaus Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Amino Acid","year":"2020","type":"Licensing Agreement","leadProduct":"L-Glutamine","moa":"CTP synthase-1","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Partner International","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Partner International \/ Emmaus Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Partner International \/ Emmaus Life Sciences"},{"orgOrder":0,"company":"AddPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"AD-214","moa":"CXCR4 receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"AddPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AddPharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AddPharma \/ Undisclosed"},{"orgOrder":0,"company":"AddPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"AD-214","moa":"CXCR4 receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"AddPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AddPharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AddPharma \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Piramal Pharma Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Aspirin","moa":"Cyclooxygenase","graph1":"Gastroenterology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Piramal Pharma Solutions","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Piramal Pharma Solutions"},{"orgOrder":0,"company":"GSK","sponsor":"Piramal Pharma Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Aspirin","moa":"Cyclooxygenase","graph1":"Gastroenterology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Piramal Pharma Solutions","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Piramal Pharma Solutions"},{"orgOrder":0,"company":"E2Bio Life Sciences","sponsor":"Hematology Center after Prof. R. Yeolyan","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Benzydamine Hydrochloride","moa":"Cyclooxygenase","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"E2Bio Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Gargle\/Mouthwash","sponsorNew":"E2Bio Life Sciences \/ Hematology Center after Prof. R. Yeolyan","highestDevelopmentStatusID":"7","companyTruncated":"E2Bio Life Sciences \/ Hematology Center after Prof. R. Yeolyan"},{"orgOrder":0,"company":"Angelini Pharma","sponsor":"PPD","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Benzydamine Hydrochloride","moa":"Cyclooxygenase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Angelini Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Gargle\/Mouthwash","sponsorNew":"Angelini Pharma \/ PPD","highestDevelopmentStatusID":"11","companyTruncated":"Angelini Pharma \/ PPD"},{"orgOrder":0,"company":"Sanofi","sponsor":"Arcadia Consumer Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Acquisition","leadProduct":"Bismuth Subsalicylate","moa":"Cyclooxygenase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Arcadia Consumer Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Arcadia Consumer Healthcare"},{"orgOrder":0,"company":"Centers for Disease Control and Prevention","sponsor":"PROCTER AND GAMBLE | The New York Center for Travel and Tropical Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Bismuth Subsalicylate","moa":"Cyclooxygenase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Centers for Disease Control and Prevention","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"Centers for Disease Control and Prevention \/ PROCTER AND GAMBLE | The New York Center for Travel and Tropical Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Centers for Disease Control and Prevention \/ PROCTER AND GAMBLE | The New York Center for Travel and Tropical Medicine"},{"orgOrder":0,"company":"Centers for Disease Control and Prevention","sponsor":"PROCTER AND GAMBLE | Health Oriented Preventive Education","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Bismuth Subsalicylate","moa":"Cyclooxygenase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Centers for Disease Control and Prevention","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"Centers for Disease Control and Prevention \/ PROCTER AND GAMBLE | Health Oriented Preventive Education","highestDevelopmentStatusID":"10","companyTruncated":"Centers for Disease Control and Prevention \/ PROCTER AND GAMBLE | Health Oriented Preventive Education"},{"orgOrder":0,"company":"University of Cincinnati","sponsor":"PROCTER AND GAMBLE","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Bismuth Subsalicylate","moa":"Cyclooxygenase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"University of Cincinnati","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"University of Cincinnati \/ PROCTER AND GAMBLE","highestDevelopmentStatusID":"11","companyTruncated":"University of Cincinnati \/ PROCTER AND GAMBLE"},{"orgOrder":0,"company":"Corporacion Parc Tauli","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SPAIN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Corporacion Parc Tauli","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Corporacion Parc Tauli \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Corporacion Parc Tauli \/ Undisclosed"},{"orgOrder":0,"company":"Oxford Pharmascience","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Oxford Pharmascience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oxford Pharmascience \/ Quotient Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Oxford Pharmascience \/ Quotient Sciences"},{"orgOrder":0,"company":"Hackensack Meridian Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Hackensack Meridian Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hackensack Meridian Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hackensack Meridian Health \/ Undisclosed"},{"orgOrder":0,"company":"POZEN","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Naproxen","moa":"Cyclooxygenase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"POZEN","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"POZEN \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"POZEN \/ Undisclosed"},{"orgOrder":0,"company":"Galeno Desenvolvimento de Pesquisas Cl\u00ednicas","sponsor":"Biolab Sanus Farmaceutica","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"BRAZIL","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Naproxen","moa":"Cyclooxygenase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Galeno Desenvolvimento de Pesquisas Cl\u00ednicas","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galeno Desenvolvimento de Pesquisas Cl\u00ednicas \/ Biolab Sanus Farmaceutica","highestDevelopmentStatusID":"10","companyTruncated":"Galeno Desenvolvimento de Pesquisas Cl\u00ednicas \/ Biolab Sanus Farmaceutica"},{"orgOrder":0,"company":"Tehran University of Medical Sciences","sponsor":"Tillotts Pharma AG","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Cyclooxygenase | Peroxisome proliferator-activated receptor gamma | Arachidonate 5-lipoxygenase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Tehran University of Medical Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tehran University of Medical Sciences \/ Tillotts Pharma AG","highestDevelopmentStatusID":"11","companyTruncated":"Tehran University of Medical Sciences \/ Tillotts Pharma AG"},{"orgOrder":0,"company":"Napo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Cystic fibrosis transmembrane conductance regulator | Anoctamin-1","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Napo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Napo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Napo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Napo Therapeutics","sponsor":"SPRIM Global Investments","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Miscellaneous","year":"2023","type":"Private Placement","leadProduct":"Crofelemer","moa":"Cystic fibrosis transmembrane conductance regulator | Anoctamin-1","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Napo Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.059999999999999998,"dosageForm":"Solution","sponsorNew":"Napo Therapeutics \/ SPRIM Global Investments","highestDevelopmentStatusID":"8","companyTruncated":"Napo Therapeutics \/ SPRIM Global Investments"},{"orgOrder":0,"company":"Napo EU","sponsor":"Oasis Capital","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Crofelemer","moa":"Cystic fibrosis transmembrane conductance regulator | Anoctamin-1","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Napo EU","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Napo EU \/ Oasis Capital","highestDevelopmentStatusID":"15","companyTruncated":"Napo EU \/ Oasis Capital"},{"orgOrder":0,"company":"Napo EU","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Cystic fibrosis transmembrane conductance regulator | Anoctamin-1","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Napo EU","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Napo EU \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Napo EU \/ Undisclosed"},{"orgOrder":0,"company":"Napo EU","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Cystic fibrosis transmembrane conductance regulator | Anoctamin-1","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Napo EU","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Napo EU \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Napo EU \/ Undisclosed"},{"orgOrder":0,"company":"Napo EU","sponsor":"Jaguar Health","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Cystic fibrosis transmembrane conductance regulator | Anoctamin-1","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Napo EU","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Napo EU \/ Jaguar Health","highestDevelopmentStatusID":"10","companyTruncated":"Napo EU \/ Jaguar Health"},{"orgOrder":0,"company":"Napo EU","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Cystic fibrosis transmembrane conductance regulator | Anoctamin-1","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Napo EU","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Napo EU \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Napo EU \/ Undisclosed"},{"orgOrder":0,"company":"Napo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Cystic fibrosis transmembrane conductance regulator | Anoctamin-1","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Napo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Napo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Napo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Napo EU","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Cystic fibrosis transmembrane conductance regulator | Anoctamin-1","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Napo EU","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Napo EU \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Napo EU \/ Undisclosed"},{"orgOrder":0,"company":"Napo EU","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Cystic fibrosis transmembrane conductance regulator | Anoctamin-1","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Napo EU","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Napo EU \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Napo EU \/ Undisclosed"},{"orgOrder":0,"company":"University of Texas Health Science Center at Houston","sponsor":"Napo EU","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Cystic fibrosis transmembrane conductance regulator | Anoctamin-1","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"University of Texas Health Science Center at Houston","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Texas Health Science Center at Houston \/ Napo Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"University of Texas Health Science Center at Houston \/ Napo Pharmaceuticals"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Iliad Research And Trading","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Crofelemer","moa":"Cystic fibrosis transmembrane conductance regulator | Anoctamin-1","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jaguar Health \/ Iliad Research And Trading","highestDevelopmentStatusID":"10","companyTruncated":"Jaguar Health \/ Iliad Research And Trading"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Crofelemer","moa":"Cystic fibrosis transmembrane conductance regulator | Anoctamin-1","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Jaguar Health","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Jaguar Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jaguar Health \/ Undisclosed"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Cystic fibrosis transmembrane conductance regulator | Anoctamin-1","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jaguar Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jaguar Health \/ Undisclosed"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Cystic fibrosis transmembrane conductance regulator | Anoctamin-1","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jaguar Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jaguar Health \/ Undisclosed"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Cystic fibrosis transmembrane conductance regulator | Anoctamin-1","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jaguar Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jaguar Health \/ Undisclosed"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Cystic fibrosis transmembrane conductance regulator | Anoctamin-1","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jaguar Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jaguar Health \/ Undisclosed"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Cystic fibrosis transmembrane conductance regulator | Anoctamin-1","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jaguar Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jaguar Health \/ Undisclosed"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Cystic fibrosis transmembrane conductance regulator | Anoctamin-1","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Jaguar Health \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Jaguar Health \/ Undisclosed"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Cystic fibrosis transmembrane conductance regulator | Anoctamin-1","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Jaguar Health \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Jaguar Health \/ Undisclosed"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Cystic fibrosis transmembrane conductance regulator | Anoctamin-1","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Jaguar Health \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Jaguar Health \/ Undisclosed"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Napo EU","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Agreement","leadProduct":"Crofelemer","moa":"Cystic fibrosis transmembrane conductance regulator | Anoctamin-1","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Jaguar Health","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0.01,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Jaguar Health \/ Napo EU","highestDevelopmentStatusID":"15","companyTruncated":"Jaguar Health \/ Napo EU"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Crofelemer","moa":"Cystic fibrosis transmembrane conductance regulator | Anoctamin-1","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Jaguar Health \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Jaguar Health \/ Alnylam Pharmaceuticals"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Cystic fibrosis transmembrane conductance regulator | Anoctamin-1","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Jaguar Health \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Jaguar Health \/ Undisclosed"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Cystic fibrosis transmembrane conductance regulator | Anoctamin-1","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Jaguar Health \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Jaguar Health \/ Undisclosed"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Cystic fibrosis transmembrane conductance regulator | Anoctamin-1","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Jaguar Health \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Jaguar Health \/ Undisclosed"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Cystic fibrosis transmembrane conductance regulator | Anoctamin-1","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Jaguar Health \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Jaguar Health \/ Undisclosed"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Cystic fibrosis transmembrane conductance regulator | Anoctamin-1","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Jaguar Health \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Jaguar Health \/ Undisclosed"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Cystic fibrosis transmembrane conductance regulator | Anoctamin-1","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Jaguar Health \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Jaguar Health \/ Undisclosed"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Cystic fibrosis transmembrane conductance regulator | Anoctamin-1","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Jaguar Health \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Jaguar Health \/ Undisclosed"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Cystic fibrosis transmembrane conductance regulator | Anoctamin-1","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Jaguar Health \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Jaguar Health \/ Undisclosed"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Napo Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Cystic fibrosis transmembrane conductance regulator | Anoctamin-1","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Jaguar Health \/ Napo Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Jaguar Health \/ Napo Therapeutics"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Financing","leadProduct":"Crofelemer","moa":"Cystic fibrosis transmembrane conductance regulator | Anoctamin-1","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Jaguar Health","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0.01,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Jaguar Health \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Jaguar Health \/ Undisclosed"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Oasis Capital","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Crofelemer","moa":"Cystic fibrosis transmembrane conductance regulator | Anoctamin-1","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jaguar Health \/ Oasis Capital","highestDevelopmentStatusID":"15","companyTruncated":"Jaguar Health \/ Oasis Capital"},{"orgOrder":0,"company":"CinRx Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Deudomperidone","moa":"D2\/D3 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"CinRx Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CinRx Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CinRx Pharma \/ Undisclosed"},{"orgOrder":0,"company":"CinRx Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Deudomperidone","moa":"D2\/D3 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"CinRx Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CinRx Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CinRx Pharma \/ Undisclosed"},{"orgOrder":0,"company":"CinRx Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Deudomperidone","moa":"D2\/D3 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"CinRx Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CinRx Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CinRx Pharma \/ Undisclosed"},{"orgOrder":0,"company":"CinRx Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Deudomperidone","moa":"D2\/D3 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"CinRx Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CinRx Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CinRx Pharma \/ Undisclosed"},{"orgOrder":0,"company":"CinRx Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Deudomperidone","moa":"D2\/D3 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"CinRx Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CinRx Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CinRx Pharma \/ Undisclosed"},{"orgOrder":0,"company":"CinRx Pharma","sponsor":"CinRx Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Series B Financing","leadProduct":"Deudomperidone","moa":"D2\/D3 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"CinRx Pharma","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.059999999999999998,"dosageForm":"Capsule","sponsorNew":"CinRx Pharma \/ CinRx Pharma","highestDevelopmentStatusID":"8","companyTruncated":"CinRx Pharma \/ CinRx Pharma"},{"orgOrder":0,"company":"CinRx Pharma","sponsor":"CinRx Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Private Placement","leadProduct":"Deudomperidone","moa":"D2\/D3 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"CinRx Pharma","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"CinRx Pharma \/ CinRx Pharma","highestDevelopmentStatusID":"8","companyTruncated":"CinRx Pharma \/ CinRx Pharma"},{"orgOrder":0,"company":"Zunyi Medical College","sponsor":"Zunyi First People\u2019s Hospital | Af?liated Hospital of North Sichuan Medical College | Sichuan Cancer Hospital | Guizhou Provincial People's Hospital | Affiliated Hospital of Southwest Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Olanzapine","moa":"D2-like dopamine receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Zunyi Medical College","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zunyi Medical College \/ Zunyi First People\u2019s Hospital | Af?liated Hospital of North Sichuan Medical College | Sichuan Cancer Hospital | Guizhou Provincial People's Hospital | Affiliated Hospital of Southwest Medical University","highestDevelopmentStatusID":"11","companyTruncated":"Zunyi Medical College \/ Zunyi First People\u2019s Hospital | Af?liated Hospital of North Sichuan Medical College | Sichuan Cancer Hospital | Guizhou Provincial People's Hospital | Affiliated Hospital of Southwest Medical University"},{"orgOrder":0,"company":"The Hospital for Sick Children","sponsor":"Pediatric Oncology Group of Ontario","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Olanzapine","moa":"D2-like dopamine receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"The Hospital for Sick Children","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"The Hospital for Sick Children \/ Pediatric Oncology Group of Ontario","highestDevelopmentStatusID":"8","companyTruncated":"The Hospital for Sick Children \/ Pediatric Oncology Group of Ontario"},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Haisco Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Olanzapine","moa":"D2-like dopamine receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Starton Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Starton Therapeutics \/ Haisco Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Starton Therapeutics \/ Haisco Pharmaceutical"},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Olanzapine","moa":"D2-like dopamine receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Starton Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Starton Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Starton Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Olanzapine","moa":"D2-like dopamine receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Starton Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Starton Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Starton Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Anji Pharma","sponsor":"Covance","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Pradigastat","moa":"Diacylglycerol O-acyltransferase 1","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anji Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Anji Pharma \/ Covance","highestDevelopmentStatusID":"8","companyTruncated":"Anji Pharma \/ Covance"},{"orgOrder":0,"company":"Anji Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pradigastat","moa":"Diacylglycerol O-acyltransferase 1","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anji Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Anji Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Anji Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Eisai","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"E3710","moa":"Dihydrofolate reductase","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eisai \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eisai \/ Undisclosed"},{"orgOrder":0,"company":"Eurofarma Laboratorios S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"BRAZIL","productType":"Enzyme","year":"2010","type":"Inapplicable","leadProduct":"Lactase","moa":"D-lactose","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Eurofarma Laboratorios S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"Eurofarma Laboratorios S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eurofarma Laboratorios S.A \/ Undisclosed"},{"orgOrder":0,"company":"Eurofarma Laboratorios S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"BRAZIL","productType":"Enzyme","year":"2010","type":"Inapplicable","leadProduct":"Lactase","moa":"D-lactose","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Eurofarma Laboratorios S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"Eurofarma Laboratorios S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eurofarma Laboratorios S.A \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Reliance Clinical Research Services","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Plant Extract\/Herbal","year":"2012","type":"Inapplicable","leadProduct":"Metronidazole","moa":"DNA","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Reliance Clinical Research Services","highestDevelopmentStatusID":"8","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Reliance Clinical Research Services"},{"orgOrder":0,"company":"mohamed bouchoucha","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Metronidazole","moa":"DNA","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"mohamed bouchoucha","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"mohamed bouchoucha \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"mohamed bouchoucha \/ Undisclosed"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Public Offering","leadProduct":"Niclosamide","moa":"DNA","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"First Wave BioPharma","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"First Wave BioPharma \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"7","companyTruncated":"First Wave BioPharma \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Niclosamide","moa":"DNA","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"First Wave BioPharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"First Wave BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"First Wave BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"Niclosamide","moa":"DNA","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"First Wave BioPharma","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.23000000000000001,"dosageForm":"Undisclosed","sponsorNew":"First Wave BioPharma \/ AzurRx BioPharma","highestDevelopmentStatusID":"7","companyTruncated":"First Wave BioPharma \/ AzurRx BioPharma"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Niclosamide","moa":"DNA","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"First Wave BioPharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"First Wave BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Quanta Medical","sponsor":"Laboratoires Iprad-Vegebom","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibiotic","year":"2012","type":"Inapplicable","leadProduct":"Secnidazole","moa":"DNA","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Quanta Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Granules","sponsorNew":"Quanta Medical \/ Laboratoires Iprad-Vegebom","highestDevelopmentStatusID":"10","companyTruncated":"Quanta Medical \/ Laboratoires Iprad-Vegebom"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Radiolabeled Compound","year":"2015","type":"Inapplicable","leadProduct":"14-C OPS-2071","moa":"DNA gyrase","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Fidaxomicin","moa":"DNA-directed RNA polymerase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Merck & Co"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Fidaxomicin","moa":"DNA-directed RNA polymerase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Fidaxomicin","moa":"DNA-directed RNA polymerase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Fidaxomicin","moa":"DNA-directed RNA polymerase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Cosmo Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2017","type":"Inapplicable","leadProduct":"Rifamycin","moa":"DNA-directed RNA polymerase","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Cosmo Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cosmo Technologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cosmo Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Cosmo Technologies","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Rifamycin","moa":"DNA-directed RNA polymerase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Cosmo Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Cosmo Technologies \/ Bausch Health","highestDevelopmentStatusID":"15","companyTruncated":"Cosmo Technologies \/ Bausch Health"},{"orgOrder":0,"company":"Cosmo Technologies","sponsor":"RedHill Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2024","type":"Termination","leadProduct":"Rifamycin","moa":"DNA-directed RNA polymerase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Cosmo Technologies","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0.040000000000000001,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Cosmo Technologies \/ RedHill Biopharma","highestDevelopmentStatusID":"15","companyTruncated":"Cosmo Technologies \/ RedHill Biopharma"},{"orgOrder":0,"company":"Dr. Falk Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Rifamycin","moa":"DNA-directed RNA polymerase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Dr. Falk Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Dr. Falk Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Falk Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"RedHill Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Rifamycin","moa":"DNA-directed RNA polymerase","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cosmo Pharmaceuticals \/ RedHill Biopharma","highestDevelopmentStatusID":"8","companyTruncated":"Cosmo Pharmaceuticals \/ RedHill Biopharma"},{"orgOrder":0,"company":"Dr. Falk Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Rifamycin","moa":"DNA-directed RNA polymerase","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Dr. Falk Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dr. Falk Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dr. Falk Pharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Rifamycin","moa":"DNA-directed RNA polymerase","graph1":"Gastroenterology","graph2":"Phase II","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Adalvo","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Antibiotic","year":"2023","type":"Licensing Agreement","leadProduct":"Rifamycin Sodium","moa":"DNA-directed RNA polymerase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Cosmo Pharmaceuticals \/ Adalvo","highestDevelopmentStatusID":"15","companyTruncated":"Cosmo Pharmaceuticals \/ Adalvo"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Dr. Falk Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Antibiotic","year":"2023","type":"Termination","leadProduct":"Rifamycin Sodium","moa":"DNA-directed RNA polymerase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Cosmo Pharmaceuticals \/ Dr. Falk Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Cosmo Pharmaceuticals \/ Dr. Falk Pharma"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Rifamycin Sodium","moa":"DNA-directed RNA polymerase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Cosmo Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Cosmo Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Dr. Falk Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Antibiotic","year":"2020","type":"Licensing Agreement","leadProduct":"Rifamycin Sodium","moa":"DNA-directed RNA polymerase","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Cosmo Pharmaceuticals \/ Dr. Falk Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Cosmo Pharmaceuticals \/ Dr. Falk Pharma"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Rifamycin Sodium","moa":"DNA-directed RNA polymerase","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Cosmo Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cosmo Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Rifamycin Sodium","moa":"DNA-directed RNA polymerase","graph1":"Gastroenterology","graph2":"Phase II","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Adalvo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"MALTA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Rifamycin Sodium","moa":"DNA-directed RNA polymerase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Adalvo","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Adalvo \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Adalvo \/ Undisclosed"},{"orgOrder":0,"company":"EMS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"BRAZIL","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Bromopride","moa":"Dopamine D2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"EMS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EMS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EMS \/ Undisclosed"},{"orgOrder":0,"company":"Sofar Spa","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Domperidone","moa":"Dopamine D2 receptor","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Sofar Spa","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sofar Spa \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Sofar Spa \/ Undisclosed"},{"orgOrder":0,"company":"Allegiance Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Domperidone","moa":"Dopamine D2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allegiance Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allegiance Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allegiance Health \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Domperidone","moa":"Dopamine D2 receptor","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Caplin Steriles","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Prochlorperazine Edisylate","moa":"Dopamine D2 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Caplin Steriles","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Caplin Steriles \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Caplin Steriles \/ Undisclosed"},{"orgOrder":0,"company":"Shattuck Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"SL-325","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Shattuck Labs","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shattuck Labs \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Shattuck Labs \/ Undisclosed"},{"orgOrder":0,"company":"Shattuck Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"SL-325","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Shattuck Labs","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shattuck Labs \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Shattuck Labs \/ Undisclosed"},{"orgOrder":0,"company":"Shattuck Labs","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Private Placement","leadProduct":"SL-325","moa":"DR3","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Shattuck Labs","amount2":0.10000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Shattuck Labs \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Shattuck Labs \/ Undisclosed"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Itopride Hydrochloride","moa":"DRD2","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Abbott Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abbott Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Sepiapterin","moa":"eNOS||Tetrahydrobiopterin synthesis","graph1":"Gastroenterology","graph2":"Phase II","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"PTC Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PTC Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alvine Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2010","type":"Inapplicable","leadProduct":"ALV003","moa":"enzymes: enzymes\/proteases that have gluten as the substrate","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Alvine Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alvine Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alvine Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alvine Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2013","type":"Inapplicable","leadProduct":"ALV003","moa":"enzymes: enzymes\/proteases that have gluten as the substrate","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Alvine Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alvine Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alvine Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Immunogenics","sponsor":"National Institutes of Health | National Center for Complementary and Integrative Health","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2018","type":"Inapplicable","leadProduct":"Latiglutenase","moa":"enzymes: enzymes\/proteases that have gluten as the substrate","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Immunogenics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunogenics \/ National Institutes of Health | National Center for Complementary and Integrative Health","highestDevelopmentStatusID":"8","companyTruncated":"Immunogenics \/ National Institutes of Health | National Center for Complementary and Integrative Health"},{"orgOrder":0,"company":"Entero Therapeutics","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Latiglutenase","moa":"enzymes: enzymes\/proteases that have gluten as the substrate","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Entero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Entero Therapeutics \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"8","companyTruncated":"Entero Therapeutics \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"Entero Therapeutics","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases | Immunogenics","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Latiglutenase","moa":"enzymes: enzymes\/proteases that have gluten as the substrate","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Entero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Entero Therapeutics \/ National Institute of Diabetes and Digestive and Kidney Diseases | Immunogenics","highestDevelopmentStatusID":"8","companyTruncated":"Entero Therapeutics \/ National Institute of Diabetes and Digestive and Kidney Diseases | Immunogenics"},{"orgOrder":0,"company":"ImmunogenX","sponsor":"Mayo Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Latiglutenase","moa":"enzymes: enzymes\/proteases that have gluten as the substrate","graph1":"Gastroenterology","graph2":"Phase II","graph3":"ImmunogenX","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunogenX \/ Mayo Clinic","highestDevelopmentStatusID":"8","companyTruncated":"ImmunogenX \/ Mayo Clinic"},{"orgOrder":0,"company":"ImmunogenX","sponsor":"First Wave BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2024","type":"Merger","leadProduct":"Latiglutenase","moa":"enzymes: enzymes\/proteases that have gluten as the substrate","graph1":"Gastroenterology","graph2":"Phase II","graph3":"ImmunogenX","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunogenX \/ First Wave BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"ImmunogenX \/ First Wave BioPharma"},{"orgOrder":0,"company":"ImmunogenX","sponsor":"First Wave BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Merger","leadProduct":"Latiglutenase","moa":"enzymes: enzymes\/proteases that have gluten as the substrate","graph1":"Gastroenterology","graph2":"Phase II","graph3":"ImmunogenX","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunogenX \/ First Wave BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"ImmunogenX \/ First Wave BioPharma"},{"orgOrder":0,"company":"ImmunogenX","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Latiglutenase","moa":"enzymes: enzymes\/proteases that have gluten as the substrate","graph1":"Gastroenterology","graph2":"Phase II","graph3":"ImmunogenX","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunogenX \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ImmunogenX \/ Undisclosed"},{"orgOrder":0,"company":"ImmunogenX","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Latiglutenase","moa":"enzymes: enzymes\/proteases that have gluten as the substrate","graph1":"Gastroenterology","graph2":"Phase II","graph3":"ImmunogenX","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunogenX \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"ImmunogenX \/ National Institutes of Health"},{"orgOrder":0,"company":"Cadila Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Carbohydrate","year":"2025","type":"Inapplicable","leadProduct":"Lactulose","moa":"Evolved beta-galactosidase subunit alpha","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Cadila Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cadila Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Cadila Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Metacrine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"MET409","moa":"Farnesoid X-activated receptor (FXR)","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Metacrine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Metacrine \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Metacrine \/ Undisclosed"},{"orgOrder":0,"company":"Ventrus Biosciences, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"VEN 307","moa":"Fatty acid amide hydrolase-1","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ventrus Biosciences, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Ventrus Biosciences, Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ventrus Biosciences, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Children's Hospital of Philadelphia","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2017","type":"Inapplicable","leadProduct":"Pancrelipase","moa":"Fatty acids | Starch | Polypeptides","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Children's Hospital of Philadelphia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Hospital of Philadelphia \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Children's Hospital of Philadelphia \/ AbbVie Inc"},{"orgOrder":0,"company":"Beth Israel Deaconess Medical Center","sponsor":"Actavis Inc","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2015","type":"Inapplicable","leadProduct":"Pancrelipase","moa":"Fatty acids | Starch | Polypeptides","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Beth Israel Deaconess Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beth Israel Deaconess Medical Center \/ Actavis Inc","highestDevelopmentStatusID":"11","companyTruncated":"Beth Israel Deaconess Medical Center \/ Actavis Inc"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Ngm282","moa":"FGFR4-KLB | FGF1\/KLB","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NGM Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NGM Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ethicon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Fibrin Sealant","moa":"Fibrinogen \/ Thrombin","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Ethicon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ethicon \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ethicon \/ Undisclosed"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Palifermin","moa":"Fibroblast growth factor receptor 2","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Swedish Orphan Biovitrum AB \/ Undisclosed"},{"orgOrder":0,"company":"EpicentRx","sponsor":"Prothex Inc","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"RRx-001","moa":"Free radical (FRD)","graph1":"Gastroenterology","graph2":"Phase II","graph3":"EpicentRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EpicentRx \/ Prothex Inc","highestDevelopmentStatusID":"8","companyTruncated":"EpicentRx \/ Prothex Inc"},{"orgOrder":0,"company":"EpicentRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"RRx-001","moa":"Free radical (FRD)","graph1":"Gastroenterology","graph2":"Phase II","graph3":"EpicentRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EpicentRx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EpicentRx \/ Undisclosed"},{"orgOrder":0,"company":"EpicentRx","sponsor":"Dana-Farber Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"RRx-001","moa":"||Free radical (FRD)","graph1":"Gastroenterology","graph2":"Phase II","graph3":"EpicentRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EpicentRx \/ Dana-Farber Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"EpicentRx \/ Dana-Farber Cancer Institute"},{"orgOrder":0,"company":"EpicentRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"RRx-001","moa":"||Free radical (FRD)","graph1":"Gastroenterology","graph2":"Phase II","graph3":"EpicentRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EpicentRx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EpicentRx \/ Undisclosed"},{"orgOrder":0,"company":"EpicentRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"RRx-001","moa":"||Free radical (FRD)","graph1":"Gastroenterology","graph2":"Phase II","graph3":"EpicentRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EpicentRx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EpicentRx \/ Undisclosed"},{"orgOrder":0,"company":"EpicentRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"RRx-001","moa":"Free radical (FRD)","graph1":"Gastroenterology","graph2":"Phase II","graph3":"EpicentRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EpicentRx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EpicentRx \/ Undisclosed"},{"orgOrder":0,"company":"Sahlgrenska University Hospital","sponsor":"Calmino group AB","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Aloe vera","moa":"Free radicals","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Sahlgrenska University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sahlgrenska University Hospital \/ Calmino group AB","highestDevelopmentStatusID":"1","companyTruncated":"Sahlgrenska University Hospital \/ Calmino group AB"},{"orgOrder":0,"company":"Equillium","sponsor":"Metacrine","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Termination","leadProduct":"MET642","moa":"FX receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Equillium","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Equillium \/ Metacrine","highestDevelopmentStatusID":"8","companyTruncated":"Equillium \/ Metacrine"},{"orgOrder":0,"company":"Organovo Holdings","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"FXR314","moa":"FXR","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Organovo Holdings","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Organovo Holdings \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Organovo Holdings \/ Eli Lilly"},{"orgOrder":0,"company":"Oxagen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"OC000459","moa":"G protein-coupled receptor 44","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Oxagen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Oxagen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxagen \/ Undisclosed"},{"orgOrder":0,"company":"Norgine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Controlled Substance","year":"2011","type":"Inapplicable","leadProduct":"Midazolam","moa":"GABA-A receptor; anion channel","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Norgine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Norgine \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"AZD3355","moa":"GABA-B receptor 2 | GABA-B receptor 1","graph1":"Gastroenterology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Galectin Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"GEORGIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Belapectin","moa":"Galectin-3","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Galectin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galectin Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Galectin Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Hydrotalcite","moa":"Gastric acid","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Dexa Medica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDONESIA","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"DLBS2411","moa":"Gastric acid secretion","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Dexa Medica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dexa Medica \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dexa Medica \/ Undisclosed"},{"orgOrder":0,"company":"Dexa Medica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDONESIA","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"DLBS2411","moa":"Gastric acid secretion","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Dexa Medica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dexa Medica \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dexa Medica \/ Undisclosed"},{"orgOrder":0,"company":"Dexa Medica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDONESIA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"DLBS2411","moa":"Gastric acid secretion","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Dexa Medica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dexa Medica \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dexa Medica \/ Undisclosed"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Axonal-Biostatem","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Gelatin Tannate","moa":"Gastrointestinal mucosa","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ferrer Internacional \/ Axonal-Biostatem","highestDevelopmentStatusID":"10","companyTruncated":"Ferrer Internacional \/ Axonal-Biostatem"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Relamorelin","moa":"Ghrelin receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Relamorelin","moa":"Ghrelin receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Relamorelin","moa":"Ghrelin receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Relamorelin","moa":"Ghrelin receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Relamorelin","moa":"Ghrelin receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Universitaire Ziekenhuizen KU Leuven","sponsor":"Tsumura & Co","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"BELGIUM","productType":"Plant Extract\/Herbal","year":"2019","type":"Inapplicable","leadProduct":"Rikkunshito","moa":"Ghrelin receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Universitaire Ziekenhuizen KU Leuven","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universitaire Ziekenhuizen KU Leuven \/ Tsumura & Co","highestDevelopmentStatusID":"8","companyTruncated":"Universitaire Ziekenhuizen KU Leuven \/ Tsumura & Co"},{"orgOrder":0,"company":"Tranzyme, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"TZP-102","moa":"Ghrelin receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Tranzyme, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tranzyme, Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tranzyme, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Tranzyme, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"TZP-102","moa":"Ghrelin receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Tranzyme, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tranzyme, Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tranzyme, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Norgine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Ulimorelin","moa":"Ghrelin receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Norgine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Norgine \/ Undisclosed"},{"orgOrder":0,"company":"Tranzyme, Inc.","sponsor":"Norgine","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Ulimorelin","moa":"Ghrelin receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Tranzyme, Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tranzyme, Inc. \/ Norgine","highestDevelopmentStatusID":"10","companyTruncated":"Tranzyme, Inc. \/ Norgine"},{"orgOrder":0,"company":"Tranzyme, Inc.","sponsor":"Norgine","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Ulimorelin","moa":"Ghrelin receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Tranzyme, Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tranzyme, Inc. \/ Norgine","highestDevelopmentStatusID":"10","companyTruncated":"Tranzyme, Inc. \/ Norgine"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"TAK-101","moa":"Gliadin","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"NM-002","moa":"GLP-1 receptor","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"9 Meters Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"9 Meters Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"9 Meters Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Vurolenatide","moa":"GLP1R","graph1":"Gastroenterology","graph2":"Phase II","graph3":"9 Meters Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"9 Meters Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"9 Meters Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Vurolenatide","moa":"GLP1R","graph1":"Gastroenterology","graph2":"Phase II","graph3":"9 Meters Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"9 Meters Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"9 Meters Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Public Offering","leadProduct":"Vurolenatide","moa":"GLP1R","graph1":"Gastroenterology","graph2":"Phase II","graph3":"9 Meters Biopharma","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"9 Meters Biopharma \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"9 Meters Biopharma \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Public Offering","leadProduct":"Vurolenatide","moa":"GLP1R","graph1":"Gastroenterology","graph2":"Phase II","graph3":"9 Meters Biopharma","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"9 Meters Biopharma \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"9 Meters Biopharma \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Vurolenatide","moa":"GLP1R","graph1":"Gastroenterology","graph2":"Phase II","graph3":"9 Meters Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"9 Meters Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"9 Meters Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Vurolenatide","moa":"GLP1R","graph1":"Gastroenterology","graph2":"Phase II","graph3":"9 Meters Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"9 Meters Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"9 Meters Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Vurolenatide","moa":"GLP1R","graph1":"Gastroenterology","graph2":"Phase II","graph3":"9 Meters Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"9 Meters Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"9 Meters Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Duke Clinical Research Institute","sponsor":"9 Meters Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Collaboration","leadProduct":"Vurolenatide","moa":"GLP1R","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Duke Clinical Research Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Duke Clinical Research Institute \/ 9 Meters Biopharma","highestDevelopmentStatusID":"8","companyTruncated":"Duke Clinical Research Institute \/ 9 Meters Biopharma"},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Vurolenatide","moa":"GLP1R","graph1":"Gastroenterology","graph2":"Phase II","graph3":"9 Meters Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"9 Meters Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"9 Meters Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"GlyPharma Therapeutics","sponsor":"VectivBio","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Peptide, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"FE203799","moa":"GLP-2 receptor","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"GlyPharma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GlyPharma Therapeutics \/ VectivBio","highestDevelopmentStatusID":"7","companyTruncated":"GlyPharma Therapeutics \/ VectivBio"},{"orgOrder":0,"company":"GlyPharma Therapeutics","sponsor":"VectivBio","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Peptide, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"FE203799","moa":"GLP-2 receptor","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"GlyPharma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GlyPharma Therapeutics \/ VectivBio","highestDevelopmentStatusID":"7","companyTruncated":"GlyPharma Therapeutics \/ VectivBio"},{"orgOrder":0,"company":"VectivBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Apraglutide","moa":"GLP2R","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"VectivBio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio \/ Undisclosed"},{"orgOrder":0,"company":"VectivBio","sponsor":"Asahi Kasei Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2022","type":"Licensing Agreement","leadProduct":"Apraglutide","moa":"GLP2R","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0.20000000000000001,"dosageForm":"Injection","sponsorNew":"VectivBio \/ Asahi Kasei Pharma","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio \/ Asahi Kasei Pharma"},{"orgOrder":0,"company":"VectivBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Apraglutide","moa":"GLP2R","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"VectivBio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio \/ Undisclosed"},{"orgOrder":0,"company":"VectivBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Apraglutide","moa":"GLP2R","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"VectivBio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio \/ Undisclosed"},{"orgOrder":0,"company":"VectivBio","sponsor":"Ironwood Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2023","type":"Acquisition","leadProduct":"Apraglutide","moa":"GLP2R","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":1,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":1,"dosageForm":"Injection","sponsorNew":"VectivBio \/ Ironwood Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio \/ Ironwood Pharmaceuticals"},{"orgOrder":0,"company":"VectivBio","sponsor":"Ironwood Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2023","type":"Acquisition","leadProduct":"Apraglutide","moa":"GLP2R","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":1,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":1,"dosageForm":"Injection","sponsorNew":"VectivBio \/ Ironwood Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio \/ Ironwood Pharmaceuticals"},{"orgOrder":0,"company":"VectivBio","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2022","type":"Public Offering","leadProduct":"Apraglutide","moa":"GLP2R","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":0.13,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0.13,"dosageForm":"Injection","sponsorNew":"VectivBio \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio \/ Jefferies"},{"orgOrder":0,"company":"VectivBio","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2022","type":"Public Offering","leadProduct":"Apraglutide","moa":"GLP2R","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":0.13,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0.13,"dosageForm":"Injection","sponsorNew":"VectivBio \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio \/ Jefferies"},{"orgOrder":0,"company":"VectivBio","sponsor":"Surveyor Capital","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2020","type":"Financing","leadProduct":"Apraglutide","moa":"GLP2R","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":0.11,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0.11,"dosageForm":"Injection","sponsorNew":"VectivBio \/ Surveyor Capital","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio \/ Surveyor Capital"},{"orgOrder":0,"company":"VectivBio","sponsor":"SVB Securities","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2022","type":"Public Offering","leadProduct":"Apraglutide","moa":"GLP2R","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"VectivBio \/ SVB Securities","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio \/ SVB Securities"},{"orgOrder":0,"company":"VectivBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Apraglutide","moa":"GLP2R","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VectivBio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio \/ Undisclosed"},{"orgOrder":0,"company":"VectivBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Apraglutide","moa":"GLP2R","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VectivBio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio \/ Undisclosed"},{"orgOrder":0,"company":"VectivBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Apraglutide","moa":"GLP2R","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VectivBio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio \/ Undisclosed"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Apraglutide","moa":"GLP2R","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ironwood Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ironwood Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Apraglutide","moa":"GLP2R","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ironwood Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ironwood Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Apraglutide","moa":"GLP2R","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ironwood Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ironwood Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Elsiglutide","moa":"Glucagon-like peptide 2 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Helsinn Advanced Synthesis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Helsinn Advanced Synthesis \/ Undisclosed"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Chiltern International","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Elsiglutide","moa":"Glucagon-like peptide 2 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Helsinn Advanced Synthesis \/ Chiltern International","highestDevelopmentStatusID":"8","companyTruncated":"Helsinn Advanced Synthesis \/ Chiltern International"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Peptide, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Teduglutide","moa":"Glucagon-like peptide 2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Teduglutide","moa":"Glucagon-like peptide 2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Teduglutide","moa":"Glucagon-like peptide 2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Teduglutide","moa":"Glucagon-like peptide 2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Teduglutide","moa":"Glucagon-like peptide 2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Teduglutide","moa":"Glucagon-like peptide 2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Teduglutide","moa":"Glucagon-like peptide 2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SHIRE PLC \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"SHIRE PLC \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Peptide, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Teduglutide","moa":"Glucagon-like peptide 2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Peptide, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Teduglutide","moa":"Glucagon-like peptide 2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Teduglutide","moa":"Glucagon-like peptide 2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Peptide, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Teduglutide","moa":"Glucagon-like peptide 2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Teduglutide","moa":"Glucagon-like peptide 2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Teduglutide","moa":"Glucagon-like peptide 2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"Ellodi Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"APT-1011","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ellodi Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Ellodi Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ellodi Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ellodi Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"APT-1011","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ellodi Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Ellodi Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ellodi Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ellodi Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"APT-1011","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ellodi Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Ellodi Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ellodi Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adare Pharma Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Steroid","year":"2017","type":"Inapplicable","leadProduct":"APT-1011","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Adare Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Adare Pharma Solutions \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adare Pharma Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Ellodi Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"APT-1011","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ellodi Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Ellodi Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ellodi Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Soligenix","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Beclomethasone Dipropionate","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Soligenix \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Soligenix \/ National Cancer Institute"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Falk Pharma","sponsor":"Swedish Organization for Studies on Inflammatory Bowel Disease","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Steroid","year":"2011","type":"Inapplicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Dr. Falk Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Dr. Falk Pharma \/ Swedish Organization for Studies on Inflammatory Bowel Disease","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Falk Pharma \/ Swedish Organization for Studies on Inflammatory Bowel Disease"},{"orgOrder":0,"company":"Dr. Falk Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Steroid","year":"2014","type":"Inapplicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Dr. Falk Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Granules","sponsorNew":"Dr. Falk Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Falk Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Falk Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Steroid","year":"2013","type":"Inapplicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Dr. Falk Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"Dr. Falk Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dr. Falk Pharma \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Steroid","year":"2015","type":"Inapplicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Steroid","year":"2016","type":"Inapplicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Steroid","year":"2017","type":"Inapplicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"SHIRE PLC \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"SHIRE PLC \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Steroid","year":"2012","type":"Inapplicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Falk Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Steroid","year":"2014","type":"Inapplicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Dr. Falk Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Dr. Falk Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Falk Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Falk Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Steroid","year":"2015","type":"Inapplicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Dr. Falk Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dr. Falk Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Falk Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Falk Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Steroid","year":"2015","type":"Inapplicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Dr. Falk Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dr. Falk Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Falk Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Falk Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Dr. Falk Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dr. Falk Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Falk Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Falk Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Steroid","year":"2010","type":"Inapplicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Dr. Falk Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dr. Falk Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Falk Pharma \/ Undisclosed"},{"orgOrder":0,"company":"University of Calgary","sponsor":"Ferring Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"University of Calgary","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Calgary \/ Ferring Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"University of Calgary \/ Ferring Pharmaceuticals"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Steroid","year":"2011","type":"Inapplicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Bazell Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Bazell Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Bazell Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bazell Pharma \/ Undisclosed"},{"orgOrder":0,"company":"G & W Laboratories Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"G & W Laboratories Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"G & W Laboratories Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"G & W Laboratories Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Eupraxia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"EP-104IAR","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Eupraxia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eupraxia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eupraxia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EsoCap","sponsor":"FGK Clinical Research | FGK Representative Service","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"ESO-101","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"EsoCap","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"EsoCap \/ FGK Clinical Research | FGK Representative Service","highestDevelopmentStatusID":"8","companyTruncated":"EsoCap \/ FGK Clinical Research | FGK Representative Service"},{"orgOrder":0,"company":"Eupraxia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Eupraxia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eupraxia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eupraxia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eupraxia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Eupraxia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eupraxia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eupraxia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eupraxia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Steroid","year":"2025","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Eupraxia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eupraxia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eupraxia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eupraxia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Eupraxia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eupraxia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eupraxia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eupraxia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Steroid","year":"2024","type":"Private Placement","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Eupraxia Pharmaceuticals","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"Eupraxia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eupraxia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eupraxia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Steroid","year":"2025","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Eupraxia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eupraxia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eupraxia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ellodi Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ellodi Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Ellodi Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ellodi Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ellodi Pharmaceuticals","sponsor":"TPG Capital IP","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ellodi Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Ellodi Pharmaceuticals \/ TPG Capital IP","highestDevelopmentStatusID":"10","companyTruncated":"Ellodi Pharmaceuticals \/ TPG Capital IP"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Halobetasol","moa":"||Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Citius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Citius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Faes Farma","sponsor":"Dynamic Science","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SPAIN","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Faes Farma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Faes Farma \/ Dynamic Science","highestDevelopmentStatusID":"10","companyTruncated":"Faes Farma \/ Dynamic Science"},{"orgOrder":0,"company":"Endeavor Health","sponsor":"University of Chicago","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Steroid","year":"2010","type":"Inapplicable","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Endeavor Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Endeavor Health \/ University of Chicago","highestDevelopmentStatusID":"1","companyTruncated":"Endeavor Health \/ University of Chicago"},{"orgOrder":0,"company":"Nivagen Pharmaceuticals Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Hydrocortisone Acetate","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Nivagen Pharmaceuticals Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"Nivagen Pharmaceuticals Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nivagen Pharmaceuticals Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Cristcot","sponsor":"Cristcot","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydrocortisone Acetate","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Cristcot","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"Cristcot \/ Cristcot","highestDevelopmentStatusID":"10","companyTruncated":"Cristcot \/ Cristcot"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Hydrocortisone Acetate","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Citius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Citius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EsoCap","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"EsoCap","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"EsoCap \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EsoCap \/ Undisclosed"},{"orgOrder":0,"company":"EsoCap","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"EsoCap","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"EsoCap \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EsoCap \/ Undisclosed"},{"orgOrder":0,"company":"EsoCap","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"EsoCap","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"EsoCap \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EsoCap \/ Undisclosed"},{"orgOrder":0,"company":"AdventHealth","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Steroid","year":"2014","type":"Inapplicable","leadProduct":"Prednisone","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"AdventHealth","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AdventHealth \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AdventHealth \/ Undisclosed"},{"orgOrder":0,"company":"MidAmerica Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"MidAmerica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Paste","sponsorNew":"MidAmerica Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"MidAmerica Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Per Hellstr\u00f6m","sponsor":"Biohit | University of Helsinki | \u00c5bo Akademi University | CTC Clinical Trial Consultants","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Amino Acid","year":"2015","type":"Inapplicable","leadProduct":"L-Cysteine","moa":"Glutamate--cysteine ligase regulatory subunit; Glutamate--cysteine ligase catalytic subunit; Aspartate aminotransferase, cytoplasmic; Aspartate aminotransferase, mitochondrial; Cystathionine gamma-lyase; Cystathionine beta-synthase; Cysteine--tRNA ligase, cytoplasmic; Methylated-DNA--protein-cysteine methyltransferase; Glutathione synthetase; Probable cysteine--tRNA ligase, mitochondrial; Cysteine sulfinic acid decarboxylase; Cysteine desulfurase; Cysteine dioxygenase type 1","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Per Hellstr\u00f6m","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Per Hellstr\u00f6m \/ Biohit | University of Helsinki | \u00c5bo Akademi University | CTC Clinical Trial Consultants","highestDevelopmentStatusID":"8","companyTruncated":"Per Hellstr\u00f6m \/ Biohit | University of Helsinki | \u00c5bo Akademi University | CTC Clinical Trial Consultants"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"BL-7010","moa":"Gluten","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioLineRx \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioLineRx \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"TAK-062","moa":"Gluten","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"PvP Biologics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Acquisition","leadProduct":"TAK-062","moa":"Gluten","graph1":"Gastroenterology","graph2":"Phase I","graph3":"PvP Biologics","amount2":0.33000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0.33000000000000002,"dosageForm":"Undisclosed","sponsorNew":"PvP Biologics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"PvP Biologics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Basque Health Service","sponsor":"Osakidetza","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SPAIN","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Platelet Rich Plasma","moa":"Growth factor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Basque Health Service","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Dressing","sponsorNew":"Basque Health Service \/ Osakidetza","highestDevelopmentStatusID":"10","companyTruncated":"Basque Health Service \/ Osakidetza"},{"orgOrder":0,"company":"Northwestern University","sponsor":"Northwestern Memorial Hospital | EMD Serono","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Hormone","year":"2011","type":"Inapplicable","leadProduct":"Somatropin","moa":"Growth hormone receptor","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Northwestern University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northwestern University \/ Northwestern Memorial Hospital | EMD Serono","highestDevelopmentStatusID":"11","companyTruncated":"Northwestern University \/ Northwestern Memorial Hospital | EMD Serono"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Guanylate cyclase C||Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Peptide, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Guanylate cyclase C","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Ironwood Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Ironwood Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Ironwood Pharmaceuticals"},{"orgOrder":0,"company":"Augusta University","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Augusta University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Augusta University \/ Forest Laboratories","highestDevelopmentStatusID":"1","companyTruncated":"Augusta University \/ Forest Laboratories"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Manchester University NHS FT","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ironwood Pharmaceuticals \/ Manchester University NHS FT","highestDevelopmentStatusID":"15","companyTruncated":"Ironwood Pharmaceuticals \/ Manchester University NHS FT"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ironwood Pharmaceuticals \/ Forest Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Ironwood Pharmaceuticals \/ Forest Laboratories"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ironwood Pharmaceuticals \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Ironwood Pharmaceuticals \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Ironwood Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Ironwood Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Ironwood Pharmaceuticals"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Ironwood Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Ironwood Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Ironwood Pharmaceuticals"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ironwood Pharmaceuticals \/ Forest Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Ironwood Pharmaceuticals \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Ironwood Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forest Laboratories \/ Ironwood Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Forest Laboratories \/ Ironwood Pharmaceuticals"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Ironwood Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Ironwood Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Ironwood Pharmaceuticals"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ironwood Pharmaceuticals \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Ironwood Pharmaceuticals \/ AbbVie Inc"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ironwood Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ironwood Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ironwood Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ironwood Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ironwood Pharmaceuticals \/ Allergan Aesthetics","highestDevelopmentStatusID":"15","companyTruncated":"Ironwood Pharmaceuticals \/ Allergan Aesthetics"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Assia Chemical Industries Ltd","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Agreement","leadProduct":"Linaclotide","moa":"Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ironwood Pharmaceuticals \/ Assia Chemical Industries Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Ironwood Pharmaceuticals \/ Assia Chemical Industries Ltd"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Agreement","leadProduct":"Linaclotide","moa":"Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allergan Aesthetics \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ironwood Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ironwood Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Ironwood Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Forest Laboratories \/ Ironwood Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Ironwood Pharmaceuticals"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Ironwood Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Forest Laboratories \/ Ironwood Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Ironwood Pharmaceuticals"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Ironwood Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Forest Laboratories \/ Ironwood Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Ironwood Pharmaceuticals"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Ironwood Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Forest Laboratories \/ Ironwood Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Ironwood Pharmaceuticals"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Ironwood Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Peptide, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allergan \/ Ironwood Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Allergan \/ Ironwood Pharmaceuticals"},{"orgOrder":0,"company":"Nordic Biotic Sp. z o.o.","sponsor":"Medical University of Lublin","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"POLAND","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Bifidobacterium Lactis","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Nordic Biotic Sp. z o.o.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nordic Biotic Sp. z o.o. \/ Medical University of Lublin","highestDevelopmentStatusID":"1","companyTruncated":"Nordic Biotic Sp. z o.o. \/ Medical University of Lublin"},{"orgOrder":0,"company":"Shandong University","sponsor":"Linyi People's Hospital | Taian City Central Hospital | EA Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Microorganism","year":"2015","type":"Inapplicable","leadProduct":"Clostridium Butyricum","moa":"Gut microbiome","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Shandong University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shandong University \/ Linyi People's Hospital | Taian City Central Hospital | EA Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Shandong University \/ Linyi People's Hospital | Taian City Central Hospital | EA Pharma"},{"orgOrder":0,"company":"Tsumura & Co","sponsor":"Cato Research","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Plant Extract\/Herbal","year":"2011","type":"Inapplicable","leadProduct":"Daikenchuto","moa":"Gut microbiome","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Tsumura & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Granules","sponsorNew":"Tsumura & Co \/ Cato Research","highestDevelopmentStatusID":"8","companyTruncated":"Tsumura & Co \/ Cato Research"},{"orgOrder":0,"company":"Tsumura & Co","sponsor":"Cato Research","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Plant Extract\/Herbal","year":"2010","type":"Inapplicable","leadProduct":"Daikenchuto","moa":"Gut microbiome","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Tsumura & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Granules","sponsorNew":"Tsumura & Co \/ Cato Research","highestDevelopmentStatusID":"8","companyTruncated":"Tsumura & Co \/ Cato Research"},{"orgOrder":0,"company":"Tsumura & Co","sponsor":"Cato Research","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Plant Extract\/Herbal","year":"2013","type":"Inapplicable","leadProduct":"Daikenchuto","moa":"Gut microbiome","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Tsumura & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Granules","sponsorNew":"Tsumura & Co \/ Cato Research","highestDevelopmentStatusID":"7","companyTruncated":"Tsumura & Co \/ Cato Research"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Diosmectite","moa":"Gut microbiome||Undisclosed","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Sachet","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Diosmectite","moa":"Gut microbiome","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"EnteroBiotix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"EBX-102-02","moa":"Gut microbiome","graph1":"Gastroenterology","graph2":"Phase II","graph3":"EnteroBiotix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"EnteroBiotix \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EnteroBiotix \/ Undisclosed"},{"orgOrder":0,"company":"EnteroBiotix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"EBX-102-02","moa":"Gut microbiome","graph1":"Gastroenterology","graph2":"Phase II","graph3":"EnteroBiotix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"EnteroBiotix \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EnteroBiotix \/ Undisclosed"},{"orgOrder":0,"company":"EnteroBiotix","sponsor":"Thairm Bio","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Probiotic","year":"2024","type":"Financing","leadProduct":"EBX-102-02","moa":"Gut microbiome","graph1":"Gastroenterology","graph2":"Phase II","graph3":"EnteroBiotix","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.029999999999999999,"dosageForm":"Capsule","sponsorNew":"EnteroBiotix \/ Thairm Bio","highestDevelopmentStatusID":"8","companyTruncated":"EnteroBiotix \/ Thairm Bio"},{"orgOrder":0,"company":"EnteroBiotix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"EBX-102-02","moa":"Gut microbiome","graph1":"Gastroenterology","graph2":"Phase II","graph3":"EnteroBiotix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"EnteroBiotix \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EnteroBiotix \/ Undisclosed"},{"orgOrder":0,"company":"Finch Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"FIN-524","moa":"Gut microbiome","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Finch Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Finch Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Finch Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bioma Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"LITHUANIA","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"Lactobacillus Acidophilus","moa":"||Gut Microbiome","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Bioma Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bioma Health \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bioma Health \/ Undisclosed"},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Gustave Roussy","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Collaboration","leadProduct":"NM-102","moa":"Gut microbiome","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"9 Meters Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"9 Meters Biopharma \/ Gustave Roussy","highestDevelopmentStatusID":"5","companyTruncated":"9 Meters Biopharma \/ Gustave Roussy"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"RHB-105","moa":"H. pylori\/Proton pump","graph1":"Gastroenterology","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Sinorda Biomedicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"14-C X842","moa":"H+\/K+ ATPase","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Jiangsu Sinorda Biomedicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Jiangsu Sinorda Biomedicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Sinorda Biomedicine \/ Undisclosed"},{"orgOrder":0,"company":"Livzon Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ilaprazole Sodium","moa":"H+\/K+ ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Livzon Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Livzon Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Livzon Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Dolcanatide","moa":"Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Peptide, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Plecanatide","moa":"Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Luoxin Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Plecanatide","moa":"Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Luoxin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Luoxin Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Luoxin Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Plecanatide","moa":"Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Peptide, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Plecanatide","moa":"Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bausch Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Health \/ Syneos Health"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Peptide, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Plecanatide","moa":"Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Peptide, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Plecanatide","moa":"Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Peptide, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Plecanatide","moa":"Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bausch Health \/ Parexel","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Health \/ Parexel"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Plecanatide","moa":"Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Salix Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Plecanatide","moa":"Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Salix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salix Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Salix Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Salix Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Plecanatide","moa":"Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Salix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salix Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Salix Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Peptide, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Plecanatide","moa":"Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Plecanatide","moa":"Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Plecanatide","moa":"Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Plecanatide","moa":"Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"GB002","moa":"HIF-1-alpha","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Aadi Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aadi Bioscience \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aadi Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Aerpio Pharmaceuticals","sponsor":"Gossamer Bio","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"GB004","moa":"HIF-1-alpha","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Aerpio Pharmaceuticals","amount2":0.11,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0.11,"dosageForm":"Undisclosed","sponsorNew":"Aerpio Pharmaceuticals \/ Gossamer Bio","highestDevelopmentStatusID":"6","companyTruncated":"Aerpio Pharmaceuticals \/ Gossamer Bio"},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"GB004","moa":"HIF-1-alpha","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Gossamer Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gossamer Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Gossamer Bio \/ Undisclosed"},{"orgOrder":0,"company":"RWTH Aachen University","sponsor":"Biotest","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Human Normal Immunoglobulin","moa":"High affinity immunoglobulin gamma Fc receptor I; Putative high affinity immunoglobulin gamma Fc receptor IB; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B; Complement C3; Complement C4-A; Complement C4-B; Complement C5","graph1":"Gastroenterology","graph2":"Phase II","graph3":"RWTH Aachen University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RWTH Aachen University \/ Biotest","highestDevelopmentStatusID":"8","companyTruncated":"RWTH Aachen University \/ Biotest"},{"orgOrder":0,"company":"Valenta Pharm JSC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"RUSSIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Doxylamine","moa":"Histamine H1 receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Valenta Pharm JSC","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Valenta Pharm JSC \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Valenta Pharm JSC \/ Undisclosed"},{"orgOrder":0,"company":"Marksans Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Famotidine","moa":"Histamine H2 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Marksans Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Marksans Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Marksans Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Wockhardt","sponsor":"Glenmark Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Miscellaneous","year":"2022","type":"Acquisition","leadProduct":"Famotidine","moa":"Histamine H2 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Wockhardt","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Wockhardt \/ Glenmark Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Wockhardt \/ Glenmark Pharmaceuticals"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Famotidine","moa":"Histamine H2 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Famotidine","moa":"Histamine H2 receptor","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dong-A ST Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Dong-A ST Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Akums Drugs & Pharmaceuticals Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Famotidine","moa":"||Histamine H2 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Akums Drugs & Pharmaceuticals Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akums Drugs & Pharmaceuticals Ltd \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Akums Drugs & Pharmaceuticals Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Camber Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Famotidine","moa":"Histamine H2 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Camber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Camber Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Camber Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Boryung Pharmaceutical Co., Ltd","sponsor":"Catholic University of Korea","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Lafutidine","moa":"Histamine H2 receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Boryung Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boryung Pharmaceutical Co., Ltd \/ Catholic University of Korea","highestDevelopmentStatusID":"6","companyTruncated":"Boryung Pharmaceutical Co., Ltd \/ Catholic University of Korea"},{"orgOrder":0,"company":"Boryung Pharmaceutical Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Lafutidine","moa":"Histamine H2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Boryung Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boryung Pharmaceutical Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boryung Pharmaceutical Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"ClostraBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sodium Butyrate","moa":"Histone deacetylase 1 (HDAC1)","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"ClostraBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ClostraBio \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"ClostraBio \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"GSK1322888","moa":"HIV-1 integrase","graph1":"Gastroenterology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lovastatin Lactone","moa":"HMG-CoA reductase","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theriva Biologics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Theriva Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Entero Therapeutics","sponsor":"Immunogenics","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Simvastatin","moa":"HMG-CoA reductase","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Entero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Entero Therapeutics \/ Immunogenics","highestDevelopmentStatusID":"6","companyTruncated":"Entero Therapeutics \/ Immunogenics"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"SYN-010","moa":"HMG-CoA reductase","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theriva Biologics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Theriva Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"SYN-010","moa":"HMG-CoA reductase","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theriva Biologics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Theriva Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Cedars-Sinai","sponsor":"Theriva Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"SYN-010","moa":"HMG-CoA reductase","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Cedars-Sinai","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cedars-Sinai \/ Theriva Biologics","highestDevelopmentStatusID":"8","companyTruncated":"Cedars-Sinai \/ Theriva Biologics"},{"orgOrder":0,"company":"Nabiqasim","sponsor":"Dow University of Health Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Disodium Hydrogen Phosphate","moa":"Homeostasis","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Nabiqasim","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Enema","sponsorNew":"Nabiqasim \/ Dow University of Health Sciences","highestDevelopmentStatusID":"11","companyTruncated":"Nabiqasim \/ Dow University of Health Sciences"},{"orgOrder":0,"company":"University of Aarhus","sponsor":"Qufora","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Macrogol","moa":"Homeostasis","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"University of Aarhus","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Aarhus \/ Qufora","highestDevelopmentStatusID":"1","companyTruncated":"University of Aarhus \/ Qufora"},{"orgOrder":0,"company":"University of Nottingham","sponsor":"Norgine","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Macrogol","moa":"Homeostasis","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"University of Nottingham","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Sachet","sponsorNew":"University of Nottingham \/ Norgine","highestDevelopmentStatusID":"11","companyTruncated":"University of Nottingham \/ Norgine"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Macrogol","moa":"Homeostasis","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Powder for Solution","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Macrogol","moa":"Homeostasis","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Northwell Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Macrogol","moa":"Homeostasis","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Northwell Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Northwell Health \/ Undisclosed"},{"orgOrder":0,"company":"Russian Academy of Medical Sciences","sponsor":"Dr. Falk Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"RUSSIA","productType":"Plant Extract\/Herbal","year":"2013","type":"Inapplicable","leadProduct":"Psyllium","moa":"Homeostasis","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Russian Academy of Medical Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Russian Academy of Medical Sciences \/ Dr. Falk Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Russian Academy of Medical Sciences \/ Dr. Falk Pharma"},{"orgOrder":0,"company":"Chang Gung Memorial Hospital","sponsor":"TTY BIOPHARM CO LTD","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"TAIWAN","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Sodium Alginate","moa":"Homeostasis","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Chang Gung Memorial Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Chang Gung Memorial Hospital \/ TTY BIOPHARM CO LTD","highestDevelopmentStatusID":"11","companyTruncated":"Chang Gung Memorial Hospital \/ TTY BIOPHARM CO LTD"},{"orgOrder":0,"company":"TTY BIOPHARM CO LTD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"TAIWAN","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Sodium Alginate","moa":"Homeostasis","graph1":"Gastroenterology","graph2":"Phase III","graph3":"TTY BIOPHARM CO LTD","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"TTY BIOPHARM CO LTD \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"TTY BIOPHARM CO LTD \/ Undisclosed"},{"orgOrder":0,"company":"Reckitt Benckiser","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Sodium Alginate","moa":"Homeostasis","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Reckitt Benckiser","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"Reckitt Benckiser \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Reckitt Benckiser \/ Undisclosed"},{"orgOrder":0,"company":"Reckitt Benckiser","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Sodium Alginate","moa":"Homeostasis","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Reckitt Benckiser","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"Reckitt Benckiser \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Reckitt Benckiser \/ Undisclosed"},{"orgOrder":0,"company":"Reckitt Benckiser","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Sodium Alginate","moa":"Homeostasis","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Reckitt Benckiser","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"Reckitt Benckiser \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Reckitt Benckiser \/ Undisclosed"},{"orgOrder":0,"company":"Reckitt Benckiser","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Sodium Alginate","moa":"Homeostasis","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Reckitt Benckiser","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"Reckitt Benckiser \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Reckitt Benckiser \/ Undisclosed"},{"orgOrder":0,"company":"Yuria-Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UKRAINE","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Sodium Lactate","moa":"Homeostasis","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Yuria-Pharm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yuria-Pharm \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Yuria-Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Children's Hospital of Philadelphia","sponsor":"Bracco","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2018","type":"Inapplicable","leadProduct":"Sulfur Hexafluoride Microspheres","moa":"Homeostasis","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Children's Hospital of Philadelphia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Children's Hospital of Philadelphia \/ Bracco","highestDevelopmentStatusID":"10","companyTruncated":"Children's Hospital of Philadelphia \/ Bracco"},{"orgOrder":0,"company":"Arbor Biotechnologies","sponsor":"Arch Ventures","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Series C Financing","leadProduct":"ABO-101","moa":"HS","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Arbor Biotechnologies","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.070000000000000007,"dosageForm":"Infusion","sponsorNew":"Arbor Biotechnologies \/ Arch Ventures","highestDevelopmentStatusID":"7","companyTruncated":"Arbor Biotechnologies \/ Arch Ventures"},{"orgOrder":0,"company":"Arbor Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"ABO-101","moa":"HS","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Arbor Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arbor Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Arbor Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Arbor Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"ABO-101","moa":"HS","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Arbor Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arbor Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Arbor Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Darvadstrocel","moa":"IFN-gamma","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Darvadstrocel","moa":"IFN-gamma","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Enthera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Ent001","moa":"IGFBP3\/TMEM219","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Enthera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enthera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Enthera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"MAS825","moa":"IL-1?","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"RPC4046","moa":"IL-13 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Calypso Biotech SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"CALY-002","moa":"IL-15 receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Calypso Biotech SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Calypso Biotech SA \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Calypso Biotech SA \/ Undisclosed"},{"orgOrder":0,"company":"Calypso Biotech SA","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2024","type":"Acquisition","leadProduct":"CALY-002","moa":"IL-15 receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Calypso Biotech SA","amount2":0.42999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0.42999999999999999,"dosageForm":"Infusion","sponsorNew":"Calypso Biotech SA \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Calypso Biotech SA \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Calypso Biotech SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"CALY-002","moa":"IL-15 receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Calypso Biotech SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Calypso Biotech SA \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Calypso Biotech SA \/ Undisclosed"},{"orgOrder":0,"company":"Equillium","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"EQ102","moa":"IL-15\/IL-21 receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Equillium \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Equillium \/ Undisclosed"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"KAN-101","moa":"IL-2 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Anokion SA \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Pfizer Inc"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"KAN-101","moa":"IL-2 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Anokion SA \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Pfizer Inc"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"KAN-101","moa":"IL-2 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Anokion SA \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Undisclosed"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"KAN-101","moa":"IL-2 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Anokion SA \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Undisclosed"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"KAN-101","moa":"IL-2 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Anokion SA \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Undisclosed"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"KAN-101","moa":"IL-2 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Anokion SA \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Undisclosed"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"KAN-101","moa":"IL-2 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Anokion SA \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Undisclosed"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"KAN-101","moa":"IL-2 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Anokion SA \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Undisclosed"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"KAN-101","moa":"IL-2 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Anokion SA \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Undisclosed"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"KAN-101","moa":"IL-2 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Anokion SA \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Undisclosed"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Financing","leadProduct":"KAN-101","moa":"IL-2 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Anokion SA \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Pfizer Inc"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Financing","leadProduct":"KAN-101","moa":"IL-2 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Anokion SA \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Pfizer Inc"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"KAN-101","moa":"IL-2 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Anokion SA \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"KAN-101","moa":"IL-2 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Anokion SA \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Undisclosed"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Kanyos Bio","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"KAN-101","moa":"IL-2 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Anokion SA \/ Kanyos Bio","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Kanyos Bio"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"KAN-101","moa":"IL-2 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Anokion SA \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Undisclosed"},{"orgOrder":0,"company":"Alivio Therapeutics","sponsor":"PureTech Health","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Protein","year":"2021","type":"Acquisition","leadProduct":"IL-22","moa":"||IL-22 receptor","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Alivio Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alivio Therapeutics \/ PureTech Health","highestDevelopmentStatusID":"4","companyTruncated":"Alivio Therapeutics \/ PureTech Health"},{"orgOrder":0,"company":"Spyre Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"SPY003","moa":"IL-23","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Spyre Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spyre Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Spyre Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"Icotrokinra","moa":"IL23R","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Protagonist Therapeutics","amount2":0.98999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0.98999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Protagonist Therapeutics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Protagonist Therapeutics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Olamkicept","moa":"IL-6 receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ferring Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ferring Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Olamkicept","moa":"IL-6 receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ferring Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ferring Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Synmosa","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"TAIWAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Elobixibat","moa":"Ileal bile acid transporter","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Synmosa","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Synmosa \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Synmosa \/ Undisclosed"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Elobixibat","moa":"Ileal bile acid transporter","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ferring Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Elobixibat","moa":"Ileal bile acid transporter","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ferring Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Elobixibat","moa":"Ileal bile acid transporter","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ferring Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Elobixibat","moa":"Ileal bile acid transporter","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ferring Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Financing","leadProduct":"Elobixibat","moa":"Ileal bile acid transporter","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0.11,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0.11,"dosageForm":"Undisclosed","sponsorNew":"Albireo Pharma \/ Hercules Capital","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Hercules Capital"},{"orgOrder":0,"company":"Skingenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Sesame Oil","moa":"Immune","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Skingenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Skingenix \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Skingenix \/ Undisclosed"},{"orgOrder":0,"company":"Mucosa innovations","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SPAIN","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Olive","moa":"Immune","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Mucosa innovations","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Mucosa innovations \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Mucosa innovations \/ Undisclosed"},{"orgOrder":0,"company":"Wecare Probiotics Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Wecare Probiotics Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Strip","sponsorNew":"Wecare Probiotics Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Wecare Probiotics Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Wecare Probiotics Co., Ltd.","sponsor":"Methodex","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Wecare Probiotics Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wecare Probiotics Co., Ltd. \/ Methodex","highestDevelopmentStatusID":"1","companyTruncated":"Wecare Probiotics Co., Ltd. \/ Methodex"},{"orgOrder":0,"company":"Wecare Probiotics Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Wecare Probiotics Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wecare Probiotics Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Wecare Probiotics Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Wecare Probiotics Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Wecare Probiotics Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wecare Probiotics Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Wecare Probiotics Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Wecare Probiotics Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Wecare Probiotics Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wecare Probiotics Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Wecare Probiotics Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Wecare Probiotics Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Wecare Probiotics Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wecare Probiotics Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Wecare Probiotics Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Wecare Probiotics Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Wecare Probiotics Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wecare Probiotics Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Wecare Probiotics Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Universitaire Ziekenhuizen KU Leuven","sponsor":"My Health","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"BELGIUM","productType":"Probiotic","year":"2019","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Universitaire Ziekenhuizen KU Leuven","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Universitaire Ziekenhuizen KU Leuven \/ My Health","highestDevelopmentStatusID":"1","companyTruncated":"Universitaire Ziekenhuizen KU Leuven \/ My Health"},{"orgOrder":0,"company":"Danisco","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Probiotic","year":"2012","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Danisco","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Danisco \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Danisco \/ Undisclosed"},{"orgOrder":0,"company":"Danisco","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Probiotic","year":"2011","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Danisco","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Danisco \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Danisco \/ Undisclosed"},{"orgOrder":0,"company":"Danisco","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Probiotic","year":"2012","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Danisco","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Danisco \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Danisco \/ Undisclosed"},{"orgOrder":0,"company":"University of Southern Denmark","sponsor":"Mejeribrugets ForskningsFond | Arla Foods","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Probiotic","year":"2010","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"University of Southern Denmark","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Southern Denmark \/ Mejeribrugets ForskningsFond | Arla Foods","highestDevelopmentStatusID":"1","companyTruncated":"University of Southern Denmark \/ Mejeribrugets ForskningsFond | Arla Foods"},{"orgOrder":0,"company":"University of Copenhagen","sponsor":"Actial Farmaceutica | Nutricia Inc","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Probiotic","year":"2018","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"University of Copenhagen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Copenhagen \/ Actial Farmaceutica | Nutricia Inc","highestDevelopmentStatusID":"1","companyTruncated":"University of Copenhagen \/ Actial Farmaceutica | Nutricia Inc"},{"orgOrder":0,"company":"Danisco","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Probiotic","year":"2019","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Danisco","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Danisco \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Danisco \/ Undisclosed"},{"orgOrder":0,"company":"PrecisionBiotics Group Ltd.","sponsor":"Atlantia Food Clinical Trials Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"PrecisionBiotics Group Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PrecisionBiotics Group Ltd. \/ Atlantia Food Clinical Trials Ltd.","highestDevelopmentStatusID":"7","companyTruncated":"PrecisionBiotics Group Ltd. \/ Atlantia Food Clinical Trials Ltd."},{"orgOrder":0,"company":"Wageningen University and Research","sponsor":"Ministery of Economic affairs | Nexira | Wecare | Roquette Freres | Ingredion Pharma Solutions | Ingredia S.A. | Naturex | Winclove Probiotics B.V. | Bioiberica | Darling Ingredients","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Wageningen University and Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wageningen University and Research \/ Ministery of Economic affairs | Nexira | Wecare | Roquette Freres | Ingredion Pharma Solutions | Ingredia S.A. | Naturex | Winclove Probiotics B.V. | Bioiberica | Darling Ingredients","highestDevelopmentStatusID":"1","companyTruncated":"Wageningen University and Research \/ Ministery of Economic affairs | Nexira | Wecare | Roquette Freres | Ingredion Pharma Solutions | Ingredia S.A. | Naturex | Winclove Probiotics B.V. | Bioiberica | Darling Ingredients"},{"orgOrder":0,"company":"Nordic Biotic Sp. z o.o.","sponsor":"Medical University of Lodz","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"POLAND","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Nordic Biotic Sp. z o.o.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nordic Biotic Sp. z o.o. \/ Medical University of Lodz","highestDevelopmentStatusID":"1","companyTruncated":"Nordic Biotic Sp. z o.o. \/ Medical University of Lodz"},{"orgOrder":0,"company":"AB Biotics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SPAIN","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"AB Biotics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AB Biotics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"AB Biotics \/ Undisclosed"},{"orgOrder":0,"company":"Probi AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2013","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Probi AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Probi AB \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Probi AB \/ Undisclosed"},{"orgOrder":0,"company":"Probi AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2014","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Probi AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Probi AB \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Probi AB \/ Undisclosed"},{"orgOrder":0,"company":"Probi AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2015","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Probi AB","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Probi AB \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Probi AB \/ Undisclosed"},{"orgOrder":0,"company":"Probi AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2016","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Probi AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Probi AB \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Probi AB \/ Undisclosed"},{"orgOrder":0,"company":"Probi AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2017","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Probi AB","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Probi AB \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Probi AB \/ Undisclosed"},{"orgOrder":0,"company":"Probi AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Probi AB","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Probi AB \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Probi AB \/ Undisclosed"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Probiotic","year":"2013","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Undisclosed"},{"orgOrder":0,"company":"Sprim Advanced Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2010","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Sprim Advanced Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sprim Advanced Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Sprim Advanced Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Nimble Science","sponsor":"LALLEMAND HEALTH SOLUTIONS","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Nimble Science","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nimble Science \/ Lallemand Health Solutions","highestDevelopmentStatusID":"1","companyTruncated":"Nimble Science \/ Lallemand Health Solutions"},{"orgOrder":0,"company":"CEN Biotech","sponsor":"PiLeJe","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"CEN Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CEN Biotech \/ PiLeJe","highestDevelopmentStatusID":"1","companyTruncated":"CEN Biotech \/ PiLeJe"},{"orgOrder":0,"company":"Penn State University","sponsor":"Dairy Management Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2011","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Penn State University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Penn State University \/ Dairy Management Inc.","highestDevelopmentStatusID":"6","companyTruncated":"Penn State University \/ Dairy Management Inc."},{"orgOrder":0,"company":"Archer Daniels Midland","sponsor":"Vizera d.o.o.","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Archer Daniels Midland","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Archer Daniels Midland \/ Vizera d.o.o.","highestDevelopmentStatusID":"1","companyTruncated":"Archer Daniels Midland \/ Vizera d.o.o."},{"orgOrder":0,"company":"Archer Daniels Midland","sponsor":"Analyze & Realize","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Archer Daniels Midland","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Archer Daniels Midland \/ Analyze & Realize","highestDevelopmentStatusID":"1","companyTruncated":"Archer Daniels Midland \/ Analyze & Realize"},{"orgOrder":0,"company":"Archer Daniels Midland","sponsor":"Analyze & Realize","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Archer Daniels Midland","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Archer Daniels Midland \/ Analyze & Realize","highestDevelopmentStatusID":"1","companyTruncated":"Archer Daniels Midland \/ Analyze & Realize"},{"orgOrder":0,"company":"LALLEMAND HEALTH SOLUTIONS","sponsor":"BioFortis","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Gastroenterology","graph2":"Phase II","graph3":"LALLEMAND HEALTH SOLUTIONS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Sachet","sponsorNew":"LALLEMAND HEALTH SOLUTIONS \/ BioFortis","highestDevelopmentStatusID":"8","companyTruncated":"LALLEMAND HEALTH SOLUTIONS \/ BioFortis"},{"orgOrder":0,"company":"Archer Daniels Midland","sponsor":"Atlantia Food Clinical Trials | Vedic Lifesciences Pvt. Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Archer Daniels Midland","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Sachet","sponsorNew":"Archer Daniels Midland \/ Atlantia Food Clinical Trials | Vedic Lifesciences Pvt. Ltd.","highestDevelopmentStatusID":"1","companyTruncated":"Archer Daniels Midland \/ Atlantia Food Clinical Trials | Vedic Lifesciences Pvt. Ltd."},{"orgOrder":0,"company":"KGK Science","sponsor":"UAS Labs LLC","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Probiotic","year":"2015","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Gastroenterology","graph2":"Phase II","graph3":"KGK Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KGK Science \/ UAS Labs LLC","highestDevelopmentStatusID":"8","companyTruncated":"KGK Science \/ UAS Labs LLC"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Winclove Bio Industries BV","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2017","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Winclove Bio Industries BV","highestDevelopmentStatusID":"1","companyTruncated":"Massachusetts General Hospital \/ Winclove Bio Industries BV"},{"orgOrder":0,"company":"Wang Hua","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Probiotic","year":"2014","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Wang Hua","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wang Hua \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Wang Hua \/ Undisclosed"},{"orgOrder":0,"company":"Rael","sponsor":"Citruslabs","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Rael","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rael \/ Citruslabs","highestDevelopmentStatusID":"1","companyTruncated":"Rael \/ Citruslabs"},{"orgOrder":0,"company":"Ritter Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"RP-G28","moa":"Immune","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ritter Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Ritter Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ritter Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ritter Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"RP-G28","moa":"Immune","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ritter Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ritter Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ritter Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ritter Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"RP-G28","moa":"Immune","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ritter Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ritter Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ritter Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ritter Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"RP-G28","moa":"Immune","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ritter Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ritter Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ritter Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ziauddin University","sponsor":"Hilton Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"PAKISTAN","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Saccharomyces Cerevisiae","moa":"Immune","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Ziauddin University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ziauddin University \/ Hilton Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Ziauddin University \/ Hilton Pharma"},{"orgOrder":0,"company":"Santalis Pharmaceuticals","sponsor":"University of Texas Health Science Center at San Antonio","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2015","type":"Inapplicable","leadProduct":"Sandalwood Oil","moa":"Immune","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Santalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Gargle\/Mouthwash","sponsorNew":"Santalis Pharmaceuticals \/ University of Texas Health Science Center at San Antonio","highestDevelopmentStatusID":"8","companyTruncated":"Santalis Pharmaceuticals \/ University of Texas Health Science Center at San Antonio"},{"orgOrder":0,"company":"Infan Industria Quimica Farmaceutica","sponsor":"Hospital Universit\u00e1rio Oswaldo Cruz","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"BRAZIL","productType":"Plant Extract\/Herbal","year":"2019","type":"Inapplicable","leadProduct":"Schinus Terebinthifolia Raddi","moa":"Immune","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infan Industria Quimica Farmaceutica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Infan Industria Quimica Farmaceutica \/ Hospital Universit\u00e1rio Oswaldo Cruz","highestDevelopmentStatusID":"10","companyTruncated":"Infan Industria Quimica Farmaceutica \/ Hospital Universit\u00e1rio Oswaldo Cruz"},{"orgOrder":0,"company":"Jiangsu Famous Medical Technology","sponsor":"Affiliated Hospital of Nanjing University of Chinese Medicine | Guangdong Provincial Hospital of Traditional Chinese Medicine | Shanghai University of Traditional Chinese Medicine | ShuGuang Hospital | The First Affiliated Hospital, Guangzhou University o","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2018","type":"Inapplicable","leadProduct":"Shenbai","moa":"Immune","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Famous Medical Technology","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Famous Medical Technology \/ Affiliated Hospital of Nanjing University of Chinese Medicine | Guangdong Provincial Hospital of Traditional Chinese Medicine | Shanghai University of Traditional Chinese Medicine | ShuGuang Hospital | The First Affiliated Hospital, Guangzhou University o","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Famous Medical Technology \/ Affiliated Hospital of Nanjing University of Chinese Medicine | Guangdong Provincial Hospital of Traditional Chinese Medicine | Shanghai University of Traditional Chinese Medicine | ShuGuang Hospital | The First Affiliated Hospital, Guangzhou University o"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Stillen","moa":"Immune","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dong-A ST Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Dong-A ST Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"EC-18","moa":"immunomodulators","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Enzychem Lifesciences Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enzychem Lifesciences Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Enzychem Lifesciences Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Mosedipimod","moa":"immunomodulators","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Enzychem Lifesciences Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Enzychem Lifesciences Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Enzychem Lifesciences Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Mosedipimod","moa":"immunomodulators","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Enzychem Lifesciences Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Enzychem Lifesciences Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Enzychem Lifesciences Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Mosedipimod","moa":"immunomodulators","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Enzychem Lifesciences Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Enzychem Lifesciences Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Enzychem Lifesciences Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Mosedipimod","moa":"immunomodulators","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Enzychem Lifesciences Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Enzychem Lifesciences Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Enzychem Lifesciences Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Mosedipimod","moa":"immunomodulators","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Enzychem Lifesciences Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Enzychem Lifesciences Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Enzychem Lifesciences Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Mosedipimod","moa":"immunomodulators","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Enzychem Lifesciences Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Enzychem Lifesciences Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Enzychem Lifesciences Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Mosedipimod","moa":"immunomodulators","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Enzychem Lifesciences Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Enzychem Lifesciences Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Enzychem Lifesciences Corporation \/ Undisclosed"},{"orgOrder":0,"company":"SciClone Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"SCV-07","moa":"immunomodulators","graph1":"Gastroenterology","graph2":"Phase II","graph3":"SciClone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SciClone Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SciClone Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NIN Institute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Inulin","moa":"Insulin (INS)","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"NIN Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NIN Institute \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"NIN Institute \/ Undisclosed"},{"orgOrder":0,"company":"SC Fiterman Pharma SRL","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ROMANIA","productType":"Dietary Supplement","year":"2017","type":"Inapplicable","leadProduct":"Inulin","moa":"Insulin (INS)","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"SC Fiterman Pharma SRL","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SC Fiterman Pharma SRL \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"SC Fiterman Pharma SRL \/ Undisclosed"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"E6007","moa":"Integrin ?4","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eisai Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eisai Inc \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"AGA Clinical Research Associates","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Gastroenterology","graph2":"Phase II","graph3":"AGA Clinical Research Associates","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AGA Clinical Research Associates \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"AGA Clinical Research Associates \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Dana-Farber Cancer Institute | Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Massachusetts General Hospital \/ Dana-Farber Cancer Institute | Takeda Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Massachusetts General Hospital \/ Dana-Farber Cancer Institute | Takeda Pharmaceutical"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"MORF-057","moa":"Integrin alpha-4\/beta-7 (ITGA4\/B7)","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Morphic Therapeutic \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Undisclosed"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"MORF-057","moa":"Integrin alpha-4\/beta-7 (ITGA4\/B7)","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Morphic Therapeutic \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Undisclosed"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"MORF-057","moa":"Integrin alpha-4\/beta-7 (ITGA4\/B7)","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Morphic Therapeutic \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Undisclosed"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"MORF-057","moa":"Integrin alpha-4\/beta-7 (ITGA4\/B7)","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":3.2000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":3.2000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Morphic Therapeutic \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Eli Lilly"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"MORF-057","moa":"Integrin alpha-4\/beta-7 (ITGA4\/B7)","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0.23999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.28000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Morphic Therapeutic \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Jefferies"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"MORF-057","moa":"Integrin alpha-4\/beta-7 (ITGA4\/B7)","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Morphic Therapeutic \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Undisclosed"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"MORF-057","moa":"Integrin alpha-4\/beta-7 (ITGA4\/B7)","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0.28000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.28000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Morphic Therapeutic \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Jefferies"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"MORF-057","moa":"Integrin alpha-4\/beta-7 (ITGA4\/B7)","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Morphic Therapeutic \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Undisclosed"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"MORF-057","moa":"Integrin alpha-4\/beta-7 (ITGA4\/B7)","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Morphic Therapeutic \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Undisclosed"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"MORF-057","moa":"Integrin alpha-4\/beta-7 (ITGA4\/B7)","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Morphic Therapeutic \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Undisclosed"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"MORF-057","moa":"Integrin alpha-4\/beta-7 (ITGA4\/B7)","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Morphic Therapeutic \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Undisclosed"},{"orgOrder":0,"company":"EA Pharma","sponsor":"Ensho Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"NSHO-101","moa":"Integrin-alpha-4\/beta-7","graph1":"Gastroenterology","graph2":"Phase I","graph3":"EA Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EA Pharma \/ Ensho Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"EA Pharma \/ Ensho Therapeutics"},{"orgOrder":0,"company":"EA Pharma","sponsor":"Ensho Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"NSHO-101","moa":"Integrin-alpha-4\/beta-7","graph1":"Gastroenterology","graph2":"Phase I","graph3":"EA Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EA Pharma \/ Ensho Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"EA Pharma \/ Ensho Therapeutics"},{"orgOrder":0,"company":"Atlantic Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Oligonucleotide","year":"2018","type":"Inapplicable","leadProduct":"Alicaforsen","moa":"Intercellular adhesion molecule-1 mRNA 3'UTR","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Atlantic Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Atlantic Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Atlantic Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"CC-93538","moa":"Interleukin-13","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"CC-93538","moa":"Interleukin-13","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"CC-93538","moa":"Interleukin-13","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Cendakimab","moa":"Interleukin-13","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"AMG714","moa":"Interleukin-15","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"AMG714","moa":"Interleukin-15","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"AMG714","moa":"Interleukin-15","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ordesekimab","moa":"Interleukin-15","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"PRV-015","moa":"Interleukin-15","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Celiac Disease Foundation","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Partnership","leadProduct":"PRV-015","moa":"Interleukin-15","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Celiac Disease Foundation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celiac Disease Foundation \/ Provention Bio","highestDevelopmentStatusID":"8","companyTruncated":"Celiac Disease Foundation \/ Provention Bio"},{"orgOrder":0,"company":"Beyond Celiac","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Partnership","leadProduct":"PRV-015","moa":"Interleukin-15","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Beyond Celiac","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Beyond Celiac \/ Provention Bio","highestDevelopmentStatusID":"8","companyTruncated":"Beyond Celiac \/ Provention Bio"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"University of North Carolina","sponsor":"Regeneron Pharmaceuticals | Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"University of North Carolina","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of North Carolina \/ Regeneron Pharmaceuticals | Sanofi","highestDevelopmentStatusID":"11","companyTruncated":"University of North Carolina \/ Regeneron Pharmaceuticals | Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"University of California, San Diego","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"University of California, San Diego","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of California, San Diego \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"University of California, San Diego \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"UNC School of Medicine","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"UNC School of Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UNC School of Medicine \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"UNC School of Medicine \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Children's Hospital Medical Center, Cincinnati","sponsor":"Regeneron Pharmaceuticals | National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Children's Hospital Medical Center, Cincinnati","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Children's Hospital Medical Center, Cincinnati \/ Regeneron Pharmaceuticals | National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Children's Hospital Medical Center, Cincinnati \/ Regeneron Pharmaceuticals | National Institutes of Health"},{"orgOrder":0,"company":"Children's Hospital of Philadelphia","sponsor":"Regeneron Pharmaceuticals | Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Children's Hospital of Philadelphia","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Hospital of Philadelphia \/ Regeneron Pharmaceuticals | Sanofi","highestDevelopmentStatusID":"11","companyTruncated":"Children's Hospital of Philadelphia \/ Regeneron Pharmaceuticals | Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"University of North Carolina","sponsor":"GSK | University of Utah | Northwestern University | MNGI Digestive Health","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Mepolizumab","moa":"Interleukin-5","graph1":"Gastroenterology","graph2":"Phase II","graph3":"University of North Carolina","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of North Carolina \/ GSK | University of Utah | Northwestern University | MNGI Digestive Health","highestDevelopmentStatusID":"8","companyTruncated":"University of North Carolina \/ GSK | University of Utah | Northwestern University | MNGI Digestive Health"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Benralizumab","moa":"Interleukin-5 receptor subunit alpha","graph1":"Gastroenterology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Benralizumab","moa":"Interleukin-5 receptor subunit alpha","graph1":"Gastroenterology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Benralizumab","moa":"Interleukin-5 receptor subunit alpha","graph1":"Gastroenterology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Benralizumab","moa":"Interleukin-5 receptor subunit alpha","graph1":"Gastroenterology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Children's Hospital Medical Center, Cincinnati","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Benralizumab","moa":"Interleukin-5 receptor subunit alpha","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Children's Hospital Medical Center, Cincinnati","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Children's Hospital Medical Center, Cincinnati \/ AstraZeneca","highestDevelopmentStatusID":"9","companyTruncated":"Children's Hospital Medical Center, Cincinnati \/ AstraZeneca"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"ALD518","moa":"Interleukin-6","graph1":"Gastroenterology","graph2":"Phase II","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSL Behring \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CSL Behring \/ Undisclosed"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Spaulding Clinical, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"SYN-020","moa":"Intestinal alkaline phosphatase","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Theriva Biologics \/ Spaulding Clinical, LLC","highestDevelopmentStatusID":"6","companyTruncated":"Theriva Biologics \/ Spaulding Clinical, LLC"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Spaulding Clinical, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"SYN-020","moa":"Intestinal alkaline phosphatase","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Theriva Biologics \/ Spaulding Clinical, LLC","highestDevelopmentStatusID":"6","companyTruncated":"Theriva Biologics \/ Spaulding Clinical, LLC"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"SYN-020","moa":"Intestinal alkaline phosphatase","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Theriva Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Theriva Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"SYN-020","moa":"Intestinal alkaline phosphatase","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theriva Biologics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Theriva Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"SYN-020","moa":"Intestinal alkaline phosphatase","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theriva Biologics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Theriva Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Immunic Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"IMU-856","moa":"Intestinal barrier function","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daiichi Sankyo \/ Immunic Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Daiichi Sankyo \/ Immunic Therapeutics"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"IMU-856","moa":"Intestinal barrier function","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Immunic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Immunic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"IMU-856","moa":"Intestinal barrier function","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Immunic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Immunic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"IMU-856","moa":"Intestinal barrier function","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Immunic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Immunic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"IMU-856","moa":"Intestinal barrier function","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Immunic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Immunic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"IMU-856","moa":"Intestinal barrier function","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Immunic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Immunic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"IMU-856","moa":"Intestinal barrier function","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Immunic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pharmacosmos AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2011","type":"Inapplicable","leadProduct":"Ferric Derisomaltose","moa":"Iron","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Pharmacosmos AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmacosmos AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pharmacosmos AS \/ Undisclosed"},{"orgOrder":0,"company":"Medical University of Warsaw","sponsor":"Pharmabest Sp. z o.o.","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"POLAND","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Bovine Lactoferrin","moa":"Iron","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Medical University of Warsaw","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medical University of Warsaw \/ Pharmabest Sp. z o.o.","highestDevelopmentStatusID":"8","companyTruncated":"Medical University of Warsaw \/ Pharmabest Sp. z o.o."},{"orgOrder":0,"company":"Pharmacosmos AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2018","type":"Inapplicable","leadProduct":"Iron Isomaltoside","moa":"Iron","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Pharmacosmos AS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacosmos AS \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pharmacosmos AS \/ Undisclosed"},{"orgOrder":0,"company":"Pharmacosmos AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2012","type":"Inapplicable","leadProduct":"Iron Isomaltoside","moa":"Iron","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Pharmacosmos AS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacosmos AS \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pharmacosmos AS \/ Undisclosed"},{"orgOrder":0,"company":"Pharmacosmos AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Iron Isomaltoside 1000","moa":"Iron","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Pharmacosmos AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmacosmos AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pharmacosmos AS \/ Undisclosed"},{"orgOrder":0,"company":"JIANGSU VCARE PHARMATECH CO., LTD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"VC005","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"JIANGSU VCARE PHARMATECH CO., LTD","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"JIANGSU VCARE PHARMATECH CO., LTD \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"JIANGSU VCARE PHARMATECH CO., LTD \/ Undisclosed"},{"orgOrder":0,"company":"JIANGSU VCARE PHARMATECH CO., LTD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"VC005","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"JIANGSU VCARE PHARMATECH CO., LTD","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"JIANGSU VCARE PHARMATECH CO., LTD \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"JIANGSU VCARE PHARMATECH CO., LTD \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"TD-1473","moa":"Janus Kinase (JAK)","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"TD-1473","moa":"Janus Kinase (JAK)","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"TD-1473","moa":"Janus Kinase (JAK)","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"TD-1473","moa":"Janus Kinase (JAK)","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Biora Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0.01,"dosageForm":"Capsule, Liquid Filled","sponsorNew":"Biora Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"4","companyTruncated":"Biora Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Biora Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0.01,"dosageForm":"Capsule, Liquid Filled","sponsorNew":"Biora Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"4","companyTruncated":"Biora Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Tioga Pharmaceuticals","sponsor":"RTI Health Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Asimadoline","moa":"Kappa opioid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Tioga Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tioga Pharmaceuticals \/ RTI Health Solutions","highestDevelopmentStatusID":"10","companyTruncated":"Tioga Pharmaceuticals \/ RTI Health Solutions"},{"orgOrder":0,"company":"Xuanzhu Biopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Anaprazole Sodium","moa":"K-ATPase","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Xuanzhu Biopharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Xuanzhu Biopharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Xuanzhu Biopharm \/ Undisclosed"},{"orgOrder":0,"company":"Sihuan Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Anaprazole Sodium","moa":"K-ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Sihuan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sihuan Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sihuan Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Sihuan Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Anaprazole Sodium","moa":"K-ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Sihuan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sihuan Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sihuan Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Sihuan Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Anaprazole Sodium","moa":"K-ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Sihuan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sihuan Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sihuan Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Sihuan Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Anaprazole Sodium","moa":"K-ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Sihuan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sihuan Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sihuan Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Yuhan Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"YH4808","moa":"K-ATPase","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Yuhan Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Yuhan Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Yuhan Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Mozart Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"MTX-101","moa":"KIR dependent CD8 T-cell","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Mozart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mozart Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Mozart Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Mozart Therapeutics","sponsor":"Pfizer Ventures","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Series A Financing","leadProduct":"MTX-101","moa":"KIR dependent CD8 T-cell","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Mozart Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Mozart Therapeutics \/ Pfizer Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Mozart Therapeutics \/ Pfizer Ventures"},{"orgOrder":0,"company":"Mozart Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"MTX-101","moa":"KIR dependent CD8 T-cell","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Mozart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mozart Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Mozart Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"KIT","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celldex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"KIT","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celldex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BiomX","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"BX003","moa":"Klebsiella pneumoniae","graph1":"Gastroenterology","graph2":"Phase I","graph3":"BiomX","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BiomX \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BiomX \/ Undisclosed"},{"orgOrder":0,"company":"BiomX","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Microorganism","year":"2022","type":"Collaboration","leadProduct":"BX003","moa":"Klebsiella pneumoniae","graph1":"Gastroenterology","graph2":"Phase I","graph3":"BiomX","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BiomX \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"6","companyTruncated":"BiomX \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Clasado Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Carbohydrate","year":"2016","type":"Inapplicable","leadProduct":"Galacto-Oligosaccharide","moa":"Lactase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Clasado Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clasado Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Clasado Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Ritter Pharmaceuticals","sponsor":"Qualigen Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Carbohydrate","year":"2020","type":"Merger","leadProduct":"Galacto-Oligosaccharide","moa":"Lactase","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Ritter Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ritter Pharmaceuticals \/ Qualigen Therapeutics","highestDevelopmentStatusID":"9","companyTruncated":"Ritter Pharmaceuticals \/ Qualigen Therapeutics"},{"orgOrder":0,"company":"NImmune Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Omilancor","moa":"LANCL2\/MAP2K6","graph1":"Gastroenterology","graph2":"Phase I","graph3":"NImmune Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NImmune Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"NImmune Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Cara Care","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Hyoscine Butyl Bromide","moa":"M3 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Cara Care","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cara Care \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Cara Care \/ Sanofi"},{"orgOrder":0,"company":"The Third Xiangya Hospital of Central South University","sponsor":"Livzon Pharmaceutical Group Inc | Yung Shin Pharm Industrial","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Doxycycline Hyclate","moa":"Matrix metalloproteinase 8 | Matrix metalloproteinase 13 | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Bacterial 70S ribosome","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"The Third Xiangya Hospital of Central South University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"The Third Xiangya Hospital of Central South University \/ Livzon Pharmaceutical Group Inc | Yung Shin Pharm Industrial","highestDevelopmentStatusID":"11","companyTruncated":"The Third Xiangya Hospital of Central South University \/ Livzon Pharmaceutical Group Inc | Yung Shin Pharm Industrial"},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"PAS-004","moa":"MEK1\/2 receptor","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Pasithea Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pasithea Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Pasithea Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Bremelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Gastroenterology","graph2":"Phase I","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AMAG Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AMAG Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Spherium Biomed","sponsor":"Institut Catal\u00e0 d'Oncologia L'Hospitalet | Hospital Universitari de la Vall de Hebron | Hospital de la Santa Creu i Sant Pau | Institut Catal\u00e0 d'Oncologia ICO Girona | Institut Catal\u00e0 d'Oncologia ICO Badalona | Hospital Miguel Servet | Hospital Universita","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SPAIN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Spherium Biomed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spherium Biomed \/ Institut Catal\u00e0 d'Oncologia L'Hospitalet | Hospital Universitari de la Vall de Hebron | Hospital de la Santa Creu i Sant Pau | Institut Catal\u00e0 d'Oncologia ICO Girona | Institut Catal\u00e0 d'Oncologia ICO Badalona | Hospital Miguel Servet | Hospital Universita","highestDevelopmentStatusID":"7","companyTruncated":"Spherium Biomed \/ Institut Catal\u00e0 d'Oncologia L'Hospitalet | Hospital Universitari de la Vall de Hebron | Hospital de la Santa Creu i Sant Pau | Institut Catal\u00e0 d'Oncologia ICO Girona | Institut Catal\u00e0 d'Oncologia ICO Badalona | Hospital Miguel Servet | Hospital Universita"},{"orgOrder":0,"company":"Southern Arizona VA Health Care System","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Ramelteon","moa":"Melatonin receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Southern Arizona VA Health Care System","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Southern Arizona VA Health Care System \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Southern Arizona VA Health Care System \/ Undisclosed"},{"orgOrder":0,"company":"Locust Walk","sponsor":"Innovation Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Brilacidin","moa":"Membrane","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Locust Walk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Locust Walk \/ Innovation Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Locust Walk \/ Innovation Pharmaceuticals"},{"orgOrder":0,"company":"MARATHON PHARMS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"MP-101","moa":"Metabotropic glutamate receptor 2 (mGluR2)","graph1":"Gastroenterology","graph2":"Phase III","graph3":"MARATHON PHARMS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"MARATHON PHARMS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MARATHON PHARMS \/ Undisclosed"},{"orgOrder":0,"company":"MARATHON PHARMS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"MP-101","moa":"Metabotropic glutamate receptor 2 (mGluR2)","graph1":"Gastroenterology","graph2":"Phase III","graph3":"MARATHON PHARMS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"MARATHON PHARMS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MARATHON PHARMS \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"AZD2516","moa":"Metabotropic glutamate receptor 5","graph1":"Gastroenterology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Edetate Calcium Disodium","moa":"||Metal ion","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kane Biotech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Kane Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Reprocell","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Partnership","leadProduct":"HT-003","moa":"MNK1\/MNK2","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Reprocell","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Reprocell"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Isoprene Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"HT-003","moa":"MNK1\/MNK2","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Isoprene Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Isoprene Pharmaceuticals"},{"orgOrder":0,"company":"Enterome","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"EB1010","moa":"Monoamine transporter","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enterome \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"4","companyTruncated":"Enterome \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Abide Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"1,1,1,3,3,3-Hexafluoropropan-2-yl 4-[[2-pyrrolidin-1-yl-4-(trifluoromethyl)phenyl]methyl]piperazine-1-carboxylate","moa":"Monoglyceride lipase","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Abide Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abide Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Abide Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Camicinal","moa":"Motilin receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"GSK962040","moa":"Motilin receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"GSK962040","moa":"Motilin receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"GSK962040","moa":"Motilin receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"GSK962040","moa":"Motilin receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"GSK962040","moa":"Motilin receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"University of North Carolina","sponsor":"Allergan","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Eluxadoline","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"University of North Carolina","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of North Carolina \/ Allergan","highestDevelopmentStatusID":"8","companyTruncated":"University of North Carolina \/ Allergan"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"ADL5945","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"ADL5945","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"ALKS37","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alkermes Plc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alkermes Plc \/ Undisclosed"},{"orgOrder":0,"company":"University of Virginia","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Alvimopan","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"University of Virginia","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Virginia \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"University of Virginia \/ Merck & Co"},{"orgOrder":0,"company":"Medical College of Wisconsin","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Alvimopan","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Medical College of Wisconsin","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medical College of Wisconsin \/ Merck & Co","highestDevelopmentStatusID":"1","companyTruncated":"Medical College of Wisconsin \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"CB-5945","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"CB-5945","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"CB-5945","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"CB-5945","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Eluxadoline","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"Temple University","sponsor":"Allergan","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Eluxadoline","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Temple University","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Temple University \/ Allergan","highestDevelopmentStatusID":"9","companyTruncated":"Temple University \/ Allergan"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Eluxadoline","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Eluxadoline","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Eluxadoline","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Eluxadoline","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Eluxadoline","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Eluxadoline","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Eluxadoline","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Loperamide Hydrochloride","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zydus Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Loperamide Hydrochloride","moa":"||Mu opioid receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Granules India Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Loperamide Hydrochloride","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Naltrexone Methobromide","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Naltrexone Methobromide","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mayo Clinic \/ Pfizer Inc","highestDevelopmentStatusID":"11","companyTruncated":"Mayo Clinic \/ Pfizer Inc"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Lantheus Holding","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Naltrexone Methobromide","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bausch Health \/ Lantheus Holding","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Health \/ Lantheus Holding"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Naltrexone Methobromide","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Naltrexone Methobromide","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"GCS Ramsay Sant\u00e9","sponsor":"Euraxi Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Morphine Sulfate","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"GCS Ramsay Sant\u00e9","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GCS Ramsay Sant\u00e9 \/ Euraxi Pharma","highestDevelopmentStatusID":"10","companyTruncated":"GCS Ramsay Sant\u00e9 \/ Euraxi Pharma"},{"orgOrder":0,"company":"International University of Health and Welfare","sponsor":"Shionogi","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Naldemedine","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"International University of Health and Welfare","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"International University of Health and Welfare \/ Shionogi","highestDevelopmentStatusID":"11","companyTruncated":"International University of Health and Welfare \/ Shionogi"},{"orgOrder":0,"company":"Shionogi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Naldemedine","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Shionogi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shionogi \/ Undisclosed"},{"orgOrder":0,"company":"Shionogi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Naldemedine","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Shionogi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shionogi \/ Undisclosed"},{"orgOrder":0,"company":"Shionogi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Naldemedine","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shionogi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shionogi \/ Undisclosed"},{"orgOrder":0,"company":"Shionogi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Naldemedine","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shionogi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shionogi \/ Undisclosed"},{"orgOrder":0,"company":"Shionogi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Naldemedine","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shionogi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shionogi \/ Undisclosed"},{"orgOrder":0,"company":"Shionogi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Naldemedine","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shionogi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shionogi \/ Undisclosed"},{"orgOrder":0,"company":"Shionogi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Naldemedine","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shionogi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shionogi \/ Undisclosed"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Shionogi","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Naldemedine Tosylate","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Sandoz B2B \/ Shionogi","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Shionogi"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Naloxegol Oxalate","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyowa Kirin \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kyowa Kirin \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Naloxegol Oxalate","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Naloxegol Oxalate","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"TriHealth","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Naloxegol Oxalate","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"TriHealth","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Pill","sponsorNew":"TriHealth \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"TriHealth \/ Undisclosed"},{"orgOrder":0,"company":"Temple University","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Naloxegol Oxalate","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Temple University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Temple University \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Temple University \/ AstraZeneca"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Naloxegol Oxalate","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Massachusetts General Hospital \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Massachusetts General Hospital \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"RedHill Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Controlled Substance","year":"2020","type":"Agreement","leadProduct":"Naloxegol Oxalate","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daiichi Sankyo \/ RedHill Biopharma","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ RedHill Biopharma"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"RedHill Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Controlled Substance","year":"2021","type":"Partnership","leadProduct":"Naloxegol Oxalate","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cosmo Pharmaceuticals \/ RedHill Biopharma","highestDevelopmentStatusID":"15","companyTruncated":"Cosmo Pharmaceuticals \/ RedHill Biopharma"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Naloxegol Oxalate","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Apotex Inc","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Controlled Substance","year":"2021","type":"Licensing Agreement","leadProduct":"Naloxegol Oxalate","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"RedHill Biopharma \/ Apotex Inc","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Apotex Inc"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"HCR","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Naloxegol Oxalate","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"RedHill Biopharma \/ HCR","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ HCR"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Naloxegol Oxalate","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Valinor Pharma","sponsor":"Grunenthal","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Acquisition","leadProduct":"Naloxegol Oxalate","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Valinor Pharma","amount2":0.25,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0.25,"dosageForm":"Tablet","sponsorNew":"Valinor Pharma \/ Grunenthal","highestDevelopmentStatusID":"15","companyTruncated":"Valinor Pharma \/ Grunenthal"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Controlled Substance","year":"2016","type":"Inapplicable","leadProduct":"Naloxegol Oxalate","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Massachusetts General Hospital \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"Massachusetts General Hospital \/ AstraZeneca"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"RedHill Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2020","type":"Divestment","leadProduct":"Naloxegol Oxalate","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0.070000000000000007,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0.070000000000000007,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ RedHill Biopharma","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ RedHill Biopharma"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"RedHill Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2020","type":"Licensing Agreement","leadProduct":"Naloxegol Oxalate","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ RedHill Biopharma","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ RedHill Biopharma"},{"orgOrder":0,"company":"Noramco","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Naltrexone Methobromide","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Noramco","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Noramco \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Noramco \/ Undisclosed"},{"orgOrder":0,"company":"Salix Pharmaceuticals","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Naltrexone Methobromide","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Salix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Salix Pharmaceuticals \/ Bausch Health","highestDevelopmentStatusID":"15","companyTruncated":"Salix Pharmaceuticals \/ Bausch Health"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Naltrexone Methobromide","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Salix Pharmaceuticals","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Naltrexone Methobromide","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Salix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Salix Pharmaceuticals \/ Bausch Health","highestDevelopmentStatusID":"15","companyTruncated":"Salix Pharmaceuticals \/ Bausch Health"},{"orgOrder":0,"company":"Salix Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Naltrexone Methobromide","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Salix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Salix Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Salix Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Salix Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Naltrexone Methobromide","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Salix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Salix Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Salix Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"NKTR-118","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"NKTR-118","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"NKTR-118","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"NKTR-118","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"NKTR-118","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"NKTR-118","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Kuopio University Hospital","sponsor":"Admescope","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FINLAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Kuopio University Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Prolonged Release","sponsorNew":"Kuopio University Hospital \/ Admescope","highestDevelopmentStatusID":"11","companyTruncated":"Kuopio University Hospital \/ Admescope"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"TD-1211","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"TD-1211","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"TD-1211","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"TD-1211","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"OrphoMed","sponsor":"PPD","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"ORP-101","moa":"Mu opioid receptor | Kappa opioid receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"OrphoMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"OrphoMed \/ PPD","highestDevelopmentStatusID":"8","companyTruncated":"OrphoMed \/ PPD"},{"orgOrder":0,"company":"OrphoMed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"ORP-101","moa":"Mu opioid receptor | Kappa opioid receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"OrphoMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"OrphoMed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OrphoMed \/ Undisclosed"},{"orgOrder":0,"company":"OrphoMed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"ORP-101","moa":"Mu opioid receptor | Kappa opioid receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"OrphoMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"OrphoMed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OrphoMed \/ Undisclosed"},{"orgOrder":0,"company":"OrphoMed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ORP-101","moa":"Mu opioid receptor | Kappa opioid receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"OrphoMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"OrphoMed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OrphoMed \/ Undisclosed"},{"orgOrder":0,"company":"OrphoMed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ORP-101","moa":"Mu opioid receptor | Kappa opioid receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"OrphoMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"OrphoMed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OrphoMed \/ Undisclosed"},{"orgOrder":0,"company":"OrphoMed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"ORP-101","moa":"Mu opioid receptor | Kappa opioid receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"OrphoMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"OrphoMed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OrphoMed \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Plant Extract\/Herbal","year":"2013","type":"Inapplicable","leadProduct":"Iberogast","moa":"Multiple (motility, inflammation)","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Plant Extract\/Herbal","year":"2019","type":"Inapplicable","leadProduct":"Iberogast","moa":"Multiple (motility, inflammation)","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Hyoscine Butyl Bromide","moa":"Muscarinic acetylcholine receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Hyoscine Butyl Bromide","moa":"Muscarinic acetylcholine receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Hyoscine Butyl Bromide","moa":"Muscarinic acetylcholine receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Glycopyrronium Bromide","moa":"Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M3","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zydus Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Glycopyrronium Bromide","moa":"Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M3","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lupin Ltd \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Edenbridge Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Agreement","leadProduct":"Glycopyrronium Bromide","moa":"Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M3","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Catalent Pharma Solutions \/ Edenbridge Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Catalent Pharma Solutions \/ Edenbridge Pharmaceuticals"},{"orgOrder":0,"company":"University of Nottingham","sponsor":"Ironwood Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2014","type":"Inapplicable","leadProduct":"Tritriacontanoic Acid","moa":"Muscarinic acetylcholine receptor M5 (CHRM5)","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"University of Nottingham","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Nottingham \/ Ironwood Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"University of Nottingham \/ Ironwood Pharmaceuticals"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Cour Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Timp-Glia","moa":"Myelin autoantigen","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Cour Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Cour Pharmaceuticals"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Cour Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Timp-Glia","moa":"Myelin autoantigen","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takeda Pharmaceutical \/ Cour Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Cour Pharmaceuticals"},{"orgOrder":0,"company":"Cali Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"CPL-01","moa":"Na channel-alpha-subunit","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Cali Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cali Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cali Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cali Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"CPL-01","moa":"Na channel-alpha-subunit","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Cali Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cali Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cali Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EMS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"BRAZIL","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"BNP105","moa":"Natriuretic peptide receptor","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"EMS","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"EMS \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"EMS \/ Undisclosed"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Therapeutics, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CITI-002","moa":"NaV channel-alpha-subunit","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Citius Pharmaceuticals \/ Therapeutics, Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Citius Pharmaceuticals \/ Therapeutics, Inc."},{"orgOrder":0,"company":"McNeil AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Racecadotril","moa":"Neprilysin","graph1":"Gastroenterology","graph2":"Phase I","graph3":"McNeil AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"McNeil AB \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"McNeil AB \/ Undisclosed"},{"orgOrder":0,"company":"National Institute of Pediatrics, Mexico","sponsor":"Ferrer Internacional","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"MEXICO","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Racecadotril","moa":"Neprilysin","graph1":"Gastroenterology","graph2":"Phase III","graph3":"National Institute of Pediatrics, Mexico","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute of Pediatrics, Mexico \/ Ferrer Internacional","highestDevelopmentStatusID":"10","companyTruncated":"National Institute of Pediatrics, Mexico \/ Ferrer Internacional"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Racecadotril","moa":"Neprilysin","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Abbott Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abbott Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Racecadotril","moa":"Neprilysin","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abbott Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abbott Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"All India Institute of Medical Sciences, New Delhi","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Aprepitant","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"All India Institute of Medical Sciences, New Delhi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"All India Institute of Medical Sciences, New Delhi \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"All India Institute of Medical Sciences, New Delhi \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Zhejiang University","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Aprepitant","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Zhejiang University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zhejiang University \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Zhejiang University \/ Merck & Co"},{"orgOrder":0,"company":"CSPC Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Aprepitant","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"CSPC Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CSPC Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CSPC Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Aprepitant","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"Oxilio","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"Aprepitant","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Quotient Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quotient Sciences \/ Oxilio","highestDevelopmentStatusID":"6","companyTruncated":"Quotient Sciences \/ Oxilio"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Aprepitant","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunnybrook Health Sciences Centre \/ Merck Group","highestDevelopmentStatusID":"8","companyTruncated":"Sunnybrook Health Sciences Centre \/ Merck Group"},{"orgOrder":0,"company":"GOG Foundation","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Aprepitant","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"GOG Foundation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GOG Foundation \/ National Cancer Institute","highestDevelopmentStatusID":"1","companyTruncated":"GOG Foundation \/ National Cancer Institute"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Aprepitant","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Aprepitant","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Heron Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Heron Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Aprepitant","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Aprepitant","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Techdow USA","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"Fosaprepitant","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Techdow USA","highestDevelopmentStatusID":"15","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Techdow USA"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Fosaprepitant","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lupin Ltd \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Undisclosed"},{"orgOrder":0,"company":"St. Louis University","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Fosaprepitant","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"St. Louis University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"St. Louis University \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"St. Louis University \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Fosaprepitant","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Avenacy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Fosaprepitant","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Avenacy","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avenacy \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Avenacy \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Fosaprepitant","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Fosaprepitant","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Fosaprepitant","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amneal Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Odense University Hospital","sponsor":"Helsinn Advanced Synthesis","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Fosaprepitant","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Odense University Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Odense University Hospital \/ Helsinn Advanced Synthesis","highestDevelopmentStatusID":"10","companyTruncated":"Odense University Hospital \/ Helsinn Advanced Synthesis"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Fosaprepitant","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Fosaprepitant","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Fosaprepitant","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"George Clinical | Physician Services Incorporated","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Fosnetupitant","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Helsinn Advanced Synthesis \/ George Clinical | Physician Services Incorporated","highestDevelopmentStatusID":"10","companyTruncated":"Helsinn Advanced Synthesis \/ George Clinical | Physician Services Incorporated"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Fosnetupitant","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Helsinn Advanced Synthesis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Helsinn Advanced Synthesis \/ Undisclosed"},{"orgOrder":0,"company":"Taiho Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fosnetupitant Chloride","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Taiho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Taiho Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Taiho Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Taiho Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Fosnetupitant Chloride","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Taiho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Taiho Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Taiho Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Berlin Chemie","sponsor":"Helsinn Advanced Synthesis","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Fosnetupitant Chloride","moa":"||Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Berlin Chemie","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Berlin Chemie \/ Helsinn Advanced Synthesis","highestDevelopmentStatusID":"15","companyTruncated":"Berlin Chemie \/ Helsinn Advanced Synthesis"},{"orgOrder":0,"company":"Simon Williamson Clinic","sponsor":"Helsinn Advanced Synthesis","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Netupitant","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Simon Williamson Clinic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Simon Williamson Clinic \/ Helsinn Advanced Synthesis","highestDevelopmentStatusID":"8","companyTruncated":"Simon Williamson Clinic \/ Helsinn Advanced Synthesis"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Netupitant","moa":"||Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Helsinn Advanced Synthesis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ Undisclosed"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Netupitant","moa":"||Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Helsinn Advanced Synthesis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ Undisclosed"},{"orgOrder":0,"company":"FarmaMondo","sponsor":"Helsinn Advanced Synthesis","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Partnership","leadProduct":"Netupitant","moa":"||Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"FarmaMondo","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"FarmaMondo \/ Helsinn Advanced Synthesis","highestDevelopmentStatusID":"15","companyTruncated":"FarmaMondo \/ Helsinn Advanced Synthesis"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Netupitant","moa":"||Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Helsinn Advanced Synthesis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ Undisclosed"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Esteve Quimica","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2025","type":"Partnership","leadProduct":"Netupitant","moa":"||Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Helsinn Advanced Synthesis \/ Esteve Quimica","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ Esteve Quimica"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Immedica Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Netupitant","moa":"||Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Helsinn Advanced Synthesis \/ Immedica Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ Immedica Pharma"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Netupitant","moa":"||Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Helsinn Advanced Synthesis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ Undisclosed"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Netupitant","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Helsinn Advanced Synthesis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ Undisclosed"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Netupitant","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Helsinn Advanced Synthesis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ Undisclosed"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Netupitant","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Helsinn Advanced Synthesis \/ Parexel","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ Parexel"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Netupitant","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Helsinn Advanced Synthesis \/ Parexel","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ Parexel"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"PSI CRO","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Netupitant","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Helsinn Advanced Synthesis \/ PSI CRO","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ PSI CRO"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Chugai Pharma Europe","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Agreement","leadProduct":"Netupitant","moa":"||Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Helsinn Advanced Synthesis \/ Chugai Pharma Europe","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ Chugai Pharma Europe"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Netupitant","moa":"||Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Helsinn Advanced Synthesis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Helsinn Advanced Synthesis \/ Undisclosed"},{"orgOrder":0,"company":"Tesaro","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Rolapitant HCl","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Tesaro","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tesaro \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tesaro \/ Undisclosed"},{"orgOrder":0,"company":"Tesaro","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Rolapitant HCl","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Tesaro","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tesaro \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tesaro \/ Undisclosed"},{"orgOrder":0,"company":"Tesaro","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Rolapitant HCl","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Tesaro","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tesaro \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tesaro \/ Undisclosed"},{"orgOrder":0,"company":"Tesaro","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Rolapitant HCl","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Tesaro","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tesaro \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tesaro \/ Undisclosed"},{"orgOrder":0,"company":"Tesaro","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Rolapitant HCl","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Tesaro","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tesaro \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tesaro \/ Undisclosed"},{"orgOrder":0,"company":"Tesaro","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Rolapitant HCl","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Tesaro","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tesaro \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tesaro \/ Undisclosed"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Tradipitant","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tradipitant","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Tradipitant","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tradipitant","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tradipitant","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tradipitant","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tradipitant","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tradipitant","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tradipitant","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tradipitant","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tradipitant","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Accenture","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Vestipitant","moa":"Neurokinin 1 receptor||Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Accenture","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Accenture \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Accenture \/ Undisclosed"},{"orgOrder":0,"company":"Accenture","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Vestipitant","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Accenture","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Accenture \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Accenture \/ Undisclosed"},{"orgOrder":0,"company":"Menarini","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ibodutant","moa":"Neurokinin 2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Menarini \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Menarini \/ Undisclosed"},{"orgOrder":0,"company":"Menarini","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ibodutant","moa":"Neurokinin 2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Menarini \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Menarini \/ Undisclosed"},{"orgOrder":0,"company":"Menarini","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ibodutant","moa":"Neurokinin 2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Menarini \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Menarini \/ Undisclosed"},{"orgOrder":0,"company":"Menarini","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Ibodutant","moa":"Neurokinin 2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Menarini \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Menarini \/ Undisclosed"},{"orgOrder":0,"company":"Menarini","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Nepadutant","moa":"Neurokinin 2 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Menarini \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Menarini \/ Undisclosed"},{"orgOrder":0,"company":"Menarini","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Nepadutant","moa":"Neurokinin 2 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Menarini \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Menarini \/ Undisclosed"},{"orgOrder":0,"company":"Menarini","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Nepadutant","moa":"Neurokinin 2 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Menarini \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Menarini \/ Undisclosed"},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Larazotide Acetate","moa":"Neuronal acetylcholine receptor; alpha3\/beta4","graph1":"Gastroenterology","graph2":"Phase III","graph3":"9 Meters Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"9 Meters Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"9 Meters Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Larazotide Acetate","moa":"Neuronal acetylcholine receptor; alpha3\/beta4","graph1":"Gastroenterology","graph2":"Phase III","graph3":"9 Meters Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"9 Meters Biopharma \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"10","companyTruncated":"9 Meters Biopharma \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Larazotide Acetate","moa":"Neuronal acetylcholine receptor; alpha3\/beta4","graph1":"Gastroenterology","graph2":"Phase III","graph3":"9 Meters Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"9 Meters Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"9 Meters Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Larazotide Acetate","moa":"Neuronal acetylcholine receptor; alpha3\/beta4","graph1":"Gastroenterology","graph2":"Phase III","graph3":"9 Meters Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"9 Meters Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"9 Meters Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Innovate Biopharmaceuticals","sponsor":"RDD Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Merger","leadProduct":"Larazotide Acetate","moa":"Neuronal acetylcholine receptor; alpha3\/beta4","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Innovate Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovate Biopharmaceuticals \/ RDD Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Innovate Biopharmaceuticals \/ RDD Pharma"},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"TC-6499","moa":"Neuronal acetylcholine receptor; alpha3\/beta4 | Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Catalyst Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Catalyst Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Catalyst Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"TC-6499","moa":"Neuronal acetylcholine receptor; alpha3\/beta4 | Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Catalyst Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Catalyst Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Catalyst Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Bacainn Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"BT051","moa":"Neutrophil trafficking","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Bacainn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bacainn Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bacainn Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Rebamipide","moa":"N-formyl peptide receptor (FPR1)","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Daewoong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Holdings","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Rebamipide","moa":"N-formyl peptide receptor (FPR1)","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Otsuka Holdings","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Holdings \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Holdings \/ Undisclosed"},{"orgOrder":0,"company":"Korea Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Rebamipide","moa":"N-formyl peptide receptor (FPR1)","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Korea Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Korea Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Korea Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Biolab Sanus Farmaceutica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SPAIN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Rebamipide","moa":"N-formyl peptide receptor (FPR1)","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Biolab Sanus Farmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Granules","sponsorNew":"Biolab Sanus Farmaceutica \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biolab Sanus Farmaceutica \/ Undisclosed"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Usnoflast","moa":"NLRP3","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zydus Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Zydus Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"University Health Network, Toronto","sponsor":"Stryker","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Indocyanine Green","moa":"None","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"University Health Network, Toronto","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"University Health Network, Toronto \/ Stryker","highestDevelopmentStatusID":"11","companyTruncated":"University Health Network, Toronto \/ Stryker"},{"orgOrder":0,"company":"Centre for Addiction and Mental Health","sponsor":"Academic Health Science Centres","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Centre for Addiction and Mental Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre for Addiction and Mental Health \/ Academic Health Science Centres","highestDevelopmentStatusID":"8","companyTruncated":"Centre for Addiction and Mental Health \/ Academic Health Science Centres"},{"orgOrder":0,"company":"Develco Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Controlled Substance","year":"2018","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Develco Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Develco Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Develco Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Methylsamidorphan Chloride","moa":"OPRM1","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alkermes Plc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alkermes Plc \/ Undisclosed"},{"orgOrder":0,"company":"CM Chungmu Hospital","sponsor":"Korea United Pharm. Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Trimebutine Maleate","moa":"OPRM1","graph1":"Gastroenterology","graph2":"Phase III","graph3":"CM Chungmu Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CM Chungmu Hospital \/ Korea United Pharm. Inc.","highestDevelopmentStatusID":"10","companyTruncated":"CM Chungmu Hospital \/ Korea United Pharm. Inc."},{"orgOrder":0,"company":"Allena Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Public Offering","leadProduct":"Reloxaliase","moa":"Oxalate","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allena Pharmaceuticals","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0.029999999999999999,"dosageForm":"Capsule","sponsorNew":"Allena Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Allena Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Codexis","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Collaboration","leadProduct":"CDX-7108","moa":"Pancreatic enzyme","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Codexis","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Codexis \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"2","companyTruncated":"Codexis \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"BRAINTREE LABS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BLI5100","moa":"P-CAB","graph1":"Gastroenterology","graph2":"Phase III","graph3":"BRAINTREE LABS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BRAINTREE LABS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BRAINTREE LABS \/ Undisclosed"},{"orgOrder":0,"company":"BRAINTREE LABS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BLI5100","moa":"P-CAB","graph1":"Gastroenterology","graph2":"Phase III","graph3":"BRAINTREE LABS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BRAINTREE LABS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BRAINTREE LABS \/ Undisclosed"},{"orgOrder":0,"company":"BRAINTREE LABS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BLI5100","moa":"P-CAB","graph1":"Gastroenterology","graph2":"Phase III","graph3":"BRAINTREE LABS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BRAINTREE LABS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BRAINTREE LABS \/ Undisclosed"},{"orgOrder":0,"company":"Cinclus Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Linaprazan Glurate","moa":"P-CAB","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Cinclus Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cinclus Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cinclus Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Cinclus Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Linaprazan Glurate","moa":"P-CAB","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Cinclus Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cinclus Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cinclus Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Cinclus Pharma","sponsor":"Fourth Swedish National Pension Fund","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Financing","leadProduct":"Linaprazan Glurate","moa":"P-CAB","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Cinclus Pharma","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"Cinclus Pharma \/ Fourth Swedish National Pension Fund","highestDevelopmentStatusID":"10","companyTruncated":"Cinclus Pharma \/ Fourth Swedish National Pension Fund"},{"orgOrder":0,"company":"Cinclus Pharma","sponsor":"Zentiva","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Miscellaneous","year":"2025","type":"Licensing Agreement","leadProduct":"Linaprazan Glurate","moa":"P-CAB","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Cinclus Pharma","amount2":0.25,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0.25,"dosageForm":"Tablet","sponsorNew":"Cinclus Pharma \/ Zentiva","highestDevelopmentStatusID":"10","companyTruncated":"Cinclus Pharma \/ Zentiva"},{"orgOrder":0,"company":"Cinclus Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Linaprazan Glurate","moa":"P-CAB","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Cinclus Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cinclus Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cinclus Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Onconic Therapeutics","sponsor":"Livzon Pharmaceutical Group","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"Zastaprazan","moa":"P-CAB","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Onconic Therapeutics","amount2":0.13,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0.13,"dosageForm":"Capsule","sponsorNew":"Onconic Therapeutics \/ Livzon Pharmaceutical Group","highestDevelopmentStatusID":"10","companyTruncated":"Onconic Therapeutics \/ Livzon Pharmaceutical Group"},{"orgOrder":0,"company":"Onconic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Zastaprazan Citrate","moa":"P-CAB","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Onconic Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Onconic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Onconic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"LCMC Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Sucralfate","moa":"Pepsin A | Glycoproteins","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"LCMC Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LCMC Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"LCMC Health \/ Undisclosed"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"SucrAlphate","moa":"Pepsin A5","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Strides Pharma Science \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Undisclosed"},{"orgOrder":0,"company":"Clayton Pharmaceuticals","sponsor":"Vista Pharm","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"SucrAlphate","moa":"Pepsin A5","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Clayton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Clayton Pharmaceuticals \/ Vista Pharm","highestDevelopmentStatusID":"15","companyTruncated":"Clayton Pharmaceuticals \/ Vista Pharm"},{"orgOrder":0,"company":"Soligenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Dusquetide","moa":"peptides","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Soligenix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix \/ Undisclosed"},{"orgOrder":0,"company":"Soligenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Dusquetide","moa":"peptides","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Soligenix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix \/ Undisclosed"},{"orgOrder":0,"company":"Soligenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Dusquetide","moa":"peptides","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Soligenix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix \/ Undisclosed"},{"orgOrder":0,"company":"Soligenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Dusquetide","moa":"peptides","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Soligenix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix \/ Undisclosed"},{"orgOrder":0,"company":"Soligenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Dusquetide","moa":"peptides","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Soligenix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix \/ Undisclosed"},{"orgOrder":0,"company":"Soligenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Dusquetide","moa":"peptides","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Soligenix \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Soligenix \/ Undisclosed"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"IW-9179","moa":"peptides: gastrointestinal functions; normalising agent","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ironwood Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ironwood Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"IW-9179","moa":"peptides: gastrointestinal functions; normalising agent","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ironwood Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ironwood Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Larix","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Glepaglutide","moa":"peptides: GLP peptide analogs","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zealand Pharma \/ Larix","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Larix"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Glepaglutide","moa":"peptides: GLP peptide analogs","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Glepaglutide","moa":"peptides: GLP peptide analogs","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Glepaglutide","moa":"peptides: GLP peptide analogs","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Glepaglutide","moa":"peptides: GLP peptide analogs","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Danske Bank","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2022","type":"Private Placement","leadProduct":"Glepaglutide","moa":"peptides: GLP peptide analogs","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0.10000000000000001,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Danske Bank","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Danske Bank"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Danske Bank","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2022","type":"Private Placement","leadProduct":"Glepaglutide","moa":"peptides: GLP peptide analogs","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0.10000000000000001,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Danske Bank","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Danske Bank"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Glepaglutide","moa":"peptides: GLP peptide analogs","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Glepaglutide","moa":"peptides: GLP peptide analogs","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Glepaglutide","moa":"peptides: GLP peptide analogs","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Glepaglutide","moa":"peptides: GLP peptide analogs","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Teicoplanin","moa":"Peptidoglycan","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Edge Pharma","sponsor":"ANI Pharmaceuticals Inc","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Antibiotic","year":"2020","type":"Agreement","leadProduct":"Vancomycin HCl","moa":"Peptidoglycan","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Edge Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Edge Pharma \/ ANI Pharmaceuticals Inc","highestDevelopmentStatusID":"15","companyTruncated":"Edge Pharma \/ ANI Pharmaceuticals Inc"},{"orgOrder":0,"company":"Dr. Falk Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Peroxisome proliferator-activated receptor gamma | Cyclooxygenase | Arachidonate 5-lipoxygenase","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Dr. Falk Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Granules","sponsorNew":"Dr. Falk Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dr. Falk Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Falk Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Peroxisome proliferator-activated receptor gamma | Cyclooxygenase | Arachidonate 5-lipoxygenase","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Dr. Falk Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Dr. Falk Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dr. Falk Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Peroxisome proliferator-activated receptor gamma | Cyclooxygenase | Arachidonate 5-lipoxygenase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sandoz B2B \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sandoz B2B \/ Undisclosed"},{"orgOrder":0,"company":"Sofar Spa","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Peroxisome proliferator-activated receptor gamma | Cyclooxygenase | Arachidonate 5-lipoxygenase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Sofar Spa","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sofar Spa \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sofar Spa \/ Undisclosed"},{"orgOrder":0,"company":"University of Utah","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Peroxisome proliferator-activated receptor gamma | Cyclooxygenase | Arachidonate 5-lipoxygenase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"University of Utah","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Utah \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"University of Utah \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Peroxisome proliferator-activated receptor gamma | Cyclooxygenase | Arachidonate 5-lipoxygenase","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Granules","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Access Pharmaceutical","sponsor":"Advanced Clinical Research Services","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Amlexanox","moa":"Phosphodiesterase 4","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Access Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Access Pharmaceutical \/ Advanced Clinical Research Services","highestDevelopmentStatusID":"8","companyTruncated":"Access Pharmaceutical \/ Advanced Clinical Research Services"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"HPAPI","year":"2018","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ Bristol Myers Squibb","highestDevelopmentStatusID":"11","companyTruncated":"Mayo Clinic \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Amifostine","moa":"phosphoro-derivatives","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Palisade Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Undisclosed"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Palisade Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Undisclosed"},{"orgOrder":0,"company":"Newsoara Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Newsoara Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Newsoara Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Newsoara Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Palisade Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Undisclosed"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Palisade Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Undisclosed"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Palisade Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Undisclosed"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Palisade Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Undisclosed"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Newsoara Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Palisade Bio \/ Newsoara Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Newsoara Biopharma"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Public Offering","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0.01,"dosageForm":"Liquid","sponsorNew":"Palisade Bio \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Ladenburg Thalmann & Co"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Palisade Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Undisclosed"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Palisade Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Undisclosed"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Palisade Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Undisclosed"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Palisade Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Undisclosed"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Palisade Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Undisclosed"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Palisade Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Undisclosed"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Palisade Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Undisclosed"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Palisade Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Undisclosed"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Palisade Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Undisclosed"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Palisade Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Undisclosed"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Palisade Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Undisclosed"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Palisade Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Undisclosed"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Newsoara Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Palisade Bio \/ Newsoara Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Newsoara Biopharma"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Yuma Regional Medical Center","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Funding","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0.01,"dosageForm":"Liquid","sponsorNew":"Palisade Bio \/ Yuma Regional Medical Center","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Yuma Regional Medical Center"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Palisade Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Undisclosed"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Palisade Bio","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Merger","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Palisade Bio \/ Seneca Biopharma","highestDevelopmentStatusID":"8","companyTruncated":"Palisade Bio \/ Seneca Biopharma"},{"orgOrder":0,"company":"Second Genome","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"SG-5-00455","moa":"Plasminogen activator type-1\/2","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Second Genome","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Second Genome \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Second Genome \/ Undisclosed"},{"orgOrder":0,"company":"Second Genome","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"SG-5-00455","moa":"Plasminogen activator type-1\/2","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Second Genome","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Second Genome \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Second Genome \/ Undisclosed"},{"orgOrder":0,"company":"Ajou University School of Medicine","sponsor":"HK inno.N","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Sevoflurane","moa":"Potassium channel subfamily K member 3 | Potassium channel subfamily K member 10 | Potassium channel subfamily K member 18 | Glycine receptor (alpha-1\/beta) | Potassium channel subfamily K member 9 | Potassium channel subfamily K member 2 | GABA-A receptor; anion channel","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Ajou University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ajou University School of Medicine \/ HK inno.N","highestDevelopmentStatusID":"11","companyTruncated":"Ajou University School of Medicine \/ HK inno.N"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dexlansoprazole","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Dexlansoprazole","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Dexlansoprazole","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Dexlansoprazole","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Dexlansoprazole","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Dexlansoprazole","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dexlansoprazole","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dexlansoprazole","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dexlansoprazole","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Dexlansoprazole","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Dexlansoprazole","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"American University of Beirut Medical Center","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"LEBANON","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Dexlansoprazole","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"American University of Beirut Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"American University of Beirut Medical Center \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"American University of Beirut Medical Center \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"University of Washington","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Dexlansoprazole","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"University of Washington","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Washington \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"University of Washington \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Altius Healthcare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Dexlansoprazole","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Altius Healthcare","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Altius Healthcare \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Altius Healthcare \/ Undisclosed"},{"orgOrder":0,"company":"Advanced Center for Specialty Care","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Dexlansoprazole","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Advanced Center for Specialty Care","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Advanced Center for Specialty Care \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Advanced Center for Specialty Care \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Esomeprazole Magnesium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Esomeprazole Magnesium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Quintiles Inc","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Esomeprazole Magnesium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Quintiles Inc","highestDevelopmentStatusID":"11","companyTruncated":"AstraZeneca \/ Quintiles Inc"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Esomeprazole Magnesium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Esomeprazole Magnesium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Haleon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Esomeprazole Magnesium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Haleon","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Haleon \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Haleon \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Esomeprazole Magnesium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Esomeprazole Magnesium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Esomeprazole Magnesium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Esomeprazole Magnesium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Parexel","highestDevelopmentStatusID":"11","companyTruncated":"AstraZeneca \/ Parexel"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Esomeprazole Magnesium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Southern Arizona VA Health Care System","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Esomeprazole Magnesium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Southern Arizona VA Health Care System","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Southern Arizona VA Health Care System \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Southern Arizona VA Health Care System \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Esomeprazole Magnesium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Eurofarma Laboratorios S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"BRAZIL","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Esomeprazole Magnesium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Eurofarma Laboratorios S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eurofarma Laboratorios S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eurofarma Laboratorios S.A \/ Undisclosed"},{"orgOrder":0,"company":"Livzon Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Esomeprazole Magnesium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Livzon Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Livzon Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Livzon Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"YooYoung Pharmaceutical Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Esomeprazole Magnesium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase I","graph3":"YooYoung Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"YooYoung Pharmaceutical Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"YooYoung Pharmaceutical Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Effexus Pharmaceutical","sponsor":"Southern Arizona VA Health Care System","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Esomeprazole Magnesium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Effexus Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Effexus Pharmaceutical \/ Southern Arizona VA Health Care System","highestDevelopmentStatusID":"7","companyTruncated":"Effexus Pharmaceutical \/ Southern Arizona VA Health Care System"},{"orgOrder":0,"company":"Aspen Pharmacare Holdings","sponsor":"Acino Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SOUTH AFRICA","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"Esomeprazole Magnesium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Aspen Pharmacare Holdings","amount2":0.12,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0.12,"dosageForm":"Tablet","sponsorNew":"Aspen Pharmacare Holdings \/ Acino Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Aspen Pharmacare Holdings \/ Acino Pharma"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Esomeprazole Magnesium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Granules India Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Undisclosed"},{"orgOrder":0,"company":"Towa Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Esomeprazole Magnesium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Towa Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Towa Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Towa Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Esomeprazole Magnesium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glenmark Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Esomeprazole Magnesium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"IQVIA | Calyx | LabCorp | Medidata Solutions | Thermo Fisher Scientific | CISCRP | Quipment Inc. | Little Journey Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Esomeprazole Magnesium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Granules","sponsorNew":"AstraZeneca \/ IQVIA | Calyx | LabCorp | Medidata Solutions | Thermo Fisher Scientific | CISCRP | Quipment Inc. | Little Journey Ltd.","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ IQVIA | Calyx | LabCorp | Medidata Solutions | Thermo Fisher Scientific | CISCRP | Quipment Inc. | Little Journey Ltd."},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Esomeprazole Strontium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Hanmi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hanmi Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hanmi Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Esomeprazole Strontium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Hanmi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hanmi Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hanmi Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Konkuk University Medical Center","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Fexuprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Konkuk University Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Konkuk University Medical Center \/ Daewoong Pharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"Konkuk University Medical Center \/ Daewoong Pharmaceutical"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Fexuprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Daewoong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Fexuprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Daewoong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Fexuprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Daewoong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Fexuprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Daewoong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Fexuprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Daewoong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Fexuprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Daewoong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Fexuprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Daewoong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Hanyang University","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Fexuprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Hanyang University","highestDevelopmentStatusID":"10","companyTruncated":"Daewoong Pharmaceutical \/ Hanyang University"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Fexuprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daewoong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Daewoong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Fexuprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Daewoong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Daewoong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Neurogastrx","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Termination","leadProduct":"Fexuprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Neurogastrx","highestDevelopmentStatusID":"15","companyTruncated":"Daewoong Pharmaceutical \/ Neurogastrx"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Fexuprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Daewoong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"COOPER PHARMA","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Fexuprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Daewoong Pharmaceutical","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Daewoong Pharmaceutical \/ COOPER PHARMA","highestDevelopmentStatusID":"15","companyTruncated":"Daewoong Pharmaceutical \/ COOPER PHARMA"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Fexuprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Daewoong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Shanghai Haini Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Fexuprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Daewoong Pharmaceutical","amount2":3.2400000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":3.2400000000000002,"dosageForm":"Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Shanghai Haini Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Daewoong Pharmaceutical \/ Shanghai Haini Pharmaceutical"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Fexuprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Daewoong Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Daewoong Pharmaceutical"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Fexuprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daewoong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Daewoong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Neurogastrx","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Fexuprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Neurogastrx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neurogastrx \/ Daewoong Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Neurogastrx \/ Daewoong Pharmaceutical"},{"orgOrder":0,"company":"Neurogastrx","sponsor":"Vivo Capital","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Series B Financing","leadProduct":"Fexuprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Neurogastrx","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0.059999999999999998,"dosageForm":"Tablet","sponsorNew":"Neurogastrx \/ Vivo Capital","highestDevelopmentStatusID":"10","companyTruncated":"Neurogastrx \/ Vivo Capital"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Rabeprazole Sodium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Rabeprazole Sodium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Livzon Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ilaprazole","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Livzon Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Livzon Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Livzon Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Livzon Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ilaprazole","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Livzon Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Livzon Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Livzon Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Livzon Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ilaprazole","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Livzon Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Livzon Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Livzon Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Livzon Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ilaprazole","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Livzon Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Livzon Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Livzon Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Livzon Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Ilaprazole","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Livzon Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Livzon Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Livzon Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Il-Yang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ilaprazole","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Il-Yang Pharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Il-Yang Pharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Il-Yang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Il-Yang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ilaprazole","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Il-Yang Pharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Il-Yang Pharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Il-Yang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Il-Yang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ilaprazole","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Il-Yang Pharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Il-Yang Pharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Il-Yang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Il-Yang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ilaprazole","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Il-Yang Pharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Il-Yang Pharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Il-Yang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Mahidol University","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"THAILAND","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Lansoprazole","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Mahidol University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mahidol University \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Mahidol University \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lansoprazole","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"AddPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Lansoprazole","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase I","graph3":"AddPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AddPharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AddPharma \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lansoprazole","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating, Delayed Release","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Neutec Ar-Ge San ve Tic A.?","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"TURKEY","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Lansoprazole","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Neutec Ar-Ge San ve Tic A.?","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Neutec Ar-Ge San ve Tic A.? \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Neutec Ar-Ge San ve Tic A.? \/ Undisclosed"},{"orgOrder":0,"company":"Neutec Ar-Ge San ve Tic A.?","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"TURKEY","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Lansoprazole","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Neutec Ar-Ge San ve Tic A.?","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Neutec Ar-Ge San ve Tic A.? \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Neutec Ar-Ge San ve Tic A.? \/ Undisclosed"},{"orgOrder":0,"company":"Dallas VA Medical Center","sponsor":"TAP Pharmaceutical Products Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Lansoprazole","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Dallas VA Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dallas VA Medical Center \/ TAP Pharmaceutical Products Inc.","highestDevelopmentStatusID":"11","companyTruncated":"Dallas VA Medical Center \/ TAP Pharmaceutical Products Inc."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Omeprazole","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Marksans Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Omeprazole","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Marksans Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Marksans Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Marksans Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Belarusian Medical Academy of Post-Graduate Education","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"BELARUS","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Omeprazole","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Belarusian Medical Academy of Post-Graduate Education","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Belarusian Medical Academy of Post-Graduate Education \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"Belarusian Medical Academy of Post-Graduate Education \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Carlin Consumer Health","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Miscellaneous","year":"2022","type":"Acquisition","leadProduct":"Omeprazole","moa":"||Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bayer AG \/ Carlin Consumer Health","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Carlin Consumer Health"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Omeprazole","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Norgine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Omeprazole","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Norgine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Norgine \/ Undisclosed"},{"orgOrder":0,"company":"Norgine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Omeprazole","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Norgine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Norgine \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Omeprazole","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Omeprazole","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Brand Institute","sponsor":"Azurity Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Omeprazole","moa":"||Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Brand Institute","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Brand Institute \/ Azurity Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Brand Institute \/ Azurity Pharma"},{"orgOrder":0,"company":"Torax Medical Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Omeprazole","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Torax Medical Incorporated","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Torax Medical Incorporated \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Torax Medical Incorporated \/ Undisclosed"},{"orgOrder":0,"company":"Ascension Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Omeprazole","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Ascension Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascension Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Ascension Health \/ Undisclosed"},{"orgOrder":0,"company":"Azurity Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Omeprazole","moa":"||Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Azurity Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Azurity Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Azurity Pharma \/ Undisclosed"},{"orgOrder":0,"company":"PL Developments","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Omeprazole","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"PL Developments","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PL Developments \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"PL Developments \/ Undisclosed"},{"orgOrder":0,"company":"Prague Scientific","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CZECH REPUBLIC","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Omeprazole Magnesium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Prague Scientific","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Prague Scientific \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Prague Scientific \/ Undisclosed"},{"orgOrder":0,"company":"Perrigo Company plc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Omeprazole Magnesium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Perrigo Company plc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Perrigo Company plc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Perrigo Company plc \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Pantoprazole Sodium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Dong-A ST Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Pantoprazole Sodium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Seoul National University Hospital \/ Dong-A ST Co., Ltd.","highestDevelopmentStatusID":"10","companyTruncated":"Seoul National University Hospital \/ Dong-A ST Co., Ltd."},{"orgOrder":0,"company":"McMaster University","sponsor":"Canadian Institutes of Health Research | Canadian Critical Care Trials Group | Australian and New Zealand Intensive Care Society Clinical Trials Group | National Health and Medical Research Council, Australia","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Pantoprazole Sodium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"McMaster University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection, Powder","sponsorNew":"McMaster University \/ Canadian Institutes of Health Research | Canadian Critical Care Trials Group | Australian and New Zealand Intensive Care Society Clinical Trials Group | National Health and Medical Research Council, Australia","highestDevelopmentStatusID":"10","companyTruncated":"McMaster University \/ Canadian Institutes of Health Research | Canadian Critical Care Trials Group | Australian and New Zealand Intensive Care Society Clinical Trials Group | National Health and Medical Research Council, Australia"},{"orgOrder":0,"company":"Asofarma de M\u00e9xico","sponsor":"Hospital \u00c1ngeles, Cl\u00ednica Londres, Mexico City | Centro InmunoQ | Torre Mayo | Hospital \u00c1ngeles Metropolitano, Mexico City | Centro M\u00e9dico ABC","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"MEXICO","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Pantoprazole Sodium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Asofarma de M\u00e9xico","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Asofarma de M\u00e9xico \/ Hospital \u00c1ngeles, Cl\u00ednica Londres, Mexico City | Centro InmunoQ | Torre Mayo | Hospital \u00c1ngeles Metropolitano, Mexico City | Centro M\u00e9dico ABC","highestDevelopmentStatusID":"10","companyTruncated":"Asofarma de M\u00e9xico \/ Hospital \u00c1ngeles, Cl\u00ednica Londres, Mexico City | Centro InmunoQ | Torre Mayo | Hospital \u00c1ngeles Metropolitano, Mexico City | Centro M\u00e9dico ABC"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Pantoprazole Sodium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abbott Laboratories \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Abbott Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Pantoprazole Sodium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Pantoprazole Sodium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Eurofarma Laboratorios S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"BRAZIL","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Pantoprazole Sodium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Eurofarma Laboratorios S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eurofarma Laboratorios S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eurofarma Laboratorios S.A \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Pantoprazole Sodium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Pantoprazole Sodium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alembic Pharmaceuticals Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Undisclosed"},{"orgOrder":0,"company":"Royalsense","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Pantoprazole Sodium","moa":"||Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Royalsense","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royalsense \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Royalsense \/ Undisclosed"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Pantoprazole Sodium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Granules India Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Undisclosed"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Civica Rx","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Pantoprazole Sodium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sandoz B2B \/ Civica Rx","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Civica Rx"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Ildong Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Rabeprazole Sodium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Seoul National University Hospital \/ Ildong Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Seoul National University Hospital \/ Ildong Pharmaceutical"},{"orgOrder":0,"company":"Eisai","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Rabeprazole Sodium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Eisai \/ Undisclosed"},{"orgOrder":0,"company":"Eisai","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Rabeprazole Sodium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eisai \/ Undisclosed"},{"orgOrder":0,"company":"Eisai","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Rabeprazole Sodium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eisai \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eisai \/ Undisclosed"},{"orgOrder":0,"company":"Eisai","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Rabeprazole Sodium","moa":"antiulcer agents (benzimidazole derivatives)||Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eisai \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Eisai \/ Undisclosed"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Rabeprazole Sodium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"YUNGJIN PHARM. CO. LTD","sponsor":"Seoul National University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Rabeprazole Sodium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase I","graph3":"YUNGJIN PHARM. CO. LTD","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"YUNGJIN PHARM. CO. LTD \/ Seoul National University Hospital","highestDevelopmentStatusID":"6","companyTruncated":"YUNGJIN PHARM. CO. LTD \/ Seoul National University Hospital"},{"orgOrder":0,"company":"Akums Drugs & Pharmaceuticals Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Rabeprazole Sodium","moa":"||Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Akums Drugs & Pharmaceuticals Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akums Drugs & Pharmaceuticals Ltd \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Akums Drugs & Pharmaceuticals Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Neutec Ar-Ge San ve Tic A.?","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"TURKEY","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Rabeprazole Sodium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Neutec Ar-Ge San ve Tic A.?","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neutec Ar-Ge San ve Tic A.? \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Neutec Ar-Ge San ve Tic A.? \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Rabeprazole Sodium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Luoxin Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Luoxin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Luoxin Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Luoxin Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Luoxin Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Luoxin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Luoxin Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Luoxin Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Luoxin Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Luoxin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Luoxin Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Luoxin Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HK inno.N \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"HK inno.N \/ Undisclosed"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HK inno.N \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"HK inno.N \/ Undisclosed"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HK inno.N \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"HK inno.N \/ Undisclosed"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HK inno.N \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"HK inno.N \/ Undisclosed"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HK inno.N \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"HK inno.N \/ Undisclosed"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HK inno.N \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"HK inno.N \/ Undisclosed"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HK inno.N \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"HK inno.N \/ Undisclosed"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HK inno.N \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"HK inno.N \/ Undisclosed"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HK inno.N \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"HK inno.N \/ Undisclosed"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HK inno.N \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"HK inno.N \/ Undisclosed"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HK inno.N \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"HK inno.N \/ Undisclosed"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Partnership","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HK inno.N \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"HK inno.N \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"RaQualia Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"RaQualia Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"RaQualia Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"RaQualia Pharma \/ Undisclosed"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HK inno.N \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"HK inno.N \/ Undisclosed"},{"orgOrder":0,"company":"BRAINTREE LABS","sponsor":"Sebela Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Acquisition","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"BRAINTREE LABS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BRAINTREE LABS \/ Sebela Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"BRAINTREE LABS \/ Sebela Pharmaceuticals"},{"orgOrder":0,"company":"Sebela Pharmaceuticals","sponsor":"HK inno.N","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Sebela Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sebela Pharmaceuticals \/ HK inno.N","highestDevelopmentStatusID":"10","companyTruncated":"Sebela Pharmaceuticals \/ HK inno.N"},{"orgOrder":0,"company":"Carnot Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Carnot Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Carnot Laboratories \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Carnot Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Hanlim Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Hanlim Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hanlim Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hanlim Pharmaceuticals Inc \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Phathom Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Phathom Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Phathom Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Phathom Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Phathom Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Phathom Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Phathom Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Phathom Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Phathom Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Phathom Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Phathom Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Phathom Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phathom Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Phathom Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Alkem Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takeda Pharmaceutical \/ Alkem Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Alkem Laboratories"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Mankind Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takeda Pharmaceutical \/ Mankind Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Mankind Pharma"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Cipla","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takeda Pharmaceutical \/ Cipla","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Cipla"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takeda Pharmaceutical \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takeda Pharmaceutical \/ Lupin Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Lupin Ltd"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takeda Pharmaceutical \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Zydus Lifesciences","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takeda Pharmaceutical \/ Zydus Lifesciences","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Zydus Lifesciences"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Phathom Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Phathom Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Phathom Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Phathom Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Phathom Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Phathom Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Evercore ISI","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Phathom Pharmaceuticals","amount2":0.13,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0.13,"dosageForm":"Capsule","sponsorNew":"Phathom Pharmaceuticals \/ Evercore ISI","highestDevelopmentStatusID":"15","companyTruncated":"Phathom Pharmaceuticals \/ Evercore ISI"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Phathom Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Phathom Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Phathom Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Phathom Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Phathom Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Phathom Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Phathom Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Phathom Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Phathom Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Phathom Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Phathom Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Phathom Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Phathom Pharmaceuticals","amount2":0.13,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0.13,"dosageForm":"Capsule","sponsorNew":"Phathom Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Phathom Pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Encapsulated","sponsorNew":"Phathom Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Phathom Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Phathom Pharmaceuticals","amount2":0.29999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0.29999999999999999,"dosageForm":"Tablet, Encapsulated","sponsorNew":"Phathom Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Phathom Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Encapsulated","sponsorNew":"Phathom Pharmaceuticals \/ Hercules Capital","highestDevelopmentStatusID":"15","companyTruncated":"Phathom Pharmaceuticals \/ Hercules Capital"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Encapsulated","sponsorNew":"Phathom Pharmaceuticals \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Phathom Pharmaceuticals \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Financing","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Encapsulated","sponsorNew":"Phathom Pharmaceuticals \/ Hercules Capital","highestDevelopmentStatusID":"10","companyTruncated":"Phathom Pharmaceuticals \/ Hercules Capital"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Encapsulated","sponsorNew":"Phathom Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Phathom Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Encapsulated","sponsorNew":"Phathom Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Phathom Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Encapsulated","sponsorNew":"Phathom Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Phathom Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Phathom Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Phathom Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phathom Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Phathom Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Macrogol","moa":"Homeostasis||PPA-gamma receptor","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Norgine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Macrogol","moa":"Homeostasis||PPA-gamma receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Sachet","sponsorNew":"Norgine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Norgine \/ Undisclosed"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Macrogol","moa":"PPA-gamma receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Powder for Solution","sponsorNew":"Glenmark Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EA Pharma","sponsor":"Mochida Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Macrogol","moa":"PPA-gamma receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"EA Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Powder","sponsorNew":"EA Pharma \/ Mochida Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"EA Pharma \/ Mochida Pharmaceutical"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Macrogol","moa":"PPA-gamma receptor","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Sachet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"ColonaryConcepts","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Macrogol","moa":"||PPA-gamma receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"ColonaryConcepts","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ColonaryConcepts \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ColonaryConcepts \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Polyethylene Glycol 3350","moa":"PPA-gamma receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Quintiles Inc","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Polyethylene Glycol 3350","moa":"PPA-gamma receptor","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Quintiles Inc","highestDevelopmentStatusID":"11","companyTruncated":"AstraZeneca \/ Quintiles Inc"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Aclipse Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Lobeglitazone","moa":"PPST agonists (thiazolidene derivatives)","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chong Kun Dang Pharm \/ Aclipse Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Chong Kun Dang Pharm \/ Aclipse Therapeutics"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Ipamorelin","moa":"prehormones or hormone-release stimulating peptides: growth hormone-release stimulating peptides","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Helsinn Advanced Synthesis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Helsinn Advanced Synthesis \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2011","type":"Inapplicable","leadProduct":"Autologous Adipose-Derived Adult Stem Cell","moa":"Progenitor cell","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Direct Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles","moa":"Progenitor cell","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Direct Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Direct Biologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Direct Biologics \/ Undisclosed"},{"orgOrder":0,"company":"GeneScience Pharmaceuticals Co Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Megestrol Acetate","moa":"Progesterone receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"GeneScience Pharmaceuticals Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"GeneScience Pharmaceuticals Co Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GeneScience Pharmaceuticals Co Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Maastricht University Medical Center","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"PF-06801591","moa":"Programmed cell death protein 1","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Maastricht University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maastricht University Medical Center \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Maastricht University Medical Center \/ Pfizer Inc"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"ONO-8539","moa":"Prostanoid EP1 receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ono Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ono Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"ONO-8539","moa":"Prostanoid EP1 receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ono Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ono Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"GSK3179106","moa":"Proto-oncogene c-Ret (RET)","graph1":"Gastroenterology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"GSK3179106","moa":"Proto-oncogene c-Ret (RET)","graph1":"Gastroenterology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Covance","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Radiolabeled Compound","year":"2012","type":"Inapplicable","leadProduct":"13-C Uracil","moa":"Pyrimidine metabolism","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Otsuka Pharmaceutical \/ Covance","highestDevelopmentStatusID":"8","companyTruncated":"Otsuka Pharmaceutical \/ Covance"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Radiolabeled Compound","year":"2010","type":"Inapplicable","leadProduct":"13-C2 Uracil","moa":"Pyrimidine metabolism","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Granules","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Nitazoxanide","moa":"Pyruvate:ferredoxin oxidoreductase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lupin Ltd \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Romark","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Nitazoxanide","moa":"Pyruvate:ferredoxin oxidoreductase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Romark","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Romark \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Romark \/ Undisclosed"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Nitazoxanide","moa":"Pyruvate:ferredoxin oxidoreductase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"ANI Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Clinical Unit at Cambridge","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"GSK2982772","moa":"Receptor-interacting serine\/threonine-protein kinase 1","graph1":"Gastroenterology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GSK \/ Clinical Unit at Cambridge","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Clinical Unit at Cambridge"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"GSK2983559","moa":"RIPK2","graph1":"Gastroenterology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Odyssey Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"OD-07656","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Odyssey Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Odyssey Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lunan Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Capecitabine","moa":"RNA | DNA | Thymidylate synthase","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Lunan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lunan Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lunan Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Oregon Health and Science University","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sugammadex Sodium","moa":"Rocuronium","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Oregon Health and Science University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oregon Health and Science University \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Oregon Health and Science University \/ Merck & Co"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Venbio Partners","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Financing","leadProduct":"OPL-002","moa":"S1P1 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0.11,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.11,"dosageForm":"Powder","sponsorNew":"Ventyx Biosciences \/ Venbio Partners","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Biosciences \/ Venbio Partners"},{"orgOrder":0,"company":"Oppilan Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"OPL-002","moa":"S1P1 receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Oppilan Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Oppilan Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Oppilan Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Viatris","sponsor":"Trium Analysis Online GmbH | Icon Plc | Clinipace Worldwide","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Oxethazaine","moa":"SCN1A","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Viatris \/ Trium Analysis Online GmbH | Icon Plc | Clinipace Worldwide","highestDevelopmentStatusID":"10","companyTruncated":"Viatris \/ Trium Analysis Online GmbH | Icon Plc | Clinipace Worldwide"},{"orgOrder":0,"company":"University of Auckland, New Zealand","sponsor":"Cancer Trials New Zealand | Counties Manukau Health | Waikato Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NEW ZEALAND","productType":"Amino Acid","year":"2021","type":"Inapplicable","leadProduct":"Selenium Methionine","moa":"Selenoprotein","graph1":"Gastroenterology","graph2":"Phase I","graph3":"University of Auckland, New Zealand","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of Auckland, New Zealand \/ Cancer Trials New Zealand | Counties Manukau Health | Waikato Hospital","highestDevelopmentStatusID":"6","companyTruncated":"University of Auckland, New Zealand \/ Cancer Trials New Zealand | Counties Manukau Health | Waikato Hospital"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Amisulpride","moa":"Dopamine receptors; D2 & D3 | Serotonin (5-HT) receptor||Serotonin (5-HT) receptor | Dopamine receptors; D2 & D3","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Acacia Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acacia Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Acacia Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Amisulpride","moa":"Dopamine receptors; D2 & D3 | Serotonin (5-HT) receptor||Serotonin (5-HT) receptor | Dopamine receptors; D2 & D3","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Acacia Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acacia Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Acacia Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Amisulpride","moa":"Dopamine receptors; D2 & D3 | Serotonin (5-HT) receptor||Serotonin (5-HT) receptor | Dopamine receptors; D2 & D3","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Acacia Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acacia Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Acacia Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Amisulpride","moa":"Dopamine receptors; D2 & D3 | Serotonin (5-HT) receptor||Serotonin (5-HT) receptor | Dopamine receptors; D2 & D3","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Acacia Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acacia Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Acacia Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Amisulpride","moa":"Dopamine receptors; D2 & D3 | Serotonin (5-HT) receptor||Serotonin (5-HT) receptor | Dopamine receptors; D2 & D3","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Acacia Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acacia Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Acacia Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Amisulpride","moa":"Dopamine receptors; D2 & D3 | Serotonin (5-HT) receptor||Serotonin (5-HT) receptor | Dopamine receptors; D2 & D3","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Acacia Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acacia Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Acacia Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Amisulpride","moa":"Dopamine receptors; D2 & D3 | Serotonin (5-HT) receptor||Serotonin (5-HT) receptor | Dopamine receptors; D2 & D3","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Acacia Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acacia Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Acacia Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Amisulpride","moa":"Serotonin (5-HT) receptor | Dopamine receptors; D2 & D3","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Cosmo Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Financing","leadProduct":"Amisulpride","moa":"Serotonin (5-HT) receptor | Dopamine receptors; D2 & D3","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Acacia Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Acacia Pharma \/ Cosmo Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Acacia Pharma \/ Cosmo Pharmaceuticals"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Eagle Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Acquisition","leadProduct":"Amisulpride","moa":"Serotonin (5-HT) receptor | Dopamine receptors; D2 & D3","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Acacia Pharma","amount2":0.17999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0.17999999999999999,"dosageForm":"Infusion","sponsorNew":"Acacia Pharma \/ Eagle Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Acacia Pharma \/ Eagle Pharmaceuticals"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Eagle Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Acquisition","leadProduct":"Amisulpride","moa":"Serotonin (5-HT) receptor | Dopamine receptors; D2 & D3","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Acacia Pharma","amount2":0.17999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0.17999999999999999,"dosageForm":"Infusion","sponsorNew":"Acacia Pharma \/ Eagle Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Acacia Pharma \/ Eagle Pharmaceuticals"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Amisulpride","moa":"Serotonin (5-HT) receptor | Dopamine receptors; D2 & D3","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Acacia Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Acacia Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Acacia Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Amisulpride","moa":"Serotonin (5-HT) receptor | Dopamine receptors; D2 & D3","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Acacia Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Acacia Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Acacia Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Financing","leadProduct":"Amisulpride","moa":"Serotonin (5-HT) receptor | Dopamine receptors; D2 & D3","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Acacia Pharma","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Acacia Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Acacia Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Amisulpride","moa":"Serotonin (5-HT) receptor | Dopamine receptors; D2 & D3","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Acacia Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acacia Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Acacia Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Amicus CD | Premier Research Group","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Amisulpride","moa":"Serotonin (5-HT) receptor | Dopamine receptors; D2 & D3","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Acacia Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acacia Pharma \/ Amicus CD | Premier Research Group","highestDevelopmentStatusID":"15","companyTruncated":"Acacia Pharma \/ Amicus CD | Premier Research Group"},{"orgOrder":0,"company":"Ventrus Biosciences, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Iferanserin","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ventrus Biosciences, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Ventrus Biosciences, Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ventrus Biosciences, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Ventrus Biosciences, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Iferanserin","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ventrus Biosciences, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Ventrus Biosciences, Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ventrus Biosciences, Inc \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Tryp Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tryp Therapeutics \/ Massachusetts General Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Tryp Therapeutics \/ Massachusetts General Hospital"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Tryp Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tryp Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tryp Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Tryp Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tryp Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tryp Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Spectrum Health - Lakeland","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Haloperidol","moa":"Serotonin 2a (5-HT2a) receptor | D2-like dopamine receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Spectrum Health - Lakeland","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spectrum Health - Lakeland \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Health - Lakeland \/ Undisclosed"},{"orgOrder":0,"company":"Edusa Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Pumosetrag","moa":"Serotonin 3 (5-HT3) receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Edusa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Edusa Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Edusa Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ramosetron","moa":"Serotonin 3 (5-HT3) receptor","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Ramosetron","moa":"Serotonin 3 (5-HT3) receptor","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Ramosetron","moa":"Serotonin 3 (5-HT3) receptor","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Ramosetron","moa":"Serotonin 3 (5-HT3) receptor","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ondansetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Pill","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ondansetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Pill","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3 receptor||Serotonin 3a (5-HT3a) receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ondansetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Athena Pharmaceutiques","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ondansetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Athena Pharmaceutiques","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Athena Pharmaceutiques \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Athena Pharmaceutiques \/ Undisclosed"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Ondansetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Acacia Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acacia Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Acacia Pharma \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Ondansetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Ondansetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunnybrook Health Sciences Centre \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Sunnybrook Health Sciences Centre \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"OhioHealth","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ondansetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"OhioHealth","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OhioHealth \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"OhioHealth \/ Undisclosed"},{"orgOrder":0,"company":"MonoSol Rx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Ondansetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"MonoSol Rx","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MonoSol Rx \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"MonoSol Rx \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Alosetron Hydrochloride","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Granisetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyowa Kirin \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Kyowa Kirin \/ Undisclosed"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Granisetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyowa Kirin \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Kyowa Kirin \/ Undisclosed"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Granisetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Kyowa Kirin \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Kyowa Kirin \/ Undisclosed"},{"orgOrder":0,"company":"LG Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Granisetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"LG Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Patch","sponsorNew":"LG Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"LG Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"LG Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Granisetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"LG Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Patch","sponsorNew":"LG Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"LG Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Cumberland Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Acquisition","leadProduct":"Granisetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Kyowa Kirin \/ Cumberland Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Kyowa Kirin \/ Cumberland Pharmaceuticals"},{"orgOrder":0,"company":"Solasia Pharma KK","sponsor":"Proswell Medical Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Granisetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Solasia Pharma KK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Solasia Pharma KK \/ Proswell Medical Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Solasia Pharma KK \/ Proswell Medical Corporation"},{"orgOrder":0,"company":"University of Alabama at Birmingham","sponsor":"Heron Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Granisetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"University of Alabama at Birmingham","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection, Extended Release","sponsorNew":"University of Alabama at Birmingham \/ Heron Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"University of Alabama at Birmingham \/ Heron Therapeutics"},{"orgOrder":0,"company":"Indiana University","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Granisetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Indiana University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Indiana University \/ Kyowa Kirin","highestDevelopmentStatusID":"8","companyTruncated":"Indiana University \/ Kyowa Kirin"},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Verity Pharmaceuticals Inc","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"Granisetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Cumberland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Cumberland Pharmaceuticals \/ Verity Pharmaceuticals Inc","highestDevelopmentStatusID":"15","companyTruncated":"Cumberland Pharmaceuticals \/ Verity Pharmaceuticals Inc"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Granisetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Heron Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Heron Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Granisetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Heron Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Heron Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Taiho Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Palonosetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Taiho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Taiho Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Taiho Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"Helsinn Advanced Synthesis","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Palonosetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Fosun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fosun Pharmaceutical \/ Helsinn Advanced Synthesis","highestDevelopmentStatusID":"15","companyTruncated":"Fosun Pharmaceutical \/ Helsinn Advanced Synthesis"},{"orgOrder":0,"company":"Yung Shin Pharm Industrial","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"TAIWAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Palonosetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Yung Shin Pharm Industrial","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yung Shin Pharm Industrial \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Yung Shin Pharm Industrial \/ Undisclosed"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Palonosetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Helsinn Advanced Synthesis \/ Parexel","highestDevelopmentStatusID":"10","companyTruncated":"Helsinn Advanced Synthesis \/ Parexel"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Palonosetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Helsinn Advanced Synthesis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Helsinn Advanced Synthesis \/ Undisclosed"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"PSI CRO","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Palonosetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Helsinn Advanced Synthesis \/ PSI CRO","highestDevelopmentStatusID":"10","companyTruncated":"Helsinn Advanced Synthesis \/ PSI CRO"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Palonosetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Helsinn Advanced Synthesis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Helsinn Advanced Synthesis \/ Undisclosed"},{"orgOrder":0,"company":"Northside Hospital","sponsor":"Blood and Marrow Transplant Group of Georgia","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Palonosetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Northside Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northside Hospital \/ Blood and Marrow Transplant Group of Georgia","highestDevelopmentStatusID":"8","companyTruncated":"Northside Hospital \/ Blood and Marrow Transplant Group of Georgia"},{"orgOrder":0,"company":"Ohio State University","sponsor":"Eisai Inc","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Palonosetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Ohio State University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ohio State University \/ Eisai Inc","highestDevelopmentStatusID":"11","companyTruncated":"Ohio State University \/ Eisai Inc"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Palonosetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eisai Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eisai Inc \/ Undisclosed"},{"orgOrder":0,"company":"Avenacy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Palonosetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Avenacy","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avenacy \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Avenacy \/ Undisclosed"},{"orgOrder":0,"company":"LP Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Palonosetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"LP Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LP Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"LP Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"LP Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Palonosetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"LP Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LP Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"LP Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"First Wave BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Capeserod","moa":"Serotonin 4 (5-HT4) receptor","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ First Wave BioPharma","highestDevelopmentStatusID":"1","companyTruncated":"Sanofi \/ First Wave BioPharma"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Cisapride","moa":"Serotonin 4 (5-HT4) receptor","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Cisapride","moa":"Serotonin 4 (5-HT4) receptor","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Cisapride","moa":"Serotonin 4 (5-HT4) receptor","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Metoclopramide","moa":"Serotonin 4 (5-HT4) receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Evoke Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Evoke Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Evoke Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Metoclopramide","moa":"Serotonin 4 (5-HT4) receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Evoke Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Evoke Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Evoke Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Renexxion","sponsor":"Dr. Falk Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Naronapride","moa":"Serotonin 4 (5-HT4) receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Renexxion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Renexxion \/ Dr. Falk Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Renexxion \/ Dr. Falk Pharma"},{"orgOrder":0,"company":"Renexxion","sponsor":"Dr. Falk Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Naronapride","moa":"Serotonin 4 (5-HT4) receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Renexxion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Renexxion \/ Dr. Falk Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Renexxion \/ Dr. Falk Pharma"},{"orgOrder":0,"company":"Renexxion","sponsor":"Dr. Falk Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Naronapride","moa":"Serotonin 4 (5-HT4) receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Renexxion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Renexxion \/ Dr. Falk Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Renexxion \/ Dr. Falk Pharma"},{"orgOrder":0,"company":"Renexxion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Naronapride","moa":"Serotonin 4 (5-HT4) receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Renexxion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Renexxion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Renexxion \/ Undisclosed"},{"orgOrder":0,"company":"Renexxion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Naronapride","moa":"Serotonin 4 (5-HT4) receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Renexxion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Renexxion \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Renexxion \/ Undisclosed"},{"orgOrder":0,"company":"Renexxion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Naronapride","moa":"Serotonin 4 (5-HT4) receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Renexxion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Renexxion \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Renexxion \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Falk Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Naronapride","moa":"Serotonin 4 (5-HT4) receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Dr. Falk Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dr. Falk Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dr. Falk Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Renexxion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Naronapride","moa":"Serotonin 4 (5-HT4) receptor","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Renexxion","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Renexxion \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Renexxion \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Prucalopride Succinate","moa":"Serotonin 4 (5-HT4) receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Movetis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"BELGIUM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Prucalopride Succinate","moa":"Serotonin 4 (5-HT4) receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Movetis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Movetis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Movetis \/ Undisclosed"},{"orgOrder":0,"company":"Movetis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"BELGIUM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Prucalopride Succinate","moa":"Serotonin 4 (5-HT4) receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Movetis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Movetis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Movetis \/ Undisclosed"},{"orgOrder":0,"company":"Movetis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"BELGIUM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Prucalopride Succinate","moa":"Serotonin 4 (5-HT4) receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Movetis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Movetis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Movetis \/ Undisclosed"},{"orgOrder":0,"company":"Movetis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"BELGIUM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Prucalopride Succinate","moa":"Serotonin 4 (5-HT4) receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Movetis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Movetis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Movetis \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"PRA Health Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Prucalopride Succinate","moa":"Serotonin 4 (5-HT4) receptor","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"SHIRE PLC \/ PRA Health Sciences","highestDevelopmentStatusID":"11","companyTruncated":"SHIRE PLC \/ PRA Health Sciences"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Prucalopride Succinate","moa":"Serotonin 4 (5-HT4) receptor","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Prucalopride Succinate","moa":"Serotonin 4 (5-HT4) receptor","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Prucalopride Succinate","moa":"Serotonin 4 (5-HT4) receptor","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"University of Calgary","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Prucalopride Succinate","moa":"Serotonin 4 (5-HT4) receptor","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"University of Calgary","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Calgary \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"9","companyTruncated":"University of Calgary \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Prucalopride Succinate","moa":"Serotonin 4 (5-HT4) receptor","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Prucalopride Succinate","moa":"Serotonin 4 (5-HT4) receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Prucalopride Succinate","moa":"Serotonin 4 (5-HT4) receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Lupin Ltd \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Prucalopride Succinate","moa":"Serotonin 4 (5-HT4) receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Zydus Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"Undisclosed","sponsor":"Nora Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"Prucalopride Succinate","moa":"Serotonin 4 (5-HT4) receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Undisclosed \/ Nora Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Undisclosed \/ Nora Pharma"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Prucalopride Succinate","moa":"Serotonin 4 (5-HT4) receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"ANI Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Undisclosed"},{"orgOrder":0,"company":"SK Chemicals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Relenopride","moa":"Serotonin 4 (5-HT4) receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"SK Chemicals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SK Chemicals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SK Chemicals \/ Undisclosed"},{"orgOrder":0,"company":"SK Life Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Relenopride","moa":"Serotonin 4 (5-HT4) receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"SK Life Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SK Life Science \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SK Life Science \/ Undisclosed"},{"orgOrder":0,"company":"SK Life Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Relenopride","moa":"Serotonin 4 (5-HT4) receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"SK Life Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SK Life Science \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SK Life Science \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"SPD557","moa":"Serotonin 4 (5-HT4) receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"SSP-002358","moa":"Serotonin 4 (5-HT4) receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"TAK-954","moa":"Serotonin 4 (5-HT4) receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"TAK-954","moa":"Serotonin 4 (5-HT4) receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"TD-8954","moa":"Serotonin 4 (5-HT4) receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Velusetrag","moa":"Serotonin 4 (5-HT4) receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Alfasigma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alfasigma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alfasigma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Alfasigma","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Velusetrag","moa":"Serotonin 4 (5-HT4) receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theravance Biopharma \/ Alfasigma","highestDevelopmentStatusID":"8","companyTruncated":"Theravance Biopharma \/ Alfasigma"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Alfasigma","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Velusetrag","moa":"Serotonin 4 (5-HT4) receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theravance Biopharma \/ Alfasigma","highestDevelopmentStatusID":"8","companyTruncated":"Theravance Biopharma \/ Alfasigma"},{"orgOrder":0,"company":"INMUNOVA","sponsor":"KLIXAR | Linical | PHV LATAM","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ARGENTINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"INM004","moa":"Shiga Toxin","graph1":"Gastroenterology","graph2":"Phase II","graph3":"INMUNOVA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"INMUNOVA \/ KLIXAR | Linical | PHV LATAM","highestDevelopmentStatusID":"8","companyTruncated":"INMUNOVA \/ KLIXAR | Linical | PHV LATAM"},{"orgOrder":0,"company":"Allakos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"AK002","moa":"Sialic acid-binding Ig-like lectin 8","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allakos \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allakos \/ Undisclosed"},{"orgOrder":0,"company":"Allakos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"AK002","moa":"Sialic acid-binding Ig-like lectin 8","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allakos \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allakos \/ Undisclosed"},{"orgOrder":0,"company":"Allakos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"AK002","moa":"Sialic acid-binding Ig-like lectin 8","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allakos \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allakos \/ Undisclosed"},{"orgOrder":0,"company":"Allakos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"AK002","moa":"Sialic acid-binding Ig-like lectin 8","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allakos \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allakos \/ Undisclosed"},{"orgOrder":0,"company":"Allakos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Antolimab","moa":"Sialic acid-binding Ig-like lectin 8","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allakos \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allakos \/ Undisclosed"},{"orgOrder":0,"company":"Allakos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Antolimab","moa":"Sialic acid-binding Ig-like lectin 8","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allakos \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allakos \/ Undisclosed"},{"orgOrder":0,"company":"Allakos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Lirentelimab","moa":"Sialic acid-binding Ig-like lectin 8","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allakos \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allakos \/ Undisclosed"},{"orgOrder":0,"company":"Allakos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Lirentelimab","moa":"Sialic acid-binding Ig-like lectin 8","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allakos \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allakos \/ Undisclosed"},{"orgOrder":0,"company":"Allakos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Lirentelimab","moa":"Sialic acid-binding Ig-like lectin 8","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allakos \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allakos \/ Undisclosed"},{"orgOrder":0,"company":"Allakos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Lirentelimab","moa":"Sialic acid-binding Ig-like lectin 8","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allakos \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allakos \/ Undisclosed"},{"orgOrder":0,"company":"Allakos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Lirentelimab","moa":"Sialic acid-binding Ig-like lectin 8","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allakos \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allakos \/ Undisclosed"},{"orgOrder":0,"company":"Allakos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Lirentelimab","moa":"Sialic acid-binding Ig-like lectin 8","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allakos \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allakos \/ Undisclosed"},{"orgOrder":0,"company":"Allakos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Lirentelimab","moa":"Sialic acid-binding Ig-like lectin 8","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allakos \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allakos \/ Undisclosed"},{"orgOrder":0,"company":"Allakos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Lirentelimab","moa":"Sialic acid-binding Ig-like lectin 8","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allakos \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allakos \/ Undisclosed"},{"orgOrder":0,"company":"Allakos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Lirentelimab","moa":"Sialic acid-binding Ig-like lectin 8","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allakos \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Allakos \/ Undisclosed"},{"orgOrder":0,"company":"Allakos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Lirentelimab","moa":"Sialic acid-binding Ig-like lectin 8","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allakos \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allakos \/ Undisclosed"},{"orgOrder":0,"company":"Allakos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Lirentelimab","moa":"Sialic acid-binding Ig-like lectin 8","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allakos \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allakos \/ Undisclosed"},{"orgOrder":0,"company":"Allakos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Lirentelimab","moa":"Sialic acid-binding Ig-like lectin 8","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allakos \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allakos \/ Undisclosed"},{"orgOrder":0,"company":"Allakos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Lirentelimab","moa":"Sialic acid-binding Ig-like lectin 8","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allakos \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allakos \/ Undisclosed"},{"orgOrder":0,"company":"Allakos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Lirentelimab","moa":"Sialic acid-binding Ig-like lectin 8","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allakos \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Allakos \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Elobixibat Hydrate","moa":"SLC10A2","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Mayoly Spindler","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Alverine","moa":"Smooth muscle","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Mayoly Spindler","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayoly Spindler \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Mayoly Spindler \/ Undisclosed"},{"orgOrder":0,"company":"Maastricht University Medical Center","sponsor":"ZonMw","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Plant Extract\/Herbal","year":"2016","type":"Inapplicable","leadProduct":"Mentha Piperita Oil","moa":"Smooth muscle","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Maastricht University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oil","sponsorNew":"Maastricht University Medical Center \/ ZonMw","highestDevelopmentStatusID":"10","companyTruncated":"Maastricht University Medical Center \/ ZonMw"},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Avasopasem manganese","moa":"SOD","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Galera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Galera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galera Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Avasopasem manganese","moa":"SOD","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Galera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Galera Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Avasopasem manganese","moa":"SOD","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Galera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Galera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Galera Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Avasopasem manganese","moa":"SOD","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Galera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Galera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galera Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Avasopasem manganese","moa":"SOD","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Galera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Galera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galera Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Avasopasem manganese","moa":"SOD","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Galera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Galera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galera Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Avasopasem manganese","moa":"SOD","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Galera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Galera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galera Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Avasopasem manganese","moa":"SOD","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Galera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Galera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galera Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Avasopasem manganese","moa":"SOD","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Galera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Galera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galera Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Avasopasem manganese","moa":"SOD","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Galera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Galera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galera Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Avasopasem manganese","moa":"SOD","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Galera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Galera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galera Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Avasopasem manganese","moa":"SOD","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Galera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Galera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galera Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Avasopasem manganese","moa":"SOD","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Galera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Galera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galera Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Avasopasem manganese","moa":"SOD","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Galera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Galera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galera Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Avasopasem manganese","moa":"SOD","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Galera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Galera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galera Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Avasopasem manganese","moa":"SOD","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Galera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Galera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galera Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Avasopasem manganese","moa":"SOD","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Galera Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"Galera Therapeutics \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"Galera Therapeutics \/ Piper Sandler"},{"orgOrder":0,"company":"SINTETICA SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Chloroprocaine","moa":"Sodium channel alpha subunit","graph1":"Gastroenterology","graph2":"Phase II","graph3":"SINTETICA SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"SINTETICA SA \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SINTETICA SA \/ Undisclosed"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Lidocaine","moa":"||Sodium channel alpha subunit","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Citius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Citius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Lidocaine","moa":"||Sodium channel alpha subunit","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Citius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Citius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Egymedicalpedia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ropivacaine Hydrochloride","moa":"Sodium channel alpha subunit","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Egymedicalpedia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Egymedicalpedia \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Egymedicalpedia \/ Undisclosed"},{"orgOrder":0,"company":"Asklepios Kliniken Hamburg","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ropivacaine Hydrochloride","moa":"Sodium channel alpha subunit","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Asklepios Kliniken Hamburg","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asklepios Kliniken Hamburg \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Asklepios Kliniken Hamburg \/ Undisclosed"},{"orgOrder":0,"company":"Taiwan Liposome Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"TAIWAN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ropivacaine Hydrochloride","moa":"local anesthetics||Sodium channel alpha subunit","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Taiwan Liposome Company","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Taiwan Liposome Company \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Taiwan Liposome Company \/ Undisclosed"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Registrat-Mapi","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Pacira BioSciences \/ Registrat-Mapi","highestDevelopmentStatusID":"11","companyTruncated":"Pacira BioSciences \/ Registrat-Mapi"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Registrat-Mapi","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Pacira BioSciences \/ Registrat-Mapi","highestDevelopmentStatusID":"11","companyTruncated":"Pacira BioSciences \/ Registrat-Mapi"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Registrat-Mapi","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Pacira BioSciences \/ Registrat-Mapi","highestDevelopmentStatusID":"11","companyTruncated":"Pacira BioSciences \/ Registrat-Mapi"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pacira BioSciences \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pacira BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pacira BioSciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pacira BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Hvidovre University Hospital","sponsor":"Moberg Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Hvidovre University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"Hvidovre University Hospital \/ Moberg Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Hvidovre University Hospital \/ Moberg Pharma"},{"orgOrder":0,"company":"Innocoll Pharmaceuticals Limited","sponsor":"Premier Research Group","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Innocoll Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innocoll Pharmaceuticals Limited \/ Premier Research Group","highestDevelopmentStatusID":"8","companyTruncated":"Innocoll Pharmaceuticals Limited \/ Premier Research Group"},{"orgOrder":0,"company":"Innocoll Pharmaceuticals Limited","sponsor":"Premier Research Group","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Innocoll Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innocoll Pharmaceuticals Limited \/ Premier Research Group","highestDevelopmentStatusID":"8","companyTruncated":"Innocoll Pharmaceuticals Limited \/ Premier Research Group"},{"orgOrder":0,"company":"Innocoll Pharmaceuticals Limited","sponsor":"Premier Research Group","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Bupivacaine Hydrochloride","moa":"Sodium channel protein type IV alpha subunit","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Innocoll Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Innocoll Pharmaceuticals Limited \/ Premier Research Group","highestDevelopmentStatusID":"10","companyTruncated":"Innocoll Pharmaceuticals Limited \/ Premier Research Group"},{"orgOrder":0,"company":"Innocoll Pharmaceuticals Limited","sponsor":"Premier Research Group","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Bupivacaine Hydrochloride","moa":"Sodium channel protein type IV alpha subunit","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Innocoll Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Innocoll Pharmaceuticals Limited \/ Premier Research Group","highestDevelopmentStatusID":"8","companyTruncated":"Innocoll Pharmaceuticals Limited \/ Premier Research Group"},{"orgOrder":0,"company":"Innocoll Pharmaceuticals Limited","sponsor":"Medpace, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Bupivacaine Hydrochloride","moa":"Sodium channel protein type IV alpha subunit","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Innocoll Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Innocoll Pharmaceuticals Limited \/ Medpace, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Innocoll Pharmaceuticals Limited \/ Medpace, Inc"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Registrat-Mapi","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Pacira BioSciences \/ Registrat-Mapi","highestDevelopmentStatusID":"11","companyTruncated":"Pacira BioSciences \/ Registrat-Mapi"},{"orgOrder":0,"company":"Egymedicalpedia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Levobupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Egymedicalpedia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Egymedicalpedia \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Egymedicalpedia \/ Undisclosed"},{"orgOrder":0,"company":"Egymedicalpedia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Levobupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Egymedicalpedia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Egymedicalpedia \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Egymedicalpedia \/ Undisclosed"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Tenapanor","moa":"Sodium\/hydrogen exchanger 3","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ardelyx \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Ardelyx \/ Undisclosed"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Tenapanor","moa":"Sodium\/hydrogen exchanger 3","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ardelyx \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Ardelyx \/ Undisclosed"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Tenapanor","moa":"Sodium\/hydrogen exchanger 3","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ardelyx \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Ardelyx \/ Undisclosed"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Tenapanor","moa":"Sodium\/hydrogen exchanger 3","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ardelyx \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Ardelyx \/ Undisclosed"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Tenapanor","moa":"Sodium\/hydrogen exchanger 3","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ardelyx \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Ardelyx \/ Undisclosed"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tenapanor","moa":"Sodium\/hydrogen exchanger 3","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ardelyx \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Ardelyx \/ Undisclosed"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tenapanor","moa":"Sodium\/hydrogen exchanger 3","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ardelyx \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Ardelyx \/ Undisclosed"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tenapanor","moa":"Sodium\/hydrogen exchanger 3","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ardelyx \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Ardelyx \/ Undisclosed"},{"orgOrder":0,"company":"Biolab Sanus Farmaceutica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SPAIN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Isosorbide Mononitrate","moa":"Soluble guanylate cyclase","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Biolab Sanus Farmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biolab Sanus Farmaceutica \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biolab Sanus Farmaceutica \/ Undisclosed"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Nitroglycerin","moa":"Soluble guanylate cyclase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Cosette Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Nitroglycerin","moa":"Soluble guanylate cyclase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Cosette Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Cosette Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Cosette Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Cyclerion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Olinciguat","moa":"Soluble guanylate cyclase","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Cyclerion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cyclerion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cyclerion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Norgine","sponsor":"Faes Farma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Agreement","leadProduct":"Potassium Chloride","moa":"||Solute carrier family 12 member 1 (SLC12A1)","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Norgine \/ Faes Farma","highestDevelopmentStatusID":"15","companyTruncated":"Norgine \/ Faes Farma"},{"orgOrder":0,"company":"Virginia Commonwealth University","sponsor":"Thoratec Corporation | Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"Somatostatin receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Virginia Commonwealth University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Virginia Commonwealth University \/ Thoratec Corporation | Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Virginia Commonwealth University \/ Thoratec Corporation | Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Universitaire Ziekenhuizen KU Leuven","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"BELGIUM","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Lanreotide Acetate","moa":"Somatostatin receptor 5","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Universitaire Ziekenhuizen KU Leuven","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universitaire Ziekenhuizen KU Leuven \/ Ipsen","highestDevelopmentStatusID":"8","companyTruncated":"Universitaire Ziekenhuizen KU Leuven \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Lanreotide Acetate","moa":"Somatostatin receptor 5","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Lanreotide Acetate","moa":"Somatostatin receptor 5","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Northwell Health","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Lanreotide Acetate","moa":"Somatostatin receptor 5","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Northwell Health \/ Ipsen","highestDevelopmentStatusID":"8","companyTruncated":"Northwell Health \/ Ipsen"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Pasireotide Diaspartate","moa":"Somatostatin receptor 5 | Somatostatin receptor 3 | Somatostatin receptor 2 | Somatostatin receptor 1","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Bukwang Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Fenoverine","moa":"spasmolytic agents (papaverine type)","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Bukwang Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bukwang Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bukwang Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Mebeverine","moa":"spasmolytic agents (papaverine type)","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Abbott Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abbott Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Amiselimod","moa":"Sphingosine 1-phosphate receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mitsubishi Tanabe Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Mitsubishi Tanabe Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Etrasimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Etrasimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Pfizer Inc"},{"orgOrder":0,"company":"Ossium Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"OSSM-001","moa":"Stem cell proliferation","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Ossium Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ossium Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ossium Health \/ Undisclosed"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Docusate Sodium","moa":"Stool surface tension","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ferring Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"University of Miami","sponsor":"QOL Medical","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Sucrase","moa":"Sucrase","graph1":"Gastroenterology","graph2":"Phase II","graph3":"University of Miami","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"University of Miami \/ QOL Medical","highestDevelopmentStatusID":"8","companyTruncated":"University of Miami \/ QOL Medical"},{"orgOrder":0,"company":"QOL Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Sacrosidase","moa":"Sucrose","graph1":"Gastroenterology","graph2":"Phase II","graph3":"QOL Medical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"QOL Medical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"QOL Medical \/ Undisclosed"},{"orgOrder":0,"company":"Eisai","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Cinitapride","moa":"sulpride derivatives","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eisai \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eisai \/ Undisclosed"},{"orgOrder":0,"company":"Matrix Biomed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Tempol","moa":"Superoxide dismutase Cu-Zn (SOD Cu-Zn)","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Matrix Biomed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Matrix Biomed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Matrix Biomed \/ Undisclosed"},{"orgOrder":0,"company":"Zedira","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"TAK-227","moa":"TG2","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Zedira","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zedira \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Zedira \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Tezepelumab","moa":"Thymic stromal lymphopoietin","graph1":"Gastroenterology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Amgen Inc","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Amgen Inc"},{"orgOrder":0,"company":"Spyre Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"SPY002-091","moa":"TL1A","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Spyre Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spyre Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Spyre Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Dr. Falk Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Collaboration","leadProduct":"PR600","moa":"TNF receptor","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Prometheus Biosciences \/ Dr. Falk Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Prometheus Biosciences \/ Dr. Falk Pharma"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Dr. Falk Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Collaboration","leadProduct":"PR600","moa":"TNF receptor","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Prometheus Biosciences \/ Dr. Falk Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Prometheus Biosciences \/ Dr. Falk Pharma"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Dr. Falk Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Collaboration","leadProduct":"PR600","moa":"TNF receptor","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Prometheus Biosciences","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Prometheus Biosciences \/ Dr. Falk Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Prometheus Biosciences \/ Dr. Falk Pharma"},{"orgOrder":0,"company":"CMC Ambroise Par\u00e9","sponsor":"Paris IBD Center | Celltrion","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"CT-P13","moa":"TNF-alpha","graph1":"Gastroenterology","graph2":"Phase III","graph3":"CMC Ambroise Par\u00e9","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CMC Ambroise Par\u00e9 \/ Paris IBD Center | Celltrion","highestDevelopmentStatusID":"10","companyTruncated":"CMC Ambroise Par\u00e9 \/ Paris IBD Center | Celltrion"},{"orgOrder":0,"company":"Belgian Inflammatory Bowel Disease Research and Development","sponsor":"Celltrion","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Belgian Inflammatory Bowel Disease Research and Development","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Belgian Inflammatory Bowel Disease Research and Development \/ Celltrion","highestDevelopmentStatusID":"11","companyTruncated":"Belgian Inflammatory Bowel Disease Research and Development \/ Celltrion"},{"orgOrder":0,"company":"University Medical Center Groningen","sponsor":"European Crohn\u00b4s and Colitis Organisation | B\u00fchlmann Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"University Medical Center Groningen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Medical Center Groningen \/ European Crohn\u00b4s and Colitis Organisation | B\u00fchlmann Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"University Medical Center Groningen \/ European Crohn\u00b4s and Colitis Organisation | B\u00fchlmann Laboratories"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Gastroenterology","graph2":"Phase III","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"University Medical Center Groningen","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Gastroenterology","graph2":"Phase I","graph3":"University Medical Center Groningen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Medical Center Groningen \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"University Medical Center Groningen \/ AbbVie Inc"},{"orgOrder":0,"company":"Progenity","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Progenity","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Progenity \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Progenity \/ Undisclosed"},{"orgOrder":0,"company":"Athos Therapeutics","sponsor":"Lahey Hospital & Medical Center","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"ATH-63","moa":"TNF-alpha receptor","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Athos Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Athos Therapeutics \/ Lahey Hospital & Medical Center","highestDevelopmentStatusID":"4","companyTruncated":"Athos Therapeutics \/ Lahey Hospital & Medical Center"},{"orgOrder":0,"company":"Roswell Park Cancer Institute","sponsor":"National Cancer Institute | Cleveland BioLabs","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Entolimod","moa":"Toll-like receptor 5","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Roswell Park Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Roswell Park Cancer Institute \/ National Cancer Institute | Cleveland BioLabs","highestDevelopmentStatusID":"6","companyTruncated":"Roswell Park Cancer Institute \/ National Cancer Institute | Cleveland BioLabs"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"Toll-like receptor 9","graph1":"Gastroenterology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"Toll-like receptor 9","graph1":"Gastroenterology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"ONO-2952","moa":"Translocator protein","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ono Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ono Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"ONO-2952","moa":"Translocator protein","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ono Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ono Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Celsius Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"CEL383","moa":"TREM1","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Celsius Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celsius Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Celsius Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Celsius Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Acquisition","leadProduct":"CEL383","moa":"TREM1","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Celsius Therapeutics","amount2":0.25,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0.25,"dosageForm":"Injection","sponsorNew":"Celsius Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Celsius Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"Inotrem","sponsor":"Crohn\u2019s & Colitis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2023","type":"Funding","leadProduct":"INO-02","moa":"TREM1","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Inotrem","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inotrem \/ Crohn\u2019s & Colitis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Inotrem \/ Crohn\u2019s & Colitis Foundation"},{"orgOrder":0,"company":"Inotrem","sponsor":"Crohn\u2019s & Colitis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2023","type":"Funding","leadProduct":"INO-02","moa":"TREM1","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Inotrem","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inotrem \/ Crohn\u2019s & Colitis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Inotrem \/ Crohn\u2019s & Colitis Foundation"},{"orgOrder":0,"company":"Concentric Analgesics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vocacapsaicin","moa":"TRPV1","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Concentric Analgesics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Concentric Analgesics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Concentric Analgesics \/ Undisclosed"},{"orgOrder":0,"company":"Ventria Bioscience","sponsor":"National Institute on Aging","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Lactoferrin","moa":"Tryptase alpha\/beta-1 (Tryptase)","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ventria Bioscience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ventria Bioscience \/ National Institute on Aging","highestDevelopmentStatusID":"10","companyTruncated":"Ventria Bioscience \/ National Institute on Aging"},{"orgOrder":0,"company":"TerSera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Telotristat Ethyl","moa":"Tryptophan 5-hydroxylase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"TerSera Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TerSera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"TerSera Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Telotristat Ethyl","moa":"Tryptophan 5-hydroxylase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Lexicon pharmaceuticals","amount2":0.059999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Lexicon pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Lexicon pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Albendazole","moa":"Tubulin","graph1":"Gastroenterology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"University of Southern California","sponsor":"National Cancer Institute | Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2011","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Gastroenterology","graph2":"Phase II","graph3":"University of Southern California","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Southern California \/ National Cancer Institute | Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"University of Southern California \/ National Cancer Institute | Sanofi"},{"orgOrder":0,"company":"GIE Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Gastroenterology","graph2":"Phase III","graph3":"GIE Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GIE Medical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GIE Medical \/ Undisclosed"},{"orgOrder":0,"company":"GIE Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Gastroenterology","graph2":"Phase III","graph3":"GIE Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GIE Medical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GIE Medical \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Amlitelimab","moa":"Tumor necrosis factor ligand superfamily member 4","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ritlecitinib","moa":"Tyrosine-protein kinase JAK3 | TEC family kinase","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Massachusetts General Hospital \/ Pfizer Inc"},{"orgOrder":0,"company":"Boston Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"BOS-589","moa":"Tyrosine-protein kinase receptor RET","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Boston Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boston Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boston Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"BOS-589","moa":"Tyrosine-protein kinase receptor RET","graph1":"Gastroenterology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Galapagos","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"BELGIUM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galapagos \/ Gilead Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Galapagos \/ Gilead Sciences"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"BELGIUM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"EP Plus Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"MALAYSIA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Skal Pro","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"EP Plus Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Sachet","sponsorNew":"EP Plus Group \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"EP Plus Group \/ Undisclosed"},{"orgOrder":0,"company":"Cell Biotech Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Duolac7S","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Cell Biotech Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cell Biotech Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cell Biotech Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Innovacell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"aSMDC","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Innovacell","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovacell \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Innovacell \/ Undisclosed"},{"orgOrder":0,"company":"Nanjing Immunophage Biotech","sponsor":"Zhejiang Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"IPG11406","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Nanjing Immunophage Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nanjing Immunophage Biotech \/ Zhejiang Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Nanjing Immunophage Biotech \/ Zhejiang Hospital"},{"orgOrder":0,"company":"Therabel Pharma","sponsor":"ECSOR","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"BELGIUM","productType":"Probiotic","year":"2017","type":"Inapplicable","leadProduct":"Prolardii","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Therabel Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Therabel Pharma \/ ECSOR","highestDevelopmentStatusID":"1","companyTruncated":"Therabel Pharma \/ ECSOR"},{"orgOrder":0,"company":"Vedic Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Probiotic","year":"2018","type":"Inapplicable","leadProduct":"Livespo Navax","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Vedic Lifesciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vedic Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Vedic Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"Vedic Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"VL-BK-02","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Vedic Lifesciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vedic Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Vedic Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"Intrinsic Medicine","sponsor":"Phoenix Biotech Acquisition Corp","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Carbohydrate","year":"2022","type":"Termination","leadProduct":"2-Fucosyllactose-Synthetic","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Intrinsic Medicine","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.14000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Intrinsic Medicine \/ Phoenix Biotech Acquisition Corp","highestDevelopmentStatusID":"8","companyTruncated":"Intrinsic Medicine \/ Phoenix Biotech Acquisition Corp"},{"orgOrder":0,"company":"Intrinsic Medicine","sponsor":"Phoenix Biotech Acquisition Corp","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Carbohydrate","year":"2022","type":"Merger","leadProduct":"2-Fucosyllactose-Synthetic","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Intrinsic Medicine","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.14000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Intrinsic Medicine \/ Phoenix Biotech Acquisition Corp","highestDevelopmentStatusID":"8","companyTruncated":"Intrinsic Medicine \/ Phoenix Biotech Acquisition Corp"},{"orgOrder":0,"company":"a2 Milk Company Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NEW ZEALAND","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"a2 Full Cream Milk","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"a2 Milk Company Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"a2 Milk Company Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"a2 Milk Company Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Weill Medical College of Cornell University","sponsor":"Angiocrine Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"AB-207","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Weill Medical College of Cornell University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Weill Medical College of Cornell University \/ Angiocrine Bioscience","highestDevelopmentStatusID":"6","companyTruncated":"Weill Medical College of Cornell University \/ Angiocrine Bioscience"},{"orgOrder":0,"company":"AB Biotek","sponsor":"Grupo Colis\u00e9e","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"ABB i5","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"AB Biotek","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AB Biotek \/ Grupo Colis\u00e9e","highestDevelopmentStatusID":"6","companyTruncated":"AB Biotek \/ Grupo Colis\u00e9e"},{"orgOrder":0,"company":"AB Biotek","sponsor":"Colis\u00e9e Barcelona Isabel Roig | Grupo Colis\u00e9e","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"ABB S3","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"AB Biotek","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"AB Biotek \/ Colis\u00e9e Barcelona Isabel Roig | Grupo Colis\u00e9e","highestDevelopmentStatusID":"6","companyTruncated":"AB Biotek \/ Colis\u00e9e Barcelona Isabel Roig | Grupo Colis\u00e9e"},{"orgOrder":0,"company":"AB Biotics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SPAIN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Ab-Kolicare","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"AB Biotics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AB Biotics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"AB Biotics \/ Undisclosed"},{"orgOrder":0,"company":"Alpinia Laudanum GmbH","sponsor":"BioTeSys GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Acacia Gum","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Alpinia Laudanum GmbH","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alpinia Laudanum GmbH \/ BioTeSys GmbH","highestDevelopmentStatusID":"1","companyTruncated":"Alpinia Laudanum GmbH \/ BioTeSys GmbH"},{"orgOrder":0,"company":"TD Vaccines A\/S","sponsor":"Pierrel | Johns Hopkins Bloomberg School of Public Health","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"ACE527","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"TD Vaccines A\/S","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"TD Vaccines A\/S \/ Pierrel | Johns Hopkins Bloomberg School of Public Health","highestDevelopmentStatusID":"8","companyTruncated":"TD Vaccines A\/S \/ Pierrel | Johns Hopkins Bloomberg School of Public Health"},{"orgOrder":0,"company":"Ache Laboratorios Farmaceuticos SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"BRAZIL","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"ACH04","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Ache Laboratorios Farmaceuticos SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ache Laboratorios Farmaceuticos SA \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ache Laboratorios Farmaceuticos SA \/ Undisclosed"},{"orgOrder":0,"company":"Hamilton Health Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Actazin","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Hamilton Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"Hamilton Health Sciences \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Hamilton Health Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Sahlgrenska University Hospital","sponsor":"Danone Global Research & Innovation Center","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Activia","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Sahlgrenska University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sahlgrenska University Hospital \/ Danone Global Research & Innovation Center","highestDevelopmentStatusID":"1","companyTruncated":"Sahlgrenska University Hospital \/ Danone Global Research & Innovation Center"},{"orgOrder":0,"company":"AddPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"AD-115A","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"AddPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AddPharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AddPharma \/ Undisclosed"},{"orgOrder":0,"company":"AddPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"AD-120A","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"AddPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AddPharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AddPharma \/ Undisclosed"},{"orgOrder":0,"company":"AddPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"AD-203","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"AddPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AddPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AddPharma \/ Undisclosed"},{"orgOrder":0,"company":"AddPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"AD-206","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"AddPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AddPharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AddPharma \/ Undisclosed"},{"orgOrder":0,"company":"AddPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AD-213-B","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"AddPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AddPharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AddPharma \/ Undisclosed"},{"orgOrder":0,"company":"AddPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"AD-213-B","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"AddPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AddPharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AddPharma \/ Undisclosed"},{"orgOrder":0,"company":"AddPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AD-214-02","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"AddPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AddPharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AddPharma \/ Undisclosed"},{"orgOrder":0,"company":"Harvard Apparatus Regenerative Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Adipose Derived Mesenchymal Stromal Cell","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Harvard Apparatus Regenerative Technology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Harvard Apparatus Regenerative Technology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Harvard Apparatus Regenerative Technology \/ Undisclosed"},{"orgOrder":0,"company":"Oragenics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"AG013","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Gargle\/Mouthwash","sponsorNew":"Oragenics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oragenics \/ Undisclosed"},{"orgOrder":0,"company":"Oragenics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Microorganism","year":"2017","type":"Inapplicable","leadProduct":"AG013","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oil","sponsorNew":"Oragenics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oragenics \/ Undisclosed"},{"orgOrder":0,"company":"Igy Inc.","sponsor":"Vetanda Group Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Dietary Supplement","year":"2018","type":"Inapplicable","leadProduct":"AGY","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Igy Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Igy Inc. \/ Vetanda Group Ltd","highestDevelopmentStatusID":"8","companyTruncated":"Igy Inc. \/ Vetanda Group Ltd"},{"orgOrder":0,"company":"EA Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"AJG555","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"EA Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Sachet","sponsorNew":"EA Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EA Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Pendulum Therapeutics","sponsor":"Fonterra Co-operative Group","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2023","type":"Partnership","leadProduct":"Akkermansia Muciniphila","moa":"||Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Pendulum Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Pendulum Therapeutics \/ Fonterra Co-operative Group","highestDevelopmentStatusID":"15","companyTruncated":"Pendulum Therapeutics \/ Fonterra Co-operative Group"},{"orgOrder":0,"company":"PrecisionBiotics Group Ltd.","sponsor":"Instituto de Nutrici\u00f3n y Tecnolog\u00eda de los Alimentos","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Alflorex","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"PrecisionBiotics Group Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PrecisionBiotics Group Ltd. \/ Instituto de Nutrici\u00f3n y Tecnolog\u00eda de los Alimentos","highestDevelopmentStatusID":"1","companyTruncated":"PrecisionBiotics Group Ltd. \/ Instituto de Nutrici\u00f3n y Tecnolog\u00eda de los Alimentos"},{"orgOrder":0,"company":"Instituto de Investigacion Sanitaria La Fe","sponsor":"Effice Servicios Para la Investigacion","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SPAIN","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Allogeneic Adipose-Derived Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Instituto de Investigacion Sanitaria La Fe","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Instituto de Investigacion Sanitaria La Fe \/ Effice Servicios Para la Investigacion","highestDevelopmentStatusID":"7","companyTruncated":"Instituto de Investigacion Sanitaria La Fe \/ Effice Servicios Para la Investigacion"},{"orgOrder":0,"company":"Verman Oy Ab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FINLAND","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Alpha-Galactosidase","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Verman Oy Ab","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Verman Oy Ab \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Verman Oy Ab \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Altsonflex","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Altsonflex","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Bharat Biotech","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2025","type":"Licensing Agreement","leadProduct":"AltSonflex1-2-3","moa":"||Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Bharat Biotech","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Bharat Biotech"},{"orgOrder":0,"company":"Impleo Medical Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Aluvra","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Impleo Medical Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Impleo Medical Inc. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Impleo Medical Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Alivio Therapeutics","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Funding","leadProduct":"ALV-304","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Alivio Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alivio Therapeutics \/ US Department of Defense","highestDevelopmentStatusID":"4","companyTruncated":"Alivio Therapeutics \/ US Department of Defense"},{"orgOrder":0,"company":"Intermountain Health","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Alvimopam","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Intermountain Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intermountain Health \/ Merck & Co","highestDevelopmentStatusID":"1","companyTruncated":"Intermountain Health \/ Merck & Co"},{"orgOrder":0,"company":"Laborat\u00f3rio Sa\u00fade","sponsor":"Phytopharm Consulting","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"BRAZIL","productType":"Plant Extract\/Herbal","year":"2011","type":"Inapplicable","leadProduct":"Amargol","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Laborat\u00f3rio Sa\u00fade","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Laborat\u00f3rio Sa\u00fade \/ Phytopharm Consulting","highestDevelopmentStatusID":"10","companyTruncated":"Laborat\u00f3rio Sa\u00fade \/ Phytopharm Consulting"},{"orgOrder":0,"company":"AmacaThera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"AMT-143","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"AmacaThera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Hydrogel","sponsorNew":"AmacaThera \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AmacaThera \/ Undisclosed"},{"orgOrder":0,"company":"Xuanzhu Biopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Anaprazole","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Xuanzhu Biopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xuanzhu Biopharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Xuanzhu Biopharm \/ Undisclosed"},{"orgOrder":0,"company":"Valenta Pharm JSC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"RUSSIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Antareit","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Valenta Pharm JSC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Valenta Pharm JSC \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Valenta Pharm JSC \/ Undisclosed"},{"orgOrder":0,"company":"Qingfeng Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Aolanti Weikang","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Qingfeng Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Qingfeng Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Qingfeng Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Qingfeng Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Aolanti Weipang","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Qingfeng Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Qingfeng Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Qingfeng Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Aqilion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"AQ280","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Aqilion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aqilion \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aqilion \/ Undisclosed"},{"orgOrder":0,"company":"Aqilion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"AQ280","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Aqilion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aqilion \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aqilion \/ Undisclosed"},{"orgOrder":0,"company":"University College Cork","sponsor":"Marigot Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Dietary Supplement","year":"2013","type":"Inapplicable","leadProduct":"Calcium Stearate API","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"University College Cork","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University College Cork \/ Marigot Ltd.","highestDevelopmentStatusID":"1","companyTruncated":"University College Cork \/ Marigot Ltd."},{"orgOrder":0,"company":"Arrae","sponsor":"Citruslabs","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Arrae Bloat Supplement","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Arrae","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Arrae \/ Citruslabs","highestDevelopmentStatusID":"1","companyTruncated":"Arrae \/ Citruslabs"},{"orgOrder":0,"company":"Artizan Bioscience","sponsor":"Hatteras Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Series A Financing","leadProduct":"ARZC-001","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Artizan Bioscience","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Artizan Bioscience \/ Hatteras Venture Partners","highestDevelopmentStatusID":"4","companyTruncated":"Artizan Bioscience \/ Hatteras Venture Partners"},{"orgOrder":0,"company":"Artizan Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ARZC-001","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Artizan Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Artizan Bioscience \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Artizan Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Seldar Pharma, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"ASP7147","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Seldar Pharma, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Seldar Pharma, Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Seldar Pharma, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Athos Therapeutics","sponsor":"Syneos Health | Athos Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ATH-063","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Athos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Athos Therapeutics \/ Syneos Health | Athos Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Athos Therapeutics \/ Syneos Health | Athos Therapeutics"},{"orgOrder":0,"company":"Athos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Series B Financing","leadProduct":"ATH-063","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Athos Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0.040000000000000001,"dosageForm":"Capsule","sponsorNew":"Athos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Athos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ramon Gorter","sponsor":"ZonMw | Amsterdam UMC, VUmc","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Co-amoxiclav","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Ramon Gorter","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ramon Gorter \/ ZonMw | Amsterdam UMC, VUmc","highestDevelopmentStatusID":"11","companyTruncated":"Ramon Gorter \/ ZonMw | Amsterdam UMC, VUmc"},{"orgOrder":0,"company":"Anterogen Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2011","type":"Inapplicable","leadProduct":"Autologous Adipose-Derived Stem Cell","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anterogen Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Anterogen Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Anterogen Co \/ Undisclosed"},{"orgOrder":0,"company":"Cellf BIO","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Autologous Bioengineered Internal Anal Sphincter","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Cellf BIO","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Cellf BIO \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cellf BIO \/ Undisclosed"},{"orgOrder":0,"company":"Cellf BIO","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Autologous Cell","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Cellf BIO","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellf BIO \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cellf BIO \/ Undisclosed"},{"orgOrder":0,"company":"Avobis Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"AVB-114","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Avobis Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Avobis Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Avobis Bio \/ Undisclosed"},{"orgOrder":0,"company":"Avobis Bio","sponsor":"Alimentiv","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"AVB-114","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Avobis Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Insert","sponsorNew":"Avobis Bio \/ Alimentiv","highestDevelopmentStatusID":"8","companyTruncated":"Avobis Bio \/ Alimentiv"},{"orgOrder":0,"company":"Alexza Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AZ010","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Alexza Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alexza Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alexza Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Evolve BioSystems, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"B. Infantis EVC001","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Evolve BioSystems, Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evolve BioSystems, Inc. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Evolve BioSystems, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Fonterra Research Centre","sponsor":"International Flavors and Fragrances","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NEW ZEALAND","productType":"Probiotic","year":"2011","type":"Inapplicable","leadProduct":"B. Lactis Hn019","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Fonterra Research Centre","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Fonterra Research Centre \/ International Flavors and Fragrances","highestDevelopmentStatusID":"10","companyTruncated":"Fonterra Research Centre \/ International Flavors and Fragrances"},{"orgOrder":0,"company":"Morinaga Milk Industry Co., LTD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"Bifidobacterium Longum","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Morinaga Milk Industry Co., LTD","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Morinaga Milk Industry Co., LTD \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Morinaga Milk Industry Co., LTD \/ Undisclosed"},{"orgOrder":0,"company":"Kerry Group","sponsor":"Beijing Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"Bacillus Coagulans GBI-30, 6086","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Kerry Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kerry Group \/ Beijing Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Kerry Group \/ Beijing Hospital"},{"orgOrder":0,"company":"Kerry Group","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"Bacillus Subtilis ATCC 122264","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Kerry Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kerry Group \/ Nutrasource","highestDevelopmentStatusID":"1","companyTruncated":"Kerry Group \/ Nutrasource"},{"orgOrder":0,"company":"Archer Daniels Midland","sponsor":"Kennesaw State University","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2019","type":"Inapplicable","leadProduct":"Bacillus Subtilis DE111","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Archer Daniels Midland","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Archer Daniels Midland \/ Kennesaw State University","highestDevelopmentStatusID":"1","companyTruncated":"Archer Daniels Midland \/ Kennesaw State University"},{"orgOrder":0,"company":"Astel Medica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Bactecal D","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Astel Medica","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astel Medica \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Astel Medica \/ Undisclosed"},{"orgOrder":0,"company":"Colorado State University","sponsor":"George Mason University | Metabiomics Corp","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Microorganism","year":"2017","type":"Inapplicable","leadProduct":"Bacteriophage Mixture","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Colorado State University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Colorado State University \/ George Mason University | Metabiomics Corp","highestDevelopmentStatusID":"1","companyTruncated":"Colorado State University \/ George Mason University | Metabiomics Corp"},{"orgOrder":0,"company":"EMS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"BRAZIL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Bali Association","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"EMS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"EMS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EMS \/ Undisclosed"},{"orgOrder":0,"company":"Chr. Hansen","sponsor":"Atlantia Food Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Probiotic","year":"2019","type":"Inapplicable","leadProduct":"Bif195","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Chr. Hansen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chr. Hansen \/ Atlantia Food Clinical Trials","highestDevelopmentStatusID":"1","companyTruncated":"Chr. Hansen \/ Atlantia Food Clinical Trials"},{"orgOrder":0,"company":"Chr. Hansen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"Bif195","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Chr. Hansen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chr. Hansen \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Chr. Hansen \/ Undisclosed"},{"orgOrder":0,"company":"Chr. Hansen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"Bif195","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Chr. Hansen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chr. Hansen \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Chr. Hansen \/ Undisclosed"},{"orgOrder":0,"company":"Danisco Sweeteners Oy","sponsor":"Eurofins CDMO","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FINLAND","productType":"Microorganism","year":"2014","type":"Inapplicable","leadProduct":"Bifidobacterium","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Danisco Sweeteners Oy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Danisco Sweeteners Oy \/ Eurofins CDMO","highestDevelopmentStatusID":"8","companyTruncated":"Danisco Sweeteners Oy \/ Eurofins CDMO"},{"orgOrder":0,"company":"German Diabetes Center","sponsor":"Sofar Spa","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Microorganism","year":"2016","type":"Inapplicable","leadProduct":"Bifidobacterium","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"German Diabetes Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"German Diabetes Center \/ Sofar Spa","highestDevelopmentStatusID":"1","companyTruncated":"German Diabetes Center \/ Sofar Spa"},{"orgOrder":0,"company":"Sofar Spa","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Microorganism","year":"2018","type":"Inapplicable","leadProduct":"Bifidobacterium","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Sofar Spa","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sofar Spa \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Sofar Spa \/ Undisclosed"},{"orgOrder":0,"company":"PanTheryx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Bifidobacterium","moa":"||Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"PanTheryx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"PanTheryx \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"PanTheryx \/ Undisclosed"},{"orgOrder":0,"company":"M\u00f3nica Olivares Mart\u00edn; PhD","sponsor":"European Regional Development Fund | Ministry of Science and Innovation, Spain","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Microorganism","year":"2018","type":"Inapplicable","leadProduct":"Bifidobacterium Breve","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"M\u00f3nica Olivares Mart\u00edn; PhD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"M\u00f3nica Olivares Mart\u00edn; PhD \/ European Regional Development Fund | Ministry of Science and Innovation, Spain","highestDevelopmentStatusID":"8","companyTruncated":"M\u00f3nica Olivares Mart\u00edn; PhD \/ European Regional Development Fund | Ministry of Science and Innovation, Spain"},{"orgOrder":0,"company":"The Center for Applied Health Sciences, LLC","sponsor":"Biohm Health, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Bifidobacterium Breve","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"The Center for Applied Health Sciences, LLC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Center for Applied Health Sciences, LLC \/ Biohm Health, LLC","highestDevelopmentStatusID":"1","companyTruncated":"The Center for Applied Health Sciences, LLC \/ Biohm Health, LLC"},{"orgOrder":0,"company":"Hvidovre University Hospital","sponsor":"Chr. Hansen","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Bifidobacterium Breve Bif195","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Hvidovre University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hvidovre University Hospital \/ Chr. Hansen","highestDevelopmentStatusID":"1","companyTruncated":"Hvidovre University Hospital \/ Chr. Hansen"},{"orgOrder":0,"company":"American Academy of Family Physicians","sponsor":"Genova Diagnostics","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Bifidobacterium Infantis","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"American Academy of Family Physicians","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"American Academy of Family Physicians \/ Genova Diagnostics","highestDevelopmentStatusID":"11","companyTruncated":"American Academy of Family Physicians \/ Genova Diagnostics"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"McMaster University","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Probiotic","year":"2011","type":"Inapplicable","leadProduct":"Bifidobacterium Longum","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Nestle Health Sciences SA \/ McMaster University","highestDevelopmentStatusID":"7","companyTruncated":"Nestle Health Sciences SA \/ McMaster University"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Syneos Health | Medidata Solutions | McMaster University | CaligorRx, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Bifidobacterium Longum","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Nestle Health Sciences SA \/ Syneos Health | Medidata Solutions | McMaster University | CaligorRx, Inc.","highestDevelopmentStatusID":"7","companyTruncated":"Nestle Health Sciences SA \/ Syneos Health | Medidata Solutions | McMaster University | CaligorRx, Inc."},{"orgOrder":0,"company":"KGK Science","sponsor":"LALLEMAND HEALTH SOLUTIONS","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Probiotic","year":"2014","type":"Inapplicable","leadProduct":"Bifidobacterium Longum R0175","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"KGK Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"KGK Science \/ Lallemand Health Solutions","highestDevelopmentStatusID":"8","companyTruncated":"KGK Science \/ Lallemand Health Solutions"},{"orgOrder":0,"company":"Rabin Medical Center","sponsor":"Ambrosia - SupHerb Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Dietary Supplement","year":"2012","type":"Inapplicable","leadProduct":"Bio-25","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Rabin Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rabin Medical Center \/ Ambrosia - SupHerb Ltd.","highestDevelopmentStatusID":"1","companyTruncated":"Rabin Medical Center \/ Ambrosia - SupHerb Ltd."},{"orgOrder":0,"company":"Targeting Gut Disease S.R.L.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Biointestil","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Targeting Gut Disease S.R.L.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Targeting Gut Disease S.R.L. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Targeting Gut Disease S.R.L. \/ Undisclosed"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Blautia Hydrogenotrophica","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"4D Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"4D Pharma \/ Undisclosed"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Blautia Hydrogenotrophica","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"4D Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"4D Pharma \/ Undisclosed"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Blautia Hydrogenotrophica","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"4D Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"4D Pharma \/ Undisclosed"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2018","type":"Inapplicable","leadProduct":"Blautia Hydrogenotrophica","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"4D Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"4D Pharma \/ Undisclosed"},{"orgOrder":0,"company":"BRAINTREE LABS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"BLI400","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"BRAINTREE LABS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Powder","sponsorNew":"BRAINTREE LABS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BRAINTREE LABS \/ Undisclosed"},{"orgOrder":0,"company":"BRAINTREE LABS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"BLI400","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"BRAINTREE LABS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Powder","sponsorNew":"BRAINTREE LABS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BRAINTREE LABS \/ Undisclosed"},{"orgOrder":0,"company":"BRAINTREE LABS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"BLI400","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"BRAINTREE LABS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BRAINTREE LABS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BRAINTREE LABS \/ Undisclosed"},{"orgOrder":0,"company":"BRAINTREE LABS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"BLI400","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"BRAINTREE LABS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BRAINTREE LABS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BRAINTREE LABS \/ Undisclosed"},{"orgOrder":0,"company":"BRAINTREE LABS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"BLI801","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"BRAINTREE LABS","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"BRAINTREE LABS \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"BRAINTREE LABS \/ Undisclosed"},{"orgOrder":0,"company":"BRAINTREE LABS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"BLI801","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"BRAINTREE LABS","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"BRAINTREE LABS \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"BRAINTREE LABS \/ Undisclosed"},{"orgOrder":0,"company":"BRAINTREE LABS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"BLI801","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"BRAINTREE LABS","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"BRAINTREE LABS \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"BRAINTREE LABS \/ Undisclosed"},{"orgOrder":0,"company":"BRAINTREE LABS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"BLI801","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"BRAINTREE LABS","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"BRAINTREE LABS \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"BRAINTREE LABS \/ Undisclosed"},{"orgOrder":0,"company":"Brain-Gut Research Group","sponsor":"Aalborg University | Maastricht University Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Blueberry","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Brain-Gut Research Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Brain-Gut Research Group \/ Aalborg University | Maastricht University Medical Center","highestDevelopmentStatusID":"1","companyTruncated":"Brain-Gut Research Group \/ Aalborg University | Maastricht University Medical Center"},{"orgOrder":0,"company":"Boryung Pharmaceutical Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"BR6001-1","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Boryung Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boryung Pharmaceutical Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boryung Pharmaceutical Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Boryung Pharmaceutical Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BR6002","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Boryung Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Boryung Pharmaceutical Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boryung Pharmaceutical Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Boryung Pharmaceutical Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BR6002","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Boryung Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Boryung Pharmaceutical Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boryung Pharmaceutical Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Boryung Pharmaceutical Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"BRI-1501","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Boryung Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boryung Pharmaceutical Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boryung Pharmaceutical Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"BiomX","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"BX002","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"BiomX","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BiomX \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BiomX \/ Undisclosed"},{"orgOrder":0,"company":"BiomX","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"BX002","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"BiomX","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BiomX \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BiomX \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Vaccine","year":"2012","type":"Inapplicable","leadProduct":"Clostridium difficile vaccine","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"SALIENT PHARMACEUTICALS INC","sponsor":"Scott and White Hospital & Clinic | Texas A&M University","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2012","type":"Inapplicable","leadProduct":"Calcium Aluminosilicate","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"SALIENT PHARMACEUTICALS INC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SALIENT PHARMACEUTICALS INC \/ Scott and White Hospital & Clinic | Texas A&M University","highestDevelopmentStatusID":"8","companyTruncated":"SALIENT PHARMACEUTICALS INC \/ Scott and White Hospital & Clinic | Texas A&M University"},{"orgOrder":0,"company":"SALIENT PHARMACEUTICALS INC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2012","type":"Inapplicable","leadProduct":"Calcium Aluminosilicate","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"SALIENT PHARMACEUTICALS INC","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SALIENT PHARMACEUTICALS INC \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SALIENT PHARMACEUTICALS INC \/ Undisclosed"},{"orgOrder":0,"company":"Kemin Foods LC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Calcium Butyrate","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Kemin Foods LC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kemin Foods LC \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Kemin Foods LC \/ Undisclosed"},{"orgOrder":0,"company":"Naval Medical Research Center","sponsor":"Immuron","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"CampETEC","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Naval Medical Research Center","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Naval Medical Research Center \/ Immuron","highestDevelopmentStatusID":"5","companyTruncated":"Naval Medical Research Center \/ Immuron"},{"orgOrder":0,"company":"Immuron","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"AUSTRALIA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"CampETEC","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immuron \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Immuron \/ Undisclosed"},{"orgOrder":0,"company":"Immuron","sponsor":"US Naval Medical Research Command","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"AUSTRALIA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"CampETEC","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immuron \/ US Naval Medical Research Command","highestDevelopmentStatusID":"6","companyTruncated":"Immuron \/ US Naval Medical Research Command"},{"orgOrder":0,"company":"Immuron","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"AUSTRALIA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"CampETEC","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immuron \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Immuron \/ Undisclosed"},{"orgOrder":0,"company":"Omnifarma Kiev LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UKRAINE","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Urea Hydrogen Peroxide","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Omnifarma Kiev LLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Omnifarma Kiev LLC \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Omnifarma Kiev LLC \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Carbohydrate","year":"2013","type":"Inapplicable","leadProduct":"Carraghenate","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"University of Aarhus","sponsor":"Arla Foods","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Casein Glycomacropeptide","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"University of Aarhus","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Aarhus \/ Arla Foods","highestDevelopmentStatusID":"1","companyTruncated":"University of Aarhus \/ Arla Foods"},{"orgOrder":0,"company":"Oregon State University","sponsor":"Build Dairy | Agropur","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Casein Glycomacropeptide","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Oregon State University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oregon State University \/ Build Dairy | Agropur","highestDevelopmentStatusID":"1","companyTruncated":"Oregon State University \/ Build Dairy | Agropur"},{"orgOrder":0,"company":"Centre for Chinese Herbal Medicine Drug Development Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"CDD-2101","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Centre for Chinese Herbal Medicine Drug Development Limited","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Centre for Chinese Herbal Medicine Drug Development Limited \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Centre for Chinese Herbal Medicine Drug Development Limited \/ Undisclosed"},{"orgOrder":0,"company":"Ajou University School of Medicine","sponsor":"CTC Bio","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"CDFR0209","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Ajou University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ajou University School of Medicine \/ CTC Bio","highestDevelopmentStatusID":"6","companyTruncated":"Ajou University School of Medicine \/ CTC Bio"},{"orgOrder":0,"company":"CTC Bio","sponsor":"SYMYOO Inc","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"CDFR0612","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"CTC Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CTC Bio \/ SYMYOO Inc","highestDevelopmentStatusID":"10","companyTruncated":"CTC Bio \/ SYMYOO Inc"},{"orgOrder":0,"company":"Laboratorios Ordesa","sponsor":"Harrison Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SPAIN","productType":"Probiotic","year":"2014","type":"Inapplicable","leadProduct":"CECT7210","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Laboratorios Ordesa","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratorios Ordesa \/ Harrison Clinical Research","highestDevelopmentStatusID":"1","companyTruncated":"Laboratorios Ordesa \/ Harrison Clinical Research"},{"orgOrder":0,"company":"Harvard Apparatus Regenerative Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Cellspan Esophageal Implant","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Harvard Apparatus Regenerative Technology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Harvard Apparatus Regenerative Technology \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Harvard Apparatus Regenerative Technology \/ Undisclosed"},{"orgOrder":0,"company":"Laboratorios Ordesa","sponsor":"Ministry of Science and Innovation, Spain","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SPAIN","productType":"Dietary Supplement","year":"2019","type":"Inapplicable","leadProduct":"Cereal","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Laboratorios Ordesa","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratorios Ordesa \/ Ministry of Science and Innovation, Spain","highestDevelopmentStatusID":"1","companyTruncated":"Laboratorios Ordesa \/ Ministry of Science and Innovation, Spain"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Changkang","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Granules","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Changkang","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Granules","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"},{"orgOrder":0,"company":"University of Memphis","sponsor":"DSE Healthcare Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Charcocaps","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"University of Memphis","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of Memphis \/ DSE Healthcare Solutions","highestDevelopmentStatusID":"1","companyTruncated":"University of Memphis \/ DSE Healthcare Solutions"},{"orgOrder":0,"company":"Sensus","sponsor":"Atlantia Food Clinical Trials | Wageningen University","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Chicory Inulin-Type Fructan","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Sensus","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sensus \/ Atlantia Food Clinical Trials | Wageningen University","highestDevelopmentStatusID":"1","companyTruncated":"Sensus \/ Atlantia Food Clinical Trials | Wageningen University"},{"orgOrder":0,"company":"Blymum Srl","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Plant Extract\/Herbal","year":"2018","type":"Inapplicable","leadProduct":"Chitosan Hydrochloride","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Blymum Srl","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blymum Srl \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Blymum Srl \/ Undisclosed"},{"orgOrder":0,"company":"Arcadia Consumer Healthcare","sponsor":"Stony Brook University","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Chlorine Dioxide","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Arcadia Consumer Healthcare","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arcadia Consumer Healthcare \/ Stony Brook University","highestDevelopmentStatusID":"11","companyTruncated":"Arcadia Consumer Healthcare \/ Stony Brook University"},{"orgOrder":0,"company":"Aalborg University","sponsor":"Regionshospital Nordjylland | Norgine","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Citrafleet","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Aalborg University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aalborg University \/ Regionshospital Nordjylland | Norgine","highestDevelopmentStatusID":"11","companyTruncated":"Aalborg University \/ Regionshospital Nordjylland | Norgine"},{"orgOrder":0,"company":"CJ Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Microorganism","year":"2025","type":"Inapplicable","leadProduct":"CJRB-201","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"CJ Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CJ Bioscience \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"CJ Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"CKD-381","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"CKD-381","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"CKD-381","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"CKD-382","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"CKD-382","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"CKD-495","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"CKD-495","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Vaccine","year":"2019","type":"Inapplicable","leadProduct":"Clostridium Difficile Toxoid Vaccine","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Vaccine","year":"2018","type":"Inapplicable","leadProduct":"Clostridium difficile vaccine","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Vaccine","year":"2014","type":"Inapplicable","leadProduct":"Clostridium difficile vaccine","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Vaccine","year":"2015","type":"Inapplicable","leadProduct":"Clostridium difficile vaccine","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Vaccine","year":"2016","type":"Inapplicable","leadProduct":"Clostridium difficile vaccine","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Myungmoon Pharm. Co., LTD.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"CnU","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Myungmoon Pharm. Co., LTD.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Myungmoon Pharm. Co., LTD. \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Myungmoon Pharm. Co., LTD. \/ Undisclosed"},{"orgOrder":0,"company":"TriHealth","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Dietary Supplement","year":"2018","type":"Inapplicable","leadProduct":"Coffee","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"TriHealth","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Foam","sponsorNew":"TriHealth \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"TriHealth \/ Undisclosed"},{"orgOrder":0,"company":"Rousselot BVBA","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"BELGIUM","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Collagen Peptide","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Rousselot BVBA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rousselot BVBA \/ Nutrasource","highestDevelopmentStatusID":"1","companyTruncated":"Rousselot BVBA \/ Nutrasource"},{"orgOrder":0,"company":"Gangnam Severance Hospital","sponsor":"Cell Biotech Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Dietary Supplement","year":"2010","type":"Inapplicable","leadProduct":"Colostrum","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Gangnam Severance Hospital","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gangnam Severance Hospital \/ Cell Biotech Co., Ltd.","highestDevelopmentStatusID":"9","companyTruncated":"Gangnam Severance Hospital \/ Cell Biotech Co., Ltd."},{"orgOrder":0,"company":"University of Glasgow","sponsor":"Mondel?z International, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Corn Fibre","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"University of Glasgow","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Glasgow \/ Mondel?z International, Inc.","highestDevelopmentStatusID":"1","companyTruncated":"University of Glasgow \/ Mondel?z International, Inc."},{"orgOrder":0,"company":"University of California, San Francisco","sponsor":"Aradign Corportation | National Heart, Lung, and Blood Institute","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Sodium Cromoglicate","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"University of California, San Francisco","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, San Francisco \/ Aradign Corportation | National Heart, Lung, and Blood Institute","highestDevelopmentStatusID":"6","companyTruncated":"University of California, San Francisco \/ Aradign Corportation | National Heart, Lung, and Blood Institute"},{"orgOrder":0,"company":"Shilpa Medicare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Curcuma Longa","moa":"||Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Shilpa Medicare","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Shilpa Medicare \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Shilpa Medicare \/ Undisclosed"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"D026","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"D961H","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"D961H","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"D961H","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"DA-5204","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dong-A ST Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dong-A ST Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"DA-5212","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dong-A ST Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dong-A ST Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"DA-5219","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dong-A ST Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dong-A ST Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"TCI Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Dai Dai Flower","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"TCI Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TCI Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"TCI Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Lactalis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Dairy Lipid","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Lactalis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lactalis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lactalis \/ Undisclosed"},{"orgOrder":0,"company":"Olly, PBC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Dandelion","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Olly, PBC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Olly, PBC \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Olly, PBC \/ Undisclosed"},{"orgOrder":0,"company":"Sciotec Diagnostic Technologies GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"AUSTRIA","productType":"Dietary Supplement","year":"2017","type":"Inapplicable","leadProduct":"DAOSiN","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Sciotec Diagnostic Technologies GmbH","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sciotec Diagnostic Technologies GmbH \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Sciotec Diagnostic Technologies GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Biokuris s.a.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"DDI-IBS-001","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Biokuris s.a.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Biokuris s.a. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Biokuris s.a. \/ Undisclosed"},{"orgOrder":0,"company":"OrphoMed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Dibuprenorphine-ethyl-ether","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"OrphoMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OrphoMed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OrphoMed \/ Undisclosed"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dicyclomine Hydrochloride","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Upsher-Smith Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Upsher-Smith Laboratories \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Upsher-Smith Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Wageningen University and Research","sponsor":"Ministery of Economic affairs | Nexira | Wecare | Roquette Freres | Ingredion Pharma Solutions | Ingredia S.A. | Naturex | Winclove Probiotics B.V. | Bioiberica | Darling Ingredients","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Dietary Fiber","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Wageningen University and Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wageningen University and Research \/ Ministery of Economic affairs | Nexira | Wecare | Roquette Freres | Ingredion Pharma Solutions | Ingredia S.A. | Naturex | Winclove Probiotics B.V. | Bioiberica | Darling Ingredients","highestDevelopmentStatusID":"1","companyTruncated":"Wageningen University and Research \/ Ministery of Economic affairs | Nexira | Wecare | Roquette Freres | Ingredion Pharma Solutions | Ingredia S.A. | Naturex | Winclove Probiotics B.V. | Bioiberica | Darling Ingredients"},{"orgOrder":0,"company":"KGK Science","sponsor":"Global Institute of Probiotics","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Digesta Lac","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"KGK Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KGK Science \/ Global Institute of Probiotics","highestDevelopmentStatusID":"8","companyTruncated":"KGK Science \/ Global Institute of Probiotics"},{"orgOrder":0,"company":"Tehran University of Medical Sciences","sponsor":"Darman Yab Darou Co.","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRAN","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Digestive Aid","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Tehran University of Medical Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tehran University of Medical Sciences \/ Darman Yab Darou Co.","highestDevelopmentStatusID":"1","companyTruncated":"Tehran University of Medical Sciences \/ Darman Yab Darou Co."},{"orgOrder":0,"company":"Archer Daniels Midland","sponsor":"Kennesaw State University","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Digestive Enzyme Blend","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Archer Daniels Midland","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Archer Daniels Midland \/ Kennesaw State University","highestDevelopmentStatusID":"1","companyTruncated":"Archer Daniels Midland \/ Kennesaw State University"},{"orgOrder":0,"company":"Summit Pharmaceuticals Europe Srl","sponsor":"Quest Products","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Miscellaneous","year":"2020","type":"Acquisition","leadProduct":"Docusate Potassium","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Summit Pharmaceuticals Europe Srl","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Summit Pharmaceuticals Europe Srl \/ Quest Products","highestDevelopmentStatusID":"15","companyTruncated":"Summit Pharmaceuticals Europe Srl \/ Quest Products"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"DONQ52","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chugai Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Chugai Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"DONQ52","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chugai Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Chugai Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"DP Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"DPT0218","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"DP Technology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DP Technology \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"DP Technology \/ Undisclosed"},{"orgOrder":0,"company":"Drink Poppi","sponsor":"Citruslabs","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Drink Poppi Soda","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Drink Poppi","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Drink Poppi \/ Citruslabs","highestDevelopmentStatusID":"1","companyTruncated":"Drink Poppi \/ Citruslabs"},{"orgOrder":0,"company":"Beth Israel Deaconess Medical Center","sponsor":"Seed Health","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"DS-01","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Beth Israel Deaconess Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beth Israel Deaconess Medical Center \/ Seed Health","highestDevelopmentStatusID":"8","companyTruncated":"Beth Israel Deaconess Medical Center \/ Seed Health"},{"orgOrder":0,"company":"Daewon Pharm. Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"DW1401","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Daewon Pharm. Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daewon Pharm. Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Daewon Pharm. Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Daewon Pharm. Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"DW1903","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Daewon Pharm. Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daewon Pharm. Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Daewon Pharm. Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Daewon Pharm. Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"DW1903","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Daewon Pharm. Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daewon Pharm. Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Daewon Pharm. Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Daewon Pharm. Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"DW-3101","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Daewon Pharm. Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daewon Pharm. Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Daewon Pharm. Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"DWC20155","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Daewoong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"DWJ1230","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daewoong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Daewoong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"DWJ1252","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Daewoong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"DWJ1252","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Daewoong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Valneva","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"E.Coli Heat-Labile Enterotoxin","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Valneva \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Valneva \/ Undisclosed"},{"orgOrder":0,"company":"NIZO Food Research","sponsor":"PanTheryx","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"E1392-75-2A","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"NIZO Food Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NIZO Food Research \/ PanTheryx","highestDevelopmentStatusID":"1","companyTruncated":"NIZO Food Research \/ PanTheryx"},{"orgOrder":0,"company":"NIZO Food Research","sponsor":"FrieslandCampina","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"E1392-75-2A","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"NIZO Food Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NIZO Food Research \/ FrieslandCampina","highestDevelopmentStatusID":"1","companyTruncated":"NIZO Food Research \/ FrieslandCampina"},{"orgOrder":0,"company":"Eligo Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"EB003","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Eligo Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eligo Bioscience \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Eligo Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Bitop AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Ectoine","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Bitop AG","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bitop AG \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Bitop AG \/ Undisclosed"},{"orgOrder":0,"company":"Techni Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"MONACO","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Eductyl","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Techni Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"Techni Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Techni Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Nutricia Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Elemental 028 Extra","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Nutricia Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Nutricia Inc \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nutricia Inc \/ Undisclosed"},{"orgOrder":0,"company":"Rambam Health Care Campus","sponsor":"Else Nutrition GH Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Else Nutrition Formula","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Rambam Health Care Campus","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rambam Health Care Campus \/ Else Nutrition GH Ltd","highestDevelopmentStatusID":"1","companyTruncated":"Rambam Health Care Campus \/ Else Nutrition GH Ltd"},{"orgOrder":0,"company":"Nemysis","sponsor":"European Union","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Enzyme","year":"2023","type":"Funding","leadProduct":"Endoprotease 40 Glutenase","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Nemysis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nemysis \/ European Union","highestDevelopmentStatusID":"6","companyTruncated":"Nemysis \/ European Union"},{"orgOrder":0,"company":"Haleon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"ENO Lime","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Haleon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Haleon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Haleon \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Ensure Surgery Immunonutrition","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Boston Children's Hospital","sponsor":"Entrinsic Bioscience Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Enterade","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Boston Children's Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boston Children's Hospital \/ Entrinsic Bioscience Inc.","highestDevelopmentStatusID":"1","companyTruncated":"Boston Children's Hospital \/ Entrinsic Bioscience Inc."},{"orgOrder":0,"company":"Archer Daniels Midland","sponsor":"University of North Texas, Denton, TX","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Enzyme Cocktail A","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Archer Daniels Midland","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Archer Daniels Midland \/ University of North Texas, Denton, TX","highestDevelopmentStatusID":"1","companyTruncated":"Archer Daniels Midland \/ University of North Texas, Denton, TX"},{"orgOrder":0,"company":"ProDigest","sponsor":"University Ghent | Maastricht University | Embria Health Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"BELGIUM","productType":"Dietary Supplement","year":"2017","type":"Inapplicable","leadProduct":"Epicor","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"ProDigest","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ProDigest \/ University Ghent | Maastricht University | Embria Health Sciences","highestDevelopmentStatusID":"1","companyTruncated":"ProDigest \/ University Ghent | Maastricht University | Embria Health Sciences"},{"orgOrder":0,"company":"Equillium","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"EQ302","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Equillium \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Equillium \/ Undisclosed"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Plant Extract\/Herbal","year":"2015","type":"Inapplicable","leadProduct":"Eupasidin-S","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Eupatilin","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dong-A ST Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Dong-A ST Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Eupatilin","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dong-A ST Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dong-A ST Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Panacea Biotec Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Euphorbia","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Panacea Biotec Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Panacea Biotec Limited \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Panacea Biotec Limited \/ Undisclosed"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"EUR-1100","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"ExeGi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"EXE-346","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"ExeGi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ExeGi \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ExeGi \/ Undisclosed"},{"orgOrder":0,"company":"ExeGi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"EXE-346","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"ExeGi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ExeGi \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ExeGi \/ Undisclosed"},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"FB102","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Forte Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forte Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Forte Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"TD Cowen","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"FB-102","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Forte Biosciences","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Forte Biosciences \/ TD Cowen","highestDevelopmentStatusID":"8","companyTruncated":"Forte Biosciences \/ TD Cowen"},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"OrbiMed Advisors","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Private Placement","leadProduct":"FB-102","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Forte Biosciences","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Forte Biosciences \/ OrbiMed Advisors","highestDevelopmentStatusID":"8","companyTruncated":"Forte Biosciences \/ OrbiMed Advisors"},{"orgOrder":0,"company":"PharmaPlanter Technologies Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"Fecal Microbiota","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"PharmaPlanter Technologies Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"PharmaPlanter Technologies Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PharmaPlanter Technologies Inc \/ Undisclosed"},{"orgOrder":0,"company":"University of Colorado, Denver","sponsor":"OpenBiome","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"Fecal Microbiota","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"University of Colorado, Denver","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Colorado, Denver \/ OpenBiome","highestDevelopmentStatusID":"6","companyTruncated":"University of Colorado, Denver \/ OpenBiome"},{"orgOrder":0,"company":"McMaster Children's Hospital","sponsor":"London Health Sciences Centre | CHU Sainte-Justine","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Probiotic","year":"2015","type":"Inapplicable","leadProduct":"Fecal Microbiota","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"McMaster Children's Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Enema","sponsorNew":"McMaster Children's Hospital \/ London Health Sciences Centre | CHU Sainte-Justine","highestDevelopmentStatusID":"6","companyTruncated":"McMaster Children's Hospital \/ London Health Sciences Centre | CHU Sainte-Justine"},{"orgOrder":0,"company":"Beth Israel Deaconess Medical Center","sponsor":"OpenBiome","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2016","type":"Inapplicable","leadProduct":"Fecal Microbiota","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Beth Israel Deaconess Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beth Israel Deaconess Medical Center \/ OpenBiome","highestDevelopmentStatusID":"6","companyTruncated":"Beth Israel Deaconess Medical Center \/ OpenBiome"},{"orgOrder":0,"company":"Heilongjiang Feihe Dairy Co. Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Feihe Investigational Formula","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Heilongjiang Feihe Dairy Co. Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Heilongjiang Feihe Dairy Co. Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Heilongjiang Feihe Dairy Co. Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"University of Guadalajara","sponsor":"YAKULT HONSHA CO LTD","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"MEXICO","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Fermented Milk","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"University of Guadalajara","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Guadalajara \/ YAKULT HONSHA CO LTD","highestDevelopmentStatusID":"1","companyTruncated":"University of Guadalajara \/ YAKULT HONSHA CO LTD"},{"orgOrder":0,"company":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Ferrisat","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives \/ Undisclosed"},{"orgOrder":0,"company":"FutureGen","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"FG-M701","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"FutureGen","amount2":1.71,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":1.71,"dosageForm":"Undisclosed","sponsorNew":"FutureGen \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"FutureGen \/ AbbVie Inc"},{"orgOrder":0,"company":"King's College London","sponsor":"Danone Nutricia Research","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Fiber 1","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"King's College London","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"King's College London \/ Danone Nutricia Research","highestDevelopmentStatusID":"1","companyTruncated":"King's College London \/ Danone Nutricia Research"},{"orgOrder":0,"company":"Bell Cinical Service","sponsor":"LX Medical","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Fiber Supplement","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Bell Cinical Service","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bell Cinical Service \/ LX Medical","highestDevelopmentStatusID":"1","companyTruncated":"Bell Cinical Service \/ LX Medical"},{"orgOrder":0,"company":"EMS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"BRAZIL","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Florence","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"EMS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EMS \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EMS \/ Undisclosed"},{"orgOrder":0,"company":"N-Zyme Biomedical","sponsor":"LGM Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"Fosamprenavir Sodium Alginate","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"N-Zyme Biomedical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"N-Zyme Biomedical \/ LGM Pharma","highestDevelopmentStatusID":"4","companyTruncated":"N-Zyme Biomedical \/ LGM Pharma"},{"orgOrder":0,"company":"Sahlgrenska University Hospital","sponsor":"Atmo Biosciences Pty Ltd | Beneo","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Fructan","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Sahlgrenska University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sahlgrenska University Hospital \/ Atmo Biosciences Pty Ltd | Beneo","highestDevelopmentStatusID":"1","companyTruncated":"Sahlgrenska University Hospital \/ Atmo Biosciences Pty Ltd | Beneo"},{"orgOrder":0,"company":"BIO-CAT","sponsor":"Biofortis, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Fructanase","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"BIO-CAT","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BIO-CAT \/ Biofortis, Inc.","highestDevelopmentStatusID":"1","companyTruncated":"BIO-CAT \/ Biofortis, Inc."},{"orgOrder":0,"company":"Syral","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Probiotic","year":"2013","type":"Inapplicable","leadProduct":"Fructo-Oligosaccharide","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Syral","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syral \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Syral \/ Undisclosed"},{"orgOrder":0,"company":"Chongqing Peg-Bio Biopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"FT1","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Chongqing Peg-Bio Biopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chongqing Peg-Bio Biopharm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Chongqing Peg-Bio Biopharm \/ Undisclosed"},{"orgOrder":0,"company":"Future Biome SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ARGENTINA","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Fungal Fiber","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Future Biome SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Future Biome SA \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Future Biome SA \/ Undisclosed"},{"orgOrder":0,"company":"SQ Innovation","sponsor":"EB Medical Research | Quartesian","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"G3P-01","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"SQ Innovation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SQ Innovation \/ EB Medical Research | Quartesian","highestDevelopmentStatusID":"1","companyTruncated":"SQ Innovation \/ EB Medical Research | Quartesian"},{"orgOrder":0,"company":"Clasado","sponsor":"CR2O B.V.","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"4'-Galactooligosaccharide","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Clasado","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clasado \/ CR2O B.V.","highestDevelopmentStatusID":"1","companyTruncated":"Clasado \/ CR2O B.V."},{"orgOrder":0,"company":"Immunology Research Institute in Gifu","sponsor":"Dong Do Pharmaceutical Co.","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Dietary Supplement","year":"2016","type":"Inapplicable","leadProduct":"Gastimun HP","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Immunology Research Institute in Gifu","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunology Research Institute in Gifu \/ Dong Do Pharmaceutical Co.","highestDevelopmentStatusID":"1","companyTruncated":"Immunology Research Institute in Gifu \/ Dong Do Pharmaceutical Co."},{"orgOrder":0,"company":"Xinjiang Biochemical Pharmaceutical Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Gastropylor Complex","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Xinjiang Biochemical Pharmaceutical Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Xinjiang Biochemical Pharmaceutical Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Xinjiang Biochemical Pharmaceutical Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Green Cross Lab Cell","sponsor":"C&R Research | CRScube","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"GC6101A","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Green Cross Lab Cell","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Green Cross Lab Cell \/ C&R Research | CRScube","highestDevelopmentStatusID":"8","companyTruncated":"Green Cross Lab Cell \/ C&R Research | CRScube"},{"orgOrder":0,"company":"Midatech Pharma","sponsor":"PharPoint Research","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Gelclair","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Midatech Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Midatech Pharma \/ PharPoint Research","highestDevelopmentStatusID":"11","companyTruncated":"Midatech Pharma \/ PharPoint Research"},{"orgOrder":0,"company":"Devintec Sagl","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Gelsectan","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Devintec Sagl","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Devintec Sagl \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Devintec Sagl \/ Undisclosed"},{"orgOrder":0,"company":"Radicle Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"GI Health Active Product","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Radicle Science","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radicle Science \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Radicle Science \/ Undisclosed"},{"orgOrder":0,"company":"Gicare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"GIC-1001","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Gicare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gicare Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Gicare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Givaudan France Naturals","sponsor":"Analyze & Realize | University Hospital of Leuven Leuven","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Ginger Formula","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Givaudan France Naturals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Givaudan France Naturals \/ Analyze & Realize | University Hospital of Leuven Leuven","highestDevelopmentStatusID":"1","companyTruncated":"Givaudan France Naturals \/ Analyze & Realize | University Hospital of Leuven Leuven"},{"orgOrder":0,"company":"Atlantia Food Clinical Trials","sponsor":"Givaudan France Naturals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Plant Extract\/Herbal","year":"2018","type":"Inapplicable","leadProduct":"Gingest Powdered Extract","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Atlantia Food Clinical Trials","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Atlantia Food Clinical Trials \/ Givaudan France Naturals","highestDevelopmentStatusID":"1","companyTruncated":"Atlantia Food Clinical Trials \/ Givaudan France Naturals"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"GK567","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Dietary Supplement","year":"2018","type":"Inapplicable","leadProduct":"Gluten","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Dietary Supplement","year":"2019","type":"Inapplicable","leadProduct":"Gluten","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Gluten","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Oslo University Hospital","sponsor":"South-Eastern Norway Regional Health Authority | University of Oslo","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NORWAY","productType":"Dietary Supplement","year":"2010","type":"Inapplicable","leadProduct":"Gluten Challenge","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Oslo University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oslo University Hospital \/ South-Eastern Norway Regional Health Authority | University of Oslo","highestDevelopmentStatusID":"9","companyTruncated":"Oslo University Hospital \/ South-Eastern Norway Regional Health Authority | University of Oslo"},{"orgOrder":0,"company":"Ausnutria Hyproca B.V.","sponsor":"HM hospitales","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Goat Milk-Based Infant Formula","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Ausnutria Hyproca B.V.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ausnutria Hyproca B.V. \/ HM hospitales","highestDevelopmentStatusID":"1","companyTruncated":"Ausnutria Hyproca B.V. \/ HM hospitales"},{"orgOrder":0,"company":"Ausnutria Hyproca B.V.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Goat Milk-Based Infant Formula","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Ausnutria Hyproca B.V.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ausnutria Hyproca B.V. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Ausnutria Hyproca B.V. \/ Undisclosed"},{"orgOrder":0,"company":"Greenteaspoon","sponsor":"PanTheryx","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Acquisition","leadProduct":"Goodgut","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Greenteaspoon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Greenteaspoon \/ PanTheryx","highestDevelopmentStatusID":"15","companyTruncated":"Greenteaspoon \/ PanTheryx"},{"orgOrder":0,"company":"Ildong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Dietary Supplement","year":"2019","type":"Inapplicable","leadProduct":"Gq-Lab Daily","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Ildong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ildong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Ildong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"AIDP, Inc.","sponsor":"KGK Science","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2018","type":"Inapplicable","leadProduct":"Green Kiwi Powder","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"AIDP, Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AIDP, Inc. \/ KGK Science","highestDevelopmentStatusID":"1","companyTruncated":"AIDP, Inc. \/ KGK Science"},{"orgOrder":0,"company":"Pharmass\u00eatX","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Green Tea Extract","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Pharmass\u00eatX","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmass\u00eatX \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Pharmass\u00eatX \/ Undisclosed"},{"orgOrder":0,"company":"Adamas Biotech S.r.l.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Green Tea Extract","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Adamas Biotech S.r.l.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adamas Biotech S.r.l. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Adamas Biotech S.r.l. \/ Undisclosed"},{"orgOrder":0,"company":"AMWAY CANADA CORPORATION","sponsor":"Citruslabs","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Greens","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"AMWAY CANADA CORPORATION","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AMWAY CANADA CORPORATION \/ Citruslabs","highestDevelopmentStatusID":"1","companyTruncated":"AMWAY CANADA CORPORATION \/ Citruslabs"},{"orgOrder":0,"company":"Granite Bio","sponsor":"Forbion","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2025","type":"Series B Financing","leadProduct":"GRT-001","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Granite Bio","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Granite Bio \/ Forbion","highestDevelopmentStatusID":"6","companyTruncated":"Granite Bio \/ Forbion"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"GSK3915393","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"AMOREPACIFIC CORPORATION","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"GTB1","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"AMOREPACIFIC CORPORATION","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AMOREPACIFIC CORPORATION \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"AMOREPACIFIC CORPORATION \/ Undisclosed"},{"orgOrder":0,"company":"Rutgers University","sponsor":"International Flavors and Fragrances","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2020","type":"Collaboration","leadProduct":"Gut-Microbiome","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Rutgers University","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rutgers University \/ International Flavors and Fragrances","highestDevelopmentStatusID":"2","companyTruncated":"Rutgers University \/ International Flavors and Fragrances"},{"orgOrder":0,"company":"Jiangsu Carephar Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"H008","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Jiangsu Carephar Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Carephar Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Carephar Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Probiotic","year":"2012","type":"Inapplicable","leadProduct":"Heat-Treated Lactobacilli","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Sachet","sponsorNew":"Nestle Health Sciences SA \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Undisclosed"},{"orgOrder":0,"company":"Hemay Pharmaceutical","sponsor":"Tianjin Hemay Pharmaceutical Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Hemay007","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Hemay Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hemay Pharmaceutical \/ Tianjin Hemay Pharmaceutical Co., Ltd","highestDevelopmentStatusID":"6","companyTruncated":"Hemay Pharmaceutical \/ Tianjin Hemay Pharmaceutical Co., Ltd"},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"HIP0612","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Hanmi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hanmi Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hanmi Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"HIP2101","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Hanmi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hanmi Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hanmi Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"ISTITUTO FARMOCHIMICO FITOTERAPICO: EPO SRL","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Hippophae rhamnoides L","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"ISTITUTO FARMOCHIMICO FITOTERAPICO: EPO SRL","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ISTITUTO FARMOCHIMICO FITOTERAPICO: EPO SRL \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"ISTITUTO FARMOCHIMICO FITOTERAPICO: EPO SRL \/ Undisclosed"},{"orgOrder":0,"company":"ImmusanT","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Vaccine","year":"2015","type":"Inapplicable","leadProduct":"HLA-DQ2 Peptide Vaccine","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"ImmusanT","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ImmusanT \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ImmusanT \/ Undisclosed"},{"orgOrder":0,"company":"ImmusanT","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Vaccine","year":"2018","type":"Inapplicable","leadProduct":"HLA-DQ2 Peptide Vaccine","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"ImmusanT","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ImmusanT \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ImmusanT \/ Undisclosed"},{"orgOrder":0,"company":"ImmusanT","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Vaccine","year":"2018","type":"Inapplicable","leadProduct":"HLA-DQ2 Peptide Vaccine","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"ImmusanT","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ImmusanT \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ImmusanT \/ Undisclosed"},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"HM15912","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Hanmi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hanmi Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hanmi Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kyowa Hakko Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"HMO","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Kyowa Hakko Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyowa Hakko Bio \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Kyowa Hakko Bio \/ Undisclosed"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"HMO","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Undisclosed"},{"orgOrder":0,"company":"Glycom A\/S","sponsor":"Sahlgrenska University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"HMO1","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Glycom A\/S","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glycom A\/S \/ Sahlgrenska University Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Glycom A\/S \/ Sahlgrenska University Hospital"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"HONG KONG","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"HMPL-011","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"HR18034","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Fujian Shengdi Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"HR20013","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Fujian Shengdi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fujian Shengdi Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fujian Shengdi Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Fujian Shengdi Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"HR20013","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Fujian Shengdi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fujian Shengdi Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fujian Shengdi Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Fujian Shengdi Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"HR20013","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Fujian Shengdi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fujian Shengdi Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fujian Shengdi Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Shandong Suncadia Medicine Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"HRS-7085","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Shandong Suncadia Medicine Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shandong Suncadia Medicine Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shandong Suncadia Medicine Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Atridia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"AUSTRALIA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"HRS-7085","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Atridia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Atridia \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Atridia \/ Undisclosed"},{"orgOrder":0,"company":"HUM Nutrition, Inc.","sponsor":"Citruslabs","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Hum Flatter Me","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"HUM Nutrition, Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HUM Nutrition, Inc. \/ Citruslabs","highestDevelopmentStatusID":"1","companyTruncated":"HUM Nutrition, Inc. \/ Citruslabs"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Human Milk Oligosaccharide","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Royal DSM \/ Undisclosed"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Human Milk Oligosaccharides 2\\'-Ofucosyllactose","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Royal DSM \/ Undisclosed"},{"orgOrder":0,"company":"Royal DSM","sponsor":"KGK Science","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Humiome Post Lb","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ KGK Science","highestDevelopmentStatusID":"1","companyTruncated":"Royal DSM \/ KGK Science"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Huo Ma Ren Extract","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Danisco\/Dupont","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Idoform","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Danisco\/Dupont","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Danisco\/Dupont"},{"orgOrder":0,"company":"Medical University of Warsaw","sponsor":"Nutricia Foundation | Pleuran, s.r.o.","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"POLAND","productType":"Dietary Supplement","year":"2019","type":"Inapplicable","leadProduct":"Imunoglukan P4H","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Medical University of Warsaw","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medical University of Warsaw \/ Nutricia Foundation | Pleuran, s.r.o.","highestDevelopmentStatusID":"11","companyTruncated":"Medical University of Warsaw \/ Nutricia Foundation | Pleuran, s.r.o."},{"orgOrder":0,"company":"HK inno.N","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"IN-114199","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HK inno.N \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HK inno.N \/ Undisclosed"},{"orgOrder":0,"company":"Infinant Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"INF108","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Infinant Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Infinant Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Infinant Health \/ Undisclosed"},{"orgOrder":0,"company":"University of Calgary","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Vaccine","year":"2012","type":"Inapplicable","leadProduct":"Influenza Vaccine","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"University of Calgary","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Calgary \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"1","companyTruncated":"University of Calgary \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Kukje Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"INT-2150","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Kukje Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kukje Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kukje Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InQpharm Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"IQP-CL-101","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"InQpharm Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InQpharm Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InQpharm Group \/ Undisclosed"},{"orgOrder":0,"company":"CordenPharma","sponsor":"Revolo Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Peptide, Unconjugated","year":"2021","type":"Agreement","leadProduct":"IRL201104","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"CordenPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CordenPharma \/ Revolo Biotherapeutics","highestDevelopmentStatusID":"6","companyTruncated":"CordenPharma \/ Revolo Biotherapeutics"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"IRL201104","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revolo Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"IRL201104","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revolo Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"IRL201104","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revolo Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"IRL201104","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revolo Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"IRL201104","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revolo Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"IRL201104","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revolo Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"IRL201104","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revolo Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"IRL201104","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revolo Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"IRL201104","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revolo Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"IRL201104","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revolo Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"IRL201104","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revolo Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"IRL201104","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Revolo Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"HONG KONG","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ISM5411","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Insilico Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Insilico Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Insilico Medicine \/ Undisclosed"},{"orgOrder":0,"company":"ISOThrive Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Isothrive Prebiotic Nectar","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"ISOThrive Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ISOThrive Inc. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"ISOThrive Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Izun Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"IZN-6N4","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Izun Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Izun Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Izun Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Prof Stig Larsen","sponsor":"Tine","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Dietary Supplement","year":"2019","type":"Inapplicable","leadProduct":"Jarlsberg Cheese","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Prof Stig Larsen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prof Stig Larsen \/ Tine","highestDevelopmentStatusID":"1","companyTruncated":"Prof Stig Larsen \/ Tine"},{"orgOrder":0,"company":"Tongji Hospital","sponsor":"Xi'an Beilin Pharmaceutical Co. Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Jinsang Liyan","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Tongji Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tongji Hospital \/ Xi'an Beilin Pharmaceutical Co. Ltd","highestDevelopmentStatusID":"11","companyTruncated":"Tongji Hospital \/ Xi'an Beilin Pharmaceutical Co. Ltd"},{"orgOrder":0,"company":"Onconic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"JP-1366","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Onconic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Onconic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Onconic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Onconic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"JP-1366","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Onconic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Onconic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Onconic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Onconic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"JP-1366","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Onconic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Onconic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Onconic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Onconic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"JP-1366","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Onconic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Onconic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Onconic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Danielle Kim Turgeon","sponsor":"Olympus Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Peptide, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"KCC Peptide","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Danielle Kim Turgeon","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Danielle Kim Turgeon \/ Olympus Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Danielle Kim Turgeon \/ Olympus Corporation"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"KLYX","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ferring Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ferring Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Materia Medica Holding","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"RUSSIA","productType":"Dietary Supplement","year":"2017","type":"Inapplicable","leadProduct":"Kolofort","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Materia Medica Holding","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Materia Medica Holding \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Materia Medica Holding \/ Undisclosed"},{"orgOrder":0,"company":"Vasily Isakov","sponsor":"Azbuka vkusa | Russian Science Foundation | Federal Research Centre of Nutrition, Biotechnology and Food Safety","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Kombucha-Based Beverage","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Vasily Isakov","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vasily Isakov \/ Azbuka vkusa | Russian Science Foundation | Federal Research Centre of Nutrition, Biotechnology and Food Safety","highestDevelopmentStatusID":"1","companyTruncated":"Vasily Isakov \/ Azbuka vkusa | Russian Science Foundation | Federal Research Centre of Nutrition, Biotechnology and Food Safety"},{"orgOrder":0,"company":"Tauriga Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Kratom Extract","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Tauriga Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Gum, Chewing","sponsorNew":"Tauriga Sciences \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Tauriga Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"KWA-0711","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kissei Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kissei Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"KWA-0711","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kissei Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kissei Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"KWA-0711","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kissei Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kissei Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"KWA-0711","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kissei Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kissei Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"KWA-0711","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kissei Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kissei Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Canadian College of Naturopathic Medicine","sponsor":"Wakunaga Pharmaceutical Co., Ltd. | Dicentra Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Kyodophilus Multi-Strain Probiotic","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Canadian College of Naturopathic Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Canadian College of Naturopathic Medicine \/ Wakunaga Pharmaceutical Co., Ltd. | Dicentra Inc.","highestDevelopmentStatusID":"7","companyTruncated":"Canadian College of Naturopathic Medicine \/ Wakunaga Pharmaceutical Co., Ltd. | Dicentra Inc."},{"orgOrder":0,"company":"Canadian College of Naturopathic Medicine","sponsor":"Wakunaga Pharmaceutical Co., Ltd. | Dicentra Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Kyodophilus Multi-Strain Probiotic","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Canadian College of Naturopathic Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Canadian College of Naturopathic Medicine \/ Wakunaga Pharmaceutical Co., Ltd. | Dicentra Inc.","highestDevelopmentStatusID":"7","companyTruncated":"Canadian College of Naturopathic Medicine \/ Wakunaga Pharmaceutical Co., Ltd. | Dicentra Inc."},{"orgOrder":0,"company":"Bio-K Plus International Inc.","sponsor":"Sprim Advanced Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"L. Acidophilus","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Bio-K Plus International Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio-K Plus International Inc. \/ Sprim Advanced Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Bio-K Plus International Inc. \/ Sprim Advanced Life Sciences"},{"orgOrder":0,"company":"Lama Medical Care s.r.o.","sponsor":"BioGaia Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CZECH REPUBLIC","productType":"Probiotic","year":"2011","type":"Inapplicable","leadProduct":"L. Reuteri","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Lama Medical Care s.r.o.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lama Medical Care s.r.o. \/ BioGaia Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Lama Medical Care s.r.o. \/ BioGaia Pharma"},{"orgOrder":0,"company":"\u00d6rebro University","sponsor":"BioGaia Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"L. reuteri DSM 17938","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"\u00d6rebro University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"\u00d6rebro University \/ BioGaia Pharma","highestDevelopmentStatusID":"10","companyTruncated":"\u00d6rebro University \/ BioGaia Pharma"},{"orgOrder":0,"company":"Sofar Spa","sponsor":"1Med","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Probiotic","year":"2018","type":"Inapplicable","leadProduct":"L.Casei Dg","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Sofar Spa","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sofar Spa \/ 1Med","highestDevelopmentStatusID":"1","companyTruncated":"Sofar Spa \/ 1Med"},{"orgOrder":0,"company":"KGK Science","sponsor":"LALLEMAND HEALTH SOLUTIONS","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Probiotic","year":"2013","type":"Inapplicable","leadProduct":"Lacidofil","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"KGK Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KGK Science \/ Lallemand Health Solutions","highestDevelopmentStatusID":"7","companyTruncated":"KGK Science \/ Lallemand Health Solutions"},{"orgOrder":0,"company":"PiLeJe","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Probiotic","year":"2012","type":"Inapplicable","leadProduct":"Lactibiane","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"PiLeJe","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PiLeJe \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"PiLeJe \/ Undisclosed"},{"orgOrder":0,"company":"PiLeJe","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Probiotic","year":"2016","type":"Inapplicable","leadProduct":"Lactibiane","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"PiLeJe","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PiLeJe \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"PiLeJe \/ Undisclosed"},{"orgOrder":0,"company":"Sanzyme","sponsor":"J.B.Chemicals & Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Microorganism","year":"2022","type":"Acquisition","leadProduct":"Lacticacid Bacillus","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Sanzyme","amount2":0.080000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0.080000000000000002,"dosageForm":"Tablet","sponsorNew":"Sanzyme \/ J.B.Chemicals & Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanzyme \/ J.B.Chemicals & Pharmaceuticals"},{"orgOrder":0,"company":"PiLeJe","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Lactichoc","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"PiLeJe","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"PiLeJe \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"PiLeJe \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Lactiplantibacillus Pentosus ONRICb0240","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Biocare Copenhagen A\/S","sponsor":"Lviv National Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Lactobacilli","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Biocare Copenhagen A\/S","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocare Copenhagen A\/S \/ Lviv National Medical University","highestDevelopmentStatusID":"1","companyTruncated":"Biocare Copenhagen A\/S \/ Lviv National Medical University"},{"orgOrder":0,"company":"Tropical Gastroenterology & Nutrition Group (TROPGAN)","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Lactobacilli Paracasei","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Tropical Gastroenterology & Nutrition Group (TROPGAN)","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tropical Gastroenterology & Nutrition Group (TROPGAN) \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Tropical Gastroenterology & Nutrition Group (TROPGAN) \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Lemuel W. Taylor IV","sponsor":"Manzo Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"Lactobacillus Acidophilus MPH734","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Lemuel W. Taylor IV","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lemuel W. Taylor IV \/ Manzo Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Lemuel W. Taylor IV \/ Manzo Pharmaceuticals"},{"orgOrder":0,"company":"Sofar Spa","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Probiotic","year":"2014","type":"Inapplicable","leadProduct":"Lactobacillus Casei DG","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Sofar Spa","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sofar Spa \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sofar Spa \/ Undisclosed"},{"orgOrder":0,"company":"Sofar Spa","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Probiotic","year":"2015","type":"Inapplicable","leadProduct":"Lactobacillus Casei DG","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Sofar Spa","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sofar Spa \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sofar Spa \/ Undisclosed"},{"orgOrder":0,"company":"YAKULT HONSHA CO LTD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Lactobacillus Casei Shirota","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"YAKULT HONSHA CO LTD","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"YAKULT HONSHA CO LTD \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"YAKULT HONSHA CO LTD \/ Undisclosed"},{"orgOrder":0,"company":"YAKULT HONSHA CO LTD","sponsor":"Bach Mai Hospital | Vietnam National University","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Lactobacillus Casei Strain Shirota Fermented Milk","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"YAKULT HONSHA CO LTD","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"YAKULT HONSHA CO LTD \/ Bach Mai Hospital | Vietnam National University","highestDevelopmentStatusID":"1","companyTruncated":"YAKULT HONSHA CO LTD \/ Bach Mai Hospital | Vietnam National University"},{"orgOrder":0,"company":"HEM Pharma","sponsor":"Premier Research Group","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Lactobacillus Fermentum","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"HEM Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HEM Pharma \/ Premier Research Group","highestDevelopmentStatusID":"8","companyTruncated":"HEM Pharma \/ Premier Research Group"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2011","type":"Inapplicable","leadProduct":"Lactobacillus Fermentum","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"BioGaia Pharma","sponsor":"BioFortis","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Lactobacillus gasseri BGP345A","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"BioGaia Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioGaia Pharma \/ BioFortis","highestDevelopmentStatusID":"8","companyTruncated":"BioGaia Pharma \/ BioFortis"},{"orgOrder":0,"company":"BioGaia Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2015","type":"Inapplicable","leadProduct":"Lactobacillus Gasseri DSM 27123","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"BioGaia Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioGaia Pharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"BioGaia Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Adare Biome","sponsor":"Royal DSM","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Microorganism","year":"2023","type":"Acquisition","leadProduct":"Lactobacillus LB","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Adare Biome","amount2":0.29999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0.29999999999999999,"dosageForm":"Capsule","sponsorNew":"Adare Biome \/ Royal DSM","highestDevelopmentStatusID":"15","companyTruncated":"Adare Biome \/ Royal DSM"},{"orgOrder":0,"company":"Sami-Sabinsa Group","sponsor":"Postbiotics","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Probiotic","year":"2024","type":"Agreement","leadProduct":"Lactobacillus Paracasei","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Sami-Sabinsa Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sami-Sabinsa Group \/ Postbiotics","highestDevelopmentStatusID":"15","companyTruncated":"Sami-Sabinsa Group \/ Postbiotics"},{"orgOrder":0,"company":"Next Gen Pharma","sponsor":"Department of Gastroenterology, Govt. Medical College, Kozhikode, Kerala, India","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Probiotic","year":"2015","type":"Inapplicable","leadProduct":"Lactobacillus Paracasei","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Next Gen Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Next Gen Pharma \/ Department of Gastroenterology, Govt. Medical College, Kozhikode, Kerala, India","highestDevelopmentStatusID":"10","companyTruncated":"Next Gen Pharma \/ Department of Gastroenterology, Govt. Medical College, Kozhikode, Kerala, India"},{"orgOrder":0,"company":"Shanghai Children's Hospital","sponsor":"BioGaia Pharma | Suzhou University Affiliated Children's Hospital | Shanghai Children's Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Probiotic","year":"2015","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri DSM 17938","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Shanghai Children's Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Children's Hospital \/ BioGaia Pharma | Suzhou University Affiliated Children's Hospital | Shanghai Children's Medical Center","highestDevelopmentStatusID":"1","companyTruncated":"Shanghai Children's Hospital \/ BioGaia Pharma | Suzhou University Affiliated Children's Hospital | Shanghai Children's Medical Center"},{"orgOrder":0,"company":"Innovacion y Desarrollo de Estrategias en Salud","sponsor":"BioGaia Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Probiotic","year":"2017","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri DSM 17938","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Innovacion y Desarrollo de Estrategias en Salud","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovacion y Desarrollo de Estrategias en Salud \/ BioGaia Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Innovacion y Desarrollo de Estrategias en Salud \/ BioGaia Pharma"},{"orgOrder":0,"company":"Innovacion y Desarrollo de Estrategias en Salud","sponsor":"BioGaia Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Probiotic","year":"2019","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri DSM 17938","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Innovacion y Desarrollo de Estrategias en Salud","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovacion y Desarrollo de Estrategias en Salud \/ BioGaia Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Innovacion y Desarrollo de Estrategias en Salud \/ BioGaia Pharma"},{"orgOrder":0,"company":"BioGaia Pharma","sponsor":"CRC CHI Creteil France | Association Clinique Th\u00e9rapeutique Infantile du val de Marne | H\u00f4pital Universitaire Robert-Debr\u00e9","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2013","type":"Inapplicable","leadProduct":"Lactobacillus reuteri DSM17938","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"BioGaia Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oil","sponsorNew":"BioGaia Pharma \/ CRC CHI Creteil France | Association Clinique Th\u00e9rapeutique Infantile du val de Marne | H\u00f4pital Universitaire Robert-Debr\u00e9","highestDevelopmentStatusID":"1","companyTruncated":"BioGaia Pharma \/ CRC CHI Creteil France | Association Clinique Th\u00e9rapeutique Infantile du val de Marne | H\u00f4pital Universitaire Robert-Debr\u00e9"},{"orgOrder":0,"company":"BioGaia Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2017","type":"Inapplicable","leadProduct":"Lactobacillus reuteri DSM17938","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"BioGaia Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oil","sponsorNew":"BioGaia Pharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"BioGaia Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Medical University of Warsaw","sponsor":"Adamed Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"POLAND","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Lactobacillus Rhamnosus ATCC 53103","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Medical University of Warsaw","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medical University of Warsaw \/ Adamed Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Medical University of Warsaw \/ Adamed Pharma"},{"orgOrder":0,"company":"Children's Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"Lactobacillus Rhamnosus GG","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Children's Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Children's Health \/ Undisclosed"},{"orgOrder":0,"company":"Lactiga","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2025","type":"Funding","leadProduct":"LCTG-003","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Lactiga","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lactiga \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Lactiga \/ National Institutes of Health"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Lianxiaxiaopi","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Granules","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Ironwood Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"LIN-MD-63","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Ironwood Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Ironwood Pharmaceuticals"},{"orgOrder":0,"company":"Integrative Skin Science and Research","sponsor":"Biocidin","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Liquid Tincture","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Integrative Skin Science and Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Integrative Skin Science and Research \/ Biocidin","highestDevelopmentStatusID":"1","companyTruncated":"Integrative Skin Science and Research \/ Biocidin"},{"orgOrder":0,"company":"KGK Science","sponsor":"International Flavors and Fragrances","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2014","type":"Inapplicable","leadProduct":"Litesse Powder Containing Polydextrose","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"KGK Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KGK Science \/ International Flavors and Fragrances","highestDevelopmentStatusID":"8","companyTruncated":"KGK Science \/ International Flavors and Fragrances"},{"orgOrder":0,"company":"Anabio R&D","sponsor":"National Institute of Nutrition, Vietnam","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"VIETNAM","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Livespo Preg-Mom","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Anabio R&D","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anabio R&D \/ National Institute of Nutrition, Vietnam","highestDevelopmentStatusID":"1","companyTruncated":"Anabio R&D \/ National Institute of Nutrition, Vietnam"},{"orgOrder":0,"company":"Lumen Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"LMN-401","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Lumen Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lumen Bioscience \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Lumen Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Lmito Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"LMT503","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Lmito Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lmito Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Lmito Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nordsjaellands Hospital","sponsor":"Colitis-Crohn Foreningen | Ferring Pharmaceuticals | Calpro AS | Muusmann Forlag | Statens Serum Institut | Genetic Analysis AS","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Dietary Supplement","year":"2018","type":"Inapplicable","leadProduct":"Low Fodmap Diet","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Nordsjaellands Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nordsjaellands Hospital \/ Colitis-Crohn Foreningen | Ferring Pharmaceuticals | Calpro AS | Muusmann Forlag | Statens Serum Institut | Genetic Analysis AS","highestDevelopmentStatusID":"1","companyTruncated":"Nordsjaellands Hospital \/ Colitis-Crohn Foreningen | Ferring Pharmaceuticals | Calpro AS | Muusmann Forlag | Statens Serum Institut | Genetic Analysis AS"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"LRG-002","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sandoz B2B \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sandoz B2B \/ Undisclosed"},{"orgOrder":0,"company":"Vitacare Gmbh & Co. KG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Lyoph Yoghurt Bacteria","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Vitacare Gmbh & Co. KG","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vitacare Gmbh & Co. KG \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Vitacare Gmbh & Co. KG \/ Undisclosed"},{"orgOrder":0,"company":"The Center for Applied Health Sciences, LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Amino Acid","year":"2024","type":"Inapplicable","leadProduct":"Lysine Butyrate","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"The Center for Applied Health Sciences, LLC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Center for Applied Health Sciences, LLC \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"The Center for Applied Health Sciences, LLC \/ Undisclosed"},{"orgOrder":0,"company":"Rambam Health Care Campus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"MaaT011","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Rambam Health Care Campus","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Rambam Health Care Campus \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Rambam Health Care Campus \/ Undisclosed"},{"orgOrder":0,"company":"Venture Life","sponsor":"Jaguar Health","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Maltodextrin","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Venture Life","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Venture Life \/ Jaguar Health","highestDevelopmentStatusID":"15","companyTruncated":"Venture Life \/ Jaguar Health"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Maltodextrin","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Undisclosed"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Maltodextrin","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Jaguar Health \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Jaguar Health \/ Undisclosed"},{"orgOrder":0,"company":"ISOThrive","sponsor":"Virginia Catalyst","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Carbohydrate","year":"2020","type":"Funding","leadProduct":"Maltosyl-Isomaltooligosaccharide","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"ISOThrive","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ISOThrive \/ Virginia Catalyst","highestDevelopmentStatusID":"5","companyTruncated":"ISOThrive \/ Virginia Catalyst"},{"orgOrder":0,"company":"ISOThrive Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Maltosyl-Isomalto-Oligosaccharides","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"ISOThrive Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ISOThrive Inc. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"ISOThrive Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Mikrobiomik Healthcare Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"MBK-01","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Mikrobiomik Healthcare Company","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mikrobiomik Healthcare Company \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mikrobiomik Healthcare Company \/ Undisclosed"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"MD-7246","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ironwood Pharmaceuticals \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Ironwood Pharmaceuticals \/ AbbVie Inc"},{"orgOrder":0,"company":"Maastricht University Medical Center","sponsor":"ZonMw","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Mentha Piperita Oil","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Maastricht University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maastricht University Medical Center \/ ZonMw","highestDevelopmentStatusID":"8","companyTruncated":"Maastricht University Medical Center \/ ZonMw"},{"orgOrder":0,"company":"Jiangsu Topcel-KH Pharmaceutical","sponsor":"The First Affiliated Hospital of Soochow University","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Jiangsu Topcel-KH Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Topcel-KH Pharmaceutical \/ The First Affiliated Hospital of Soochow University","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Topcel-KH Pharmaceutical \/ The First Affiliated Hospital of Soochow University"},{"orgOrder":0,"company":"Jiangsu Topcel-KH Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Jiangsu Topcel-KH Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Topcel-KH Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Topcel-KH Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Ossium Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Ossium Health","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ossium Health \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Ossium Health \/ Undisclosed"},{"orgOrder":0,"company":"Societa Italiana di Chirurgia ColoRettale","sponsor":"Neopharmed Gentili","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Mesoglycan","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Societa Italiana di Chirurgia ColoRettale","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Societa Italiana di Chirurgia ColoRettale \/ Neopharmed Gentili","highestDevelopmentStatusID":"1","companyTruncated":"Societa Italiana di Chirurgia ColoRettale \/ Neopharmed Gentili"},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Metoclopramide Hydrochloride","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Evoke Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Evoke Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Evoke Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Metoclopramide Hydrochloride","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Evoke Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Evoke Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Evoke Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Metoclopramide Hydrochloride","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Evoke Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Evoke Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Evoke Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Eversana","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Metoclopramide Hydrochloride","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Evoke Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Evoke Pharma \/ Eversana","highestDevelopmentStatusID":"15","companyTruncated":"Evoke Pharma \/ Eversana"},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Metoclopramide Hydrochloride","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Evoke Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Evoke Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Evoke Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Metoclopramide Hydrochloride","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Evoke Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Evoke Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Evoke Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Metoclopramide Hydrochloride","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Evoke Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Evoke Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Evoke Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Metoclopramide Hydrochloride","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Evoke Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Evoke Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Evoke Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Metoclopramide Hydrochloride","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Evoke Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Evoke Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Evoke Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Metoclopramide Hydrochloride","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Evoke Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Evoke Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Evoke Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Metoclopramide Hydrochloride","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Evoke Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Evoke Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Evoke Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Metoclopramide Hydrochloride","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Evoke Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Evoke Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Evoke Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Metoclopramide Hydrochloride","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Evoke Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Evoke Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Evoke Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Eversana","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Metoclopramide Hydrochloride","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Evoke Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Evoke Pharma \/ Eversana","highestDevelopmentStatusID":"15","companyTruncated":"Evoke Pharma \/ Eversana"},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Metoclopramide Hydrochloride","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Evoke Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Evoke Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Evoke Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Avenacy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Metoclopramide Hydrochloride","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Avenacy","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avenacy \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Avenacy \/ Undisclosed"},{"orgOrder":0,"company":"Neurogastrx","sponsor":"Vivo Capital","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Series B Financing","leadProduct":"Metopimazine Mesylate","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Neurogastrx","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.059999999999999998,"dosageForm":"Capsule","sponsorNew":"Neurogastrx \/ Vivo Capital","highestDevelopmentStatusID":"8","companyTruncated":"Neurogastrx \/ Vivo Capital"},{"orgOrder":0,"company":"Microbiome Health Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"MHS 1031","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Microbiome Health Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Microbiome Health Sciences \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Microbiome Health Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Microbiome Health Sciences","sponsor":"VBHRC Virginia Catalyst","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"MHS-1031","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Microbiome Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Sachet","sponsorNew":"Microbiome Health Sciences \/ VBHRC Virginia Catalyst","highestDevelopmentStatusID":"8","companyTruncated":"Microbiome Health Sciences \/ VBHRC Virginia Catalyst"},{"orgOrder":0,"company":"Medical University Innsbruck","sponsor":"Servier","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"AUSTRIA","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Micronized Purified Flavonoid- Fraction","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Medical University Innsbruck","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Medical University Innsbruck \/ Servier","highestDevelopmentStatusID":"10","companyTruncated":"Medical University Innsbruck \/ Servier"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"University of the Philippines","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2010","type":"Inapplicable","leadProduct":"Milk","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ University of the Philippines","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ University of the Philippines"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2012","type":"Inapplicable","leadProduct":"Milk","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Undisclosed"},{"orgOrder":0,"company":"a2 Milk Company Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NEW ZEALAND","productType":"Dietary Supplement","year":"2015","type":"Inapplicable","leadProduct":"Milk","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"a2 Milk Company Ltd.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"a2 Milk Company Ltd. \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"a2 Milk Company Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"a2 Milk Company Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NEW ZEALAND","productType":"Dietary Supplement","year":"2016","type":"Inapplicable","leadProduct":"Milk","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"a2 Milk Company Ltd.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"a2 Milk Company Ltd. \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"a2 Milk Company Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"a2 Milk Company Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NEW ZEALAND","productType":"Dietary Supplement","year":"2017","type":"Inapplicable","leadProduct":"Milk","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"a2 Milk Company Ltd.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"a2 Milk Company Ltd. \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"a2 Milk Company Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Fonterra Research Centre","sponsor":"Sprim Advanced Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NEW ZEALAND","productType":"Dietary Supplement","year":"2013","type":"Inapplicable","leadProduct":"Milk","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Fonterra Research Centre","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fonterra Research Centre \/ Sprim Advanced Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Fonterra Research Centre \/ Sprim Advanced Life Sciences"},{"orgOrder":0,"company":"a2 Milk Company Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NEW ZEALAND","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Milk","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"a2 Milk Company Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"a2 Milk Company Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"a2 Milk Company Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Instituto de Investigaci\u00f3n Sanitaria Arag\u00f3n","sponsor":"Cooperativas Lacteas Unidas | Hospital Cl\u00ednico Universitario Lozano Blesa","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SPAIN","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Milk From Genetically Selected Homozygous-Casein-A2 Cows Fed With Forages And A Concentrate Enriched On Linseed And Selenized Yeast As Sources Of PUFAs And Selenium","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Instituto de Investigaci\u00f3n Sanitaria Arag\u00f3n","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Instituto de Investigaci\u00f3n Sanitaria Arag\u00f3n \/ Cooperativas Lacteas Unidas | Hospital Cl\u00ednico Universitario Lozano Blesa","highestDevelopmentStatusID":"1","companyTruncated":"Instituto de Investigaci\u00f3n Sanitaria Arag\u00f3n \/ Cooperativas Lacteas Unidas | Hospital Cl\u00ednico Universitario Lozano Blesa"},{"orgOrder":0,"company":"US Oncology Research","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Miracle Mouthwash","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"US Oncology Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"US Oncology Research \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"US Oncology Research \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Ente Ospedaliero Ospedali Galliera","sponsor":"Fondazione Umberto Veronesi | Indena","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Mirtoselect","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Ente Ospedaliero Ospedali Galliera","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ente Ospedaliero Ospedali Galliera \/ Fondazione Umberto Veronesi | Indena","highestDevelopmentStatusID":"1","companyTruncated":"Ente Ospedaliero Ospedali Galliera \/ Fondazione Umberto Veronesi | Indena"},{"orgOrder":0,"company":"MitoImmune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"MIT-001","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"MitoImmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MitoImmune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MitoImmune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MitoImmune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"MIT-001","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"MitoImmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MitoImmune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MitoImmune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bright Dairy & Food Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Momchilovtsi Yogurt","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Bright Dairy & Food Co., Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bright Dairy & Food Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Bright Dairy & Food Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"MSP Starch Products Inc.","sponsor":"Source Nutraceutical, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2019","type":"Inapplicable","leadProduct":"Msprebiotic","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"MSP Starch Products Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MSP Starch Products Inc. \/ Source Nutraceutical, Inc.","highestDevelopmentStatusID":"1","companyTruncated":"MSP Starch Products Inc. \/ Source Nutraceutical, Inc."},{"orgOrder":0,"company":"Mirador Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"MT-501","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Mirador Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mirador Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mirador Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Medical University of Warsaw","sponsor":"Winclove Probiotics B.V.","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"POLAND","productType":"Probiotic","year":"2017","type":"Inapplicable","leadProduct":"Multispecies Probiotic","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Medical University of Warsaw","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medical University of Warsaw \/ Winclove Probiotics B.V.","highestDevelopmentStatusID":"1","companyTruncated":"Medical University of Warsaw \/ Winclove Probiotics B.V."},{"orgOrder":0,"company":"Renew Life Formulas Inc","sponsor":"Sprim Advanced Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2012","type":"Inapplicable","leadProduct":"Multistrain Probiotic","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Renew Life Formulas Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Renew Life Formulas Inc \/ Sprim Advanced Life Sciences","highestDevelopmentStatusID":"9","companyTruncated":"Renew Life Formulas Inc \/ Sprim Advanced Life Sciences"},{"orgOrder":0,"company":"Larena SAS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"COLOMBIA","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Multistrain Probiotic","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Larena SAS","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Larena SAS \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Larena SAS \/ Undisclosed"},{"orgOrder":0,"company":"METAGENICS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2025","type":"Inapplicable","leadProduct":"Multivitamin","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"METAGENICS","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"METAGENICS \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"METAGENICS \/ Undisclosed"},{"orgOrder":0,"company":"University of South Carolina","sponsor":"M2 Ingredients | Substantiation Sciences, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Mushroom Blend","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"University of South Carolina","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of South Carolina \/ M2 Ingredients | Substantiation Sciences, LLC","highestDevelopmentStatusID":"1","companyTruncated":"University of South Carolina \/ M2 Ingredients | Substantiation Sciences, LLC"},{"orgOrder":0,"company":"Nature Science Sp. z o.o.","sponsor":"Medical Network M. Woynarowski, J. Kierku? Sp\u00f3?ka jawna (MED-NET)","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"POLAND","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Mycobiotic","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Nature Science Sp. z o.o.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Sachet","sponsorNew":"Nature Science Sp. z o.o. \/ Medical Network M. Woynarowski, J. Kierku? Sp\u00f3?ka jawna (MED-NET)","highestDevelopmentStatusID":"1","companyTruncated":"Nature Science Sp. z o.o. \/ Medical Network M. Woynarowski, J. Kierku? Sp\u00f3?ka jawna (MED-NET)"},{"orgOrder":0,"company":"Atlantia Food Clinical Trials","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Natural Fibre","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Atlantia Food Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Atlantia Food Clinical Trials \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Atlantia Food Clinical Trials \/ Undisclosed"},{"orgOrder":0,"company":"Novome Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"NB1000S","moa":"||Undisclosed","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Novome Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Novome Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novome Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Vivtex","sponsor":"Orbis Medicines","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"nCycles","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Discovery Platform","graph3":"Vivtex","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vivtex \/ Orbis Medicines","highestDevelopmentStatusID":"3","companyTruncated":"Vivtex \/ Orbis Medicines"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Kaken Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"ND081","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Numab Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Numab Therapeutics \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Numab Therapeutics \/ Kaken Pharmaceuticals"},{"orgOrder":0,"company":"NexEos Diagnostics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"NDX-3315","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"NexEos Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"NexEos Diagnostics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NexEos Diagnostics \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Nektar 118","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Aboca","sponsor":"Doppel Pharma | University of Roma La Sapienza | BMR Genomics","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Neobianacid","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Aboca","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aboca \/ Doppel Pharma | University of Roma La Sapienza | BMR Genomics","highestDevelopmentStatusID":"11","companyTruncated":"Aboca \/ Doppel Pharma | University of Roma La Sapienza | BMR Genomics"},{"orgOrder":0,"company":"Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey","sponsor":"Atabay","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Neoven 225","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey \/ Atabay","highestDevelopmentStatusID":"11","companyTruncated":"Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey \/ Atabay"},{"orgOrder":0,"company":"Neurenati Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"NEU-001","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Neurenati Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Enema","sponsorNew":"Neurenati Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Neurenati Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Neurenati Therapeutics","sponsor":"Genson Capital","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Protein","year":"2024","type":"Funding","leadProduct":"NEU-001","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Neurenati Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Enema","sponsorNew":"Neurenati Therapeutics \/ Genson Capital","highestDevelopmentStatusID":"5","companyTruncated":"Neurenati Therapeutics \/ Genson Capital"},{"orgOrder":0,"company":"Neurenati Therapeutics","sponsor":"Investissement Qu\u00e9bec","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Protein","year":"2024","type":"Financing","leadProduct":"NEU-001","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Neurenati Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Enema","sponsorNew":"Neurenati Therapeutics \/ Investissement Qu\u00e9bec","highestDevelopmentStatusID":"5","companyTruncated":"Neurenati Therapeutics \/ Investissement Qu\u00e9bec"},{"orgOrder":0,"company":"United Pharmaceuticals","sponsor":"Delta Consultants","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JORDAN","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"New Infant Formula","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"United Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Pharmaceuticals \/ Delta Consultants","highestDevelopmentStatusID":"1","companyTruncated":"United Pharmaceuticals \/ Delta Consultants"},{"orgOrder":0,"company":"United Pharmaceuticals","sponsor":"Axiodis CRO","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JORDAN","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"New Infant Formula","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"United Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Pharmaceuticals \/ Axiodis CRO","highestDevelopmentStatusID":"1","companyTruncated":"United Pharmaceuticals \/ Axiodis CRO"},{"orgOrder":0,"company":"United Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JORDAN","productType":"Dietary Supplement","year":"2015","type":"Inapplicable","leadProduct":"New Thickened Formula","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"United Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"United Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Neurogastrx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"NG101","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Neurogastrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Neurogastrx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Neurogastrx \/ Undisclosed"},{"orgOrder":0,"company":"VasoDynamics Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"NG11-2","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"VasoDynamics Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"VasoDynamics Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"VasoDynamics Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Laboratorio Industrial de Herbodietetica Aplicada S.L","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SPAIN","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Normodigest Classic","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Laboratorio Industrial de Herbodietetica Aplicada S.L","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratorio Industrial de Herbodietetica Aplicada S.L \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Laboratorio Industrial de Herbodietetica Aplicada S.L \/ Undisclosed"},{"orgOrder":0,"company":"National Vaccine and Serum Institute China","sponsor":"Lanzhou Institute of Biological Products Co., Ltd | Beijing Zhong Sheng Heng Yi Pharmaceutical Technology | Zhengzhou University","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Vaccine","year":"2019","type":"Inapplicable","leadProduct":"Norovirus Bivalent (GI.1 \/ GII.4) Vaccine","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"National Vaccine and Serum Institute China","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Vaccine and Serum Institute China \/ Lanzhou Institute of Biological Products Co., Ltd | Beijing Zhong Sheng Heng Yi Pharmaceutical Technology | Zhengzhou University","highestDevelopmentStatusID":"6","companyTruncated":"National Vaccine and Serum Institute China \/ Lanzhou Institute of Biological Products Co., Ltd | Beijing Zhong Sheng Heng Yi Pharmaceutical Technology | Zhengzhou University"},{"orgOrder":0,"company":"Atrium Innovations","sponsor":"Dr. Nathan Morris, MD | Genova Diagnostics","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Dietary Supplement","year":"2018","type":"Inapplicable","leadProduct":"Novel Supplement Based Therapy","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Atrium Innovations","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Atrium Innovations \/ Dr. Nathan Morris, MD | Genova Diagnostics","highestDevelopmentStatusID":"6","companyTruncated":"Atrium Innovations \/ Dr. Nathan Morris, MD | Genova Diagnostics"},{"orgOrder":0,"company":"NIHON PHARMACEUTICAL","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"NPO-13","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"NIHON PHARMACEUTICAL","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NIHON PHARMACEUTICAL \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NIHON PHARMACEUTICAL \/ Undisclosed"},{"orgOrder":0,"company":"NIHON PHARMACEUTICAL","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"NPO-13","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"NIHON PHARMACEUTICAL","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NIHON PHARMACEUTICAL \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NIHON PHARMACEUTICAL \/ Undisclosed"},{"orgOrder":0,"company":"NorthSea Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"NST 6179","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"NorthSea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NorthSea Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"NorthSea Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Elgan Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"NTRA-9620","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Elgan Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elgan Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Elgan Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Nutrabiotix, LLC","sponsor":"Rush University Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Dietary Supplement","year":"2014","type":"Inapplicable","leadProduct":"NTX-1","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Nutrabiotix, LLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutrabiotix, LLC \/ Rush University Medical Center","highestDevelopmentStatusID":"8","companyTruncated":"Nutrabiotix, LLC \/ Rush University Medical Center"},{"orgOrder":0,"company":"Shandong Sibote Biotechnology Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"Nuotelande Shuhuajun","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Shandong Sibote Biotechnology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Shandong Sibote Biotechnology Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Shandong Sibote Biotechnology Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"University of Texas Health Science Center at Houston","sponsor":"Mead Johnson Nutrition","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Nutramigen","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"University of Texas Health Science Center at Houston","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Texas Health Science Center at Houston \/ Mead Johnson Nutrition","highestDevelopmentStatusID":"1","companyTruncated":"University of Texas Health Science Center at Houston \/ Mead Johnson Nutrition"},{"orgOrder":0,"company":"Children's Hospital of Philadelphia","sponsor":"Beneo","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2018","type":"Inapplicable","leadProduct":"Oligofructose-Enriched Inulin","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Children's Hospital of Philadelphia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Hospital of Philadelphia \/ Beneo","highestDevelopmentStatusID":"1","companyTruncated":"Children's Hospital of Philadelphia \/ Beneo"},{"orgOrder":0,"company":"Catalysis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Dietary Supplement","year":"2018","type":"Inapplicable","leadProduct":"Oncoxin","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Catalysis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Catalysis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Catalysis \/ Undisclosed"},{"orgOrder":0,"company":"BIO-CAT","sponsor":"KGK Science","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2016","type":"Inapplicable","leadProduct":"Opti-Biome Bacillus Subtilis MB40","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"BIO-CAT","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BIO-CAT \/ KGK Science","highestDevelopmentStatusID":"8","companyTruncated":"BIO-CAT \/ KGK Science"},{"orgOrder":0,"company":"Beneo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Plant Extract\/Herbal","year":"2015","type":"Inapplicable","leadProduct":"Orafti Inulin","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Beneo","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beneo \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Beneo \/ Undisclosed"},{"orgOrder":0,"company":"Institut Investigacio Sanitaria Pere Virgili","sponsor":"Beneo","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SPAIN","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Oraftir Inulin-Type Fructans","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Institut Investigacio Sanitaria Pere Virgili","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institut Investigacio Sanitaria Pere Virgili \/ Beneo","highestDevelopmentStatusID":"1","companyTruncated":"Institut Investigacio Sanitaria Pere Virgili \/ Beneo"},{"orgOrder":0,"company":"Orexa","sponsor":"QPS Holdings","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ORE001","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Orexa","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orexa \/ QPS Holdings","highestDevelopmentStatusID":"8","companyTruncated":"Orexa \/ QPS Holdings"},{"orgOrder":0,"company":"Oxford Pharmascience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"OXP001","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Oxford Pharmascience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oxford Pharmascience \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Oxford Pharmascience \/ Undisclosed"},{"orgOrder":0,"company":"Oxford Pharmascience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"OXP005","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Oxford Pharmascience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oxford Pharmascience \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Oxford Pharmascience \/ Undisclosed"},{"orgOrder":0,"company":"Microbiome Health Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Panosyl Isomaltooligosaccharides","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Microbiome Health Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Microbiome Health Sciences \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Microbiome Health Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Laboratorios Ordesa","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SPAIN","productType":"Dietary Supplement","year":"2019","type":"Inapplicable","leadProduct":"Partially Hydrolysed Formula","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Laboratorios Ordesa","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratorios Ordesa \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Laboratorios Ordesa \/ Undisclosed"},{"orgOrder":0,"company":"A-Mansia Biotech S.A.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"LUXEMBOURG","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Pasteurized A. Muciniphila","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"A-Mansia Biotech S.A.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"A-Mansia Biotech S.A. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"A-Mansia Biotech S.A. \/ Undisclosed"},{"orgOrder":0,"company":"Prolacta Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"PBCLN-003","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Prolacta Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prolacta Bioscience \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Prolacta Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Pharmbio Korea","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"PBK_M2101","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Pharmbio Korea","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmbio Korea \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pharmbio Korea \/ Undisclosed"},{"orgOrder":0,"company":"Pharmbio Korea","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"PBK_M2502","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Pharmbio Korea","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmbio Korea \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pharmbio Korea \/ Undisclosed"},{"orgOrder":0,"company":"Pharmbio Korea","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"PBK-1701TC","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Pharmbio Korea","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmbio Korea \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pharmbio Korea \/ Undisclosed"},{"orgOrder":0,"company":"Seed Health","sponsor":"Curebase Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"PDS-08","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Seed Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seed Health \/ Curebase Inc.","highestDevelopmentStatusID":"1","companyTruncated":"Seed Health \/ Curebase Inc."},{"orgOrder":0,"company":"Universit\u00e0 Politecnica delle Marche","sponsor":"Noos S.r.l.","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Pentabiocel","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Universit\u00e0 Politecnica delle Marche","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universit\u00e0 Politecnica delle Marche \/ Noos S.r.l.","highestDevelopmentStatusID":"1","companyTruncated":"Universit\u00e0 Politecnica delle Marche \/ Noos S.r.l."},{"orgOrder":0,"company":"Gazi University","sponsor":"Enbiosis Biotechnology | TC Erciyes University","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"TURKEY","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Personalized Microbiome Diet","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Gazi University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gazi University \/ Enbiosis Biotechnology | TC Erciyes University","highestDevelopmentStatusID":"1","companyTruncated":"Gazi University \/ Enbiosis Biotechnology | TC Erciyes University"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"PF 06687234","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"PF-06480605","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Phgg","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Undisclosed"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Phgg","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Undisclosed"},{"orgOrder":0,"company":"Iuppa Industriale Srl","sponsor":"Tigermed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Physiomanna Baby","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Iuppa Industriale Srl","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Iuppa Industriale Srl \/ Tigermed","highestDevelopmentStatusID":"1","companyTruncated":"Iuppa Industriale Srl \/ Tigermed"},{"orgOrder":0,"company":"Chongqing Peg-Bio Biopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"PJ009","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Chongqing Peg-Bio Biopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chongqing Peg-Bio Biopharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chongqing Peg-Bio Biopharm \/ Undisclosed"},{"orgOrder":0,"company":"Chongqing Peg-Bio Biopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"PJ009","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Chongqing Peg-Bio Biopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chongqing Peg-Bio Biopharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chongqing Peg-Bio Biopharm \/ Undisclosed"},{"orgOrder":0,"company":"PLX Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"PL2200","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"PLX Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PLX Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PLX Pharma \/ Undisclosed"},{"orgOrder":0,"company":"PLX Pharma","sponsor":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"PL3100","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"PLX Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PLX Pharma \/ National Institute of Arthritis and Musculoskeletal and Skin Diseases","highestDevelopmentStatusID":"8","companyTruncated":"PLX Pharma \/ National Institute of Arthritis and Musculoskeletal and Skin Diseases"},{"orgOrder":0,"company":"Fudan University","sponsor":"Amway (China) Daily-Use Commodity Co.,Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Plant Nutrient","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Fudan University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fudan University \/ Amway (China) Daily-Use Commodity Co.,Ltd","highestDevelopmentStatusID":"1","companyTruncated":"Fudan University \/ Amway (China) Daily-Use Commodity Co.,Ltd"},{"orgOrder":0,"company":"Laboratorios Ordesa","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SPAIN","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Plant-Based Food Fibers","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Laboratorios Ordesa","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratorios Ordesa \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Laboratorios Ordesa \/ Undisclosed"},{"orgOrder":0,"company":"PharmaKing","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"PMK-S005","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"PharmaKing","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmaKing \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PharmaKing \/ Undisclosed"},{"orgOrder":0,"company":"PharmaKing","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"PMK-S005","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"PharmaKing","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmaKing \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"PharmaKing \/ Undisclosed"},{"orgOrder":0,"company":"Danisco","sponsor":"Sprim Advanced Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Plant Extract\/Herbal","year":"2012","type":"Inapplicable","leadProduct":"Polydextrose","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Danisco","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Danisco \/ Sprim Advanced Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Danisco \/ Sprim Advanced Life Sciences"},{"orgOrder":0,"company":"Tate & Lyle","sponsor":"Oy Foodfiles Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Polydextrose","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Tate & Lyle","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tate & Lyle \/ Oy Foodfiles Ltd","highestDevelopmentStatusID":"1","companyTruncated":"Tate & Lyle \/ Oy Foodfiles Ltd"},{"orgOrder":0,"company":"University of Ulm","sponsor":"Technical University of Munich | Medical University of Graz | Specialized Medical Office for Gastroenterology Dornstadt | QIAGEN Gaithersburg, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Polypectomy","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"University of Ulm","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Ulm \/ Technical University of Munich | Medical University of Graz | Specialized Medical Office for Gastroenterology Dornstadt | QIAGEN Gaithersburg, Inc","highestDevelopmentStatusID":"1","companyTruncated":"University of Ulm \/ Technical University of Munich | Medical University of Graz | Specialized Medical Office for Gastroenterology Dornstadt | QIAGEN Gaithersburg, Inc"},{"orgOrder":0,"company":"LiveLeaf Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2016","type":"Inapplicable","leadProduct":"Polyphenol","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"LiveLeaf Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LiveLeaf Inc. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"LiveLeaf Inc. \/ Undisclosed"},{"orgOrder":0,"company":"AronPharma Sp. z o. o.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"POLAND","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Polyphenol Extract","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"AronPharma Sp. z o. o.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AronPharma Sp. z o. o. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"AronPharma Sp. z o. o. \/ Undisclosed"},{"orgOrder":0,"company":"AronPharma Sp. z o. o.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"POLAND","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Polyphenol Extract","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"AronPharma Sp. z o. o.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AronPharma Sp. z o. o. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"AronPharma Sp. z o. o. \/ Undisclosed"},{"orgOrder":0,"company":"A-Mansia Biotech S.A.","sponsor":"Vedic Lifesciences Pvt. Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"LUXEMBOURG","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"Postbiotic","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"A-Mansia Biotech S.A.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"A-Mansia Biotech S.A. \/ Vedic Lifesciences Pvt. Ltd.","highestDevelopmentStatusID":"1","companyTruncated":"A-Mansia Biotech S.A. \/ Vedic Lifesciences Pvt. Ltd."},{"orgOrder":0,"company":"Peritech Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"PP110","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Peritech Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Peritech Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Peritech Pharma \/ Undisclosed"},{"orgOrder":0,"company":"University of Reading","sponsor":"Danisco","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Probiotic","year":"2012","type":"Inapplicable","leadProduct":"Prebiotic","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"University of Reading","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Reading \/ Danisco","highestDevelopmentStatusID":"1","companyTruncated":"University of Reading \/ Danisco"},{"orgOrder":0,"company":"Colorado State University","sponsor":"Ritual","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"Prebiotic","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Colorado State University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Colorado State University \/ Ritual","highestDevelopmentStatusID":"1","companyTruncated":"Colorado State University \/ Ritual"},{"orgOrder":0,"company":"Xinhua Hospital, Shanghai Jiaotong University School of Medicine","sponsor":"Beneo","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Probiotic","year":"2019","type":"Inapplicable","leadProduct":"Prebiotic Fructan","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Xinhua Hospital, Shanghai Jiaotong University School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xinhua Hospital, Shanghai Jiaotong University School of Medicine \/ Beneo","highestDevelopmentStatusID":"1","companyTruncated":"Xinhua Hospital, Shanghai Jiaotong University School of Medicine \/ Beneo"},{"orgOrder":0,"company":"Yara El Helou","sponsor":"Pharma M","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Probiolife","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Yara El Helou","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yara El Helou \/ Pharma M","highestDevelopmentStatusID":"1","companyTruncated":"Yara El Helou \/ Pharma M"},{"orgOrder":0,"company":"S&D Pharma SK s.r.o.","sponsor":"National Cancer Institute, Slovakia","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SLOVAKIA","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Probio-Tec BG-VCap-6.5","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"S&D Pharma SK s.r.o.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"S&D Pharma SK s.r.o. \/ National Cancer Institute, Slovakia","highestDevelopmentStatusID":"10","companyTruncated":"S&D Pharma SK s.r.o. \/ National Cancer Institute, Slovakia"},{"orgOrder":0,"company":"Sanzyme","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Probiotic Strain SNZ 1969","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Sanzyme","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sanzyme \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sanzyme \/ Undisclosed"},{"orgOrder":0,"company":"Wecare Probiotics Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Probiotic Yogurt","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Wecare Probiotics Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wecare Probiotics Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Wecare Probiotics Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Universiti Sains Malaysia","sponsor":"Morinaga Milk Industry Co., LTD","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"MALAYSIA","productType":"Probiotic","year":"2017","type":"Inapplicable","leadProduct":"Probiotics M-63","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Universiti Sains Malaysia","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Sachet","sponsorNew":"Universiti Sains Malaysia \/ Morinaga Milk Industry Co., LTD","highestDevelopmentStatusID":"9","companyTruncated":"Universiti Sains Malaysia \/ Morinaga Milk Industry Co., LTD"},{"orgOrder":0,"company":"Geophyt S.r.l.s.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Proklama","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Geophyt S.r.l.s.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Geophyt S.r.l.s. \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Geophyt S.r.l.s. \/ Undisclosed"},{"orgOrder":0,"company":"Aboca","sponsor":"Euromed Pharma Services | Ceinge | Latis | PhAST Consulting","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Promelaxin","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Aboca","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Enema","sponsorNew":"Aboca \/ Euromed Pharma Services | Ceinge | Latis | PhAST Consulting","highestDevelopmentStatusID":"11","companyTruncated":"Aboca \/ Euromed Pharma Services | Ceinge | Latis | PhAST Consulting"},{"orgOrder":0,"company":"Soci\u00e9t\u00e9 Guaranteed Gluten Free (GGF)","sponsor":"Institut Polytechnique UniLaSalle | Institut Pasteur de Lille | Association Fran\u00e7aise des Intol\u00e9rants au Gluten","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Dietary Supplement","year":"2018","type":"Inapplicable","leadProduct":"Protalsafe","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Soci\u00e9t\u00e9 Guaranteed Gluten Free (GGF)","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Soci\u00e9t\u00e9 Guaranteed Gluten Free (GGF) \/ Institut Polytechnique UniLaSalle | Institut Pasteur de Lille | Association Fran\u00e7aise des Intol\u00e9rants au Gluten","highestDevelopmentStatusID":"1","companyTruncated":"Soci\u00e9t\u00e9 Guaranteed Gluten Free (GGF) \/ Institut Polytechnique UniLaSalle | Institut Pasteur de Lille | Association Fran\u00e7aise des Intol\u00e9rants au Gluten"},{"orgOrder":0,"company":"Plakous Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Protein","year":"2020","type":"Funding","leadProduct":"Protego-PD","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Plakous Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Plakous Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"Plakous Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"University of Colorado, Denver","sponsor":"PanTheryx","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Dietary Supplement","year":"2015","type":"Inapplicable","leadProduct":"PTM202","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"University of Colorado, Denver","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Colorado, Denver \/ PanTheryx","highestDevelopmentStatusID":"1","companyTruncated":"University of Colorado, Denver \/ PanTheryx"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Enzyme","year":"2018","type":"Inapplicable","leadProduct":"PvP001","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Resilience","sponsor":"Parvus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Partnership","leadProduct":"PVT401","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Resilience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Resilience \/ Parvus Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Resilience \/ Parvus Therapeutics"},{"orgOrder":0,"company":"Parvus Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Collaboration","leadProduct":"PVT-401","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Parvus Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Parvus Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"Parvus Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"Pharmabiotix Inc","sponsor":"University of Alberta","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Dietary Supplement","year":"2015","type":"Inapplicable","leadProduct":"PX0612","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Pharmabiotix Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharmabiotix Inc \/ University of Alberta","highestDevelopmentStatusID":"1","companyTruncated":"Pharmabiotix Inc \/ University of Alberta"},{"orgOrder":0,"company":"Shenzhen Precision Health Food Technology Co. Ltd.,","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Qimeiyan Probiotic","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Shenzhen Precision Health Food Technology Co. Ltd.,","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen Precision Health Food Technology Co. Ltd., \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Shenzhen Precision Health Food Technology Co. Ltd., \/ Undisclosed"},{"orgOrder":0,"company":"China Resources Sanjiu","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Qizhi Weitong","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"China Resources Sanjiu","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"China Resources Sanjiu \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"China Resources Sanjiu \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"QLM2010","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Dong-A Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Recoflavone","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Dong-A Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dong-A Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dong-A Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"MARIA CRISTINA COMELLI","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Recolix","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"MARIA CRISTINA COMELLI","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MARIA CRISTINA COMELLI \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MARIA CRISTINA COMELLI \/ Undisclosed"},{"orgOrder":0,"company":"Healthgen Biotechnology","sponsor":"Beijing Friendship Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Recombinant Human Chymotrypsin","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Healthgen Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Healthgen Biotechnology \/ Beijing Friendship Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Healthgen Biotechnology \/ Beijing Friendship Hospital"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Peptide, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Recombinant Human Epidermal Growth Factor","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Daewoong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Daewoong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Alexander Hawkins","sponsor":"Lynch Regenerative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Recombinant Human PDGF-BB","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Alexander Hawkins","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alexander Hawkins \/ Lynch Regenerative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Alexander Hawkins \/ Lynch Regenerative Medicine"},{"orgOrder":0,"company":"University of Wisconsin, Madison","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Recombinant Zoster Vaccine, Adjuvanted","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"University of Wisconsin, Madison","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Wisconsin, Madison \/ GSK","highestDevelopmentStatusID":"11","companyTruncated":"University of Wisconsin, Madison \/ GSK"},{"orgOrder":0,"company":"Nordisk Rebalance","sponsor":"University Hospital, Linkoeping | Linkoeping University","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Referm","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Nordisk Rebalance","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nordisk Rebalance \/ University Hospital, Linkoeping | Linkoeping University","highestDevelopmentStatusID":"1","companyTruncated":"Nordisk Rebalance \/ University Hospital, Linkoeping | Linkoeping University"},{"orgOrder":0,"company":"Catalysis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Dietary Supplement","year":"2010","type":"Inapplicable","leadProduct":"Renalof","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Catalysis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Catalysis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Catalysis \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"RHB-106","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"ortis","sponsor":"CEN Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Rhubarbe","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"ortis","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ortis \/ CEN Biotech","highestDevelopmentStatusID":"1","companyTruncated":"ortis \/ CEN Biotech"},{"orgOrder":0,"company":"Motus Therapeutics, Inc.","sponsor":"Mayo Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"RM-131","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Motus Therapeutics, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Motus Therapeutics, Inc. \/ Mayo Clinic","highestDevelopmentStatusID":"8","companyTruncated":"Motus Therapeutics, Inc. \/ Mayo Clinic"},{"orgOrder":0,"company":"Motus Therapeutics, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"RM-131","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Motus Therapeutics, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Motus Therapeutics, Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Motus Therapeutics, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Centre for Infectious Disease Research in Zambia","sponsor":"PATH | Christian Medical College, Vellore, India | Children's Hospital Medical Center, Cincinnati | Bharat Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ZAMBIA","productType":"Vaccine","year":"2018","type":"Inapplicable","leadProduct":"Rotavirus Vaccine (Live Attenuated, Oral)","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Centre for Infectious Disease Research in Zambia","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre for Infectious Disease Research in Zambia \/ PATH | Christian Medical College, Vellore, India | Children's Hospital Medical Center, Cincinnati | Bharat Biotech","highestDevelopmentStatusID":"9","companyTruncated":"Centre for Infectious Disease Research in Zambia \/ PATH | Christian Medical College, Vellore, India | Children's Hospital Medical Center, Cincinnati | Bharat Biotech"},{"orgOrder":0,"company":"Revogenex, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"RVX-100","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Revogenex, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revogenex, Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Revogenex, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Lesaffre International","sponsor":"BioFortis | University of Nottingham","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Probiotic","year":"2012","type":"Inapplicable","leadProduct":"Saccharomyces Cerevisiae CNCM I-3856","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Lesaffre International","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lesaffre International \/ BioFortis | University of Nottingham","highestDevelopmentStatusID":"1","companyTruncated":"Lesaffre International \/ BioFortis | University of Nottingham"},{"orgOrder":0,"company":"Lesaffre International","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Probiotic","year":"2017","type":"Inapplicable","leadProduct":"Saccharomyces Cerevisiae CNCM I-3856","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Lesaffre International","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lesaffre International \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Lesaffre International \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Probiotic","year":"2019","type":"Inapplicable","leadProduct":"Salix Probiotic","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Syral","sponsor":"Biofortis M\u00e9rieux Nutriscience | CreaBio Rhone-Alpes","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Probiotic","year":"2018","type":"Inapplicable","leadProduct":"scFOS","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Syral","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syral \/ Biofortis M\u00e9rieux Nutriscience | CreaBio Rhone-Alpes","highestDevelopmentStatusID":"1","companyTruncated":"Syral \/ Biofortis M\u00e9rieux Nutriscience | CreaBio Rhone-Alpes"},{"orgOrder":0,"company":"NIZO Food Research","sponsor":"Ingredion Pharma Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Probiotic","year":"2014","type":"Inapplicable","leadProduct":"SC-FOS","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"NIZO Food Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NIZO Food Research \/ Ingredion Pharma Solutions","highestDevelopmentStatusID":"1","companyTruncated":"NIZO Food Research \/ Ingredion Pharma Solutions"},{"orgOrder":0,"company":"Effexus Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Secretrol","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Effexus Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Effexus Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Effexus Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Effexus Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Secretrol","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Effexus Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Effexus Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Effexus Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Seed Health","sponsor":"The Craftory","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2021","type":"Series A Financing","leadProduct":"SEED Synbiotic","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Seed Health","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.040000000000000001,"dosageForm":"Capsule","sponsorNew":"Seed Health \/ The Craftory","highestDevelopmentStatusID":"8","companyTruncated":"Seed Health \/ The Craftory"},{"orgOrder":0,"company":"St. Joseph's Health, New York","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Senna","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"St. Joseph's Health, New York","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"St. Joseph's Health, New York \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"St. Joseph's Health, New York \/ Undisclosed"},{"orgOrder":0,"company":"TriHealth","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2014","type":"Inapplicable","leadProduct":"Senna","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"TriHealth","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"TriHealth \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"TriHealth \/ Undisclosed"},{"orgOrder":0,"company":"Nova Scotia Health Authority","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2017","type":"Inapplicable","leadProduct":"Senna","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Nova Scotia Health Authority","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nova Scotia Health Authority \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Nova Scotia Health Authority \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Famous Medical Technology","sponsor":"The First Affiliated Hospital with Nanjing Medical University | The Second Hospital of Shandong University | Shengjing Hospital | Shenzhen Hospital of Southern Medical University | Sixth Affiliated Hospital, Sun Yat-sen University | Sichuan Provincial Peo","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Shenbai Granules","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Jiangsu Famous Medical Technology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Granules","sponsorNew":"Jiangsu Famous Medical Technology \/ The First Affiliated Hospital with Nanjing Medical University | The Second Hospital of Shandong University | Shengjing Hospital | Shenzhen Hospital of Southern Medical University | Sixth Affiliated Hospital, Sun Yat-sen University | Sichuan Provincial Peo","highestDevelopmentStatusID":"1","companyTruncated":"Jiangsu Famous Medical Technology \/ The First Affiliated Hospital with Nanjing Medical University | The Second Hospital of Shandong University | Shengjing Hospital | Shenzhen Hospital of Southern Medical University | Sixth Affiliated Hospital, Sun Yat-sen University | Sichuan Provincial Peo"},{"orgOrder":0,"company":"Jiangsu Famous Medical Technology","sponsor":"The First Affiliated Hospital with Nanjing Medical University | First Affiliated Hospital of Harbin Medical University | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | The Second Affiliated Hospital of Chongqing Me","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Shenbai Granules","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Jiangsu Famous Medical Technology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Granules","sponsorNew":"Jiangsu Famous Medical Technology \/ The First Affiliated Hospital with Nanjing Medical University | First Affiliated Hospital of Harbin Medical University | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | The Second Affiliated Hospital of Chongqing Me","highestDevelopmentStatusID":"1","companyTruncated":"Jiangsu Famous Medical Technology \/ The First Affiliated Hospital with Nanjing Medical University | First Affiliated Hospital of Harbin Medical University | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | The Second Affiliated Hospital of Chongqing Me"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Simethicone","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Wonderberlly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Simethicone","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Wonderberlly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"Wonderberlly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Wonderberlly \/ Undisclosed"},{"orgOrder":0,"company":"Neopharm Bulgaria Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"BULGARIA","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Sinquanon","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Neopharm Bulgaria Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Neopharm Bulgaria Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Neopharm Bulgaria Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Zhiyi Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SK08","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Zhiyi Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Zhiyi Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zhiyi Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Zhiyi Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"SK10","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Zhiyi Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Zhiyi Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Zhiyi Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Zhiyi Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"SK10","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Zhiyi Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Zhiyi Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Zhiyi Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Zhiyi Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"SK10","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Zhiyi Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zhiyi Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Zhiyi Biotech \/ Undisclosed"},{"orgOrder":0,"company":"SK Chemicals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"SKI3246","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"SK Chemicals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SK Chemicals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SK Chemicals \/ Undisclosed"},{"orgOrder":0,"company":"SK Chemicals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"SK-MS10","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"SK Chemicals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SK Chemicals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SK Chemicals \/ Undisclosed"},{"orgOrder":0,"company":"Changi General Hospital","sponsor":"GenieBiome Limited | National University Hospital, Singapore","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SINGAPORE","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"SMT04 Pro","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Changi General Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Changi General Hospital \/ GenieBiome Limited | National University Hospital, Singapore","highestDevelopmentStatusID":"1","companyTruncated":"Changi General Hospital \/ GenieBiome Limited | National University Hospital, Singapore"},{"orgOrder":0,"company":"Universiti Sains Malaysia","sponsor":"GenieBiome Limited","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"MALAYSIA","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"SMT04 Pro","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Universiti Sains Malaysia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universiti Sains Malaysia \/ GenieBiome Limited","highestDevelopmentStatusID":"1","companyTruncated":"Universiti Sains Malaysia \/ GenieBiome Limited"},{"orgOrder":0,"company":"Menarini","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"Sodium Picosulfate","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Menarini","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0.01,"dosageForm":"Solution","sponsorNew":"Menarini \/ Lupin Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Menarini \/ Lupin Ltd"},{"orgOrder":0,"company":"Ahn-Gook Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Pantoprazole Sodium","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ahn-Gook Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ahn-Gook Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ahn-Gook Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ahn-Gook Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Pantoprazole Sodium","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ahn-Gook Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ahn-Gook Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ahn-Gook Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Pharmaceuticals Holding Co.,Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SPH7854","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Shanghai Pharmaceuticals Holding Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Pharmaceuticals Holding Co.,Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Pharmaceuticals Holding Co.,Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases | National Center for Research Resources | Advanced Breath Diagnostics, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Spirulina","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ National Institute of Diabetes and Digestive and Kidney Diseases | National Center for Research Resources | Advanced Breath Diagnostics, LLC","highestDevelopmentStatusID":"1","companyTruncated":"Mayo Clinic \/ National Institute of Diabetes and Digestive and Kidney Diseases | National Center for Research Resources | Advanced Breath Diagnostics, LLC"},{"orgOrder":0,"company":"Leadiant Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"STP206","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Leadiant Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leadiant Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Leadiant Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"University of Aarhus","sponsor":"Medtronic Plc","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Subsensory","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"University of Aarhus","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Aarhus \/ Medtronic plc","highestDevelopmentStatusID":"1","companyTruncated":"University of Aarhus \/ Medtronic plc"},{"orgOrder":0,"company":"Romanian Society for Enteral and Parenteral Nutrition","sponsor":"Fresenius Kabi AB Brunna | Carol Davila University of Medicine and Pharmacy | Bucharest Emergency Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ROMANIA","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Supplemental Parenteral Nutrition","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Romanian Society for Enteral and Parenteral Nutrition","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Romanian Society for Enteral and Parenteral Nutrition \/ Fresenius Kabi AB Brunna | Carol Davila University of Medicine and Pharmacy | Bucharest Emergency Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Romanian Society for Enteral and Parenteral Nutrition \/ Fresenius Kabi AB Brunna | Carol Davila University of Medicine and Pharmacy | Bucharest Emergency Hospital"},{"orgOrder":0,"company":"SymBio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"SyB D-0701","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"SymBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Patch","sponsorNew":"SymBio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SymBio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"TBF Genie Tissulaire","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Sygelix-F","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"TBF Genie Tissulaire","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Insert","sponsorNew":"TBF Genie Tissulaire \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"TBF Genie Tissulaire \/ Undisclosed"},{"orgOrder":0,"company":"Synlogic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"SYNB8802","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Synlogic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Synlogic \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Synlogic \/ Undisclosed"},{"orgOrder":0,"company":"Synlogic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"SYNB8802","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Synlogic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Synlogic \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Synlogic \/ Undisclosed"},{"orgOrder":0,"company":"Synlogic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"SYNB8802","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Synlogic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Synlogic \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Synlogic \/ Undisclosed"},{"orgOrder":0,"company":"Vesale Pharmaceutica","sponsor":"Universit\u00e9 Catholique de Louvain | University of Liege","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SPAIN","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"Synbiotic","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Vesale Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vesale Pharmaceutica \/ Universit\u00e9 Catholique de Louvain | University of Liege","highestDevelopmentStatusID":"1","companyTruncated":"Vesale Pharmaceutica \/ Universit\u00e9 Catholique de Louvain | University of Liege"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"TAK-951","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Trobix Bio","sponsor":"Chartered Group","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Microorganism","year":"2023","type":"Series A Financing","leadProduct":"TBX201","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Trobix Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trobix Bio \/ Chartered Group","highestDevelopmentStatusID":"4","companyTruncated":"Trobix Bio \/ Chartered Group"},{"orgOrder":0,"company":"TCI Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"TCI604","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"TCI Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TCI Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"TCI Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ardelyx \/ Undisclosed"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ardelyx \/ Undisclosed"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ardelyx \/ Undisclosed"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Kyowa Kirin","highestDevelopmentStatusID":"15","companyTruncated":"Ardelyx \/ Kyowa Kirin"},{"orgOrder":0,"company":"Scandinavian Biopharma","sponsor":"G\u00f6teborg University | United Medix Laboratories Ltd. | Medfiles Ltd | University of Helsinki | University of Virginia","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Vaccine","year":"2018","type":"Inapplicable","leadProduct":"Tetravalent Etec Vaccine","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Scandinavian Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Scandinavian Biopharma \/ G\u00f6teborg University | United Medix Laboratories Ltd. | Medfiles Ltd | University of Helsinki | University of Virginia","highestDevelopmentStatusID":"8","companyTruncated":"Scandinavian Biopharma \/ G\u00f6teborg University | United Medix Laboratories Ltd. | Medfiles Ltd | University of Helsinki | University of Virginia"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"TEV-53408","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"St. Vincent's East, Birmingham, Alabama","sponsor":"Master Supplements, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Theralac","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"St. Vincent's East, Birmingham, Alabama","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"St. Vincent's East, Birmingham, Alabama \/ Master Supplements, Inc","highestDevelopmentStatusID":"1","companyTruncated":"St. Vincent's East, Birmingham, Alabama \/ Master Supplements, Inc"},{"orgOrder":0,"company":"United Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JORDAN","productType":"Dietary Supplement","year":"2016","type":"Inapplicable","leadProduct":"Thickened Infant Formula","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"United Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"United Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Topcel-KH Pharmaceutical","sponsor":"Changhai Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"TH-SC01","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Jiangsu Topcel-KH Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Topcel-KH Pharmaceutical \/ Changhai Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Jiangsu Topcel-KH Pharmaceutical \/ Changhai Hospital"},{"orgOrder":0,"company":"Jiangsu Topcel-KH Pharmaceutical","sponsor":"Xiangya Hospital, Central South University","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TH-SC01","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Jiangsu Topcel-KH Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Topcel-KH Pharmaceutical \/ Xiangya Hospital, Central South University","highestDevelopmentStatusID":"7","companyTruncated":"Jiangsu Topcel-KH Pharmaceutical \/ Xiangya Hospital, Central South University"},{"orgOrder":0,"company":"Devonian Health Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Thylakoid extract","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Devonian Health Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Devonian Health Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Devonian Health Group \/ Undisclosed"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Tiropramide Hydrochloride","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daewoong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Daewoong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Topas Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"TPM502","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Topas Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Topas Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Topas Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Topas Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"TPM502","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Topas Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Topas Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Topas Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"TQH3906","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Sprim Advanced Life Sciences","sponsor":"The National Institute of Probiotics","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Trenev Trio","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Sprim Advanced Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sprim Advanced Life Sciences \/ The National Institute of Probiotics","highestDevelopmentStatusID":"9","companyTruncated":"Sprim Advanced Life Sciences \/ The National Institute of Probiotics"},{"orgOrder":0,"company":"Tsumura & Co","sponsor":"Icon Plc","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"TU-100","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Tsumura & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tsumura & Co \/ Icon Plc","highestDevelopmentStatusID":"8","companyTruncated":"Tsumura & Co \/ Icon Plc"},{"orgOrder":0,"company":"Korea United Pharm. Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"UI058","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Korea United Pharm. Inc.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Korea United Pharm. Inc. \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Korea United Pharm. Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Korea United Pharm. Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"UI059","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Korea United Pharm. Inc.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Korea United Pharm. Inc. \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Korea United Pharm. Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Korea United Pharm. Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"UI059","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Korea United Pharm. Inc.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Korea United Pharm. Inc. \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Korea United Pharm. Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Korea United Pharm. Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"UI05MSP015CT","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Korea United Pharm. Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Korea United Pharm. Inc. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Korea United Pharm. Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Next Biomedical Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Ui-Ewd Hemostatic System","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Next Biomedical Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Next Biomedical Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Next Biomedical Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Jinling Hospital, China","sponsor":"Jiangsu Topcel-KH Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Umbilical Cord Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Jinling Hospital, China","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jinling Hospital, China \/ Jiangsu Topcel-KH Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Jinling Hospital, China \/ Jiangsu Topcel-KH Pharmaceutical"},{"orgOrder":0,"company":"Primus Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Dietary Supplement","year":"2015","type":"Inapplicable","leadProduct":"Vasculera","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Primus Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Primus Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Primus Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"JSR Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2020","type":"Series C Financing","leadProduct":"VE202","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Vedanta Biosciences","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0.070000000000000007,"dosageForm":"Undisclosed","sponsorNew":"Vedanta Biosciences \/ JSR Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Vedanta Biosciences \/ JSR Life Sciences"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2021","type":"Financing","leadProduct":"VE202","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Vedanta Biosciences","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Vedanta Biosciences \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Vedanta Biosciences \/ Pfizer Inc"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"PureTech Health","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"VE202","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Vedanta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vedanta Biosciences \/ PureTech Health","highestDevelopmentStatusID":"6","companyTruncated":"Vedanta Biosciences \/ PureTech Health"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"VE202","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Vedanta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vedanta Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Vedanta Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Vecta Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Vecam","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Vecta Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vecta Ltd. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vecta Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"CEN Biotech","sponsor":"Vesale Pharmaceutica","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"VES002","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"CEN Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Sachet","sponsorNew":"CEN Biotech \/ Vesale Pharmaceutica","highestDevelopmentStatusID":"1","companyTruncated":"CEN Biotech \/ Vesale Pharmaceutica"},{"orgOrder":0,"company":"Danisco","sponsor":"Almarai | Clinart International","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Vetal Laban","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Danisco","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Danisco \/ Almarai | Clinart International","highestDevelopmentStatusID":"11","companyTruncated":"Danisco \/ Almarai | Clinart International"},{"orgOrder":0,"company":"Factor Therapeutics","sponsor":"Parexel | ARANZ Medical | Almac Group","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"VF001-DP","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Factor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Factor Therapeutics \/ Parexel | ARANZ Medical | Almac Group","highestDevelopmentStatusID":"8","companyTruncated":"Factor Therapeutics \/ Parexel | ARANZ Medical | Almac Group"},{"orgOrder":0,"company":"International Centre for Diarrhoeal Disease Research, Bangladesh","sponsor":"Unilever Nederland Holdings","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"BANGLADESH","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"VHH batch 203027","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"International Centre for Diarrhoeal Disease Research, Bangladesh","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"International Centre for Diarrhoeal Disease Research, Bangladesh \/ Unilever Nederland Holdings","highestDevelopmentStatusID":"8","companyTruncated":"International Centre for Diarrhoeal Disease Research, Bangladesh \/ Unilever Nederland Holdings"},{"orgOrder":0,"company":"Children's Hospital of Philadelphia","sponsor":"DBV Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Viaskin Milk","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Children's Hospital of Philadelphia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Children's Hospital of Philadelphia \/ DBV Technologies","highestDevelopmentStatusID":"8","companyTruncated":"Children's Hospital of Philadelphia \/ DBV Technologies"},{"orgOrder":0,"company":"Lunan Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Vonorasan Fumarate","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Lunan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lunan Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lunan Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"International Centre for Diarrhoeal Disease Research, Bangladesh","sponsor":"Entrinsic Bioscience Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"BANGLADESH","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"VS002A","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"International Centre for Diarrhoeal Disease Research, Bangladesh","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"International Centre for Diarrhoeal Disease Research, Bangladesh \/ Entrinsic Bioscience Inc.","highestDevelopmentStatusID":"1","companyTruncated":"International Centre for Diarrhoeal Disease Research, Bangladesh \/ Entrinsic Bioscience Inc."},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"VTP-1000","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Barinthus Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Barinthus Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Barinthus Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"VTP-1000","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Barinthus Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Barinthus Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Barinthus Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Creighton University","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2010","type":"Inapplicable","leadProduct":"Wheat Dextrin","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Creighton University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Creighton University \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"11","companyTruncated":"Creighton University \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Exosomm Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Whey Protein Milk-Derived Extracellular Vesicle","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Exosomm Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Exosomm Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Exosomm Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Providence Health & Services","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Dietary Supplement","year":"2015","type":"Inapplicable","leadProduct":"Whole Food","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Providence Health & Services","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Providence Health & Services \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Providence Health & Services \/ Undisclosed"},{"orgOrder":0,"company":"Providence Health & Services","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Dietary Supplement","year":"2015","type":"Inapplicable","leadProduct":"Whole Food","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Providence Health & Services","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Providence Health & Services \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Providence Health & Services \/ Undisclosed"},{"orgOrder":0,"company":"Dairy Goat Co-operative (N.Z.) Limited","sponsor":"Chulalongkorn University","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NEW ZEALAND","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Whole Goat Milk","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Dairy Goat Co-operative (N.Z.) Limited","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dairy Goat Co-operative (N.Z.) Limited \/ Chulalongkorn University","highestDevelopmentStatusID":"1","companyTruncated":"Dairy Goat Co-operative (N.Z.) Limited \/ Chulalongkorn University"},{"orgOrder":0,"company":"Werewolf Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"WTX-921","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Werewolf Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Werewolf Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Werewolf Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Sinorda Biomedicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"X842","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Jiangsu Sinorda Biomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Jiangsu Sinorda Biomedicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Sinorda Biomedicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Sinorda Biomedicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"X842","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Jiangsu Sinorda Biomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Jiangsu Sinorda Biomedicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Sinorda Biomedicine \/ Undisclosed"},{"orgOrder":0,"company":"Cinclus Pharma","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"X842","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Cinclus Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cinclus Pharma \/ Parexel","highestDevelopmentStatusID":"8","companyTruncated":"Cinclus Pharma \/ Parexel"},{"orgOrder":0,"company":"Athena Institute, Netherlands","sponsor":"Yakult Europe BV","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Probiotic","year":"2016","type":"Inapplicable","leadProduct":"Yakult","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Athena Institute, Netherlands","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Athena Institute, Netherlands \/ Yakult Europe BV","highestDevelopmentStatusID":"11","companyTruncated":"Athena Institute, Netherlands \/ Yakult Europe BV"},{"orgOrder":0,"company":"Inner Mongolia Yili Industrial Group Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Yili Chang Qing Pro-Abb Yoghurt","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Inner Mongolia Yili Industrial Group Co., Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inner Mongolia Yili Industrial Group Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Inner Mongolia Yili Industrial Group Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"YooYoung Pharmaceutical Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"YYD601","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"YooYoung Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"YooYoung Pharmaceutical Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"YooYoung Pharmaceutical Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"YooYoung Pharmaceutical Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"YYD601","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"YooYoung Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"YooYoung Pharmaceutical Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"YooYoung Pharmaceutical Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"YooYoung Pharmaceutical Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"YYD601","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"YooYoung Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"YooYoung Pharmaceutical Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"YooYoung Pharmaceutical Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Z0063","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Z0063","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Zeria Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Z-215","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Zeria Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zeria Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zeria Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"CES University","sponsor":"Nutreva S.A.S. | Foundation Child Care - FAN","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"COLOMBIA","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Zinc Amino Acid Chelate","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"CES University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CES University \/ Nutreva S.A.S. | Foundation Child Care - FAN","highestDevelopmentStatusID":"11","companyTruncated":"CES University \/ Nutreva S.A.S. | Foundation Child Care - FAN"},{"orgOrder":0,"company":"Main Line Health","sponsor":"Sharpe-Strumia Research Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Zinc Gluconate","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Main Line Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Main Line Health \/ Sharpe-Strumia Research Foundation","highestDevelopmentStatusID":"6","companyTruncated":"Main Line Health \/ Sharpe-Strumia Research Foundation"},{"orgOrder":0,"company":"Grupo de Investigaci\u00f3n Cl\u00ednica","sponsor":"Norgine","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SPAIN","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Ziverel","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Grupo de Investigaci\u00f3n Cl\u00ednica","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Grupo de Investigaci\u00f3n Cl\u00ednica \/ Norgine","highestDevelopmentStatusID":"1","companyTruncated":"Grupo de Investigaci\u00f3n Cl\u00ednica \/ Norgine"},{"orgOrder":0,"company":"Fujian Shengdi Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"HRS5580","moa":"Unknown","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Fujian Shengdi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fujian Shengdi Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Fujian Shengdi Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Cook MyoSite","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Iltamiocel","moa":"Unknown","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Cook MyoSite","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cook MyoSite \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cook MyoSite \/ Undisclosed"},{"orgOrder":0,"company":"Cook MyoSite","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2012","type":"Inapplicable","leadProduct":"Iltamiocel","moa":"Unknown","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Cook MyoSite","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cook MyoSite \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cook MyoSite \/ Undisclosed"},{"orgOrder":0,"company":"Tosk","sponsor":"Crystal Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"TK-112690","moa":"Uridine phosphorylase (UPP)","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Tosk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tosk \/ Crystal Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Tosk \/ Crystal Life Sciences"},{"orgOrder":0,"company":"Tosk","sponsor":"SIRO Clinpharm","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TK-112690","moa":"Uridine phosphorylase (UPP)","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Tosk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tosk \/ SIRO Clinpharm","highestDevelopmentStatusID":"8","companyTruncated":"Tosk \/ SIRO Clinpharm"},{"orgOrder":0,"company":"Tosk","sponsor":"SIRO Clinpharm","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TK-112690","moa":"Uridine phosphorylase (UPP)","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Tosk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tosk \/ SIRO Clinpharm","highestDevelopmentStatusID":"8","companyTruncated":"Tosk \/ SIRO Clinpharm"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Paracetamol","moa":"Vanilloid receptor | Anandamide amidohydrolase | Cyclooxygenase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Eventide Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Financing","leadProduct":"PRA023","moa":"Vascular endothelial cell growth inhibitor (TNFSF15)","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Prometheus Biosciences","amount2":0.13,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0.13,"dosageForm":"Undisclosed","sponsorNew":"Prometheus Biosciences \/ Eventide Asset Management","highestDevelopmentStatusID":"5","companyTruncated":"Prometheus Biosciences \/ Eventide Asset Management"},{"orgOrder":0,"company":"Weill Medical College of Cornell University","sponsor":"Angiocrine Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"E-CEL UVEC","moa":"Vascular endothelium","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Weill Medical College of Cornell University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Weill Medical College of Cornell University \/ Angiocrine Bioscience","highestDevelopmentStatusID":"6","companyTruncated":"Weill Medical College of Cornell University \/ Angiocrine Bioscience"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Terlipressin Acetate","moa":"Vasopressin V2 receptor | Vasopressin V1 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"University Medical Center Groningen","sponsor":"Helmholtz Zentrum M\u00fcnchen","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Bevacizumab-IRDye800CW","moa":"VEGF receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"University Medical Center Groningen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Medical Center Groningen \/ Helmholtz Zentrum M\u00fcnchen","highestDevelopmentStatusID":"8","companyTruncated":"University Medical Center Groningen \/ Helmholtz Zentrum M\u00fcnchen"},{"orgOrder":0,"company":"Hadassah Medical Organization","sponsor":"Rambam Health Care Campus | Carmel Medical Center | Soroka University Medical Center | Tel Aviv Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Warfarin Sodium","moa":"Vitamin k epoxide reductase complex subunit 1 isoform 1","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Hadassah Medical Organization","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hadassah Medical Organization \/ Rambam Health Care Campus | Carmel Medical Center | Soroka University Medical Center | Tel Aviv Medical Center","highestDevelopmentStatusID":"1","companyTruncated":"Hadassah Medical Organization \/ Rambam Health Care Campus | Carmel Medical Center | Soroka University Medical Center | Tel Aviv Medical Center"},{"orgOrder":0,"company":"59th Medical Wing","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Gabapentin","moa":"Voltage-gated calcium channel","graph1":"Gastroenterology","graph2":"Phase III","graph3":"59th Medical Wing","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"59th Medical Wing \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"59th Medical Wing \/ Pfizer Inc"},{"orgOrder":0,"company":"CinPhloro Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Phloroglucinol","moa":"Voltage-gated calcium channel","graph1":"Gastroenterology","graph2":"Phase II","graph3":"CinPhloro Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CinPhloro Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CinPhloro Pharma \/ Undisclosed"},{"orgOrder":0,"company":"SLA Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Diltiazem Hydrochloride","moa":"Voltage-gated L-type calcium channel","graph1":"Gastroenterology","graph2":"Phase III","graph3":"SLA Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SLA Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SLA Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ventrus Biosciences, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Diltiazem Hydrochloride","moa":"Voltage-gated L-type calcium channel","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Ventrus Biosciences, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ventrus Biosciences, Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ventrus Biosciences, Inc \/ Undisclosed"},{"orgOrder":0,"company":"RDD Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Nifedipine","moa":"Voltage-gated L-type calcium channel","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"RDD Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"RDD Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"RDD Pharma \/ Undisclosed"},{"orgOrder":0,"company":"RDD Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Nifedipine","moa":"Voltage-gated L-type calcium channel","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"RDD Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"RDD Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"RDD Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Surrozen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"SZN-1326","moa":"Wnt signalling pathway","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Surrozen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Surrozen \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Surrozen \/ Undisclosed"},{"orgOrder":0,"company":"Surrozen","sponsor":"Consonance-HFW","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Merger","leadProduct":"SZN-1326","moa":"Wnt signalling pathway","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Surrozen","amount2":0.20999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0.20999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Surrozen \/ Consonance-HFW","highestDevelopmentStatusID":"4","companyTruncated":"Surrozen \/ Consonance-HFW"},{"orgOrder":0,"company":"Surrozen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"SZN-1326","moa":"Wnt signalling pathway","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Surrozen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Surrozen \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Surrozen \/ Undisclosed"},{"orgOrder":0,"company":"Church & Dwight Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Zinc Sulfate Monohydrate","moa":"Zinc","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Church & Dwight Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Church & Dwight Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Church & Dwight Co \/ Undisclosed"},{"orgOrder":0,"company":"National Cheng-Kung University Hospital","sponsor":"ProBio","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"TAIWAN","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"National Cheng-Kung University Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cheng-Kung University Hospital \/ ProBio","highestDevelopmentStatusID":"11","companyTruncated":"National Cheng-Kung University Hospital \/ ProBio"},{"orgOrder":0,"company":"Upadia Holding","sponsor":"EsoCap","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Upadia Holding","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Upadia Holding \/ EsoCap","highestDevelopmentStatusID":"4","companyTruncated":"Upadia Holding \/ EsoCap"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sosei Group Corporation \/ Undisclosed","highestDevelopmentStatusID":"2","companyTruncated":"Sosei Group Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"University of Oxford","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sosei Heptares \/ University of Oxford","highestDevelopmentStatusID":"4","companyTruncated":"Sosei Heptares \/ University of Oxford"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sosei Heptares \/ Undisclosed","highestDevelopmentStatusID":"2","companyTruncated":"Sosei Heptares \/ Undisclosed"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Sosei Heptares","amount2":0.47999999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0.47999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Sosei Heptares \/ GSK","highestDevelopmentStatusID":"4","companyTruncated":"Sosei Heptares \/ GSK"},{"orgOrder":0,"company":"University Hospital T\u00fcbingen","sponsor":"SymbioPharm GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"University Hospital T\u00fcbingen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital T\u00fcbingen \/ SymbioPharm GmbH","highestDevelopmentStatusID":"1","companyTruncated":"University Hospital T\u00fcbingen \/ SymbioPharm GmbH"},{"orgOrder":0,"company":"Danisco","sponsor":"BioFortis","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Danisco","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Danisco \/ BioFortis","highestDevelopmentStatusID":"1","companyTruncated":"Danisco \/ BioFortis"},{"orgOrder":0,"company":"Vibrant Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Vibrant Ltd.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vibrant Ltd. \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Vibrant Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mundipharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Mundipharma \/ Undisclosed"},{"orgOrder":0,"company":"Novozymes","sponsor":"Analyze & Realize","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Novozymes","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novozymes \/ Analyze & Realize","highestDevelopmentStatusID":"1","companyTruncated":"Novozymes \/ Analyze & Realize"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Innate Pharma","amount2":0.41999999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0.41999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Innate Pharma \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Innate Pharma \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"ThirtyFiveBio","sponsor":"Innovate Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"ThirtyFiveBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ThirtyFiveBio \/ Innovate Biopharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"ThirtyFiveBio \/ Innovate Biopharmaceuticals"},{"orgOrder":0,"company":"PharmaBiome","sponsor":"Ferring Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Discovery","graph3":"PharmaBiome","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmaBiome \/ Ferring Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"PharmaBiome \/ Ferring Pharmaceuticals"},{"orgOrder":0,"company":"Inotrem","sponsor":"Crohn\u2019s & Colitis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Inotrem","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inotrem \/ Crohn\u2019s & Colitis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Inotrem \/ Crohn\u2019s & Colitis Foundation"},{"orgOrder":0,"company":"ThirtyFiveBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"ThirtyFiveBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ThirtyFiveBio \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"ThirtyFiveBio \/ Undisclosed"},{"orgOrder":0,"company":"SNIPR Biome","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Discovery","graph3":"SNIPR Biome","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SNIPR Biome \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"SNIPR Biome \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"OMass Therapeutics","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"GPR65","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"OMass Therapeutics","amount2":0.41999999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0.41999999999999998,"dosageForm":"Undisclosed","sponsorNew":"OMass Therapeutics \/ Genentech","highestDevelopmentStatusID":"4","companyTruncated":"OMass Therapeutics \/ Genentech"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"OPKO Health","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"EnteraBio Ltd","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"EnteraBio Ltd \/ OPKO Health","highestDevelopmentStatusID":"4","companyTruncated":"EnteraBio Ltd \/ OPKO Health"},{"orgOrder":0,"company":"Cytoreason","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Undisclosed","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Cytoreason","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cytoreason \/ Sanofi","highestDevelopmentStatusID":"2","companyTruncated":"Cytoreason \/ Sanofi"},{"orgOrder":0,"company":"University of Alabama at Birmingham","sponsor":"Argon Medical Devices","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"University of Alabama at Birmingham","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Alabama at Birmingham \/ Argon Medical Devices","highestDevelopmentStatusID":"7","companyTruncated":"University of Alabama at Birmingham \/ Argon Medical Devices"},{"orgOrder":0,"company":"Oral Defense, LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Oral Defense, LLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oral Defense, LLC \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oral Defense, LLC \/ Undisclosed"},{"orgOrder":0,"company":"Hawthorne Effect Inc.","sponsor":"HLNatural, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Hawthorne Effect Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hawthorne Effect Inc. \/ HLNatural, Inc.","highestDevelopmentStatusID":"1","companyTruncated":"Hawthorne Effect Inc. \/ HLNatural, Inc."},{"orgOrder":0,"company":"Radicle Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Radicle Science","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radicle Science \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Radicle Science \/ Undisclosed"},{"orgOrder":0,"company":"Prisma Health-Upstate","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Prisma Health-Upstate","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prisma Health-Upstate \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Prisma Health-Upstate \/ Undisclosed"},{"orgOrder":0,"company":"RDD Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"RDD Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"RDD Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"RDD Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Hilma","sponsor":"Biocodex","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Hilma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Powder in Sachet","sponsorNew":"Hilma \/ Biocodex","highestDevelopmentStatusID":"15","companyTruncated":"Hilma \/ Biocodex"},{"orgOrder":0,"company":"RDD Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"RDD Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"RDD Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"RDD Pharma \/ Undisclosed"},{"orgOrder":0,"company":"RDD Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"RDD Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"RDD Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"RDD Pharma \/ Undisclosed"},{"orgOrder":0,"company":"LALLEMAND HEALTH SOLUTIONS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"LALLEMAND HEALTH SOLUTIONS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LALLEMAND HEALTH SOLUTIONS \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"LALLEMAND HEALTH SOLUTIONS \/ Undisclosed"},{"orgOrder":0,"company":"Pinnacle Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Pinnacle Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pinnacle Biologics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pinnacle Biologics \/ Undisclosed"},{"orgOrder":0,"company":"LALLEMAND HEALTH SOLUTIONS","sponsor":"ProbiSearch SL","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"LALLEMAND HEALTH SOLUTIONS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LALLEMAND HEALTH SOLUTIONS \/ ProbiSearch SL","highestDevelopmentStatusID":"8","companyTruncated":"LALLEMAND HEALTH SOLUTIONS \/ ProbiSearch SL"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"GentiBio","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Discovery Platform","graph3":"GentiBio","amount2":1.8999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Gastroenterology","amount2New":1.8999999999999999,"dosageForm":"Undisclosed","sponsorNew":"GentiBio \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"GentiBio \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Novome Biotechnologies","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Novome Biotechnologies","amount2":0.60999999999999999,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0.60999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Novome Biotechnologies \/ Genentech","highestDevelopmentStatusID":"2","companyTruncated":"Novome Biotechnologies \/ Genentech"},{"orgOrder":0,"company":"Second Genome","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Second Genome","amount2":1.54,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":1.54,"dosageForm":"Undisclosed","sponsorNew":"Second Genome \/ Gilead Sciences","highestDevelopmentStatusID":"2","companyTruncated":"Second Genome \/ Gilead Sciences"},{"orgOrder":0,"company":"Sonoma Biotherapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Sonoma Biotherapeutics","amount2":0.12,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0.12,"dosageForm":"Undisclosed","sponsorNew":"Sonoma Biotherapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Sonoma Biotherapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Celsius Therapeutics","sponsor":"University of Oxford","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Celsius Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celsius Therapeutics \/ University of Oxford","highestDevelopmentStatusID":"2","companyTruncated":"Celsius Therapeutics \/ University of Oxford"},{"orgOrder":0,"company":"Scipher Medicine","sponsor":"Galapagos","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Scipher Medicine","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scipher Medicine \/ Galapagos","highestDevelopmentStatusID":"2","companyTruncated":"Scipher Medicine \/ Galapagos"},{"orgOrder":0,"company":"Sinopia Biosciences","sponsor":"NIDCR","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Sinopia Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinopia Biosciences \/ NIDCR","highestDevelopmentStatusID":"2","companyTruncated":"Sinopia Biosciences \/ NIDCR"},{"orgOrder":0,"company":"Synlogic","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Termination","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Synlogic","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Synlogic \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"Synlogic \/ AbbVie Inc"},{"orgOrder":0,"company":"Avexegen Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Avexegen Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avexegen Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"Avexegen Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Harvard Apparatus Regenerative Technology","sponsor":"Children\u2019s Hospital Capital institute of Pediatrics","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Harvard Apparatus Regenerative Technology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Harvard Apparatus Regenerative Technology \/ Children\u2019s Hospital Capital institute of Pediatrics","highestDevelopmentStatusID":"6","companyTruncated":"Harvard Apparatus Regenerative Technology \/ Children\u2019s Hospital Capital institute of Pediatrics"},{"orgOrder":0,"company":"Nexilico","sponsor":"Siolta Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Discovery Platform","graph3":"Nexilico","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nexilico \/ Siolta Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Nexilico \/ Siolta Therapeutics"},{"orgOrder":0,"company":"Siolta Therapeutics","sponsor":"Cowellnex","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Siolta Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Siolta Therapeutics \/ Cowellnex","highestDevelopmentStatusID":"2","companyTruncated":"Siolta Therapeutics \/ Cowellnex"},{"orgOrder":0,"company":"Kallyope","sponsor":"Sosei Group Corporation","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Kallyope","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kallyope \/ Sosei Group Corporation","highestDevelopmentStatusID":"2","companyTruncated":"Kallyope \/ Sosei Group Corporation"},{"orgOrder":0,"company":"Atmo Biosciences Pty Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"AUSTRALIA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Atmo Biosciences Pty Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Atmo Biosciences Pty Ltd \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Atmo Biosciences Pty Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Nancy Mouradian","sponsor":"Invicare","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Nancy Mouradian","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Nancy Mouradian \/ Invicare","highestDevelopmentStatusID":"6","companyTruncated":"Nancy Mouradian \/ Invicare"},{"orgOrder":0,"company":"Stuart Wright","sponsor":"Soothing Scents, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Stuart Wright","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Stuart Wright \/ Soothing Scents, Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Stuart Wright \/ Soothing Scents, Inc."},{"orgOrder":0,"company":"Enhanced Genomics","sponsor":"BGF","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2025","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Enhanced Genomics","amount2":0.02,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Enhanced Genomics \/ BGF","highestDevelopmentStatusID":"1","companyTruncated":"Enhanced Genomics \/ BGF"},{"orgOrder":0,"company":"OncoZenge","sponsor":"University of California","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Miscellaneous","year":"2025","type":"Collaboration","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Gastroenterology","graph2":"Phase II","graph3":"OncoZenge","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"OncoZenge \/ University of California","highestDevelopmentStatusID":"8","companyTruncated":"OncoZenge \/ University of California"},{"orgOrder":0,"company":"Veristat","sponsor":"Cook MyoSite","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Partnership","leadProduct":"Iltamiocel","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Veristat","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Veristat \/ Cook MyoSite","highestDevelopmentStatusID":"10","companyTruncated":"Veristat \/ Cook MyoSite"},{"orgOrder":0,"company":"Eupraxia Pharmaceuticals","sponsor":"Cantor","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Steroid","year":"2025","type":"Public Offering","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Eupraxia Pharmaceuticals","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.080000000000000002,"dosageForm":"Injection, Extended Release","sponsorNew":"Eupraxia Pharmaceuticals \/ Cantor","highestDevelopmentStatusID":"7","companyTruncated":"Eupraxia Pharmaceuticals \/ Cantor"},{"orgOrder":0,"company":"Eupraxia Pharmaceuticals","sponsor":"Cantor","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Steroid","year":"2025","type":"Public Offering","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Eupraxia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.080000000000000002,"dosageForm":"Injection, Extended Release","sponsorNew":"Eupraxia Pharmaceuticals \/ Cantor","highestDevelopmentStatusID":"7","companyTruncated":"Eupraxia Pharmaceuticals \/ Cantor"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"C4X Discovery","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Alpha-4-beta-7 integrin","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"C4X Discovery","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"C4X Discovery \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"C4X Discovery \/ Undisclosed"},{"orgOrder":0,"company":"Lee's Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"HONG KONG","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Irsogladine Maleate","moa":"Gap junctions\/Unknown","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Lee\\'s Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lee\\'s Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Lee\\'s Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Wecare Probiotics Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Wecare Probiotics Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Serum","sponsorNew":"Wecare Probiotics Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Wecare Probiotics Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"SAR444336","moa":"IL-2","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Onconic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"JP-1366","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Onconic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Onconic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Onconic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Novozymes","sponsor":"Citruslabs","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"Limosilactobacillus Reuteri Strain","moa":"Microbiome","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Novozymes","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novozymes \/ Citruslabs","highestDevelopmentStatusID":"1","companyTruncated":"Novozymes \/ Citruslabs"},{"orgOrder":0,"company":"Biocodex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"Saccharomyces Boulardii","moa":"Immune","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Biocodex","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biocodex \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biocodex \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"LY3537021","moa":"Gastric inhibitory polypeptide receptor (GIPR)","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Getz Pharma","sponsor":"Rawalpindi Medical College, Pakistan","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"PAKISTAN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Acotiamide","moa":"Acetylcholinesterase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Getz Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Getz Pharma \/ Rawalpindi Medical College, Pakistan","highestDevelopmentStatusID":"10","companyTruncated":"Getz Pharma \/ Rawalpindi Medical College, Pakistan"},{"orgOrder":0,"company":"Catalysis - S.L.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SPAIN","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Carminal","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Catalysis - S.L.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Catalysis - S.L. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Catalysis - S.L. \/ Undisclosed"},{"orgOrder":0,"company":"BioGaia Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"Limosilactobacillus Reuteri","moa":"Microbiome","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"BioGaia Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Drops","sponsorNew":"BioGaia Pharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"BioGaia Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Glepaglutide","moa":"peptides: GLP peptide analogs","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Eupraxia Pharmaceuticals","sponsor":"Cantor","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Steroid","year":"2025","type":"Public Offering","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Eupraxia Pharmaceuticals","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.080000000000000002,"dosageForm":"Injection, Extended Release","sponsorNew":"Eupraxia Pharmaceuticals \/ Cantor","highestDevelopmentStatusID":"7","companyTruncated":"Eupraxia Pharmaceuticals \/ Cantor"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Tabuk Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"HK inno.N \/ Tabuk Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"HK inno.N \/ Tabuk Pharmaceuticals"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Tabuk Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2025","type":"Licensing Agreement","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"HK inno.N \/ Tabuk Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"HK inno.N \/ Tabuk Pharmaceuticals"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Boryung Pharmaceutical Co., Ltd","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"HK inno.N \/ Boryung Pharmaceutical Co., Ltd","highestDevelopmentStatusID":"15","companyTruncated":"HK inno.N \/ Boryung Pharmaceutical Co., Ltd"},{"orgOrder":0,"company":"Analog Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Doxylamine Succinate","moa":"||Histamine H1 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Analog Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Analog Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Analog Pharma \/ Undisclosed"},{"orgOrder":0,"company":"BRAINTREE LABS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"BRAINTREE LABS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"BRAINTREE LABS \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BRAINTREE LABS \/ Undisclosed"},{"orgOrder":0,"company":"United Italian Trading Corporation","sponsor":"HK inno.N","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SINGAPORE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"United Italian Trading Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"United Italian Trading Corporation \/ HK inno.N","highestDevelopmentStatusID":"15","companyTruncated":"United Italian Trading Corporation \/ HK inno.N"},{"orgOrder":0,"company":"HK inno.N","sponsor":"BRAINTREE LABS","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"HK inno.N \/ BRAINTREE LABS","highestDevelopmentStatusID":"15","companyTruncated":"HK inno.N \/ BRAINTREE LABS"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"HK inno.N \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"HK inno.N \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"HK inno.N \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"HK inno.N \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"HK inno.N \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"HK inno.N \/ Undisclosed"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Carnot Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"HK inno.N \/ Carnot Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"HK inno.N \/ Carnot Laboratories"},{"orgOrder":0,"company":"HK inno.N","sponsor":"United Italian Trading Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"HK inno.N \/ United Italian Trading Corporation","highestDevelopmentStatusID":"15","companyTruncated":"HK inno.N \/ United Italian Trading Corporation"},{"orgOrder":0,"company":"HK inno.N","sponsor":"BRAINTREE LABS","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"HK inno.N \/ Braintree Labs","highestDevelopmentStatusID":"15","companyTruncated":"HK inno.N \/ Braintree Labs"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Luoxin Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"HK inno.N \/ Luoxin Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"HK inno.N \/ Luoxin Pharmaceutical"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Vimedimex Medi Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"HK inno.N \/ Vimedimex Medi Pharma","highestDevelopmentStatusID":"15","companyTruncated":"HK inno.N \/ Vimedimex Medi Pharma"},{"orgOrder":0,"company":"Arbor Biotechnologies","sponsor":"Chiesi Group","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Collaboration","leadProduct":"ABO-101","moa":"GOX","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Arbor Biotechnologies","amount2":2.1200000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":2.1200000000000001,"dosageForm":"Infusion","sponsorNew":"Arbor Biotechnologies \/ Chiesi Group","highestDevelopmentStatusID":"7","companyTruncated":"Arbor Biotechnologies \/ Chiesi Group"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Eurofarma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"HK inno.N \/ Eurofarma","highestDevelopmentStatusID":"15","companyTruncated":"HK inno.N \/ Eurofarma"},{"orgOrder":0,"company":"Biocodex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"Bacillus coagulans MY01","moa":"Microbiome","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Biocodex","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biocodex \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Biocodex \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Liangzhou Wei","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Mosapride Citrate","moa":"Serotonin 4 (5-HT4) receptor | Serotonin 3 (5-HT3) receptor","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Sumitomo Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo Pharma \/ Liangzhou Wei","highestDevelopmentStatusID":"11","companyTruncated":"Sumitomo Pharma \/ Liangzhou Wei"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Gary E. Stein","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Tigecycline","moa":"Bacterial 70S ribosome","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Gary E. Stein","highestDevelopmentStatusID":"1","companyTruncated":"Pfizer Inc \/ Gary E. Stein"},{"orgOrder":0,"company":"Ossium Health","sponsor":"Amy Lightner","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Ossium vBM-MSC","moa":"Bone marrow cell","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Ossium Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ossium Health \/ Amy Lightner","highestDevelopmentStatusID":"7","companyTruncated":"Ossium Health \/ Amy Lightner"},{"orgOrder":0,"company":"Pharmbio Korea","sponsor":"Bo-In Lee","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2016","type":"Inapplicable","leadProduct":"Oral Sulfate","moa":"Colon","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Pharmbio Korea","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmbio Korea \/ Bo-In Lee","highestDevelopmentStatusID":"11","companyTruncated":"Pharmbio Korea \/ Bo-In Lee"},{"orgOrder":0,"company":"Tillotts Pharma AG","sponsor":"Hans T\u00f6rnblom","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Cyclooxygenase | Peroxisome proliferator-activated receptor gamma | Arachidonate 5-lipoxygenase","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Tillotts Pharma AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tillotts Pharma AG \/ Hans T\u00f6rnblom","highestDevelopmentStatusID":"8","companyTruncated":"Tillotts Pharma AG \/ Hans T\u00f6rnblom"},{"orgOrder":0,"company":"Napo EU","sponsor":"Lindsey Russell, MD","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Cystic fibrosis transmembrane conductance regulator | Anoctamin-1","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Napo EU","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Powder for Solution","sponsorNew":"Napo EU \/ Lindsey Russell, MD","highestDevelopmentStatusID":"6","companyTruncated":"Napo EU \/ Lindsey Russell, MD"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Hee Jun Kim","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Olanzapine","moa":"D2-like dopamine receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HK inno.N \/ Hee Jun Kim","highestDevelopmentStatusID":"1","companyTruncated":"HK inno.N \/ Hee Jun Kim"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Michael Camilleri, MD","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Aldafermin","moa":"FGFR4-KLB | FGF1\/KLB","graph1":"Gastroenterology","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"NGM Biopharmaceuticals \/ Michael Camilleri, MD","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopharmaceuticals \/ Michael Camilleri, MD"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Klaus Gottlob M\u00fcller","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Klaus Gottlob M\u00fcller","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Klaus Gottlob M\u00fcller"},{"orgOrder":0,"company":"Ambrosia - SupHerb Ltd.","sponsor":"Ferass Abu Hanna","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Ambrosia - SupHerb Ltd.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ambrosia - SupHerb Ltd. \/ Ferass Abu Hanna","highestDevelopmentStatusID":"11","companyTruncated":"Ambrosia - SupHerb Ltd. \/ Ferass Abu Hanna"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Nielsen Fernandez-Becker","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"PTG-100","moa":"Integrin alpha-4 (ITGA4)","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Protagonist Therapeutics \/ Nielsen Fernandez-Becker","highestDevelopmentStatusID":"6","companyTruncated":"Protagonist Therapeutics \/ Nielsen Fernandez-Becker"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Sharon Stein","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Alvimopan","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Sharon Stein","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Sharon Stein"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Joseph Ma","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Naloxegol Oxalate","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Joseph Ma","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Joseph Ma"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Michael Camilleri","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Naloxegol Oxalate","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Michael Camilleri","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Michael Camilleri"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Katy Peters","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Aprepitant","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Katy Peters","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Katy Peters"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Lawrence Einhorn","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Fosaprepitant","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Lawrence Einhorn","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Lawrence Einhorn"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Christina Ruhlmann","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Netupitant","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Helsinn Advanced Synthesis \/ Christina Ruhlmann","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ Christina Ruhlmann"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Spencer Dorn, MD, MPH","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Milnacipran","moa":"Norepinephrine transporter","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Spencer Dorn, MD, MPH","highestDevelopmentStatusID":"8","companyTruncated":"Forest Laboratories \/ Spencer Dorn, MD, MPH"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Mark Feinglos","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Tadalafil","moa":"Phosphodiesterase 5A","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Mark Feinglos","highestDevelopmentStatusID":"11","companyTruncated":"Eli Lilly \/ Mark Feinglos"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"David A. Johnson, MD","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Esomeprazole Magnesium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ David A. Johnson, MD","highestDevelopmentStatusID":"11","companyTruncated":"AstraZeneca \/ David A. Johnson, MD"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"YongChan Lee","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Lansoprazole","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Otsuka Pharmaceutical \/ YongChan Lee","highestDevelopmentStatusID":"11","companyTruncated":"Otsuka Pharmaceutical \/ YongChan Lee"},{"orgOrder":0,"company":"The Emmes Company, LLC","sponsor":"Phillip Brian Smith","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Pantoprazole Sodium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase I","graph3":"The Emmes Company, LLC","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Emmes Company, LLC \/ Phillip Brian Smith","highestDevelopmentStatusID":"6","companyTruncated":"The Emmes Company, LLC \/ Phillip Brian Smith"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Mohamed Saad","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Pantoprazole Sodium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abbott Laboratories \/ Mohamed Saad","highestDevelopmentStatusID":"1","companyTruncated":"Abbott Laboratories \/ Mohamed Saad"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Amsterdam UMC, VUmc","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Psyllium","moa":"quaternary ammonium derivatives","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Teva Pharmaceutical Industries \/ Amsterdam UMC, VUmc","highestDevelopmentStatusID":"1","companyTruncated":"Teva Pharmaceutical Industries \/ Amsterdam UMC, VUmc"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyle Staller","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tenapanor","moa":"Sodium\/hydrogen exchanger 3","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ardelyx \/ Kyle Staller","highestDevelopmentStatusID":"11","companyTruncated":"Ardelyx \/ Kyle Staller"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Karen Noblett","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Botulinum Toxin","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Karen Noblett","highestDevelopmentStatusID":"9","companyTruncated":"AbbVie Inc \/ Karen Noblett"},{"orgOrder":0,"company":"Merck & Co","sponsor":"David Binion, MD","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Bezlotoxumab","moa":"Toxin B","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ David Binion, MD","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ David Binion, MD"},{"orgOrder":0,"company":"Danone Global Research & Innovation Center","sponsor":"Misha D.P. Luyer","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Dietary Supplement","year":"2014","type":"Inapplicable","leadProduct":"Enriched Enteral Nutrition","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Danone Global Research & Innovation Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Danone Global Research & Innovation Center \/ Misha D.P. Luyer","highestDevelopmentStatusID":"1","companyTruncated":"Danone Global Research & Innovation Center \/ Misha D.P. Luyer"},{"orgOrder":0,"company":"Prolacta Bioscience","sponsor":"Thomas Abrahamsson, MD, PhD","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Dietary Supplement","year":"2019","type":"Inapplicable","leadProduct":"H2MF","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Prolacta Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prolacta Bioscience \/ Thomas Abrahamsson, MD, PhD","highestDevelopmentStatusID":"9","companyTruncated":"Prolacta Bioscience \/ Thomas Abrahamsson, MD, PhD"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Dennis Clements","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Vaccine","year":"2013","type":"Inapplicable","leadProduct":"Pentavalent Rotavirus Vaccine","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Dennis Clements","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Dennis Clements"},{"orgOrder":0,"company":"PvP Biologics","sponsor":"Danielle Kim Turgeon","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2018","type":"Inapplicable","leadProduct":"PvP001","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"PvP Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PvP Biologics \/ Danielle Kim Turgeon","highestDevelopmentStatusID":"6","companyTruncated":"PvP Biologics \/ Danielle Kim Turgeon"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Kathirvel Subramaniam","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Paracetamol","moa":"Vanilloid receptor | Anandamide amidohydrolase | Cyclooxygenase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Kathirvel Subramaniam","highestDevelopmentStatusID":"11","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Kathirvel Subramaniam"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Dr. Reddy's Laboratories

                            India
                            CPhI WW Frankfurt
                            Booth #9.1B48
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

                            Lead Product(s) : Tegoprazan

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dr. Reddy’s launches Tegoprazan in India

                            Details : PCAB (tegoprazan) is a potassium-competitive acid blocker that reversibly blocks gastric acid secretion by competitively binding with potassium to the proton pumps present in gastric wall cells.

                            Product Name : PCAB

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 17, 2025

                            Lead Product(s) : Tegoprazan

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Dr Reddy Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : SAR444336

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Investigate the Efficacy and Safety of SAR444336 in Adults With Microscopic Colitis in Clinical Rem...

                            Details : SAR444336 is a Protein drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Colitis, Microscopic.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            September 05, 2025

                            Lead Product(s) : SAR444336

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Dr. Reddy's Laboratories

                            India
                            CPhI WW Frankfurt
                            Booth #9.1B48
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

                            Lead Product(s) : Linaclotide

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dr Reddy’s launches Linaclotide for chronic constipation treatment in India

                            Details : Colozo (linaclotide) is a guanylate cyclase-C agonist indicated for treatment of chronic idiopathic constipation (CIC) in adults.

                            Product Name : Colozo

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            August 27, 2025

                            Lead Product(s) : Linaclotide

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Dr Reddy Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Dr. Reddy's Laboratories

                            India
                            CPhI WW Frankfurt
                            Booth #9.1B48
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

                            Lead Product(s) : Elobixibat Hydrate

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dr Reddy's Launches Medication to Treat Chronic Constipation

                            Details : Bixibat (elobixibat hydrate) is a bile acid transporter inhibitor, small molecule drug candidate, which is indicated for the treatment of chronic constipation.

                            Product Name : Bixibat

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 28, 2024

                            Lead Product(s) : Elobixibat Hydrate

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Dr Reddy Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Amlitelimab

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac ...

                            Details : Amlitelimab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Celiac Disease.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            August 16, 2024

                            Lead Product(s) : Amlitelimab

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Strides Pharma Science

                            India
                            CPhI WW Frankfurt
                            Booth # 9.1F6 & 9.1G41
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSynergice, a Strides Pharma initiative, is a new gen B2B platform for diverse portofolio needs.

                            Lead Product(s) : SucrAlphate

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Strides receives USFDA approval for Sucralfate Oral Suspension, 1gm/10 mL

                            Details : Carafate-generic (sucralfate) is a USFDA approved pepsin A inhibitor small molecule drug candidate, which is indicated for the treatment of active duodenal ulcer.

                            Product Name : Carafate-Generic

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 23, 2024

                            Lead Product(s) : SucrAlphate

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Strides Pharma Science

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            AbbVie Inc

                            U.S.A
                            Indonesia Pharmaceutical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Risankizumab

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Assess the Concentrations of Risankizumab in the Breast Milk of Adult Lactating Women With Inflamma...

                            Details : Risankizumab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Inflammatory Bowel Diseases.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            April 04, 2024

                            Lead Product(s) : Risankizumab

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Towa Pharmaceutical

                            Japan
                            CPhI WW Frankfurt
                            Booth #9.2A94
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothTowa Pharma is dedicated to researching, developing, producing, and promoting generic drugs.

                            Lead Product(s) : Esomeprazole Magnesium

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Notice of Approval for Esomeprazole Capsules with New Manufacturing Plant Addition

                            Details : Esomeprazole magnesium hydrate capsules is a proton pump inhibitor indicated for the treatment of gastroesophageal reflux disease and NSAID-associated gastric ulcer.

                            Product Name : Esomeprazole-Generic

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 14, 2024

                            Lead Product(s) : Esomeprazole Magnesium

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Towa Pharmaceutical

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Granules India Limited

                            India
                            CPhI WW Frankfurt
                            Booth #H9.1A48
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothGranules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

                            Lead Product(s) : Pantoprazole Sodium

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Granules India Limited Received ANDA Approval for Pantoprazole Sod Delayed-Release Tablets

                            Details : Pantoprazole Sodium Delayed-Release tablets are indicated for short-term treatment of Erosive Esophagitis Associated with GERD and Pathological Hypersecretory Conditions.

                            Product Name : Protonix-Generic

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 13, 2023

                            Lead Product(s) : Pantoprazole Sodium

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Granules India

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Dupilumab

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase IV

                            Sponsor : Regeneron Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followe...

                            Details : Dupilumab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Eosinophilic Esophagitis.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            October 25, 2023

                            Lead Product(s) : Dupilumab

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase IV

                            Sponsor : Regeneron Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth